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1. HEMATOPOIESIS AND LEUKEMIA
Hematopoiesis is the deterministic process of blood cell formation taking place in the bone 
marrow.1 Mature blood cells are produced by a tightly controlled mechanism from hematopoietic 
stem cells (HSCs) residing in the bone marrow. Upon maturation blood cells are released into the 
peripheral blood and from this point onward can be transported to the different locations of the 
body. The mature blood cells exert different functions dependent on a strictly controlled path of 
maturation. The distinct leukocytes comprising granulocytes, monocytes, macrophages, natural 
killer cells and lymphocytes are essential for the defense against pathogens and foreign invaders, 
erythrocytes play a pivotal role in the transportation of oxygen to remote organs, and platelets 
confer the process of blood clotting.
 Mature blood cells are short-lived and require continuous replenishment. The control of 
the production and the total number of blood cells is conferred by multipotent progenitors 
and a small population of pluripotent HSCs (Figure 1). HSCs reside in the bone marrow of adult 
mammals at the apex of a hierarchy of progenitors which become progressively restricted to 
several and eventually single lineages of blood cells.2 Additionally these pluripotent stem cells 
have the unique ability to self-renew, generating a source for continuous replenishment of the 
complete blood cell system. The hematopoietic stem cell compartment contains stem cells with 
progressively decreased self-renewal capacity with the retention of multi-lineage reconstitution. 
The rare long term HSC (LT-HSC) is at the pinnacle of the hematopoietic hierarchy and is mainly 
quiescent. With the most conserved rate of self-renewal it prevents the depletion of the stem 
cell pool.3 The less rare short term HSC (ST-HSC) still retains a minimal ability for self-renewal 
and is the more active effector cell for hematopoietic replenishment in normal situations.4 The 
main constituent of the hematopoietic stem cell compartment is the multipotent progenitor 
(MPP) which lost its self-renewal capacity, however, kept the ability to give rise to daughter 
cells of different lineages. The daughter cells, common myeloid progenitor (CMP)5 and common 
lymphoid progenitor (CLP)6, are still oligopotent as they give rise to multiple blood cell types, e.g., 
lymphocytes, granulocytes, platelets and erythrocytes.
 The production of mature blood cells is a strictly controlled process that adapts to the needs 
of human physiology, e.g., erythrocyte production after blood loss. The control is asserted mainly 
by external stimuli, e.g., hematopoietic cytokines or growth factors, which are produced by 
constituents of the regulatory microenvironment within the bone marrow niche, other blood 
cells or cytokine secreting organs.7-9 The microenvironment plays a pivotal role in the formation 
of adequate numbers of blood cells of the correct type10 and the hematopoietic cytokines it 
produces allows the hematopoietic system to dynamically adapt to extramedullary events, e.g., 
blood loss, infection or cancer immunoediting.11
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Figure 1. Hematopoiesis. (adapted from Reya et al.3) Within the hematopoietic stem cell compartment reside 
pluripotent stem cells with the ability to differentiate into any mature blood cell type. The hematopoietic 
stem cell compartment comprises three subtypes, at the apex the long term HSC (LT-HSC) which mainly 
self-renews, the short term HSC (ST-HSC) with self-renewal capacity and which transiently differentiates, the 
multi-potent progenitor (MPP) which has lost the self-renewal capacity but still gives rise to daughter cells 
of different lineages. The first single lineage progenitors are the common myeloid progenitor (CMP) and the 
common lymphoid progenitor (CLP). The CMP can give rise to the GMP; granulocyte myeloid precursor, MEP; 
megakaryocyte erythrocyte precursor, ErP; erythrocyte precursor, MkP; megakaryocyte precursor and finally 
the mature blood cells. The CLP gives rise to Pro-B, Pro-T and Pro-NK cells, which upon subsequent maturation 
give rise to B-cell, T-cell, and natural killer cell lymphocytes.
 The malignant transformation of normal hematopoietic stem and progenitor cells (HSPC) 
results in the accumulation of hematopoietic cells in the bone marrow lacking the ability to 
differentiate with increased capacity for proliferation and survival. Sufficient accumulation of these 
non-functional hematopoietic cells impairs the function of the residual normal hematopoietic 
cells, eventually precluding the production of functional mature blood cells. The final outcome 
of this malignant process is termed leukemia and can be subdivided in chronic leukemia and 
acute leukemia. Chronic leukemia is characterized by an increased and unregulated production 
of white blood cells with differentiation capacity whereas acute leukemia is characterized by 
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the accumulation of the most immature hematopoietic stem and progenitor cells without 
differentiation capacity. Acute leukemia is a broad term for heterogeneous malignancies affecting 
the hematopoietic system and can be further subdivided based on the affected lineage, i.e., acute 
myeloid leukemia (AML)12,13 and acute lymphoblastic leukemia (ALL).14,15 The clinical distinction 
can be made on the basis of cell morphology, cell surface marker expression measured by 
immunohistochemical staining or specific gene expression patterns.16,17
2. ACUTE MYELOID LEUKEMIA
The focus of this thesis is primarily set on the genetic and epigenetic delineation of AML 
pathogenesis. AML is characterized by the accumulation of immature hematopoietic cells of 
the myeloid lineage in the bone marrow lacking the ability to differentiate towards functional 
granulocytes or monocytes and in rare cases also affecting the development of erythrocytes and 
megakaryocytes. The term AML specifies a broad spectrum of hematological malignancies and 
could be considered heterogeneous evidenced by the multitude of underlying abnormalities 
conferring variegated prognosis and response to therapy.
Epidemiology and clinical facets
AML is a rare disease with an incidence of approximately 3.8 cases per 100.000 individuals per year 
with a median age of 70 at presentation.13 Additionally, myelodysplastic syndrome (MDS)18 and 
myeloproliferative neoplasm (MPN)19 are pre-leukemic disease entities which can progress towards 
AML. The first clinical symptoms observed at AML onset are infections, fatigue, hemorrhage and 
more rarely extramedullary involvement such as gingival hyperplasia, i.e., abnormal increased 
size of the gum, in cases of acute myelomonocytic or monoblastic leukemia.20 The symptoms 
are the result of impaired normal hematopoiesis due to the accumulation of leukemic blasts in 
the bone marrow, precluding the production of functional mature blood cells. The dysfunction 
and aberrant distribution of malignant blood cells could readily explain the symptoms; infections 
(lack of granulocytes), fatigue (lack of erythrocytes), hemorrhage (lack of platelets), gingival 
hyperplasia (infiltration of malignant blood cells).
 Treatment of AML is divided into an induction phase followed by a post-induction phase. 
The induction phase aims at eradicating the leukemic blasts by treatment with combinatorial 
intensive chemotherapy. Subsequent consolidation therapy is performed, when complete 
remission is received, aiming at the elimination of residual undetectable leukemic blasts by 
means of allogeneic or autologous stem cell transplantation or conventional chemotherapy. The 
type of consolidation therapy is highly dependent on a set of different clinical parameters, e.g., 
age, genetic markers and suitable stem cell donor.
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The genetic and epigenetic landscape of AML
AML is a heterogeneous disease evidenced by the increasing number of cytogenetic and 
molecular abnormalities unveiled over the past decades. Traditionally, the classification of AML 
has been based on morphology, immunohistochemistry and immunophenotyping following 
the French-American-British (FAB) classification system.21 The karyotype of leukemic blasts has 
been a pivotal prognostic marker for many years, although recent years have demonstrated 
that molecular genetic analyses are equally important, particularly for AML patients lacking any 
cytogenetic aberrations. In 2008 the AML classification model has been updated by the World 
Health Organization (WHO), which incorporates besides morphology also cytogenetics and 
molecular abnormalities.22
Cytogenetics in AML
A subgroup within this classification system comprises AML with recurrent cytogenetic 
abnormalities each with distinct clinical behavior and outcome (Table 1). Predominant among 
those are AML entities harboring cytogenetic abnormalities involving inv(16)(p13q22)/t(16;16)
(p13;q22), t(8;21)(q22;q22), t(15;17)(q22;q12) or t(9;11)(p22;q21). These cytogenetic abnormalities 
are well characterized and could be further subdivided on the basis of additionally acquired 
abnormalities or gene expression markers.23-26 Recent addendums to the classification model has 
introduced the AML entity with the cytogenetic abnormality inv(3)(q21q26.2) or t(3;3)(q21;q26.2), 
which results in the overexpression of the gene ecotropic viral integration site-1 (EVI1) localized at 
3q26.2. Evi1 is identified as a common retroviral integration site in murine myeloid disorders.27
Table 1. Recurrent cytogenetic abnormalities in AML.
Cytogenetic abnormality Frequency (%) Genes involved Prognostic significance
Normal karyotype 45 - Intermediate
Complex karyotype 11 TP53 Unfavorable
+8 9 Unknown Intermediate
t(15;17)(q22;q12) 8 PML-RARA Favorable
-7/-7q 8 CUX1, MLL3 Unfavorable
-5/-5q 7 Unknown Unfavorable
t(8;21)(q22;q22) 6 RUNX1-ETO Favorable
inv(16)(p13q22)/t(16;16)(p13;q22) 5 CBFB-MYH11 Favorable
t/inv(11q23) 4 KMT2A Favorable(BRE+)  
Unfavorable(EVI1+)
+21 3 Unknown Intermediate
inv(3)(q21q26)/t(3;3)(q21;q26) 2 EVI1, GATA2 Unfavorable
Adapted from 29-32
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The protein EVI1 is a transcriptional regulator which invokes DNA interaction through its two 
zinc finger domains.28 The cytogenetic abnormality does not result in a transcript fusion and the 
overexpression has long been postulated to be conferred by the repositioning of an enhancer 
element belonging to the gene RPN1 located at 3q21. Hence the definition RPN1-EVI1 for inv(3)
(q21q26.2) or t(3;3)(q21;q26.2) malignancies in the WHO 2008 AML classification. In this thesis, 
and shown by others29, we demonstrate that EVI1 overexpression is conferred by the repositioning 
of a distal GATA2 enhancer towards the human chromosome 3q26.2 region.
Mutational landscape and patterns in AML
The initiation of AML is not conferred by a single aberration as observed in the core binding factor 
(CBF) leukemias24,33,34, i.e., AML with inv(16) or t(8;21) chromosomal abnormalities. Detailed studies 
have demonstrated that combinations of genetic alterations are necessary for the development 
of overt leukemia.35,36 These alterations mainly perturb cellular mechanisms associated with 
differentiation, survival, apoptosis, self-renewal and proliferation. These genetic lesions can be 
dichotomized on size, e.g., large cytogenetic events (translocation, inversions, duplications, 
deletions, and amplifications), and small genetic lesions (mutations and small insertions 
and deletions).   Recent efforts, in conjunction with a new technology called next generation 
sequencing (NGS), has brought to light the multitude of small recurrent genetic lesions acquired 
during leukemogenesis. These combinatorial mutational patterns reflect the heterogeneous 
nature of AML (Figure 2). Several of these recurrently acquired molecular abnormalities, such 
as mutations in the genes nucleophosmin 1 (NPM1), CCAAT enhancer binding protein alpha 
(CEBPA), fms-related tyrosine kinase 3 (FLT3, in particular internal tandem duplication [FLT3-ITD]), 
have independent prognostic values, especially in AML with normal cytogenetics (Table 2). The 
application of NGS has brought to light the existence of mutational patterns in AML.35 Mutations 
in additional sex combs-like 1 (ASXL1) were initially identified in MDS37 and subsequently observed 
in AML. Mutations in ASXL1 confer a dismal prognosis38 and are inversely correlated with NPM1 
mutations and FLT3-ITD.39 Recent efforts have led to the discovery of GATA2 mutations in AML 
patients, more frequently in patients harboring biallelic mutations in CEBPA.40 Strikingly, both 
mutations have been linked to familial predisposition for MDS or AML.41,42
Mutational mutual exclusivity: an example
Mutations in the gene tet methyl-cytosine dioxygenase 2 (TET2)43,44 were initially identified in MDS 
and subsequently detected in AML. The introduction of NGS led to the discovery of isocitrate 
dehydrogenease (IDH) mutations, i.e., IDH1 and IDH245, conferring dismal prognosis in particular 
AML subtypes.46 The protein TET2 plays an important role in the reversion of 5-methylcytosine 
(5-mC) towards ordinary cytosine and requires the cofactor alpha-ketoglutarate (α-KG) to exert 
its function. Mutations in this gene impairs the iterative hydroxylation of 5-mC resulting in its 
accumulation.47 The cofactor α-KG is produced by IDH1 and IDH2 and mutations within each of the 
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genes encoding these proteins give rise to a neomorphic function, which confers α-KG processing 
into 2-hydroxyglutarate (2-HG). The oncometabolite 2-HG binds to TET2 and subsequently 
impairs its hydroxylation function.48 Mutations in TET2, IDH1 and IDH2 are mutually exclusive and 
all perturb the hydroxylation of 5-mC by impairing TET248, providing an example of a mutually 
exclusive mutation pattern affecting the same pathway. Additionally, recurrent mutations in the 
gene DNA (cytosine-5)-methyltransferase 3 alpha (DNMT3A) were observed in AML.49 The DNMT3A 
protein confers the de novo methylation of cytosines, implying that mutations in DNMT3A, TET2, 
IDH1 and IDH2 play a role in leukemogenesis by perturbing DNA methylation dynamics.
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Figure 2. Molecular heterogeneity of AML. Circos plot illustrating the interrelationships of translocations 
and mutations found in a cohort of 498 de novo AML cases. Colored lines illustrate concurrent lesions found in 
one AML patient. Of note, patients can have more than two lesions.
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Epigenetics
The field of epigenetics concerns the discipline investigating the dynamics of DNA conformation or 
accessibility. The DNA sequence serves as a blueprint for the production of functional messenger 
ribonucleic acid (mRNA), which in turn is translated into a protein exerting its functional properties 
according the necessities of the cell. Epigenetic alterations, e.g., DNA methylation50, histone 
modification51, chromatin looping52,53, confers transcriptional control without changing the DNA 
sequence and could be considered as an additional layer of regulation by which the cell controls 
its requirements. Aberrant epigenetic patterns have been observed in AML54,55 and adds a layer 
of complexity to the unraveling of AML pathogenesis. Recent NGS efforts have demonstrated 
that many epigenetic modifiers are recurrently mutated in AML56, potentially resulting in aberrant 
epigenetic alterations.
Table 2. Recurrent molecular abnormalities in AML.
Gene symbol Frequency (%) Prognostic significance Association with cytogenetics
ASXL1 5-10 Unfavorable Normal
BCOR1 4 Undetermined Normal
BCORL1 6 Undetermined Normal
CBL 5 - CBF AMLs
CEBPA 5-10 Favorable Normal
Cohesin complex 5-10 - Normal
DNMT3A 20-25 Unfavorable Normal
FLT3-ITD 20 Unfavorable Normal, t(15;17)
FLT3-TKD 5-10 Controversial Normal
GATA2 2 Controversial CEBPA, inv(3)/t(3;3)
IDH1 8 Unfavorable Normal
IDH2 8 Unfavorable Normal
KIT 2-8 Unfavorable CBF AMLs
KRAS 5 - inv(3)/t(3;3)
MLL-PTD 5-11 (CN-AML) Unfavorable Normal/Trisomy 11
NPM1 25-35 Favorable Normal
NRAS 10-15 - inv(16)/inv(3)/t(3;3)
RUNX1 10 Unfavorable Normal/Trisomy 21
SF3B1 2-5 Undetermined AML with ringed sideroblasts/
inv(3)/t(3;3)
TET2 20 Unfavorable Normal
TP53 <10 Unfavorable Complex karyotype (69%)
U2AF1 4 Undetermined Secondary AML
WT1 10 Controversial Normal
Adapted from 57-61
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3. ACUTE LYMPHOBLASTIC LEUKEMIA
A single chapter of this thesis is dedicated to ALL and therefore mandates a brief introduction 
into this hematological malignancy. ALL is characterized by the accumulation of primitive 
lymphoblastic cells in the bone marrow that have lost the ability to differentiate towards functional 
T-cells, B-cells or NK-cells. Within each respective lineage (Figure 1) there is still a heterogeneous 
group of disorders with variegated underlying genetic abnormalities and clinical behavior. This 
thesis only focusses on adult B-cell ALL (B-ALL) and T-cell ALL (T-ALL).
Epidemiology
The incidence of ALL is approximately 1 case per 50.000 individuals.14,15 Pediatric leukemia 
accounts for approximately 70% of ALL cases and is the most common childhood cancer. The 
incidence of ALL peaks at 0-5 years, while in the adult cases the incidence peaks in patients older 
than 65 years. Clinical symptoms range from general weakness and fatigue to anemia, bone pain, 
and enlarged lymph nodes and spleen. The five-year event-free survival is nearly 80 percent for 
children and approximately 40 percent for adults.62,63
Cytogenetic and genetic lesions
Cytogenetics and the mutational landscape of ALL
Cytogenetics and cytology play a pivotal role in the classification of ALL. Although a FAB 
classification exists for ALL, it is far less used than for AML. First, ALL is stratified according to 
cytomorphology or cell surface markers into B-ALL or T-ALL. Secondly, cytogenetics is used for the 
determination of recurrent chromosomal aberrations. Most of these cytogenetic abnormalities 
are the result of translocations leading to the expression of oncogenic fusion transcripts (Table 
3). Specific B-ALL aberrations comprise: t(12;21)(p13;q22) (ETV6-RUNX1), t(1;19)(q23;p13.3) 
(TCF3-PBX1), t(9;22)(q34;q11.2) (BCR-ABL1) and MLL-rearrangements. Specific T-ALL aberrations 
comprise: del(1p32) (SIL-TAL1). Prognostication in adult ALL is limited to a few prognostic genetic 
markers, e.g., BCR-ABL1 and MLL-AF4. Traditional non-genetic markers, such as age, sex and WBC, 
have a significant effect on treatment outcome. Numerical changes of chromosomes has been 
determined to affect treatment outcome: strong hyperdiploidy (more than 50 chromosomes) 
results in a favorable prognosis status and normal or low hypoploidy results in an intermediate 
and unfavorable prognosis status, respectively.64 The presence of the BCR-ABL fusion results in 
a dismal prognosis and is commonly observed in adult ALL. The determined ALL mutational 
landscape revealed specific mutations in different ALL subtypes: (I) frequent DNMT3A mutations 
in adult early thymocytes progenitor-ALL (ETP-ALL)65, (II) frequent tumor protein P53 (TP53), IKAROS 
family zinc finger 2 (IKZF2) and retinoblastoma 1 (RB1) lesions in pediatric hypodiploid ALL66, (III) 
kinase-activating lesions in BCR-ABL1-like ALL.67
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Table 3. Recurrent cytogenetic abnormalities in ALL.
Cytogenetic abnormality Frequency (%) Genes involved Prognostic significance
Normal karyotype 15-34 - Intermediate
t(9;22)(q34;q11.2) 11-29 BCR-ABL1 Unfavorable
t(4;11)(q21;q23) 4-9 KMT2A-AFF1 Unfavorable
Hyperdiploidy 7-8 - Favorable/intermediate
Hypodiploidy 7-8 - Unfavorable
t(1;19)(q23;p13.3) 1-6 TCF3-PBX1 Intermediate
t(12;21)(p13;q22) 0-4 ETV6-RUNX1 Undetermined
SIL-SCL deletion 3 SIL-TAL1 Unfavorable
Adapted from 64
Recurrent focal genetic lesions in ALL
Beside recurrent cytogenetic abnormalities and small mutations, ALL is characterized by 
recurrent deletions and amplifications perturbing single or multiple genes in both pediatric and 
adult ALL.68,69 A small number of novel and recurrent genetic lesions have been demonstrated 
to be acquired in B-ALL and T-ALL, e.g., the deletion of cyclin dependent kinase inhibitor 2A and 
2B (CDKN2A/B) and the deletion of RB1. The remainder of recurrent genetic lesions are specific 
for B-ALL; deletion of IKAROS family zinc finger 1 (IKZF1), paired box 5 (PAX5), B and T lymphocyte 
associated (BTLA), while others are more specific for T-ALL; deletion of Wilms tumor 1 (WT1) and 
neurofibromin 1 (NF1). These genetic lesions are observed in varying degrees within pediatric and 
adult ALL, e.g., IKZF1 deletions are more prominent in adult than pediatric ALL cases lacking the 
t(9;22) cytogenetic aberration.70 The underlying mechanism for these deletions has long been 
debated to be associated with illegitimate RAG-mediated rearrangements.71 The adaptive immune 
system requires diversification in defense of pathogens or other foreign invaders. It maintains this 
diversity by generating a vast repertoire of antigens by combining the antigen constituents in a 
combinatorial manner.72 The antigen constituents comprise variable (V), diversity (D) and joining 
(J) gene segments in the antigen receptor gene regions. This recombination process is mediated 
by the recombination activating gene (RAG) proteins, i.e., RAG1 and RAG2, which recognize 
recombination signal sequences (RSS) flanking the gene segments. The existence of cryptic RSS 
flanking deletion breakpoints has led to the hypothesis that deletion events are invoked by the 
RAG complex71,73 and recently been shown to be a prominent driver of rearrangements in ETV6-
RUNX1 ALL cases.74
4. GENOME-WIDE APPROACHES FOR THE DELINEATION OF AML
Recent technological advances have allowed for the genome-wide characterization of AML. 
This progression can be explained by the improvement and flexibility of novel experimental 
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tools, the quick procession of measuring devices and statistical or algorithmic developments. 
Detailing each genome-wide characterization technology is warranted for the discernment of its 
advantages and caveats.
Gene expression profiling
The human genome contains thousands of genes and their products, i.e., mRNA and proteins, 
function within a complicated web of biological mechanisms. The attainment of gene expression 
levels allows the researcher to unravel this complex web of interactions. In human disease, gene 
expression level assessment enables the determination of aberrant gene expression patterns 
potentially allowing for the further subcategorization of established AML entities or delineation 
of aberrant mechanisms affiliated to leukemogenesis. Technological advances in the past 
decades have led to a major breakthrough enabling the genome-wide characterization of tumor 
material by array-based technologies. First among these array-based technologies was the gene 
expression array that allows for the genome-wide measurement of the human transcriptome 
(Figure 3A). This genome-wide technique measures the level of thousands of mRNA transcripts 
simultaneously by a process called gene expression profiling (GEP). The glass slide of the array is 
spotted by thousands of DNA probes that can, based on their sequence specificity, competitively 
hybridize to complementary cDNA/cRNA produced from mRNA. The rate of hybridization is 
measured and used for the estimation of gene expression levels. These expression profiles 
have several biologically and clinical relevant applications. Initially, GEPs were utilized for the 
identification of different AML subtypes17,75,76 and were pivotal in cementing the homogeneity of 
AML entities with recurrent cytogenetic abnormalities, i.e., t(15;17), t(8;21) and inv(16)/t(16;16), 
as well as the identification of novel AML subtypes with specific gene expression patterns.77-79 
Prognostic expression markers for clinical purposes can be discerned from GEPs for further 
classification of AML.26,80-82 Importantly, GEP could give insight into the biological mechanisms 
perturbed by the underlying genetic abnormality.78 A multitude of relevant applications can be 
devised for the delineation of AML pathogenesis by GEP, however, it is limited to the single facet 
of gene expression levels and is therefore unable to identify all aberrant processes.
DNA mapping arrays
The gain or loss of chromosomal regions may result in the perturbation of AML initiating genes. 
Traditionally, cytogenetics was employed to detect large chromosomal abnormalities, but was 
limited in its resolution and therefore unable to detect smaller genetic alterations. DNA mapping 
arrays, likewise to gene expression arrays, are utilized by means of hybridization procedures. The 
glass slide is spotted by DNA probes that can, based on their sequence specificity, bind to particular 
segments of DNA. Specific probes are generated to measure the genotype of single nucleotide 
polymorphisms (SNPs), which are variants in the genome observed in at least some percentage 
of the healthy human population. One probe measures the ‘A’ allele of a specific DNA segment 
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while another slightly different probe measures the ‘B’ allele for the same segment. The amount 
of hybridization can be used for the determination of the copy number when compared to an 
appropriate base line control. In a normal situation the copy number equals 2, one chromosome 
from the father and the other chromosome of the mother. The loss or gain of DNA material leads 
to copy number variations (CNVs) and have been implicated in oncogenesis (Figure 3C).83 With 
an appropriate control, e.g., normal tissue or remission material, the loss of heterozygous SNP 
genotypes, i.e., loss-of-heterozygosity (LOH), can highlight regions with cancer-critical genes.84 In 
general AML is characterized by the frequent acquisition of LOH in comparison to the low number 
of observed CNVs85, which are more frequently observed in ALL.68,69 
Next generation sequencing
Technical advances of the last decade have led to the introduction of NGS. Different NGS 
methodologies take as input RNA or DNA derivatives and determine the sequence of millions of 
DNA fragments simultaneously in a manner reminiscent to Sanger sequencing. These fragments 
can be partially sequenced from one side, called single-end sequencing, or partially sequenced 
from both sides, called paired-end sequencing. Different applications for NGS have hitherto been 
developed, e.g., whole genome sequencing (WGS), whole exome sequencing (WES), (m)RNA 
sequencing (RNA-Seq), chromatin conformation capture sequencing (4C-Seq), and chromatin 
immunoprecipitation sequencing (Chip-Seq). These techniques result in millions of reads and 
alignment of these reads to the genome of interest allows for the quantification of processes of 
interest, e.g., gene expression levels, or the identification of genetic lesions (Figure 3C). Due to 
its high sensitivity and accuracy NGS rapidly replaces array based technologies.86 All mentioned 
NGS techniques, vide supra, will be employed during this thesis and therefore mandates a brief 
introduction detailing its use, benefits and pitfalls. 
Whole exome and genome sequencing
The determination of the complete DNA sequence can be achieved by WGS. DNA from the tissue 
of interest is isolated and preprocessed without any form of sequence enrichment. Contemporary 
NGS technology allows for the sequencing of the complete genome, albeit with a low coverage. 
The coverage implies the number or depth of DNA or RNA fragments that have been sequenced 
for a particular region. A higher coverage increases detection power of somatic mutations or a 
better estimation of quantities of interest. Subsequently, WGS is not preferable when mutations 
could be expected to be present in only a fraction of leukemic blasts. A higher coverage is 
achieved by selectively isolating DNA regions of interest, e.g., the exome, and are procured by 
target enrichment or exome capture, before sequencing is performed. WES supersedes WGS at 
detecting mutations within the exome or determining the clonal architecture of AML. The caveat 
of capture procedures concerns the accidental capture of regions with high homology, sometimes 
resulting in biased estimations or false positive mutations.
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Whole transcriptome sequencing
RNA-Seq quantifies the gene expression levels reminiscent to gene expression arrays (Figure 3A). 
RNA-Seq requires no a priori knowledge about the transcriptome which is needed for array-based 
technologies. The number of fragments aligning to a gene, corrected for gene length and the 
total number of sequenced fragments, is used for gene expression level estimation.87 The mRNA 
transcripts originating from a gene can have different forms owing to gene isoforms or RNA splicing 
and could possibly encode proteins with vastly different functions.88 Additionally, RNA-Seq can 
be used for the detection of fusion transcripts89 or mutations in genes if they are expressed.90 
Finally, the accurate detection of gene expression levels is highly correlated with the coverage.
Chip-Seq
Chip-Seq is used for mainly two reasons. First, Chip-Seq can be used for the identification of 
protein-DNA interactions and to quantify the frequency of this interaction (Figure 3B). Second, 
it allows for the detection of epigenetic alterations, e.g., histone modifications. The protein of 
interest is cross-linked with DNA in viable cells and immunoprecipitated.91 The isolated DNA 
fragments are sequenced and the resultant reads are aligned against the genome of interest. 
Subsequently an interaction profile is generated from the aligned reads representing the 
interaction frequency of the protein of interest with particular DNA segments. Gene expression 
is a tightly controlled process that is modulated by the binding of proteins to functional genomic 
elements affiliated with the gene. Classically, these genomic elements comprise promoters, 
enhancers, insulators or CpG islands. Recently, the term super-enhancers is introduced to signify 
highly active epigenetic regions comprising clusters of enhancers and have been associated with 
cell identity and disease.92,93 Chip-Seq allows for the identification of these genomic elements and 
the proteins that bind to them (Figure 3B).
4C-Seq
4C-Seq quantifies the frequency of two DNA segments being in close proximity or interacting.94 
Chromatin loops, under the direction of the cohesion complex, bring specific genomic elements 
in proximity, e.g., the promoter of a gene and an affiliated enhancer, invoking transcriptional 
control.95 In brief, at first a region of interest is chosen and polymerase chain reaction (PCR) 
primers are designed accordingly. DNA segments in close proximity are cross-linked in viable 
cells and DNA is fragmented with a restriction enzyme. Subsequently, the ends of the fragmented 
cross-linked DNA are ligated and cross-linking is removed resulting in circular DNA. Further 
processing with a second restriction enzyme is enacted and PCR amplification is performed with 
the designed primers. These primers are specific for the region of interest and therefore only 
amplifies the interacting DNA segment. These amplified fragments are subsequently sequenced 
and aligned. Interaction profiles are extracted and the density of interaction fragments in a region 
of interest relates to the interaction frequency. 
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Gene expression profilingProtein-DNA binding (Chip-Seq)
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...ATTCGAGGGTAGCAT... ...TCGGCGCGA... ...CTGTGGTTACG... ...CTTATAAA... ...CTTACTGCCCTGAA...
AB
C
Figure 3. Genome-wide approaches in human disease. DNA is the blueprint of life and its sequence contains 
a large number of functional genomic elements. (A) The transcription of a gene results in the production of 
mRNA and its expression level can be determined by gene expression profiling. (B) The expression of genes 
is under control of many different genomic elements, e.g., promoters, enhancers, CpG islands and super-
enhancers, on which many different proteins can bind to exert mRNA level control and this binding can be 
ascertained by Chip-Seq. (C) Perturbations of the genetic material is a hallmark of cancer and changes can 
be ascertained by DNA mapping arrays or next-generation sequencing. DNA helix was generated by the 
Illustrator DNA brush of James Hedberg.
5. SCOPE AND OUTLINE OF THE THESIS
The use of different genome-wide analysis approaches has provided avenues for further 
delineation of AML and ALL pathogenesis. This thesis focuses on the use and extension of these 
approaches to provide further insight into these diseases on a genetic and epigenetic level. 
The analytical tools for processing the results from these approaches have thus far been limited 
and therefore novel statistical models have been devised, focusing on their applicability to the 
procured data. Additionally, the functional and prognostic role of the novel detected genetic 
aberrations are further investigated.
 The thesis consists out of three parts related to the different types of genome-wide approaches 
used. The first part (chapter 2, 3) concerns research utilizing gene expression profiling for 
prognostication or AML subtype classification. Classification methodologies for gene expression 
data are limited and unable to provide interpretable prediction signatures. This question is 
addressed in chapter 2 and led to the development of the group lasso penalization framework for 
the multinomial logistic regression model. In chapter 3, we determine if AML patients harboring 
biallelic mutations in the gene CEBPA (CEBPAdm) have distinct prognostic outcomes and GEPs. The 
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multinomial logistic regression model with lasso penalization is used for determining the gene 
expression signature of CEBPAdm AML patients. We demonstrate in a validation cohort that our 
gene expression signature can perfectly discern CEBPAdm cases from all other AML cases.
 The second part (chapter 4, 5) focuses on the use of DNA mapping arrays to determine 
recurrent genetic alterations in AML and ALL. In chapter 4, we describe a software package for 
visualizing CNV profiles in conjunction with GEPs. In chapter 5, we identify recurrent genetic 
lesions in ALL and AML using DNA mapping arrays. We report on the recurrence of particular 
genetic lesions and with the use of NGS we demonstrate that many of the genetic alterations are 
the result of illegitimate RAG-mediated rearrangements in particular ALL subtypes.
 The third part (chapter 6, 7, 8, 9, 10, 11) focuses on the use of NGS to address a multitude of 
research questions concerning the delineation of AML pathogenesis. The first five chapters focus 
on the determination of mutations or genetic aberrations in AML, while the last chapter describes 
a statistical framework for the determination of CNVs from NGS data. In chapter 6, we performed 
a mutational time-series analysis on pre-leukemic or leukemic material from a patient with severe 
congenital neutropenia who progressed towards AML with substantial delay. In chapter 7, we 
focus on understanding the underlying leukemogenic mechanism of inv(3)(q21q26) and t(3;3)
(q21;q26) AML entities. Initially, we determined all the breakpoints in the 3q21 and 3q26 loci 
and discerned an asymptotic pattern of breakpoints in 3q21. The integration of RNA-Seq, Chip-
Seq and 4C-Seq revealed that EVI1 overexpression is the result of the repositioning of a distal 
GATA2 enhancer towards the 3q26 locus, concurrently resulting in the hemizygous and reduced 
expression of GATA2. In chapter 8, we determine mutational patterns in the inv(3)(q21q26) 
and t(3;3)(q21;q26) AML subtypes. We reveal the predominant presence of activating RAS/RTK 
mutations in 98% of the cases and additionally reveal recurrent mutations in GATA2, SF3B1 and 
RUNX1. In chapter 9, we utilized RNA-Seq to discover a previously unreported KMT2A-MYH11 
fusion transcript. In chapter 10, we used targeted resequencing to identify jumping translocations 
involving the gene BCL11B. We demonstrate that the jumping translocation integrates into super-
enhancers with subsequent overexpression of BCL11B. In chapter 11, we develop a new algorithm 
that can determine CNV profiles from WGS and WES data. Algorithms determining CNVs from NGS 
data are still lacking or do not employ valuable noise statistics derived from a NGS reference set 
of diploid cases. We demonstrate that we can attenuate systematic bias and artifacts conferred by 
repeat regions on a set of AML cases characterized by WGS or WES. Finally, the results presented 
in this thesis are summarized and discussed in chapter 12.
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ABSTRACT
Continuous variable selection using shrinkage procedures have recently been considered as 
favorable models in a wide range of scientific research; in particular biomedical research. In 
some cases, it is desirable to select as few predictors as possible, to increase the interpretability 
of the attained prediction rule. One frequently used shrinkage procedure; the lasso, imposes a 
L1 regularization on the regression coefficients of general linear models, inherently leading to 
sparse prediction rules. For multi-class prediction in generalized linear models each predictor has 
a regression coefficient for each class. A major disadvantage is that the lasso selects individual 
regression coefficients instead of the more logical selection of complete predictors. Here we 
demonstrate a new regularization procedure, based on the group lasso in the multinomial logistic 
regression model. This methodology results in a lower number of retained predictors, but with 
similar prediction accuracy when compared to the lasso regularization scheme. To illustrate the 
new regularization applicability we have employed it on a large cohort of acute myeloid leukemia 
patients (AML, n=540) who are characterized on a gene expression microarray.
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter2/
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INTRODUCTION
Regression models put an emphasis on determining explanatory variables which predict response 
variables accurately. Contemporary high-throughput technologies, have given rise to vast 
amounts of high-dimensional data. Given the high-dimensionality of the data, it is worthwhile to 
perform variable selection, as sparser prediction rules are generally more interpretable and give 
more prediction power. Best-subset procedures are in most cases computationally intensive; even 
for a moderate number of variables, and are known to be unstable due to their discrete nature.1 
More robust strategies have been proposed for the multinomial logistic regression model2-4 by 
imposing a penalty on the regression coefficients.5 In these logistic regression models each class 
has its own set of regression coefficients and imposing penalizations on these coefficients confers 
modeling constraints. The lasso penalization scheme6 puts a L1 regularization on the regression 
coefficients. If predictors are pair-wise correlated, e.g., genes co-regulated, the penalization 
scheme will only retain one predictor, discarding the remainder of correlated predictors. In the 
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For large values of λ, some coefficients of the estimator β
^
   become exactly zero and are considered 
unassociated to the response variable. The lasso procedure provides sparse prediction rules, a 
beneficial feature when utilizing high-dimensional data.7 In a multi-class prediction setting each 
class is associated with one set of regression coefficients, reflecting the impact of the predictors 
on the class prediction, and predictors are retained in the model when at least one associated 
regression coefficient is non-zero, irrespective from which class. Table 1 illustrates the regression 
coefficients sets obtained from a four-class classification setting with the lasso penalization 
scheme. The major disadvantage of the lasso penalization scheme relates to the selection of 
individual regression coefficients instead of complete predictors, resulting in the retention of an 
increased number of selected predictors.
 The group lasso penalization scheme8,9 overcomes this problem by defining a suitable 
penalization function. This penalization procedure could be considered as an intermediate 
between the lasso and ridge10 penalization schemes and additionally has the attractive property 
of performing variable selection on predefined groups of predictors. Most logistic regression 
models, which have hitherto solely been based on single predictors, can now be replaced by 
entities reflecting group structures, e.g., pathways or gene sets. This predefined grouping has 
given the possibility to integrate prior knowledge into the model and create structures relevant 
to research; such as pathway analysis. The elastic net11 was developed to take advantage of the 
grouping effect; however it lacks the ability to predefine group structures, which could inherently 
increase the interpretability of the derived prediction signature.
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Table 1. Regression coefficients derived from a 4-class classification problem.
 Probe set Other t(15;17) t(8;21) inv(16) Gene symbol
1553588_at 9.55E-05 0 0 -0.0003 ND3 
200026_at 9.91E-05 0 0 0 RPL34
200665_s_at 0 0 0 0.000659 SPARC
201324_at -0.00024 0 0 0 EMP1
201360_at -0.00014 0 0 0.000246 CST3
201432_at 0.00173 0 0 -0.00039 CAT
201502_s_at 0.000318 0 0 0 NFKBIA
201721_s_at 0 0 -0.00053 0 LAPTM5
202746_at 0 0 0 0.000388 ITM2A
202859_x_at 0 0 0.000122 0 IL8
202902_s_at 0 0 0 0.000201 CTSS
202917_s_at 0 0 0 0.00021 S100A8
203535_at 0 0 0 0.000762 S100A9
The lasso penalization scheme sets many individual regression coefficients to zero.
We have extended the group lasso penalization scheme for the multinomial logistic regression 
model. The imposition of a novel group structure results in the retention of complete predictors 
instead of individual regression coefficients, implying that retained predictors comprise non-zero 
regression coefficients for all defined classes. Interestingly, regression coefficients from the same 
predictor, belonging to the prediction signature of different classes, are now comparable. We utilize 
the gene expression data from a large cohort of AML patients (n=531), with distinct molecular 
entities adaptable as classification subjects, and demonstrate that the new penalization scheme 
has a prediction accuracy comparable to the lasso penalization scheme, with the retention of 
less predictors. We devised two classification problems to test our novel classification framework: 
(1)  the AML entities harboring the favorable cytogenetic abnormalities inv(16)(p13q22), t(8;21)
(q22;q22) or t(15;17)(q22;q12) and the mutually exclusive mutations in the gene CEBPA, (2) AML 
cases harboring combinations of mutations in NPM1 or FLT3 (internal tandem duplications, 
FLT3-ITD). In the former classification setting we demonstrate similar prediction efficiencies, 
compared to the lasso penalization scheme, with less predictors and in the latter case we 
demonstrate increased prediction efficiency, compared to previous efforts12, with less predictors.
METHODS
Multinomial logistic regression
The multinomial logistic regression model is a multi-class prediction procedure, which predicts 
the probability of a class by fitting the data to a logistic curve. Initially, we have a specific number 
of observations; n (e.g., AML cases), a specific number of predictors; p (e.g., genes), and each 
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observation can be assigned to g outcome categories (e.g., classes). The outcome variables Y1,···,Yn 
are associated to each observation and a n×p matrix X, containing the data (e.g., gene expression 
levels), is constructed. For convenience the outcome variables are encoded by indicator functions 
corresponding to class participation. We define y
is
= 1{Yi=s} (i = 1 ···, n; s = 1,···, g), and each class has 
its own regression coefficients vector, βi Є � ∈ ℝ  
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The model defined in (2) is overparameterized as replacing (βk1, ···, βkg)  by (βk1+ c, ···, βkg + c), for 
any 
� ∈ ℝ  
� ∈ ℝ� 
�� = argmax
�
�−ℓ(�) � ������
�
���
� (1) 
�� ∈ ℝ��(� = 1�� � �) 
���� � �� 
�(�� = �) = ��� =
����������
∑ � �����������
(2) 
�� ∈ ℝ��(� = 1�� � �) 
� ∈ �1�� � �� 
� ∈ ℝ 
�∗ = ����� � ���� 
ℓ(�∗) = ���������(���)
�
���
�
���
(3) 
��(�)
�� = �
�(� − �) 
���(�)
����� = −�
��� 
� = �
��� ��� � ���
��� ��� ⋮
⋮ ⋱
��� � ���
� 
�� =
�
��
�
���� ��� � ������ ��� ���
⋮ ⋱ ⋮
��� ��� � ����
��
�
�
= ��� � � ��� 
�� ∈ ℝ� 
����� ∈ ℝ��� 
�(�� = �) = ��� =
�����∑ ����� ��������
∑ �� ��∑ ����� ����
�
�������
(4) 
� ∈ ℝ� 
 and c Є � ∈ ℝ  
� ∈ ℝ� 
� = argmax
�
�−ℓ(�) � ������
�
���
� (1) 
�� ∈ ℝ��(� = 1� � �) 
���� � �� 
�(�� = �) = ��� =
����������
∑ ��������������
(2) 
�� ∈ ℝ��(� = 1�� � �) 
� ∈ �1�� � �� 
� ∈ ℝ 
�∗ = � ��� � ���� 
ℓ(�∗) = �������(���)
� �
�
���
(3) 
��(�)
�� =
�(� − ) 
���(�)
��� � = −�
�  
� = �
��� �� ���
��� ��� ⋮
⋮ ⋱
��� � ���
� 
�� =
�
��
�
���� ��� � ������ ��� ���
⋮ ⋱ ⋮
��� ��� � ����
��
�
�
= ��� �� � ��� 
�� ∈ ℝ� 
����� ∈ ℝ��� 
�(�� = �) = ��� =
�����∑ ����� ��������
∑ �����∑ ����� ����
�
�������
(4) 
� ∈ ℝ� , results in the same probabilities. Commonly, this problem is solved 
by defining one outcome category as a reference category. The choice of reference category 
facilitates the interpretation of the resulting parameter estimates. Instead of choosing a reference 
category, we will treat the outcome categories as symmetrical13,14 as penalized models are not 
invariant to setting reference categories resulting in different prediction rules. Furthermore, the 
penalized general linear models are not affected by overparameterization in terms of function 
identifiability problems. For notational convenience we rewrite the regression coefficient vectors 
into a long vector format: β* = (β1,···, βg ). We also rewrite yis , μis into ng×1 vectors: y = (y11,···, yn1 ,···, 
y
1g 
,···, y
ng
 ), μ = (μ11,···, μn1 ,···, μ1g ,···, μng ) and the design matrix into X = XƒIg, where ƒ is the Kronecker 
product. The log-likelihood of this model is:
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which has the gradient    = X'( y − μ) and the Hessian    = X'WX.
The ng×ng  matrix W is given by:
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Where diag( ) = diag( ) ( )( ) ( )
The Newton-Raphson algorithm is used to maximize the likelihood due to the convex likelihood 
function. Overparameterization of the model results into a singular Hessian matrix. Moore-
Penrose or projection procedures resolve this issue, however, this caveat plays no role in the 
group lasso penalization scheme as it remains unaffected by overparameterization.
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Penalty structure
The penalized log-likelihood under Lasso regulation (equation 1), imposes a L1 regularization on 
each individual regression coefficient per predictor. Most regression coefficients become zero 
under strong penalization, resulting in sparse prediction rules. In essence the lasso penalization 
scheme selects individual regression coefficients rather than complete predictors, resulting in 
larger number of retained predictors than necessary. In addition, most regression coefficients 
become zero prohibiting the comparison of these coefficients between predefined classes. The 
group lasso penalization scheme allows for the definition of groups of predictors as entities of 
the model, instead of single regression coefficients, retaining predefined groups, facilitating 
interpretation of the obtained prediction signature. We propose a novel group lasso scheme for 
integration into the multinomial logistic regression model.8,9 The beta matrix comprises columns 
of regression coefficient vectors affiliated to each class:
� ∈ ℝ  
� ∈ ℝ� 
�� = argmax
�
�−ℓ(�) � ������
�
���
� (1) 
�� ∈ ℝ��(� = 1�� � �) 
���� � �� 
�(�� = �) = ��� =
����������
∑ ��������������
(2) 
�� ∈ ℝ��(� = 1�� � �) 
� ∈ �1�� � �� 
� ∈ ℝ 
�∗ = ����� � ���� 
ℓ(�∗) = ���������(���)
�
���
�
���
(3) 
��(�)
�� = �
�(� − �) 
���(�)
����� = −�
��� 
� = �
��� ��� � ���
��� ��� ⋮
⋮ ⋱
��� � ���
� 
�� =
�
��
�
���� ��� � ������ ��� ���
⋮ ⋱ ⋮
��� ��� � ����
��
�
�
= ��� �� � ��� 
�� ∈ ℝ� 
����� ∈ ℝ��� 
�(�� = �) = ��� =
�����∑ ����� ��������
∑ �����∑ ����� ����
�
�������
(4) 
� ∈ ℝ� 
From the beta matrix many different group structures can be defined and illustrates the underlying 
mechanism of the group lasso penalization scheme. We would like to discard complete predictors; 
i.e. rows of the beta matrix, by setting all regression coefficients of the predictor simultaneously to 
zero. This is accomplished by defining each row vector of regression coefficients as a group in the 
group lasso penalization scheme. We have a p-dimensional feature vector xi = Є � ∈ ℝ  
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out of J groups and denote by df
j
  the degrees of freedom of group j, rewrite xi  = (x'i,1, x'i,2, ···, 
x'
i,J 
) and denote the group of variables by x'
i,j 
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(4) 
� ∈ ℝ� dfj,  j = 1, ···, J. The regression coefficient vector is 
parameterized as β
t
 = ( β0t, β1t, β2,t, ···,βJ,t )', t = 1, ···, G.
Given the defined groups of regression coefficients we rewrite (equation 2) as:
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The group lasso estimator β
λ
 is given by the maximizer of the function:
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Hence, the penalty function sums the norm of each row of the beta matrix β
~  . Note, we integrate the 
square root of the degrees of freedom of each group in the summation, as described previously.8,9 
The degrees of freedom term is omitted due to equal size for all groups.
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Group lasso estimator
To optimize the penalized log-likelihood function (equation 5), the low-memory BFGS algorithm 
(L-BFGS-B)15 is used. This Quasi-Newton algorithm necessitates a limited number of previous 
function and gradient evaluations to estimate the inverse Hessian. The gradient of the penalized 
log-likelihood function is given by:
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where the gradient of the penalty function is defined as:
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Reparameterization and parameter identifiability
Optimizing the penalized log-likelihood function leads to major problems, as the function is 
only strictly convex and continuous in all internal subspaces of the regression coefficients. The 
derivative of the penalized log-likelihood function remains undefined when one of the regression 
coefficients equals zero. This issue is resolved by reparameterizing the model to a higher 
dimension where the function is strictly convex and continuous. The following reparameterization 
is proposed:
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The reparameterization is realized by decomposing the individual regression coefficients into a 
positive part function (PPF) and a negative part function (NPF). These functions are constrained 
by the fact that each must be non-negative. For this reason we make use of the box constraints 
definable in the L-BFGS-B algorithm. Note that at the convergence either the PPF, NPF or both 
should be equal to zero. This reparameterization results in a model with twice as many parameters, 
which are restricted to a subspace of non-negative regression coefficients. In this single subspace 
the penalized log-likelihood function is strictly convex, continuous, and is differentiable at each 
internal point. Hence, instead of dealing with distinct continuous subspaces where the function 
is non-differentiable at their borders, i.e. when one of the regression coefficients is set to zero, we 
now have one subspace where the function is differentiable. The log-likelihood gradient remains 
unchanged under the reparameterization, but the penalty function gradients are given by:
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A problem occurs when all the regression coefficients of a group become zero, as the penalty 
function is no longer differentiable. To solve this problem the following limit is taken for the sake 
of continuity:
ℓ������(�∗� �) = ℓ(�∗) − �������
�
���
= ℓ(�∗) − �(�∗)	(5) 
�ℓ������(�∗)
��∗ =
�ℓ(�∗)
��∗ − �
��(�∗)
��∗ (6) 
��(�∗)
���� =
�
���� �����
� + ⋯+ ���� + ⋯+ ����� + ⋯+ ���� � =
���
����� + ⋯+ ����
(7) 
��� = ���� − ���� �
���� = m������� 0�� ���� ≥ 0	
		���� = −mi������ 0� � ���� ≥ 0
 
��(�∗)
�����
= ��(�
∗)
����
����
�����
= ��(�
∗)
����  
��(�∗)
�����
= ��(�
∗)
����
����
�����
= −��(�
∗)
����  
lim�����
���
����� + ⋯+ ����
= 1�			��	��� = ⋯ = ��(���) =��(���) = ⋯ = ��� = 0 
�(�∗) 
�� 
���� = ����� − �����
� = ����� − ��������� + �����(8) 
���� 
���� 
����  
���� = ����� + �����(9) 
ℓ������(�∗� �) = ℓ(�∗) − ���������
� + ������
�
�
���
(10) 
�������
� + ������
� ≥ ����� − �����
� = �������
� − ������
���� + ������
�(11) 
 
Reparameterization affects the optimization of the penalized log-likelihood due to the parameter 
identifiability problem. The penalty function 
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β*) (equations 5-7) sums the norms of the row 
vectors of the beta matrix β
~  , determined by the squared regression coefficients β 
ij
2  belonging to 
the same group. Under the reparameterization this squared regression coefficient is given by:
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Multiple instances of β 
ij
+ or β 
ij
-  could give the exact same β 
ij
2  (equation 8). This problem can be 
resolved by imposing a constraint on this equation. At convergence either the PPF, NPF or both 
should be equal to zero. This implies that the middle term of the factorization of β 
ij
2   should be 
forced to be zero. This leads to the following redefinition of equation 8:
β 
ij
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-2    (9)
Redefinition of the penalty function leads to the following rewritten penalized log-likelihood 
function:
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The triangle-inequality shows that:
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β*) is always larger or equal than its original definition. 
Given the inequality (equation 11) and the fact that either the PPF, NPF or both are zero at 
convergence, the redefined penalty function becomes equal to the original definition. By this 
redefinition we have solved the parameter identifiability problem and proven the obtainment of 
the exact same prediction rules without convergence problems.
 Table 2 illustrates the results from the same 4-class classification problem, defined earlier, 
based on the modified group lasso penalization scheme. In comparison with Table 1 it becomes 
clear that: (1) the number of predictors is decreased (2) none of the regression coefficient of the 
retained predictors became zero, and (3) the new group structure facilitates comparison of the 
regression coefficients between classes.
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Table 2. Regression coefficients from a 4-class classification problem with the modified group lasso.
 Probe set Other t(15;17) t(8;21) inv(16) Gene symbol
1553588_at 0.00018085 -8.59E-05 5.97E-05 -0.0001546 ND3 
200665_s_at -0.00014592 -1.73E-05 -7.23E-05 0.000235584 SPARC
201324_at -0.00017254 1.18E-05 2.64E-05 0.000134331 EMP1
201360_at -0.00020149 9.67E-06 -6.17E-05 0.000253532 CST3
201432_at 0.000946723 -0.00025838 -3.35E-05 -0.0006548 CAT
201502_s_at 0.000131047 -0.00012284 6.43E-05 -7.25E-05 NFKBIA
201721_s_at 0.000325746 1.74E-05 -0.00034902 5.93E-06 LAPTM5
202746_at -0.00012466 1.67E-05 -0.00011551 0.000223436 ITM2A
202902_s_at -7.06E-06 -1.00E-05 -5.58E-06 2.27E-05 CTSS
202917_s_at -6.06E-05 -0.0001884 -8.16E-05 0.000330612 S100A8
203535_at -0.00018007 -6.25E-05 -9.28E-05 0.000335433 S100A9
The modified group lasso penalization scheme produces sparser prediction rules and facilitates the 
comparison of regression coefficients between classes. 
RESULTS
AML is not a single disease, but a group of neoplasms with various genetic aberrations and variable 
prognosis and response to treatment.16,17 The search for novel molecular markers is essential for 
therapeutical decision-making. A large number of molecular markers have been identified in 
the last decade, however, the complete underlying mechanism of leukomogenesis still remains 
elusive. With the use of gene expression profiling (GEP), the challenge lies in generating reliable 
prediction rules that can discriminate the different AML subtypes; for instance for the improvement 
of treatment decisions or classification. We applied our algorithm to the GEPs of 540 clinically and 
molecularly well-characterized AML cases originating from two different cohorts. The first cohort 
comprises 269 AML cases previously analyzed12,18, while the second cohort was subsequently 
generated and analyzed.12,19,20 All samples are analyzed with Affymetrix Human Genome U133 
Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA, USA). All clinical, cytogenetic and molecular 
information as well as the gene expression data are available at Gene Expression Omnibus 
(www.ncbi.nlm.nih.gov/geo, accession number GSE6981). All data has been preprocessed as 
previously described.12 AML cohort 1 (n=269) has been used as training set while AML cohort 
2 (n=261) is subsequently used as test set. The optimal value for the regularization parameter 
λ was determined by 5-fold cross-validation. The gene expression signatures are available in 
Supplementary Tables 1 and 2.
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Classification problem 1: AML entities with favorable cytogenetics or 
mutations in CEBPA
Background and classification objective
The first classification objective concerns the correct classification of AML cases belonging  to 
favorable risk categories, i.e. with the cytogenetic abnormalities inv(16)(p13q22), t(8;21)(q22;q22) 
or t(15;17)(q22;q12). An additional class was created for AML cases harboring  mutations in 
the transcription factor CEBPA19-21 associated with myelopoiesis.22 Usually, these molecular 
abnormalities are mutually exclusive, and no overlapping  gene expression patterns were 
expected. Finally, an additional class ‘Other’, was created for the remaining AML cases. Table 3 
depicts the distribution of the different classes over the two cohorts. 
Table 3. Distribution of the AML samples over the predefined classes.
Classes AML cohort 1 (n=261) AML cohort 2 (n=264) Risk
Other 180 (70%) 204(77%) -
t(15;17) 18(7%) 7(3%) Favorable
t(8;21) 22(8%) 16(6%) Favorable
inv(16) 23(8%) 18(7%) Favorable
CEBPa 18(7%) 18(7%) Favorable
Results
Initially, we applied the global test for the multinomial logistic regression model23 to test whether 
the GEPs contain any information for the discrimination of the AML subtypes. This hypothesis 
test determines whether the global expression patterns significantly relate to the AML subtypes. 
The H0-hypothesis was rejected (p < 0.0001) implying that the GEPs have discriminatory power. 
The optimal regularization parameter λ for the modified group lasso penalization scheme was 
estimated to be 50 by 5-fold cross-validation, resulting in a predictive signature comprising 74 
probe sets (Supplementary Table 1). Figure 1 illustrates the estimated test error curve for eleven 
evaluations of λ. The optimal regularization parameter λ for the lasso penalization was determined 
by the same cross-validation procedure. The regularization parameter was set at 0.02 with 75 
retained probe sets (Supplementary Table 3). For this classification problem it does not matter 
whether to select the lasso or the modified group lasso penalization scheme with respect to the 
number of retained predictors. The retained predictors of both procedures greatly overlap, with 
the exception of a few predictors. Strikingly, the lasso makes four additional miss-classifications 
compared to the group lasso (Table 5 vs. Supplementary Table 6).
 AML subtypes harboring the prognostic favorable cytogenetic abnormalities (t(15;17), t(8;21) 
and inv(16)) were predicted with 100% accuracy (Table 5), which was consistent with previous 
work.12 A substantial proportion of the samples with CEBPA mutations were classified as belonging 
to the ‘Other’ category. After further investigation it became apparent that all misclassified 
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samples contain a single mutation in CEBPA (CEBPAsm) instead of biallelic mutations (CEBPAdm). 
Previous work noted that double, but not single mutated samples have a distinct GEP and can be 
accurately predicted.19,20 Furthermore, overall survival (OS) is significantly different between the 
CEBPAsm and CEBPAdm cases (Figure 2), indicating that CEBPAdm AML cases have a more favorable 
prognosis, compared to CEBPAsm and CEBPAwt AML cases, but also a distinct gene expression 
signature. 
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Figure 1. 5-fold cross-validated error curve for classification problem 1.
Interpretation
In addition to determining the prediction accuracy, the interpretation of the obtained prediction 
signatures could provide vital insight into AML pathobiology. Previous work by Kohlmann et 
al.24 demonstrated accurate discrimination of the same set of AML subtypes (excluding CEBPA 
mutations) by selecting 23 genes. We extracted the gene expression levels of 17 genes belonging 
to the 74-gene prediction signature and performed clustering of the genes (Figure 3 [Top]). The 
bottom of Figure 3 contains regression coefficients for a subset of the genes taken from the 
obtained prediction rule, demonstrating that the regression coefficients of each gene strongly 
reflect the up- or downregulation tendency of that specific class.
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 Note that the retained predictors are not always fully explanatory for the underlying 
leukemogenic mechanism. For instance for inv(16) AML cases, the partial inversion of chromosome 
16 results in a fusion protein, namely CBFB-MYH11. Due to the fusion, the expression level of 
MYH11 is substantially increased compared to other AML subtypes and is used as a gene expression 
marker for this particular AML subtype. Many classification algorithms based on differential 
expression would select this gene, however, this is not the case when the lasso or group lasso 
penalization schemes are applied. These penalization schemes select only one predictor if there 
is a group of pair-wise correlated genes and this could be the case for MYH11.
0.00
0.25
0.50
0.75
1.00
0 50 100 150 200
Time (months)
C
u
m
u
la
ti
ve
 s
u
rv
iv
al
 (%
)
CEBPA status
CEBPA double mutant 
CEBPA single mutant 
CEBPA wild type
Overall survival
Figure 2. Overall survival and event-free survival. Overall survival among CEBPAdm, CEBPAsm and CEBPAwt 
AML cases, pooled: p=0.011. 
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Figure 3. (Top) Clustering. Clustered genes, colors of the cells relate to up- or downregulation of the gene 
for that particular sample: (green) downregulation, (red) upregulation. (Bottom) Regression coefficients for a 
selection of genes.
Previous work by Wunderlich et al.25 has demonstrated that other genes, such as SPARC and EMP1, 
are highly correlated with MYH11 in inv(16) AML cases. Figure 4 illustrates that these genes are 
significantly upregulated in inv(16) AML cases. Additionally, these genes belong to the top 20 
of highest upregulated genes in inv(16) compared to other groups (Supplementary Table 5). In 
conclusion, we demonstrated that the imposed group structure on the beta matrix β
~   results in less 
retained predictors with equal prediction accuracy compared to the lasso penalization scheme. 
In addition, many retained genes (Supplementary Table 1) have been previously associated with 
leukemogenesis. For example, the genes HOXA9 and TRIB1 are known to be deregulated in AML, 
and have been identified as cooperative genes together with MEIS1.26,27
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Figure 4. SPARC and EMP1 are elevated in the inv(16) AML subgroup. Correlation view of the 531 AML 
patients. Colors of the cells relate to pair-wise Pearson’s correlation coefficient values: red indicates higher 
positive and blue indicates higher negative correlation between samples. The inv(16) aberration status is 
indicated by the first row next to the heatmap (red, mutant; green, wild-type). Histograms next to the heatmap 
reflect the expression levels SPARC and EMP1 respectively, and shows a significant elevated expression for the 
inv(16) AML cases. 
Previous work by Wunderlich et al.25, has demonstrated that other genes, such as SPARC and EMP1, 
are highly correlated with MYH11 in inv(16) AML cases. Figure 4 illustrates that these genes are 
significantly up regulated for in inv(16) AML cases. Additionally, these genes belong to the top 20 
of highest up-regulated genes in inv(16) compared to other groups (Supplementary Table 5). In 
conclusion, we demonstrated that the imposed group structure on the beta matrix  β
~    results in less 
retained predictors with equal prediction accuracy compared to the lasso penalization scheme. 
In addition, many retained genes (Supplementary Table 1) have been previously associated with 
leukemogenesis. For example, the HOXA9 and TRIB1 genes are known to be deregulated in AML, 
and have been identified as cooperative genes together with MEIS1.26,27.
Figure 4. Gene expression levels of SPARC and EMP1 are elevated in the inv(16) AML subgroup. 
Correlation view of the 531 AML patients. Colors of the cells relate to pair-wise Pearson’s correlation coefficient 
values: red indicates higher positive and blue indicates higher negative correlation between samples. The 
inv(16) aberration status is indicated by the first row next to the heatmap (red, mutant; green, wild-type). 
Histograms next to the heatmap reflect the expression levels SPARC and EMP1 respectively, and shows a 
significant elevated expression for the inv(16) AML cases. 
Classification problem 2: NPM1 mutations and FLT3-ITD
Background and classification objective
The NPM1 mutation is the most frequent molecular abnormality observed in AML.28 NPM1 is 
predominantly found in the nucleolus and is thought to be an important chaperone protein and 
to play a role in ribosome biogenesis.29 NPM1 is disrupted by mutations introducing a nuclear 
export signal, which replaces the nucleolar localization signal, resulting in its displacement to the 
cytoplasm.30 It has been demonstrated that NPM1 mutations frequently coincide with FLT3-ITDs 
and frequently occur in AML patients with a normal karyotype. The NPM1 mutation is considered 
a favorable prognostic marker with respect to overall and event-free survival.28
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Table 4. Distribution of the AML samples over the predefined classes.
 Classes AML cohort 1 (n=261) AML cohort 2 (n=268)
NPM1-/FLT3-ITD- 149(57%) 160(60%)
NPM1+/FLT3-ITD- 44(17%) 32(12%)
NPM1-/FLT3-ITD+ 28(11%) 33(12%)
NPM1+/FLT3-ITD+ 40(15%) 43(16%)
 FLT3 is a receptor tyrosine kinase protein situated on the cell membrane, where it is activated 
by cytokines31 initiating a cascade of transduction signals through secondary messengers, such 
as STAT532, and is known to play an important role in cell differentiation, survival and proliferation. 
Frequently the gene FLT3 contains an internal tandem duplication which contributes to the 
development of AML. Furthermore, the FLT3-ITD aberration is considered a poor prognostic 
marker with respect to overall and event-free survival. 
 In this classification problem, we classify patients which have the NPM1 mutation alone 
(NPM1+/FLT3-ITD-), FLT3-ITD alone (NPM1-/FLT3-ITD+), both mutations (NPM1+/FLT3-ITD+) or 
none (NPM1-/FLT3-ITD-). Table 4 depicts the distribution of these classes.
Table 5. Prediction accuracy established with the group lasso penalization scheme integrated into the 
multinomial logistic regression model.
 
 Classes
Test set error Sensitivity Specificity Predictive Value
  Neg Pos % % Neg Pos
Case 1              
  Other 6/81 0/180 100 93 100 97
  t(15;17) 0/243 0/18 100 100 100 100
  t(8;21) 0/239 0/22 100 100 100 100
  inv(16) 0/238 0/23 100 100 100 100
  CEBPAmut 0/243 6/18 67 100 98 100
Case 2              
  Other 23/119 7/160 96 81 93 87
  NPM1+/FLT3-ITD- 17/237 9/32 72 93 96 58
  NPM1-/FLT3-ITD+ 6/236 23/33 30 97 91 63
  NPM1+/FLT3-ITD+ 10/226 17/43 60 96 93 72
The following calculations were used for evaluation: sensitivity=true positives/(true positive + false negatives), 
specificity=true negatives/(true negatives + false positives), positive predictive value=true positives/(true 
positives + false positives), negative predictive value=true negatives /(true negatives + false negatives)
Results
The global test determined that the GEPs contain discriminatory power given the defined AML 
subtypes (p < 0.0001). With 5-fold cross-validation, we have determined the optimal regularization 
parameter (λ=375) for the group lasso penalization scheme as illustrated in Figure 5. The model 
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retained 110 probe sets (Supplementary Table 2). For the lasso penalization scheme we determined 
the optimal regularization parameter to be 10 with 152 retained probe sets. The group lasso 
penalization scheme substantially decreased the number of necessary predictors with a similar 
prediction accuracy compared to the lasso penalization scheme. The group lasso penalization 
scheme misclassifies 56 AML cases whereas the lasso penalization scheme misclassifies 62 AML 
cases (Table 5 vs. Supplementary Table 6).
 Previous gene expression analyses have demonstrated that NPM1 mutations are strongly 
associated with a discriminative HOX-signature.28,32 The obtained prediction signature indicates 
that the HOXA9 and HOXB3 gene expression levels have a strong impact on the classification 
of NPM1+ AML cases. A relatively high number of AML cases were misclassified as having the 
NPM1 mutation. This could have several reasons: (1) many false positives contained an 11q23 
abnormality affecting the MLL protein, which is an important HOX gene expression regulator28 (2) 
some FLT3-ITD AML cases also exhibit strong HOX gene expression deregulation. 
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Figure 5. 5-fold cross-validated error curve for classification problem 2.
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 The major classification problem stem from AML cases harboring the FLT3-ITD abnormality. 
AML cases harboring the abnormality can only be moderately classified as indicated in Table 
5, possibly due to the following reasons: (1) the FLT3-ITD abnormality is sub-clonal. AML cases 
with a sub-clonal FLT3-ITD abnormality might have a weak discriminative expression signature 
(2) a subgroup of AML cases harboring the FLT3-ITD abnormality have different gene expression 
patterns due to concurrent mutations. 
 We can conclude that determining samples with a FLT3-ITD abnormality is difficult based on 
their GEP alone. Most of the NPM1-/FLT3-ITD+ samples are misclassified as wild-type (NPM1-/FLT3-
ITD-). This is in line with the observation that some, if not most, of the NPM1-/FLT3-ITD+ AML 
cases exhibit a weak distinctive GEP. The same holds for the NPM1+/FLT3-ITD+ samples which are 
mostly misclassified as NPM1+/FLT3-ITD-, and vice versa. It seems that the lack of a discriminative 
FLT3-ITD expression signature makes it difficult to concurrently predict all classes with a high 
accuracy. 
3.2.3 Interpretation
The retained predictors show an enrichment for ribosomal, heatshock, immunoglobulin and HOX 
genes. Many genes in the gene expression signature are related to processes of cellular stress, 
inflammation response and DNA repair mechanisms. The large number of ribosomal genes present 
in the signature could be due: (1) the activation of DNA repair or cell homeostasis mechanisms 
in response to stress conferred by the molecular abnormalities, (2) the NPM1 mutation results 
in the dislocation of the protein from the nucleolus to the cytoplasm. The protein is known as a 
chaperon protein for ribosomes; however these results could indicate that it may also be involved 
in ribosome biogenesis.
DISCUSSION
The aim of this study was to develop a sparse multi-class classification model based on the 
group lasso penalization scheme in the multinomial logistic regression model. To create 
such an algorithm, we have developed a new group structure based on the beta matrix. This 
group structure facilitates the selection of an entire predictor instead of individual regression 
coefficients. We have demonstrated that the prediction accuracy is similar to that of the lasso 
penalization scheme, yet with the retention of less predictors. To illustrate that our approach is 
effective we have applied the algorithm on microarray gene expression data of a large cohort of 
well characterized AML patients. Not only have we demonstrated that the group lasso penalization 
scheme achieves good prediction accuracy, but also that it obtains a sparse prediction rule 
containing many previously affiliated genes. We would like to note that the algorithm does not 
always converge under specific circumstances, such as situations with very low number of cases, 
which might be related to numerical instability.
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 We have demonstrated that our algorithm behaves as expected and we would like to make 
note that many different group structures can be developed. We expect in the near future that 
singular entities in contemporary classification procedures will be replaced by group structures, 
which increase the interpretability of the prediction signature and generate the opportunity 
to analyze different aspects of the model. As a final remark we would like to conclude that the 
development of novel group structures could increase the interpretability of the prediction rule, 
the prediction accuracy, and possibly further our understanding of cancer and its pathogenesis.
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ABSTRACT
We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures of 
CEBPA double (CEBPAdm) versus single (CEBPAsm) mutations in 1182 cytogenetically normal AML 
(CN-AML) patients (16-60 years). We identified 151 (12.8%) patients with CEBPA mutations (91 
CEBPAdm and 60 CEBPAsm). The incidence of germline mutations was 7% (5 out of 71), including 
three C-terminal mutations. CEBPAdm patients had a lower frequency of concurrent mutations 
than CEBPAsm patients (P<.0001). Both, CEBPAdm and CEBPAsm were associated with favorable 
outcome compared to CEBPAwt [5-year overall survival (OS), 63% and 56% versus 39%; P<.0001 
and P=.05, respectively]. However, in multivariable analysis only CEBPAdm was a prognostic factor 
for favorable outcome [OS, hazard ratio (HR): .36, P<.0001; event-free survival, HR: .41, P<.0001; 
relapse-free survival, HR: .55, P=.001)]. Outcome in CEBPAsm is dominated by concurrent NPM1 
and/or FLT3 internal tandem duplication (ITD) mutations. Unsupervised and supervised GEP 
analyses showed that CEBPAdm AML (n=42), but not CEBPAsm AML (n=18) expressed a unique 
gene signature. A 25-probeset prediction signature for CEBPAdm AML showed 100% sensitivity 
and specificity. Based on these findings, we propose that CEBPAdm should be clearly defined from 
CEBPAsm AML and considered as a separate entity in the classification of AML.
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter3/
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INTRODUCTION
In the current World Health Organization (WHO) classification of acute myeloid leukemia (AML), 
“AML with mutated CEBPA (CCAAT/enhancer binding protein alpha)” has been designated as a 
provisional disease entity in the category “AML with recurrent genetic abnormalities”.1,2 CEBPA 
encodes a transcription factor that is essential for neutrophil development. Targeted disruption 
of Cebpa in mice results in a selective block in early granulocyte development, a hallmark of 
AML.3,4 Two proteins may be translated from the CEBPA mRNA transcript, i.e., a 42kDa (p42) and 
a shorter 30kDa (p30) protein. The p42 isoform contains two regulatory transactivation domains 
(TAD1 and TAD2) in the N-terminus, while the shorter p30 isoform only carries the TAD2 domain. 
Both isoforms contain the C-terminal basic DNA-binding domain and the leucine zipper (bZIP), 
involved in DNA-binding and protein dimerization. In AML, CEBPA mutations mainly occur in 
cytogenetically normal AML (CN-AML) with an incidence of 5-14%.5-14 Two main types of mutations 
can be distinguished: N-terminal frame-shift mutations resulting in the translation of the 30-kDa 
protein only, and the C-terminal in-frame mutations in the basic zipper region affecting DNA-
binding and homo- and heterodimerization.8,15 As a consequence, these mutations create an 
imbalance between proliferation and differentiation of hematopoietic progenitors.10,16 
 AML with CEBPA mutations can be separated into two subgroups, i.e., those with a single 
mutation (CEBPAsm) and those with double mutations (CEBPAdm).17-21 In the majority of CEBPAdm 
AML, both alleles are mutated.19 These biallelic mutations frequently consist of an N-terminal 
mutation on one allele and a C-terminal bZIP mutation on the other. In CEBPAsm AML, mutations 
occur either in the N- or in the C-terminus of the gene. In previous studies, in which these two 
subgroups were not considered, AML with mutated CEBPA had a relatively good outcome.5,7,12,13 
More recent data suggest that this favorable outcome is mainly observed in AML with CEBPAdm 
and not CEBPAsm.17-21 Moreover, it has been suggested that concurrent mutations may occur more 
frequently in CEBPAsm than in CEBPAdm AML. The impact of coexisting mutations remains elusive 
and needs to be validated in large cohorts. 
 By applying gene expression profiling (GEP), it was demonstrated that CEBPAdm AML can be 
distinguished from CEBPAsm and the majority of CEBPAwt AML based on a characteristic signature.18 
However, a CEBPAdm GEP signature did not predict CEBPAdm AML with maximum accuracy, since 
AML in which CEBPA was silenced by promoter hypermethylation (CEBPAsilenced) carried a highly 
similar signature.22,23 Objectives of this study were to evaluate the impact of CEBPAdm versus 
CEBPAsm on clinical outcome of CN-AML and to investigate the impact of concurrent NPM1mutant 
and/or FLT3ITD. In addition, we searched for CEBPA-associated gene signatures and determined 
the frequency of predisposing CEBPA germline mutations. For these purposes, we combined data 
sets from the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for 
Clinical Cancer Research (SAKK) and the German-Austrian AML Study Group (AMLSG).
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PATIENTS AND METHODS
Patients and molecular analyses
Diagnostic bone marrow (BM) or peripheral blood (PB) samples from 1182 younger adults (16-60 
years) with CN-AML were analyzed; 193 patients were enrolled on HOVON/SAKK protocols -04, 
-04A, -29, and -42 (available at www.hovon.nl)24-27, and 989 patients on AMLSG protocols AMLHD93 
(n=74)28, AML HD98A (n=313)29, AMLSG 07-04 (n=376; ClinicalTrials.gov Identifier NCT00151242), 
AML SHG 02-95 (n=94)30, and AML SHG 01-99 (n=180, ClinicalTrials.gov Identifier NCT00209833). 
All patients provided written informed consent in accordance with the Declaration of Helsinki. 
All trials were approved by the Institutional Review Board of Erasmus University Medical Center, 
University of Ulm, and Hannover Medical School.
 Mutation analyses for the genes FLT3 (internal tandem duplications [ITD] and tyrosine kinase 
domain mutations [TKD]) and NPM1 were performed as described previously.31-33 CEBPAdm and 
CEBPAsm AML were identified by denaturing high-performance liquid chromatography (dHPLC) or 
direct sequencing as described.18 Cases that carried an insertion polymorphism18,21 (http://www.
ncbi.nlm.nih.gov/sites/snp; http://genome.ucsc.edu/cgi-bin/hgGateway; http://www.ensembl.
org/Homo_sapiens/Gene/Variation_Gene) or variation(s) that did not lead to amino acid changes 
were considered wild-type. Cases were categorized as CEBPAdm when two different mutations 
or one homozygous mutation were present as determined by sequencing analysis; cases with 
only a single heterozygous mutation were designated as CEBPAsm. In 71 of the 151 patients with 
CEBPA mutations, DNA obtained from buccal swabs (n=52), PB (n=8) or BM (n=11) in complete 
remission (CR) was studied for the presence of CEBPA germline mutations. Patient demographics 
and molecular characteristics are summarized in Table 1. All CEBPA-mutated patients, except for 
07-04 treated patients within the AMLSG protocol, have been previously reported in different 
studies.7,13,18
Gene expression profiling
Data from GEP analysis were available for 674 AML (53% CN-AML, HOVON-SAKK and AMLSG-
cohorts), generated using Affymetrix (Santa Clara, CA, USA; Table S1). Sample processing and 
quality control were carried out as described previously.23,34 For both cohorts, normalization of 
raw data was processed with Affymetrix Microarray Suite 5 (MAS5) to target intensity values at 
100. Intensity values were log2 transformed and mean centered per probeset per cohort. GEP 
data are available at the NCBI Gene Expression Omnibus [accession numbers GSE14468 (HOVON-
SAKK cohort) and GSE22845 (AMLSG-cohort)]. There were 42 CEBPAdm and 18 CEBPAsm cases for 
which the GEP was determined (Table S1). 
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Table 1. Demographics, clinical and molecular characteristics of CEBPAwt, CEBPAsm, and CEBPAdm CN-AML.
Characteristic
CEBPAwt CEBPAsm P, CEBPAsm CEBPAdm P, CEBPAdm P, CEBPAsm 
(n = 1031) (n = 60) vs CEBPAwt (n = 91) vs CEBPAwt vs CEBPAdm
Median age, years (range) 48 (16-60) 46 (18-60) 0.28  44 (16-60) 0.04* 0.66
Sex, n (%) 0.79 0.74 0.74
Male 500 (48) 28 (47) 46 (51)
Female 531 (52) 32 (53) 45 (49)
WBC count, x109/L 0.23 0.062 0.86
Median (range) 28 (0.2-372) 25 (1.1-345) 28 (1.5-262)
Missing 34 1 4
Platelet count, x109/L 0.77 < 0.0001* < 0.0001*
Median (range) 65 (5-746) 62 (10-361) 38 (4-265)
Missing 40 3 4
Bone marrow blasts 0.83 0.53 0.76
Median (range) 80 (0-100) 80 (0-97) 78 (2-100)
Missing 80 7 4
Molecular abnormalities
FLT3ITD, n (%) 347 (33.7) 18 (30) 1 7 (7.7) < 0.0001* 0.00015*
Missing 69 9 5
FLT3TKD, n (%) 95 (9.2) 4 (6.7) 0.81 2 (2.2) 0.018* 0.2
Missing 48 6 3
NPM1+, n (%) 560 (54.3) 21 (35) 0.018* 3 (3.3) 0 < 0.0001*
Missing 88 10 8
Number of cases (percentage), median, range, or missing values are indicated. WBC indicates white blood cell.
*P < .05 computed using the Mann-Whitney U test (continuous variables) and 2-sided Fisher exact test 
(categorical variables).
Statistical analyses
Statistical analyses were performed using Mathworks (Matlab R2009b) with the statistical, 
bioinformatics and pattern recognition toolbox (Prtools). For clinical, molecular, univariate and 
multivariate analyses, patients with CN-AML and age ≤ 60 (Table S1) were included. Molecular 
and clinical variables of both patient cohorts (HOVON-SAKK and AMLSG) were comparable. 
Differences were assessed for CEBPAsm and CEBPAdm groups in comparison with CEBPAwt group 
(Table 1), by using the Mann-Whitney-U test for continuous variables and the two-sided Fisher 
exact test for categorical variables.
 For univariate analysis significance was assessed using the stratified log-rank test and Kaplan-
Meier estimates for overall survival (OS), event-free survival (EFS) and relapse-free survival 
(RFS). The recommended consensus criteria35 were used for the definition of CR and survival. 
Multivariate analysis was performed by using a stratified Cox’s proportional hazard model. For all 
analyses, a P-value ≤ .05 was considered statistically significant and for survival analyses, P-values 
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were computed using the full time span. Note that the closed testing procedure36 was applied 
and a correction for multiple testing37 was only performed if the global log-rank test resulted in 
a P-value ≤ .05. For gene expression-based classification of CEBPAdm cases, GEP of the HOVON-
SAKK cohort was used to derive the 25-probeset predictive signature and the AMLSG-cohort as 
validation set. To summarize, a logistic regression model with Lasso regularization (a continuous 
feature selection procedure) was used as it takes the correlation structure between the probesets 
into account (see Supplementary material).
RESULTS
Frequency and types of acquired CEBPAdm and CEBPAsm mutations
CEBPA mutations were detected in 151 of the 1182 (12.8%) CN-AML; 91 (60%) patients had 
CEBPAdm, within these the combination of N- and C-terminal mutations was the predominant 
genotype (82/91). CEBPAdm cases with only N-terminal or C-terminal mutations were less frequently 
observed (4/91 and 5/91, respectively). Sixty of the 151 (40%) CEBPA-mutated cases had CEBPAsm 
which occurred most frequently in the N-terminus (47/60). Only 13 of the 60 CEBPAsm cases had 
in-frame insertion or deletion mutations affecting the bZIP domain (Figure 1).
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Figure 1. Distribution of concurrent mutations in CEBPAdm and CEBPAsm patients. Columns represent 
patients and rows the genotypes FLT3TKD, FLT3ITD and NPM1mutant (black), wildtype (white) or missing (grey). The 
in-frame insertion or deletion in bZIP and N-terminal truncation mutations in CEBPA are highlighted in black. 
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Table 2. Germline patient demographics and molecular characteristics.
Patient ID
Age at 
diagnosis, 
(year)
Germline 
mutation
Acquired
 mutation*
Additional 
mutation†
Familial 
AML
History 
CEBPA 
mutation
98A-751 28 338delC 1080insGAA None Yes CEBPAdm
07/04-268 (ULM_10) 25 307delG 1122_1123ins
1075_1225
KRAS, WT1 Yes CEBPAdm
BioID 769 51 1096T>C 478_485del None No CEBPAdm
98A-543 33 1164G>A None FLT3TKD, 
NPM1
No CEBPAsm
07/04-48 (ULM_20) 59 1036G>T 1086insAAG None No CEBPAdm
Characteristics of 5 of 71 (7%) CEBPA-mutant AML patients who carried CEBPA germline mutations. KRAS, 
Kirsten Rat sarcoma; WT1, Wilms tumor 1. * Data according to GenBank accession no. Y11525.
Association of acquired CEBPAdm and CEBPAsm mutations with concurrent 
gene mutations and clinical characteristics
Concurrent mutations were seen less frequently in CEBPAdm than in CEBPAsm AML (22% versus 
60%; P<.0001, Figure 1); frequencies for NPM1mutant were 3.3% and 35% (P<.0001), and for FLT3ITD 
were 7.7% and 30% (P=.00015), respectively (Table 1). When comparing CEBPAsm and CEBPAwt AML, 
NPM1mutant were slightly less frequent in CEBPAsm AML (35% versus 54.3%; P=.018); the frequency 
of FLT3ITD was comparable between the two groups (30% versus 33.7%). Regarding presenting 
clinical characteristics, CEBPAdm mutations were associated with younger age (median 44 versus 
48 years; P=.04) and lower platelet counts (median 38x109/L versus 65x109/L; P<.0001) compared 
with CEBPAwt patients (Table 1).
Impact of CEBPAdm and CEBPAsm on response to induction therapy and 
clinical outcome
For clinical outcome analyses, 1182 CN-AML were considered. CEBPAdm was associated with a 
higher CR rate when compared with CEBPAsm (92% versus 78%, P=.02) and CEBPAwt (92% versus 
79%, P=.002). There was no difference in CR probability between CEBPAsm and CEBPAwt patients 
(78% versus 79%, P=.86). The median follow-up time for survival in the 1182 CN-AML patients was 
33 months (95%-CI, 25.6 to 40.4); the estimated 5-year OS and RFS were 42% (95%-CI, 39% to 45%) 
and 34% (95%-CI, 31% to 38%), respectively. 
CEBPAdm AML was associated with a significantly superior outcome compared with CEBPAwt 
AML (5-year OS, 63% versus 39%, P<.0001; EFS, 45% versus 28%, P<.0001; RFS, 44% versus 32%, 
P=.05; Figures 2A and Supplementary Figures S3A and S3D). A somewhat better outcome was 
also found for CEBPAsm AML compared with CEBPAwt AML (5-year OS, 55% versus 39%, P=.05; 
RFS, 49% versus 32%, P=.02; but not EFS, 37% versus 28%, P=.22). No significant difference was 
evident between CEBPAdm and CEBPAsm AML (5-year OS, P=.06; EFS, P=.16; RFS, P=.48). Of note, no 
differences in outcome were observed between CEBPAsm patients with either C-terminal (n=13) 
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or N-terminal (n=47) mutations (5-year OS, 54% versus 56%, P= .58; Figure S4). In multivariate 
analyses considering other prognostic indicators (listed in Table 3), the presence of CEBPAdm was 
an independent prognostic factor for favorable OS (HR, .36, P<.0001), EFS (HR, .41, P<.0001) and 
RFS (HR, .55, P=.001), whereas CEBPAsm did not impact these three endpoints (Table 3). 
Table 3. Multivariate analysis for overall, event-free and relapse-free survival in CN-AML.
Variables HR 95% CI P-value
Overall survival
CEBPAsmα 0.70 0.46 - 1.07 0.1
CEBPAdmα 0.36 0.23 - 0.55 < 0.0001*
FLT3ITDβ 1.78 1.49 - 2.14 < 0.0001*
FLT3TKDβ 0.84 0.61 - 1.15 0.28
NPM1+β 0.56 0.46 - 0.67 < 0.0001*
WBC countδ, x109/L 1.35 1.12 - 1.62 < 0.0001*
AgeЄ 1.02 1.01 - 1.03 < 0.0001*
Event-free survival   
CEBPAsmα 0.86 0.6 - 1.22 0.4
CEBPAdmα 0.41 0.29 - 0.57 < 0.0001*
FLT3ITDβ 1.56 1.33 - 1.84 < 0.0001*
FLT3TKDβ 0.8 0.6 - 1.07 0.13
NPM1+β 0.45 0.39 - 0.53 < 0.0001*
WBC countδ, x109/L 1.27 1.08 - 1.5 0.003*
AgeЄ 1.01 1.01 - 1.02 0.003*
Relapse-free survival   
CEBPAsmα 0.79 0.51 - 1.22 0.3
CEBPAdmα 0.55 0.38 - 0.79 0.001*
FLT3ITDβ 1.75 1.45 - 2.12 < 0.0001*
FLT3TKDβ 0.82 0.59 - 1.13 0.22
NPM1+β 0.56 0.46 - 0.68 < 0.0001*
WBC countδ, x109/L 1.33 1.1 - 1.61 0.002*
AgeЄ 1.01 1 - 1.02 0.001*
Stratified Cox’s proportional hazard model for multivariable analysis of CEBPAdm and CEBPAsm as prognostic 
markers for overall, event-free and relapse-free survival. Analyses included 1182 CN-AML patients with age ≤ 60.
Subgroup: α CEBPA status versus CEBPAwt, β FLT3ITD versus no FLT3ITD mutation, β FLT3TKD versus no FLT3TKD 
mutation, β NPM1mutant versus no NPM1wt, δ WBC count higher than 20x109/L versus lower than 20x109/L, Є Age 
is used as continuous variable 
*P-value ≤ 0.05
Treatment outcome of AML with CEBPAsm is dominated by FLT3/NPM1 
genotypes
We performed explorative subgroup analyses in CEBPAsm and CEBPAwt AML to evaluate the impact 
of four FLT3/NPM1 genotype subgroups: FLT3ITD/NPM1mutant (n=10); FLT3ITD/NPM1wt (n=8); FLT3wt/
NPM1mutant (n=11); and FLT3
wt/NPM1wt (n=21). Ten cases from the CEBPAsm group were excluded 
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for which the genotypes were unknown. Among patients with CEBPAsm AML, the FLT3ITD/NPM1wt 
genotype had an inferior OS compared to those with the FLT3wt/NPM1wt genotype (5-year OS, 
25% versus 49%, P=.05; Figure 2B); for EFS and RFS, there was a trend towards an inferior outcome 
(Figure S3B and S3E); in contrast, the FLT3wt/NPM1mutant genotype associated in trend with a 
favorable outcome compared with the FLT3wt/NPM1wt genotype (5-year OS, 78% versus 49%, P=.2, 
EFS: 59% versus 32%, P=.08, RFS: 66% versus 40%, P=.38, Figure 2B, S3B and S3E). In analogy, in 
the CEBPAwt group the FLT3ITD/NPM1wt genotype had a significantly inferior survival compared with 
the FLT3wt/NPM1wt genotype (5-year OS, 17% versus 34%, P=.001; EFS, 11% versus 14%, P=.04; RFS, 
15% versus 24%, P=.002; Figure 2C, S3C and S3F), whereas the FLT3wt/NPM1mutant genotype was 
associated with a favorable outcome (5-year OS, 57% versus 34%, P<.0001; EFS, 47% versus 14%, 
P<.0001; RFS: 50% versus 24%, P<.0001; Figure 2C, S3C and S3F). Thus, we observed comparable 
trends for favorable (FLT3wt/NPM1mutant) and inferior (FLT3ITD/NPM1wt) outcome in the CEBPAsm and 
CEBPAwt subgroups. The outcome for all CEBPAsm FLT3/NPM1 genotypes was higher (not significant, 
P> .05), compared to the CEBPAwt genotypes, however, the distinct groups were relatively small. 
For CEBPAdm AML, sample sizes of the composite genotypic subgroups were too small for analysis.
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Figure 2. Kaplan-Meier survival curves of overall survival. (A) Kaplan-Meier survival curves for OS among 
the three groups CEBPAdm, CEBPAsm and CEBPAwt. (B) Survival curves for OS of the four genotypes FLT3ITD/
NPM1mutant, FLT3ITD/NPM1wt, FLT3wt/NPM1mutant, and FLT3wt/NPM1wt within the CEBPAsm group. (C) Survival curves 
for OS of the four genotypes within CEBPAwt. * P-value by the global log-rank test.
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Unsupervised analyses of GEP showed homogeneity in CEBPAdm AML cases
GEP was performed in a subset of the CN-AMLs patients and also includes cytogenetically 
abnormal patients (Table S1; n=674). Unsupervised analyses, by hierarchical clustering, revealed 
distinct GEP clusters (Figure 3A), including the known clusters of AML with inv(16), t(15;17) or 
t(8;21), as shown previously.23 These subtypes revealed high correlation within the GEP cluster 
(average correlation: .42, .49 and .49, respectively) and differed significantly between the AML 
cases with any of these aberrations (P<.0001, P<.0001, and P<.0001, Figure S5B, S5C and S5E). We 
observed that the CEBPAdm AML cases were highly similar within the cluster (average correlation: 
.35) and differed significantly from cases without a CEBPAdm (P<.0001, Figure S5D). CEBPAsm AML 
cases showed reduced similarity (average correlation: .15) and did not differ from cases without 
CEBPAsm (P=.12, Figure S5A and Figure 3A). 
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Figure 3. Unsupervised analyses and classification results of candidate CEBPAdm cases with their gene 
expression profile and their molecular characteristics. (A) Pair-wise correlations between the 674 AML 
cases; color coding cells: positive (red) or negative (blue) correlations, as indicated by the scale bar. Presence 
of molecular abnormalities, indicated at the top of the plot, are depicted on the diagonal by a red or blue 
bar. CEBPAC-terminal mutation and CEBPAN-terminal mutation indicates the presence of homozygous mutations. (B) Gene 
expression levels of CEBPAdm and CEBPAsm patients for the defined 25-probeset signature. The colors are 
relative to the mean per probeset. (C) Ordered computed posterior probabilities for the CEBPAdm signature 
given the 25-probeset signature. (D) (black) presence of mutation, (white) wildtype, (grey) missing value. 
* germline CEBPAdm cases.
CEBPAdm AML is accurately predicted based on GEP
The previously predictive CEBPAdm signature18 was hampered by the recently reported CEBPA 
silenced AML cases that carry a similar GEP.22 Two independent AML cohorts were used to train 
and evaluate the predictive value of the CEBPAdm signature in terms of sensitivity and specificity. 
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A predictive signature was created, containing 25-probesets by using a logistic regression model 
with Lasso regularization (Figure 3B and Supplementary material Table S2)38,39, which selects 
discriminative probesets between the classes, CEBPAdm (n=26) and all other AML cases, i.e., 
CEBPAwt and CEBPAsm (n=494). Subsequently, a classifier was trained on the entire HOVON-SAKK 
cohort based on a two class approach; 26 CEBPAdm versus 494 cases (CEBPAwt and CEBPAsm). This 
trained classifier subsequently classified 16 candidate CEBPAdm cases (Supplementary Table S3) in 
the AMLSG-cohort out of 154 AML cases (16 CEBPAdm, 6 CEBPAsm and 132 CEBPAwt: Supplementary 
material Table S1). Among the CEBPAdm cases were 5 cases with either homozygous N- or C-terminal 
CEBPAdm mutations, and a CEBPAdm patient with a germline C-terminal mutation. This approach 
showed perfect sensitivity and specificity (both 100%, Figure 3C). In addition, we performed a 
classification between CEBPAdm, CEBPAsm, and CEBPAwt  to infer, if we were able to accurately classify 
CEBPAsm cases. We observed that all CEBPAsm cases were classified as CEBPAwt, thus CEBPAsm cases 
do not have a consistent gene expression pattern and were different from the CEBPAdm group.
DISCUSSION
Here, we established the value of the CEBPAdm mutation in a large cohort of CN-AML patients from 
AMLSG and HOVON-SAKK treatment trials. We detected 91 (7.7%) double CEBPA and 60 (5.1%) 
single CEBPA mutations among 1182 patients. In multivariate analyses, we demonstrate that the 
presence of CEBPAdm, but not CEBPAsm, is an independent factor for favorable outcome in AML, 
which confirms previous findings reported in studies with relatively small cohorts.17-19,21
 Concurrent mutations were significantly less frequent in CEBPAdm compared with CEBPAsm 
AML. This was true for FLT3ITD and in particular for NPM1mutant that were virtually not present among 
CEBPAdm cases, a finding that is consistent with previously published data.20 Compared to previous 
studies17-21, and the large number of cases, we were able to evaluate the prognostic impact of 
the CEBPA mutational status in the context of the FLT3/NPM1 genotypes. Among CEBPAsm AML, 
the four combined genotypes showed similar trend with regard to outcome as compared with 
CEBPAwt AML (Figure 2B and 2C). Nevertheless, we observed a higher outcome (not significant) 
for all CEBPAsm FLT3/NPM1 genotypes compared to the CEBPAwt genotypes, but these groups are 
relatively small. These findings, supported by data from multivariable analysis, strongly suggest 
that not the existence of CEBPAsm per se but rather the combined effects of CEBPAsm and FLT3ITD 
and/or NPM1mutant determine outcome in these AML patients. 
 Here, we generated a refined GEP signature, consisting out of 25-probesets that predict 
CEBPAdm AML cases. This signature showed sensitivity and specificity of 100% and has a better 
predictive power than the CEBPAdm signature previously defined.18 In fact, in contrast to the previous 
signature, the new signature also discriminates CEBPAdm from AML with hypermethylation of the 
proximal promoter region of CEBPA.22 Classification results were not affected by homozygous 
N- or C-terminal CEBPAdm mutations or those due to germline mutation. Currently, nucleotide 
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sequencing is used as the gold standard for the identification of CEBPA mutations. Due to the 
much higher effort of gene expression profiling this technique should not be considered as 
a primary diagnostic tool in AML. However, GEP can be confirmatory, especially in cases where 
the CEBPA gene appears difficult to sequence. More importantly, GEP provides relevant insights 
in the biology of the disease and the affected signaling pathways and therefore allows further 
classification/refinement of AML. 
 Finally, we evaluated the frequency of CEBPA germline mutations in this large cohort of 
CEBPA-mutated cases. Among 71 mutated patients, 5 revealed germline mutations. Of these cases 
4 developed CEBPAdm AML, i.e., these cases acquired a mutation in the second allele, in line with 
previous data.40,41 Interestingly, we for the first time identified 3 C-terminal germline mutations of 
which 2 cases acquired a second CEBPA mutation at the time of AML diagnosis. In GEP analysis 
both cases clustered within the CEBPAdm group and were classified as a CEBPAdm, providing 
evidence that these C-terminal sequence variations are mutations rather than polymorphisms. 
All 3 C-terminal germline mutations were predicted to be damaging for the function and the 
structure of the protein.
 In the current World Health Organization (WHO) AML classification, “AML with mutated CEBPA” 
has been designated as a provisional disease entity in the category “AML with recurrent genetic 
abnormalities”. Based on our data obtained from a large patient cohort together with findings 
from previous reports we propose that CEBPAdm AML should be clearly distinguished from CEBPAsm 
AML and that only “AML with CEBPAdm” should be considered as an independent entity in the 
classification of the disease.
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ABSTRACT 
Background. Accurate analyses of comprehensive genome-wide single nucleotide polymorphism 
(SNP) genotyping and gene expression data sets is challenging for many researchers. In fact, 
obtaining an integrated view of both large scale SNP genotyping and gene expression is currently 
complicated since only a limited number of appropriate software tools are available. 
Results. We present SNPExpress, a software tool to accurately analyze SNP genotype calls, copy 
numbers, polymorphic copy number variations and gene expression in a combinatorial and 
efficient way. In addition, SNPExpress allows concurrent interpretation of these items with Hidden 
Markov Model inferred loss-of-heterozygosity and copy number regions. 
Conclusion. The combined analyses with the easily accessible software tool SNPExpress will not 
only facilitate the recognition of recurrent genetic lesions, but also the identification of critical 
pathogenic genes.
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INTRODUCTION
High-density genome-wide views of biological samples using high-throughput DNA mapping 
and mRNA gene expression microarrays facilitate the identification of recurrent molecular lesions. 
Both types of microarrays, which are being produced by different manufacturers, e.g., Nimblegen, 
Agilent, Sequenom, Applied Biosystems, Illumina and Affymetrix, typically contain large numbers 
of small oligonucleotides that interrogate the genome. Currently available DNA arrays contain 
over 500.000 probe sets, while the gene expression arrays target over 20.000 genes. Efficient 
analysis of these large datasets remains a challenge for many researchers. 
 The Affymetrix and Illumina DNA mapping platforms have been designed to specifically target 
sequences containing single nucleotide polymorphisms (SNPs). SNPs are currently estimated 
to be present at a frequency of 1 out of 300 nucleotides.1 By including different probe sets to 
detect the possible SNP variants, genome-wide genotyping is feasible and these platforms can 
easily be applied to determine copy numbers of these chromosomal markers, similar to array 
comparative genomic hybridization (CGH). Due to the high number of SNPs, sample DNA can be 
examined with an inter-marker distance of 6 to 12 kb, and (micro) deletions and/or amplifications 
are detectable. By comparing disease samples to normal germ line DNA, a detailed overview 
of acquired gains and losses of the genome is obtained. In fact, although our knowledge is still 
developing, it has recently become apparent that that copy number variation (CNV) accounts for 
a substantial amount of genetic variation in the human genome.2 
 The high-resolution scanning technologies enable the analyses of CNV and associated 
phenotypes.2 The power of DNA mapping has been shown extensively in cancer research. 
Chromosomal gains and losses as well as regions of loss-of-heterozygosity (LOH) have been 
shown in, for instance, leukemia3,4, lung cancer5-7 and colon cancer.8 Recognition of recurrent 
lesions will ultimately result in the identification of pathogenic genes. For instance, SNP array 
analysis of a set of cancer cell lines has led to the identification of the microphthalmia-associated 
transcription factor MITF as a melanoma oncogene.9 
 On the Illumina platform genotypes are determined using hybridization of genomic DNA to 
BeadChips followed by an enzymatic discrimination step. On the Affymetrix platform, genotype 
calls and copy numbers are determined by a probe set. In analogy with the expression probe set, 
the genotype and copy number of an individual SNP is dependent on the balance of genotype 
calls in the associated probe set. Several methods for genotype calling10-13 and assessment of copy 
number14,15 have been developed. Advanced analysis methods of DNA mapping array data have 
focused on the identification of regions of LOH, or gains and losses.16-19
 A particular SNP genotype or numerical changes in chromosome copy number can have 
profound effects on gene expression. A possible relation to tumor development was shown in 
breast cancer, where a 17q23 amplification was related to increased expression of genes at this 
locus20 and in acute myeloid leukemia (AML), where amplification of 8p24 was associated with 
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increased expression of genes such as MYC.21 In fact, SNPs as well as CNVs have recently been 
shown to have consistent effects, often in cis, on gene expression.22,23 The integrated analysis of 
gene expression and SNP array data is a prerequisite to recognize these effects. To our knowledge, 
only one software package is able to visualize chromosome copy number and gene expression 
levels.17 Here, we present a package, SNPExpress, which allows concurrent interpretation of 
genotype, HMM inferred LOH regions, CNVs, HMM inferred copy number and gene expression 
data. Due to the simple format of the input data, our package is not restricted to specific methods 
to determine genotype, copy numbers or expression level. Little knowledge of software is 
necessary to use SNPExpress, making the tool widely accessible.
IMPLEMENTATION
SNPExpress, written in JAVA (version 1.5), uses tab-delimited files as input and is currently available 
for use with Affymetrix DNA mapping arrays (10K 2.0, 100K and 500K set), Illumina HumanHap550 
Genotyping BeadChip and Affymetrix GeneChips (HG-U95Av2, HG-U133A and B, HG-U133 plus 
2.0). A file containing a matrix with each column representing the genotypes of one array and 
rows starting with Illumina or Affymetrix SNP IDs is mandatory. The genotype should be formatted 
as homozygous ‘AA’ or ‘BB’, heterozygous ‘AB’, or, ‘noCall’ (Affymetrix)/ ‘NC’ (Illumina). Similar matrix 
files containing copy numbers or gene expression values are optional.  Copy numbers should be 
centered around 2, where 2 represents the normal copy number of the autosomes and 1 for the 
male X chromosome. The maximum displayed copy number is 4, in case the copy number is above 
4 this is indicated by a darkblue background. Copy number-, genotype- and gene expression files 
required for SNPExpress can be generated through tools such as Affymetrix BRLMM13, GCOS/CNAT 
4.024, or dChipSNP.17 In case of Illumina data, SNPExpress includes the non-synonymous SNPs and 
the MHC region, however, mitochondrial SNPs and Y-chromosome SNPs are not visualized. All 
files can be optionally uploaded as tab- or comma-delimited .txt files or binary files. These binary 
files can be created from .txt files by the menu item ‘convert data source’.
 SNPExpress maps both the SNP IDs (Illumina and Affymetrix) and the expression probe set 
IDs (Affymetrix) to the genome through internal alignment tables, using annotation provided by 
the manufacturer. Annotation was generated using NCBI build 36.1. Regions showing LOH are 
calculated through a Hidden Markov Model (HMM), described previously.18 The probability values 
for heterogeneous calls required for the HMM have been generated through sets of genotypes 
of normal samples. For the 100K and 500K array, 90 samples and 270 samples, respectively, of 
different ethnical background from the HapMap project are available through the NCBI GEO 
website (and provided by the manufacturer).28,29 For the 10K array normal matched blood samples 
available through the GEO public repository have been processed.30 Since reference normal 
Illumina genotype datasets are currently not publicly available, LOH regions using this platform 
are not supported in this version of SNPExpress. SNPExpress includes the option to visualize the 
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results of a novel analytical method that infers the copy number of each SNP based on a HMM 
model, which is implemented in dChipSNP.17,31 Also, all CNVs2, currently cataloged in the Database 
of Genome Variants32, can be visualized.
 Example expression, copy number, genotype and HMM copy number example files of two 
AML patients can be downloaded.33
RESULTS
Genotypes and copy numbers are displayed as sequential blocks by which color indicates 
genotype, horizontal coordinate indicates position on the chromosome and vertical coordinate 
indicates copy number (Figure 1). The colored genotype blocks are drawn sequentially in a 
chromosome-wide view and proportional to chromosomal location when zoomed into a region 
of interest. Gene expression levels are visualized as a vertical bar at the chromosomal position of 
the gene-specific probe set. The height of the bar is proportional to the gene expression value. 
The default value is 500 and expression higher than 500 is capped at 500, however, these values 
are user-definable. In the event that multiple probe sets span the same region in the chromosome-
wide view the vertical gene expression bars are red and proportional to the highest expression 
value. Zooming into the location of interest discloses the individual probe sets. Links of SNP IDs to 
public databases are available by holding the ctrl-key and clicking on a SNP ID.
Distinct background colors are used to accentuate genomic changes. Individual copy numbers 
are indicated as gain (pink background) or loss (green background) when their value exceeds a 
user-defined value. The default deviation threshold is 0.5. LOH is highlighted at diploid level by a 
bold magenta line (Figure 1). All colors can be adapted to the users’ preferences.
From the menu, the user is able to choose to visualize either one chromosome of multiple 
samples or the complete genome of one sample. Detailed information, such as SNP ID, associated 
gene symbol, probe set ID, cytoband and expression value, is shown on a mouse-over display. 
Furthermore, a gene of interest is directly visualized through a search function, and its associated 
SNPs are indicated with an orange background color. The options to display known CNVs (purple 
background) or the HMM copy number results (thin magenta line) are included (Figure 1C). 
Finally, relevant data of a particular minimal deleted of amplified region can be exported (i.e., 
Sample, Probe_set_id, Chromosome, Location (bp), Cytoband, Associated gene, Genotype, Copy 
number and Inferred LOH of the selected region) and high-resolution images of the visualization 
can be saved in the Portable Network Graphic (PNG) format. 
To illustrate the power of SNPExpress, DNA mapping array profiles of tumor samples of a series of 
48 AML patients were generated using Affymetrix 250K NspI DNA mapping arrays. Ficoll separation 
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of the mononuclear cells from AML typically yields >80% pure population of leukemic blast cells. 
High molecular weight DNA was isolated from these malignant cells and the Affymetrix mapping 
arrays were used according to the protocol of the manufacturer. Genotypes were calculated using 
BRLMM and copy numbers were assessed using dChipSNP. Biotin-labeled cRNA of the same AML 
samples was hybridized on Affymetrix HG-U133 plus 2.0 GeneChips, as previously described.34 
The resulting dataset was imported in SNPExpress for analyses. Large chromosomal regions 
showing loss or gains of genetic material are known to be apparent in leukemic blasts of AML 
patients. Well-known examples of chromosomal lesions in AML are monosomies of chromosome 
5 and 7, which have been associated with a poor prognosis.35 Using SNPExpress, monosomies of 
chromosome 7 were evidently demonstrated in AML samples, previously shown by cytogenetics 
(Figure 1). SNPExpress also correctly predicted the presence of LOH as a result of the absence of one 
chromosome 7. In fact, 17 out of 21 numerical cytogenetic aberrations, i.e., whole chromosomes 
and interstitial deletions, in 48 AML samples analyzed, were recognized by using SNPExpress. Four 
numerical abnormalities, present in less than 30% of the AML cells, were missed. Chromosomal 
gains, losses as well as uniparental disomy (UPD) may also have other important consequences, 
such as affecting expression of (imprinted) genes. Combinatorial visualization of genotype, copy 
number and gene expression is a prerequisite to recognize these aberrations. For example, the 
majority of genes show located on chromosome 7 show an overall decrease in expression in AML 
cases with a monosomy 7 (Figure 1).
Large regions of homozygosity are present in approximately 20% of primary AML cases as a 
result of segmental UPD.3,36 These regions of UPD seemed to be non-random and may be used 
to unmask pre-existing recessive mutations in leukemia genes, such as CEBPA, WT1, FLT3 and 
RUNX1.3,37 SNPExpress adequately identified regions of UPD involving e.g. chromosome 11p 
(Figure 1D), in two patients with a normal karyotype. UPD involving chromosome 11 is associated 
with homozygous mutations in WT1.37 Interestingly, in 13 out of 48 AML patients (27%) large 
regions of segmental UPD continuing to the telomere were recognized using SNPExpress.
These examples demonstrate the power of SNPExpress. To our knowledge, no tool is currently 
available that allows concurrent interpretation of genotype, HMM inferred LOH regions, copy 
number, HMM inferred copy number and gene expression data. Moreover, no specialized 
knowledge is necessary to work with SNPExpress.
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Figure 1. SNPExpress screenshot. A. DNA mapping array data from the Affymetrix 250K NspI DNA mapping 
array depicting chromosome 7 of four AML samples. Copy numbers (n=0, 1, 2, 3, 4) are shown for each 
individual patient by horizontal lines. (A) SNP genotypes are sequentially aligned along the chromosome 
(AA: red; BB: yellow; AB: blue, noCall: white). LOH is indicated by a thick magenta horizontal bar (B), gains 
(default n>2.5) by a pink and losses (default n<1.5) by a turquoise background (C). Gene expression levels 
are visualized as vertical white bars. Multiple probe sets spanning the same locus is depicted by a red vertical 
gene expression bar proportional to the highest expression value. The two upper samples display a complete 
monosomy (sample 1) or a deletion of the q-arm of chromosome 7 (sample 2). The chromosome selecter 
(D; where 23 is the X chromosome), the mouse-over function showing info of each SNP or probe set (E), full 
chromosome view (F), zoom function (G) gene search function (H), the links to external databases (I), display 
CNVs (J) and export selected data (K) options are indicated. B. Full chromosome view of samples from Figure 
1A. C. CNV (purple background) and copy number of each SNP based on a HMM model (HMM copy number, 
magenta line) for two AML cases. D. An example of large scale UPD on chromosome 11 in the upper two AML 
patients in comparison to two other AML samples. The overall copy number is two and large regions of LOH 
are indicated by the thick magenta line across the chromosome. SNPs associated with WT1 are depicted with 
an orange background.
DISCUSSION
Since genome-wide DNA mapping array and mRNA expression studies become more cost 
effective, the number of samples profiled on these platforms will increase. Specialized user-
friendly tools for efficient visualization, such as SNPExpress, will therefore be indispensable. In 
fact, the initial version of SNPExpress has already been successfully applied in showing segmental 
uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid 
leukemia.38
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 Other tools for visualizing and processing SNP array data, such as SNPScan39, SIGMA40, 
ArrayFusion41, Partek Genomics Suite42 and GenePattern43 have been developed. Most of these 
tools incorporate visualization options for displaying LOH (GenePattern, Partek Genomics Suite, 
SNPScan) and copy number (all but ArrayFusion), whereas SNPScan and ArrayFusion have output 
functionality that facilitates linking SNP data to the UCSC genome browser.39,41 Some are linked to a 
private database, which restricts pre-processing of the array data, but gives the advantage of data 
storage.40 GenePattern and the Partek Genomics Suite provide normalization and data smoothing 
functionality. These two packages and SNPScan have also incorporated options for combined 
analysis of paired samples, i.e., tumor and normal. Like SNPExpress, SNPscan, GenePattern, and 
the Partek Genomics Suite can detect regions of LOH, amplification and deletion. None of these 
tools describe the ability to process Illumina BeadArray files. Where SNPExpress may lack the 
opportunity to directly process raw data files (such as Affymetrix CEL-files), it adds integrated 
visualization of expression (Affymetrix) and DNA copy number and genotype (Affymetrix and 
Illumina) data. Moreover, we believe that this is provided in a user-friendly way that does not 
require specialist computer knowledge.
 SNPExpress has some limitations. A full-length chromosome view depicting gains, losses and 
the regions showing LOH is feasible using SNPExpress. However, the large datasets generated 
by the 500K mapping array platform makes it impossible to visualize the sequentially aligned 
SNPs of the full-length chromosomes on one screen. Selecting the most informative SNPs, i.e., 
representative for particular haplotypes, may solve this issue. Such algorithms are currently in 
development. Furthermore, the current implementation of the HMM could also be improved by 
implementing a HMM that takes into account the effects of linkage disequilibrium, i.e., LD-HMM.18 
The number of samples to be visualized concurrently is limited by the memory available to the 
application.
CONCLUSIONS
The power of SNPExpress, as with previously developed tools44, is its high accessibility and 
powerful visualization, which facilitates the identification of biologically and clinically relevant 
entities. We have shown that recurrent biologically relevant entities, such as chromosomal gains 
or losses and LOH in AML, are accurately identified with SNPExpress. Hence, SNPExpress will be 
beneficial to genome-wide studies by providing an integrated view of data from DNA mapping 
and mRNA expression arrays in an easily accessible and accurate way.
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ABSTRACT
Acute leukemia is characterized by the accumulation of somatic genetic alterations in 
hematopoietic stem and progenitor cells eventually resulting in overt leukemia. To characterize 
somatic events associated with leukemic transformation, we performed detailed genome-wide 
copy number analyses of 53 adult B-cell acute lymphoblastic leukemia (ALL), 20 adult T-cell ALL 
(T-ALL) and 100 adult acute myeloid leukemia (AML) cases. We observed recurrent aberrations 
involving CDKN2A/B, IKZF1, PAX5 and BTG1 at relatively high frequencies, with the CDKN2A/B 
pathway being perturbed in all adult T-ALL cases. In adult AML, focal copy number alterations were 
virtually lacking. Interestingly, genetic lesions simultaneously perturbing the genes encoding 
for NF1, involved in RAS pathway inhibition, and SUZ12, a pivotal polycomb repressive complex 
2 (PRC2) member, were recurrently found in T-ALL and AML. Gene expression profiling (GEP) 
analysis revealed the substantial down regulation of both genes supporting the notion that PRC2 
loss cooperates with RAS pathway activation in acute leukemia. Finally, targeted resequencing 
of regions harboring recurrent genetic alterations in 5 selected B-ALL cases revealed extensive 
involvement of the recombination activating genes (RAG) complex as a mutational mechanism 
invoking large deletions as well as complex insertions and deletions in promoters, enhancers and 
open chromatin proximal to genes regulating B-cell development.
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter5/
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease characterized by a clonal 
proliferation of malignant lymphoblasts, initiated by the accumulation of genetic alterations in 
B- or T-lymphoid precursor cells. ALL is the most common leukemia in children (26% of all cancer 
types and 80% of all paediatric leukemias), but is a rare disease in adults (2-3% of all cancer types 
and 56% of all adult acute leukemias).1-3 With the introduction of different genome characterization 
methodologies much has been learned about the molecular biology of ALL leading to risk-
adapted treatments, however, the long-term survival of adults is still inferior to that of children 
(5-year event-free survival rate 80% versus 40%, respectively).1-3 Cytogenetic characterization of 
adult ALL revealed recurrent interchromosomal aberrations involving BCR-ABL1, E2A-PBX1 and 
MLL-rearrangements in B-cell ALL (B-ALL), and SIL-TAL1 in T-cell ALL (T-ALL).4 Genetic analysis of 
especially paediatric ALL has been extensively carried out, while the genome of adult ALL remains 
scarcely characterized. Array-based genome characterization of predominantly paediatric ALL has 
revealed frequent and recurrent genetic alterations, mostly comprising deletions of promoters 
or complete genes involved in the development of B- or T-lymphoid precursor cells5,6, such as 
deletions affecting CDKN2A/B, IKZF1, PAX5, EBF1 and BTG1. The adaptive immune system requires 
diversification for the defence against the invasion of variegated pathogens. This defence is 
conferred by the diversification of antibody production by cutting and recombining variable 
(V), diversification (D) and joining (J) gene segments by a process named V(D)J recombination. 
Previous studies have postulated that many of the recurrent deletions may be effectuated by 
illegitimate V(D)J recombination utilizing cryptic recombination signal sequence (RSS) motifs in 
the vicinity of the nascent copy number alteration (CNA) breakpoint boundaries.7,8 Recent efforts 
have shown that a substantial number of CNAs are flanked by cryptic RSS motifs in specifically 
paediatric ETV6-RUNX1 ALL patients9, especially in regions marked by active histone markers, such 
as H3K4me3. The RAG complex mediates V(D)J recombination within recombination centre foci 
located in antigen receptor loci, characterized by an enrichment of H3K4me3, H3 acetylation and 
RNA polymerase II binding.10 Altogether, these studies culminate into the hypothesis postulating 
that the RAG endonuclease complex is aberrantly targeted to loci accommodating cryptic RSS 
motifs and subsequently invoking illegitimate genetic lesions perturbing developmental genes 
associated with leukemic and clonal evolution.
 Acute myeloid leukemia (AML) is a malignant and heterogeneous disease characterized by 
the acquisition of genetic lesions in hematopoietic stem and progenitor cells.11 Cytogenetic 
characterization has revealed recurrent interchromosomal aberrations, e.g. t(15;17), t(8;21), 
inv(16) and MLL-rearrangements, which have consecutively been used for prognostication. 
Recent studies adopting next generation sequencing (NGS) technologies have revealed recurrent 
molecular aberrations involving genes associated with transcription activity12, epigenetic 
modifications13,14, spliceosome machinery15, and cohesion complex formation.16 The prognostic 
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significance of many of these newly identified molecular aberrations remains equivocal. Array-
based characterization of the AML genome revealed the general scarcity of CNAs precluding the 
identification of many novel genes involved in leukemogenesis17 and ostensibly highlighting its 
stability.
 In order to determine the frequency of recurrent aberrations and to identify novel genetic 
aberrations in adult acute leukemia, we have characterized 53 B-ALL, 20 T-ALL, and 100 AML cases 
at diagnosis by copy number variation (CNV) analysis. Additionally, we determined which genetic 
lesions are acquired, potentially driving leukemic transformation in concert.
 Subsequently, the CNV analyses revealed that a substantial fraction of the adult ALL cases 
acquired multiple focal deletions located proximal to the transcription start site (TSS) or involving 
the complete promoter of genes associated with development and differentiation processes in B- 
or T-lymphoid precursor cells.5,6 We selected 5 B-ALL cases substantially exhibiting this behaviour 
and with the advent of NGS demonstrated that almost all deletion events are flanked by cryptic 
RSS motifs.
METHODS
Patients samples
After informed consent, bone marrow aspirates or peripheral blood samples of a representative 
cohort of adult ALL and AML patients were collected. Eligible patients had a diagnosis of primary 
ALL or AML, confirmed by cytological examination and immunophenotyping of blood and 
bone marrow. The majority of these cases were treated following the HOVON (Dutch-Belgian 
Hematology-Oncology Co-operative group) protocols (http://www.hovon.nl). Blasts and 
mononuclear cells were purified by Ficoll-Hypaque (Nygaard, Oslo, Norway) centrifugation and 
cryopreserved. All samples contained 80-to-100 percent blast cells after thawing, regardless of 
the blast count at diagnosis.
Gene expression profiling
RNA was isolated from 136 B-ALL, 55 T-ALL and 661 AML adult cases using RNABee. Gene 
expression profiles of the samples were generated using Affymetrix HG-U133 plus 2.0, as described 
elsewhere.18 Gene expression data is available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress), see Supplementary material. The different cohorts have been made comparable 
by mean-centering the expression levels to 0 per dataset. Differential gene expression analysis 
was performed with the Mann–Whitney U test in the R environment. All additional plots were 
generated by ggplot2.19
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Array based copy number analysis
Genome-wide genotyping data of 73 ALL patients, i.e., 53 B-ALL and 20 T-ALL diagnostic samples 
in conjunction with paired remission samples, were generated using Affymetrix 6.0 NspI/StyI DNA 
mapping arrays and for the 100 AML diagnostic samples alone with the Affymetrix 500K NspI/StyI 
DNA mapping arrays. DNA mapping array data is available in the ArrayExpress database (www.ebi.
ac.uk/arrayexpress), see Supplementary material. High-molecular-weight DNA was isolated using 
columns (Qiagen, Hilden, Germany) and the Affymetrix DNA mapping arrays were used according 
to the protocol of the manufacturer (Affymetrix, Santa Clara, CA). In brief, 250 ng of genomic 
DNA was digested with NspI or StyI and ligated to NspI or StyI adapters using T4 DNA ligase (New 
England Biolabs, Ipswich, MA, USA). Samples were then amplified by PCR using TITANIUM Taq 
polymerase (Clontech, Mountain View, CA, USA). PCR products were pooled and purified using 
the Clontech purification kit and subjected to fragmentation using DNaseI. The DNA fragments 
were subsequently biotin-labeled with terminal deoxynucleotidyl transferase, hybridized on the 
array in a GeneChip® Hybridization Oven 640, washed and stained in a GeneChip® Fluidics Station 
450. Data was obtained using the GeneChip Scanner 3000 7G.
Genotypes were calculated using the Birdseed algorithm and copy numbers were assessed using 
dChip.20 The copy numbers of all AML samples were calculated using diploid references. CNV 
profiles of the ALL and AML cases where manually scrutinized with SNPExpress21 and aberrations 
were selected when displaying constitutive loss or gain, i.e., 10 probe sets or more, and not 
observable in matched remission samples or not observable in all leukemia cases, e.g., copy 
number polymorphisms or systematic bias in copy number. Subclonal CNVs were selected only 
when 20 or more probe sets displayed constitutive reduced or increased copy number levels. 
Genes afflicted by CNAs were ranked according to frequency, but due to hyperdiploidy and 
chromosomal losses many passenger genes were simultaneously identified. To ascertain genes 
perturbed by or directly flanking CNAs we have utilized kernel density estimation with a flat-
top Gaussian kernel distribution to account for the unequidistant nature of the probe sets.22 In 
brief, the region encompassing the CNA is weighted equally, while flanking regions are weighted 
according to an exponential decay function based on distance and size of the CNA. To prevent the 
substantial weighting of very small aberration we have put a gamma distribution as a conjugate 
prior on the kernel distribution.
PCR, nucleotide sequencing and denaturing high performance liquid 
chromatography
All PCR reactions were carried out in the presence of 25mM dNTP, 15 pmol primers, 2mM 
MgCl2, Taq polymerase and 1xbuffer (Invitrogen Life Technologies, Breda, The Netherlands) 
at an annealing temperature of 600C. The 16 exons of the SUZ12 were amplified using the 
primers indicated in Supplementary Table 1 and the promoter of BTLA by a forward primer 
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(5’-GAGCCTGGATGATTTTGTGAA-3’) and a reverse primer (5’-CCGTGACATGTACAGGAAAA-3’). 
Cycling conditions were: 1 cycle 5 min at 940C, 35 cycles 1 min at 940C, 1 min at 600C, 1 min at 
720C, and 1 cycle 7 min at 720C. PCR products were purified using the Multiscreen-PCR 96-well 
system (Millipore, Bedford, MA) followed by direct sequencing with the appropriate forward and 
reverse primers using an ABI-PRISM3100 genetic analyzer (Applied Biosystems, Foster City, CA). 
All SUZ12 PCR products of exon 14-15-16 or the BTLA promoter were subjected to denaturing high 
performance liquid chromatography (dHPLC) analyses using a Transgenomics (Omaha, NE) WAVE 
system. Samples were run at 55.60C.
Roche 454 next-generation sequencing
Amplicon sequencing was performed using the Roche GS Junior 454 system (Roche, Basel, 
Switzerland) following the protocols of the manufacturer. Sequence reads were processed and 
analyzed using the GS Amplicon Variant Analyzer (Roche, Basel, Switzerland). The SUZ12 zinc 
finger and VEFS domain are encoded by exons 12-to-16. Primers are indicated in Supplementary 
Table 2). Amplicons carrying MIDs were generated and purified according to the Amplicon 
Library Preparation Method Manual (Roche, Basel, Switzerland). DNA enriched beads, carrying the 
amplification products, were generated according to the emPCR Amplification Method Manual-
Lib-A (Roche, Basel, Switzerland); a beads-to-amplicon ratio of 1:2 was used.
Exome sequencing and targeted resequencing
From the diagnostic and remission material of 5 ALL cases the genomic DNA was sheared with 
the Covaris S2 (Covaris) with default settings for exome sequencing. Subsequently, the sample 
libraries were prepared using the TruSeq DNA Sample Preparation Guide (Illumina). The target 
chromosomal regions were derived from the DNA mapping array identified CNAs of the 5 ALL 
cases. The exons and the targeted regions (Supplementary Table 13) were captured by employing 
custom in-solution oligonucleotide baits (Nimblegen SeqCap EZ plus). The sample libraries were 
subjected to paired-end sequencing (2x100bp) on the HiSeq 2000 (Illumina) and were aligned 
against hg19 using the Burrows Wheeler Aligner (BWA)23 with default settings. Reads aligning into 
undetermined regions of the human genome (hg19), e.g., segments of intron 3 belonging to the 
IKZF1 gene, were aligned against the updated human genome sequence (hg38) containing these 
regions. Whole exome sequencing (WES) and targeted resequencing data derived from patient 
specimens have been deposited at the European Genome-phenome Archive (EGA, http://www.
ebi.ac.uk/ega/), see Supplementary material.
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Variant detection
Variants were determined with SAMtools24, annotated with ANNOVAR25, and filtered by an 
in-house developed algorithm. In brief, the algorithm compares the variant frequency of the 
diagnostic sample to a control sample, e.g., healthy tissue or remission material, taking into 
account the alignment quality of the reads and the local sequence context of the detected variant. 
Somatic complex mutations comprising a combination of insertions, deletions and mutations are 
detected with Pindel.26
Exact breakpoint and RSS detection
Copy number variation profiles from the NGS data of the 5 B-ALL cases were produced with 
CNVsvd (M.A.S., R.H, and P.J.M.V., manuscript in preparation). Exact breakpoint locations were 
determined with BreakDancer27 (v1.12) or were manually scrutinized when undetected. Adjacent 
to either side of the breakpoint 150 base pair of sequence was extracted from hg19 using the 
SAMtools API.24 To ascertain cryptic RSSs we uploaded all the breakpoint sequences to RSSsite28 
for detection of 12-bp spacer RSS or 23-bp spacer RSS based on the human detection algorithm. 
De novo motifs near the breakpoints were inferred by uploading all the breakpoints sequences 
to the MEME website.29 The sequence logo for the detected cryptic RSS motifs by RSSsite were 
constructed with seqLogo.30
Histone markers and protein binding
We procured the histone marker data H3K4me3, H3K27ac, H3K27me3, RNA polymerase II for 
the B-lymphoblastoid cell line GM12878 from the Encyclopedia of DNA Elements (ENCODE) 
project.31 Genome segmentation into 15 definable chromatin states, e.g. active promoter, based 
on combinations of epigenetic markers was constructed by the ENCODE project and procured 
from the UCSC website. Background probability of each chromatin state was determined by 
calculating the ratio of the summarized total length of all regions affiliated with this chromatin 
state with respect to the full genome length. To infer if RAG2 could bind in the vicinity of the 
detected CNA breakpoints we performed a UCSC liftOver from hg19 to mm9 to compare the 
breakpoint loci to Chip-Seq data of Rag2 binding in wild type murine thymocytes10 (GEO omnibus 
GSM530318). Enrichment plots were generated with ngs.plot.32
RESULTS
Copy number variation analysis of adult ALL and AML
We have performed CNV analysis of diagnostic material of 53 B-ALL, 20 T-ALL and 100 AML cases 
(Table 1). In total we observed 1005 genomic alterations in ALL amounting to a mean of 13.77 
genetic alterations per ALL case. In total we detected 268 genetic lesions in AML, amounting to 
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a mean of 2.68 genetic alterations per AML case. Subcategorization of recurrent genetic lesions 
demonstrate that certain aberrations are highly specific for AML or an ALL subtype (Table 2, 
Supplementary Table 3, and Supplementary Table 4). Common amongst B-ALL and T-ALL is the 
deletion of CDKN2A and CDKN2B33 (Figure 1), 57% and 90% respectively, and RB1, 15% in both 
ALL subtypes. Strikingly, the two T-ALL cases without a deletion of CDKN2A/B have a deletion 
involving CDKN2AIP (CDKN2A interacting protein) and CDKN2AIPNL (CDKN2A interacting protein 
N-terminal like), implicating the perturbation of CDKN2A/B through different pathways. We 
detected genetic lesions highly specific for B-ALL involving IKZF1 (47%), PAX5 (36%), CRLF2 (22%), 
BTG1 (19%), BTLA (13%), MKKS (13%) and EBF1 (6%). Additionally, we detected genetic lesions 
highly specific for T-ALL involving NF1/SUZ12 (15%), WT1 (15%) and unbalanced translocations 
affecting TAL-1 (25%).
ALL
DNA mapping arrays
n=73
AML
n=100
Copy number analysis
NF1 microdeletion
GEP 
signatures
Mutation 
detection
NGS selected B-ALL cases
Examine RSS-like sequences
Mutation 
detection
Structural 
variants
CNVs
50 B-ALL 23 T-ALL
Figure 2. Analysis workflow for this study. Genomic characterization of acute lymphoblastic leukemia 
(53 B-ALL and 20 T-ALL) and acute myeloid leukemia by DNA mapping arrays is performed on each data set 
separately. AML and ALL cases with an acquired NF1 microdeletion were compared to all other leukemia cases 
to determine if this subgroup is characterized by a GEP signature. A subset of B-ALL patients was selected, due 
to an increased number of focal deletions, for further genomic characterization. Mutations, structural variants 
and CNVs are detected for these patients and subsequently used for the determination of RSS-like sequences 
near breakpoints. Next generation sequencing (NGS), gene expression profiling (GEP), copy number variation 
(CNV), recombination signal sequence (RSS).
Grouping the adult ALL cases on the basis of molecular subtype reveals specific patterns in relation 
to the total number of deletions and amplifications (Supplementary Table 5). ALL cases have on 
average 8.15 deletions and 4.56 amplifications, which changes negligible when dichotomized on 
B-ALL, 8.06 deletions and 4.74 amplifications and T-ALL, 8.40 deletions and 4.10 amplifications. 
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Table 1. Clinical and molecular data of ALL and AML patients characterized on DNA mapping arrays.
Characteristics
All 
patients
B-ALL 
patients
T-ALL 
patients Characteristics
AML 
patients
n=73 n=53 n=20 n=100
Age (years) Age (years)
median (range) 34 (17-69) 36 (17-69) 31 (18-65) median (range) 43 (15-72)
Gender Gender
male 43(59%) 27 16 male 54 (54%)
female 30(41%) 26 4 female 46 (46%)
WBC count  (x109/L) WBC count  (x109/L)
median (range) 17 (1-375) 49 (1-375) 67(6-338) median (range) 36 (1-234)
>30 15 15 0 Blasts at diagnosis 
 (before ficoll)
>100 4 0 4 median (range) 73 (2-96)
Blasts at diagnosis 
 (before ficoll)
FAB classification
Bone marrow (%) 93 (26-99) 83 (25-98) 78 (43-99) Unknown 8 (8%)
Peripheral blood (%) 66 (10-94) 54 (1-97) 56 (8-93) M1 5 (5%)
Immunophenotype M2 30 (30%)
B-cell 49 (67%) 49 (92%) 0 M3 13 (13%)
T-cell 20 (27%) 0 20 (100%) M4 23 (23%)
Biphenotypic 4 (6%) 4 (8%) 0 M5 17 (17%)
Cytogenetics M6 1 (1%)
t(9;22) (BCR-ABL) 15 (21%) 15 (28%) 0 RAEB 1 (1%)
Hyperdiploid 9 (12%) 9 (17%) 0 RAEB-T 1 (1%)
t(1;19) (E2A-PBX) 1 (1%) 1 (2%) 0 Cytogenetics
TEL-AML1 0 0 0 Favorable karyotype 14 (14%)
SIL-TAL1 4 (5%) 0 4 (20%) 11q23 abnormalities 2 (2%)
NUP214-ABL1 1 (1%) 0 1 (5%) inv(3)/t(3;3) 6 (6%)
SET-NUP214 1 (1%) 0 1 (5%) -7/7q 8 (8%)
11q23 abnormalities 5 (7%) 5 (9%) 0 Normal karyotype 55 (55%)
Normal karyotype 7 (10%) 5 (9%) 2 (10%) Failure 8 (8%)
Failure 5 (7%) 3 (6%) 2 (10%) Molecular aberrations
FLT3-ITD 31 (31%)
NPM1c+ 33 (33%)
DNMT3A mutant 20 (20%)
CEBPA double mutants 12 (12%)
Favorable karyotype comprises AML cases with the inv(16)(p13q22)/t(16;16)(p13;q22), t(8;21)(q22;q22) or 
t(15;17)(q22;q12) cytogenetic aberrations.
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There is a substantial lower number of deletions in ALL cases with a MLL-translocation, while 
hyperdiploid cases are characterized with an increased number of amplifications due to the 
additional chromosomes. Strikingly, we observe a substantial higher number of deletions (17.50) 
in patients with genetic alterations resulting in the overexpression of the receptor CRLF234, 
recently demonstrated to frequently coincide with JAK2 abnormalities35 in BCR-ABL1-like ALL 
cases.36 Finally, the subtypes encompassing BCR-ABL1, SIL-TAL and hyperdiploid ALL have similar 
numbers of deletions and amplifications with respect to ALL on average.
 CNV analysis of AML cases revealed only a few specific recurrent large genetic aberrations 
comprising the loss of chromosome 7 or 7q, gain of chromosome 13, gain of chromosome 11, and 
the gain of chromosome 8. This analysis also revealed the focal deletion of the locus encompassing 
the genes NF1 and SUZ12 in 5 AML cases (Table 2, Supplementary Table 4), as previously reported 
in paediatric AML.37 Interestingly, this deletion was also observed in 3 T-ALL cases highlighting 
that NF1 inactivation might play a role in both myeloid and lymphoblastic adult leukemia.37
The NF1 microdeletion perturbs both NF1 and SUZ12
The NF1 microdeletion is the only common genetic aberration observed in ALL and AML, 
including AML cases with acquired NPM1 mutations or the cytogenetic abnormality t(16;16)
(p13;q22) (Supplementary Table 6), and involves the deletion of a small region of chromosome 
17, i.e., del(17)(q11.2). We normalized the gene expression profiles to ascertain if this deletion 
confers a specific gene expression signature (Figure 2). Empirically, the commonly deleted region 
encompasses the genes encoding for NF1 and SUZ12 (Figure 3), both known to play a pivotal role 
in the malignant transformation of cancer.37-41 Recent NGS efforts demonstrated that both genes 
are perturbed in a multitude of cancers, due to microdeletions or loss of function mutations38,41, 
culminating into the hypothesis that PRC2 loss cooperates with the activation of the RAS pathway. 
Mutations in the remaining wild type allele of NF1 or SUZ12 could exacerbate the phenotype due 
to the complete loss of a functional protein. Previous studies demonstrated that most mutations 
in SUZ12 are located in the VEFS-box domain40,41, important for the interaction with the polycomb 
repressive complex 2 (PRC2) catalytic subunit EZH2. Genomic characterization of exons 12-16, 
encompassing the SUZ12 VEFS-box domain, through dHPLC and targeted deep sequencing 
in 230 unselected ALL patients, revealed somatic mutations in 3 T-ALL cases lacking the NF1 
microdeletion (Figure 4). Subsequent targeted sequencing of the complete coding sequences 
of NF1 in patients with a NF1 microdeletion revealed 1 AML and 1 T-ALL case with a complete 
loss of functional NF1 due to premature stop codon introducing mutations in the remaining 
wild type allele (Supplementary Table 6).  In total we have 5 AML and 3 T-ALL cases with NF1 
microdeletions perturbing both NF1 and SUZ12, and we identified 3 additional T-ALL cases with 
acquired mutations in SUZ12, including one case with a focal EZH2 deletion.
 Differential gene expression analysis of the normalized GEPs comparing acute leukemia cases 
with the NF1 microdeletion (n=8) to those without (n=844) demonstrated that NF1 and SUZ12 are 
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the most strongly down regulated genes (Figure 5A-B, Supplementary Table 7), suggesting and 
underpinning the hypothesis that the RAS pathway is activated in concert with the loss of PRC2.38
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Figure 3. NF1 microdeletion detected in T-ALL and AML. (top) The most commonly deleted genes due to 
the NF1 microdeletion. (bottom) The colored bars represent the regions deleted for T-ALL and AML patients. 
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SUZ12. (A) Comparison of NF1 expression between acute leukemia patients with the deletion to all AML/
ALL cases without reveals a substantial down regulation of NF1. (B) SUZ12 expression levels are lower in NF1 
microdeletion acute leukemia cases as compared to all other AML/ALL cases.
Mutation and structural variation detection in 5 B-ALL cases
Copy number analysis revealed a substantial number of ALL cases with genetic lesions perturbing 
promoters or complete gene bodies of genes important in lymphoid development, postulated to 
be originating from illegitimate V(D)J recombinations.8,9 To investigate whether this mechanism 
invokes the accumulation of genetic lesions in ALL we have performed WES and targeted 
resequencing of all breakpoint regions. We selected 5 B-ALL cases with substantial higher 
number of genetic lesions affecting promoters or genes involved in lymphoid development 
and determined all somatic mutations and structural variants. Of these 5 cases, 3 carry BCR-
ABL1, 1 exhibits a BCR-ABL1-like GEP and 1 is a normal karyotype B-ALL case (Supplementary 
Table 8). In total 102 somatic mutations were detected, amounting to 20.4 somatic mutations 
per ALL case (Supplementary Table 9). No recurrent somatic mutation was detected precluding 
the identification of a commonly perturbed pathway on the basis of somatic mutation data. A 
complex JAK2 mutation (I682>SP, Supplementary Figure 1) was detected in the BCR-ABL1-like 
patient with CRLF2 overexpression, which is in line with previous studies.36
 Structural variant analysis confirmed the copy number changes observed with DNA mapping 
arrays and the CNVsvd algorithm (Supplementary Table 10). In total 64 structural variants were 
detected, amounting to 12.8 structural variants per case on average. All cases had a complete or 
partial deletion of the IKZF1 gene. We detected recurrent deletions of the promoters of MKKS (all 
cases), BTLA (3 cases), and KRAS (3 cases). Notably, other genes reported to be associated with ALL 
are recurrently deleted, i.e., BTG1, PAX5, RB1, and CDKN2A/B.
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Proximal cryptic RSS motifs imputes RAG activity
The 128 proximal breakpoint sequences of all the 64 structural variants were extracted and 
subsequently used for de novo motif detection with MEME.29 This analysis discovered 1 significant 
motif characterized by the heptamer sequence CACAGTG (E-value 5.68X10-91, Figure 6A) present 
in 121 out of the 128 breakpoints. Strikingly, this motif equals the conserved heptamer sequence 
that is part of the RSS motif involved in V(D)J recombination. This process is mainly conferred by 
the RAG complex which targets V(D)J recombination sites by utilizing RSS motifs comprising of 
a highly conserved heptamer (CACAGTG), a 12-bp or 23-bp spacer without sequence specificity, 
and a less conserved nonamer (ACAAAAACC). This de novo analysis provides strong evidence that 
off-target RAG activity could mediate the deletions perturbing lymphoid specific genes.
 To ascertain if the breakpoints boundaries are flanked by cryptic RSS motifs we uploaded the 
breakpoint sequences to RSSsite28, which is designed to specifically detect cryptic RSS motifs, and 
demonstrated that most of the breakpoint boundaries are characterized by cryptic RSS motifs. 
Overall, in 58 out of the 64 rearrangements (90.6%), a confident RSS motif was found at one or 
both sides of the lesion (Supplementary Table 10). Strikingly, all IKZF1 deletions in our 5 selected 
B-ALLs were characterized by a cryptic RSS motif proximal to the breakpoint on at least one side 
(Figure 7). All cryptic RSS motifs were extracted from RSSsite and used for the construction of a 
position weight matrix and sequence logo (Supplementary Table 11). As expected, we observed 
the 12-bp spacer RSS motif (Figure 6B) and the 23-bp spacer RSS motif (Figure 6C) with less 
conservation for the nonamer.
 Further diversification of antigen loci is conferred by the amendment of palindromic 
sequences, through the opening of the recombination hairpins by the protein Artemis, or non-
templated sequences randomly incorporated by terminal deoxynucleotidyl transferase (TdT).42 We 
observed that 54 out of the 63 (85.7%) resolved rearrangements demonstrated the incorporation 
of non-templated sequences at the breakpoint (Supplementary Table 10), providing further 
evidence that RAG-mediated cleavage and further processing of the DNA ends play a pivotal role 
in the invocation of rearrangements in ALL.
Epigenetic state at RAG-induced structural variation boundaries
Most of the structural variants are characterized by a flanking cryptic RSS motif on one or both 
sides. We examined if the breakpoint junctions are enriched for particular epigenetic states or 
binding of known proteins. We procured the genome segmentation and Chip-Seq data of the 
B-lymphoblastic cell line GM12878 from ENCODE31 due to its complete characterization. In total, 
we examined 125 breakpoint junctions (Supplementary Table 10), omitting 3 breakpoint junctions 
located in undetermined regions of the human genome sequence (hg19) and lacking ENCODE 
data for the updated human genome sequence (hg38). The genome segmentation divides 
the genome into 15 chromatin states based on different combinations of epigenetic markers. 
We observed a 39.9-fold enrichment of the breakpoints (p < 2.2 X10-16), within active promoter 
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regions (39 out of the 125 of the breakpoints) (Figure 8, Supplementary Table 12). Strikingly, the 
active promoter chromatin state is only assigned to 0.78% of the GM12878 genome. Additionally, 
we observed a strong enrichment for weak promoters (11.4-fold), poised promoters (19.3-fold), 
and strong enhancers (8.5-fold). Overall, this data implies that most breakpoints are not only 
characterized by cryptic RSS motifs, but also active epigenetic markers, e.g., H3K4me3.
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Figure 7. Detection of cryptic RSS sequences near the observed breakpoints affecting IKZF1. (top) 
Genes located in the region encompassing IKZF1. (middle) Colored bars illustrate the deletion events, 
perturbing IKZF1, detected in the 5 ALL patients. (bottom) Proximal and distal breakpoint sequences for every 
deletion event. The dashed line represents the breakpoint, while the red letters highlights the cryptic RSS 
detected by RSSsite.
Previous studies have shown that recombination foci in the V(D)J loci are characterized by 
H3K4me3, H3 acetylation, and RNA polymerase II binding.10,43,44 We explored if particular histone 
markers and the binding of relevant proteins were enriched at the breakpoint loci using data 
generated from the cell line GM12878. The breakpoint loci are strongly enriched for H3K4me3 
and H3K27ac (Figure 9A-B), while it is completely devoid for the repressive epigenetic marker 
H3K27me3 (Figure 9C). Reminiscent of the V(D)J rearrangement foci in the antigen receptors the 
breakpoints are likewise enriched for the binding of RNA polymerase II (Figure 9D). The RAG2 
protein is able to bind H3K4me3 through its plant homology domain (PHD) and has been shown 
to bind to multiple regions outside of the antigen receptors in murine thymocytes.10 We extracted 
Rag2 Chip-Seq data derived from murine thymocytes and translated the breakpoints positions 
detected in the B-ALL cases to homologous mouse genome positions. From the 125 breakpoint 
positions 65 could be translated to the murine genome. Strikingly, we observe a strong enrichment 
of Rag2 binding in murine thymocytes at the breakpoint loci (Figure 9E).
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Figure 8. Chromatin state distribution of somatic structural variants. Somatic structural variations are 
segmented according to 1 of the 15 chromatin states extracted from ENCODE project data derived from the 
lymphoblastoid cell line GM12878. The structural variants are mainly located in active promoter regions which 
constitute only a small fraction, i.e., 0.78%, of the human genome.
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Illegitimate RAG-mediated mutagenesis of RSS motifs in promoters and 
gene bodies
Exhaustive detection of complex insertion and deletion mutations revealed a substantial number 
of complex mutations situated within gene promoters and gene bodies. Careful inspection 
revealed that most of the complex insertions and deletions take place within cryptic RSS motifs, 
as determined by RSSsite, providing evidence of frequent open-and-shut joints outside antigen 
receptor loci invoked by the RAG complex.45 Interestingly, we detected open-and-shut events in 3 
out of the 5 B-ALL cases within a cryptic RSS motif located in the core promoter of BTLA. Strikingly, 
2 out of the 3 B-ALL cases also lost the other allele due to a large genomic deletion (Figure 10). 
dHPLC analysis of the BTLA promoter revealed 8 additional B-ALL cases, predominantly (6 out 
of 8 cases) belonging to the BCR-ABL1 and BCR-ABL1-like subgroups, with open-and-shut joint 
events in the cryptic RSS motif (Supplementary Table 14). We also detected affected RSS motifs in 
the core promoter of ADAR, in conjunction with the loss of the other allele, and LILRA2 (data not 
shown). Complex insertions and deletions in RSS motifs located within gene bodies have been 
observed in TCF12, ARMC2, ZCCHC7, SCFD2, and PBX3 (Supplementary Figure 2). Finally, these 
complex mutations were also observed in RSS motifs located in classical V(D)J recombination foci 
within T-cell receptor and immunoglobulin genes.
Figure 10. B-ALL somatic lesions in the promoter of BTLA. Somatic complex mutations have been detected 
in the promoters of developmental genes. For BTLA 3 B-ALL cases harbor complex mutations in a RSS motif 
within its promoter of which 2 B-ALL cases also have a deletion encompassing the complete gene. 
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DISCUSSION
This study provides the detailed genomic characterization of 50 B-ALL, 23 T-ALL, and 100 AML 
adult leukemia cases. We observed that many of the genetic lesions identified in paediatric ALL 
are likewise present in adult ALL. In comparison to array-based genome characterization studies 
performed on adult ALL6 and paediatric ALL5, we observed a substantial higher frequency of 
the most common loci perturbed by genetic lesions, e.g. CDKN2A/B, IKZF1, and PAX5. Strikingly, 
we demonstrated that all T-ALL cases acquired CNAs perturbing the CDKN2A/B pathway. An 
explanation of this divergence of genetic lesion frequency is the use of higher resolution DNA 
mapping arrays. In the case of the adult ALL cohort the Affymetrix 250K DNA mapping array was 
used6, while for the paediatric cohort the Affymetrix 50K DNA mapping array.5 We have utilized 
the Affymetrix 6.0 DNA mapping array which has approximately 8-fold and 20-fold more CNA 
measuring probe sets that the Affymetrix 250K and 50K DNA mapping array, respectively.
  Interestingly, joint analysis of ALL and AML revealed a recurrent deletion affecting both 
the genes encoding for NF1 and SUZ12 in 3 T-ALL and 5 AML cases. The NF1 gene encodes for 
neurofibromin 1 and is postulated to be a negative regulator of the RAS signal transduction 
pathway.46 Loss of function mutations in the NF1 locus results in hereditary neurofibromatosis 
type I47, juvenile myelomonocytic leukemia39, and AML.46 The gene encoding SUZ12, a pivotal 
subunit of the polycomb repressive complex 2 (PRC2), which mediates the trimethylation of 
H3K27 (H3K27me3)48 resulting in a repressive epigenetic mark. Recent sequencing efforts 
have demonstrated that the SUZ12 gene is frequently perturbed by loss of function mutations 
in a multitude of cancers, including T-ALL40 and malignant peripheral nerve sheet tumors 
(MPNSTs).41 Subsequent GEP analyses revealed that both genes are substantially down regulated 
underpinning the recently proposed hypothesis that PRC2 complex loss cooperates with RAS 
pathway activation in a multitude of cancers. Finally, sequencing efforts revealed mutations 
within the VEFS-box domain of SUZ12, necessary for the interaction with EZH2, in additional 
T-ALL cases. In 2 out of 11 leukemia cases with perturbations in SUZ12, i.e., mutations or deletions, 
we observed premature stop codon introducing mutations in the remaining NF1 wild type allele, 
demonstrating that aberrations affecting NF1 and SUZ12 could cooperate in the pathogenesis of 
adult leukemia.
 A previous study has demonstrated that RAG-mediated recombination is a prominent driver 
of rearrangements in ETV6-RUNX1 ALL9, a rarely observed fusion protein in adult ALL. Here, we 
report on 5 BCR-ABL1/BCR-ABL1-like B-ALL cases for which the genomic rearrangements are 
predominantly driven by RAG recombination. Initial mutational analysis provided no recurrent 
somatic mutations, precluding the identification of a common pathway associated with 
leukemogenesis. However, de novo motif detection of breakpoint sequences hinted towards the 
pre-eminence of RAG-mediated rearrangements since 90.6% of the structural variants harbored 
a cryptic 12-bp or 23-bp spacer RSS motif flanking one or both of the breakpoint positions. We 
examined the enrichment of epigenetic markers near breakpoint loci and demonstrated, likewise 
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to classical V(D)J recombination10, that these breakpoints are enriched for H3K4me3, H3 acetylation 
and RNA polymerase II binding. Chip-Seq data revealed Rag2 binding near the identified 
breakpoints in murine thymocytes, suggesting that these regions could be predispositioned for 
RAG-mediated recombination.
 Finally, we observed open-and-shut joining events in gene promoters and gene bodies 
involving RSS motifs which are likely introduced by illegitimate RAG activity. RAG-mediated 
deletion of one allele in conjunction with the open-and-shut mutagenic event on the remaining 
allele could result in the complete knockout of a gene. Recurrence of these open-and-shut 
events, e.g. the BTLA core promoter, suggests that these mutagenic events are associated with 
leukemogenesis. The complex mutational patterns hint towards the binding of the RAG complex, 
subsequent nicking, addition of non-templated nucleotides, but the failure to form the synaptic 
complex leading to error-prone non-homologous end joining (NHEJ). This mutational process 
requires additional studies to elucidate the exact mechanism and it would therefore be interesting 
to replicate these results in additional ALL cases or subtypes.
 The prospect of prominent RAG-mediated oncogenic rearrangements in adult leukemia 
provides an interesting topic for further research. Although, we have shown that it is a prominent 
mutational process, especially in regions characterized by RSS motifs and epigenetic markers 
native to V(D)J regions within antigen receptors, it is still unknown why the RAG recombinase 
invokes these lesions outside the antigen loci. Strikingly, most cases with a BTLA promoter 
mutation belong to the BCR-ABL1 or BCR-ABL1-like group. Previous studies have demonstrated 
that c-ABL1 and BCR-ABL1 modulate the activity and protein expression level of the NHEJ 
component DNA-dependent protein kinase catalytic subunit (DNA-PKcs).49,50 Interestingly, a 
recent study has demonstrated that BCR-ABL1-like cases frequently acquire activating lesions in 
kinases36 likewise to the BCR-ABL1 fusion product. However, if kinase-activating lesions modulate 
the NHEJ DNA repair pathway activity or behaviour remains a topic for further investigation.
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ABSTRACT
Severe congenital neutropenia (SCN) is a bone marrow failure syndrome with a high risk to 
progress towards acute myeloid leukemia (AML). The underlying genetic changes involved in 
SCN evolution to AML are largely unknown. We obtained serial hematopoietic samples of an SCN 
patient who developed AML 17 years after initiation of granulocyte-colony stimulating factor 
(G-CSF) treatment. Next-generation sequencing was done to identify mutations during disease 
progression. In the AML phase, we found 12 acquired non-synonymous mutations. Three of these, 
in CSF3R, LLGL2 and ZC3H18, co-occurred in a subpopulation of progenitor cells already in the early 
SCN phase. This population expanded in time, whereas clones solely harboring CSF3R mutations 
disappeared from the bone marrow. The other 9 mutations were only apparent in the AML phase 
and affected known AML-associated genes (RUNX1 and ASXL1) and chromatin remodelers (SUZ12 
and EP300). In addition, a novel CSF3R mutation was found conferring autonomous proliferation 
to myeloid progenitors. We conclude that progression from SCN towards AML is a multistep 
process with distinct mutations arising early during the SCN phase and others later in AML 
development. Sequential gain of two CSF3R mutations implicates abnormal G-CSF signaling as a 
driver of leukemic transformation in this case of SCN.
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter6/
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INTRODUCTION
Severe congenital neutropenia (SCN) is a bone marrow failure syndrome characterized by strongly 
reduced neutrophil counts and recurrent, potentially life threatening, opportunistic bacterial 
infections. Treatment with granulocyte-colony stimulating factor (G-CSF) elevates peripheral 
neutrophil counts and reduces the risk of infections.1 Leukemic progression of SCN is a major 
concern with an estimated overall cumulative incidence of approximately 20% after 15 years of 
G-CSF treatment.2 
 Constitutional mutations in the gene encoding neutrophil elastase (ELANE) are common 
defects in SCN.3 In addition, the acquisition of nonsense mutations in the gene encoding the 
granulocyte-colony stimulating factor receptor (CSF3R) is a unique feature in SCN patients.4-7 
These mutations lead to expression of truncated CSF3R proteins, also known as delta forms. 
In cell line models, truncated CSF3R proteins are hampered in transducing signals required for 
proper neutrophil differentiation. Additionally, they confer increased proliferative responses to 
G-CSF treatment but do not cause leukemia in mice.4-6,8-11 CSF3R delta mutations can be detected 
in approximately 30% of SCN patients. In some cases, distinct clones with different CSF3R delta 
mutations are present for many years.7,12 After evolution of SCN towards AML, CSF3R delta 
mutations are found in approximately 80% of the cases.12 Until now, all reported SCN/AML cases 
harboring a CSF3R delta mutation in the SCN phase also carry this mutation in the leukemic 
phase. These observations suggest that leukemic progression in SCN follows a unique pattern, 
with CSF3R delta mutations as an early event, followed by additional genetic and epigenetic 
events that are essential for full leukemic transformation. Chromosomal aberrations, such as loss 
of chromosome 7 and gain of chromosome 21, are apparent in AML arising from SCN and other 
bone marrow failure syndromes like Fanconi anemia and Shwachman-Diamond syndrome.13 
However, mutations that are quite commonly seen in de novo AML have not been reported in 
AML arising from SCN.14 Thus, the additional molecular events involved in leukemic progression 
of SCN remain largely unknown.
 To identify the sequential genetic events in leukemic progression of SCN towards AML, we 
collected serial hematopoietic samples of an SCN patient who developed AML after 17 years of 
G-CSF therapy. Using whole exome sequencing, we found 12 somatic non-synonymous mutations 
in the leukemic blasts of this patient. Three of these mutations, the known CSF3R mutation 
and mutations in LLGL2 and ZC3H18, were already present at low frequencies in the early SCN 
phase, 15 years before AML was diagnosed. Myeloid colony analysis showed that these 3 “early” 
mutations co-existed in the same hematopoietic progenitors in a small subpopulation of bone 
marrow cells. Six years later, in the “intermediate” SCN phase, still 9 years before the AML became 
overt, we observed an expansion of the clone harboring all 3 mutations. The other 9 mutations 
were only apparent in the AML. The latter “late” appearing mutations comprise a second, novel, 
CSF3R mutation in addition to a series of novel and known AML-associated mutations. The novel 
CSF3R mutation is located on the already mutated CSF3R-d715 allele and causes growth factor 
independence of myeloid progenitors.
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MATERIAL AND METHODS
Case report
A 27-year old male SCN patient was diagnosed with AML 17 years after the start of G-CSF treatment 
(10μg/kg/day), on which he reached normal neutrophil counts. The patient had a constitutional 
heterozygous ELANE mutation, G174R. At the age of 12, 2 years after G-CSF treatment was 
initiated, a CSF3R delta mutation (CSF3R-d715) was discovered in the bone marrow.6 At the time 
of AML diagnosis, the peripheral blood contained 24% blasts and dysplasia was observed in the 
bone marrow. G-CSF treatment was stopped at this point. Six weeks later, a bone marrow analysis 
revealed 17% blasts. Immunophenotypically, these blasts were of myeloid origin, i.e., positive for 
CD34, CD117, CD13, CD133, CD33, MPO and CD90. Because no HLA-identical donor was available, 
the patient received a matched unrelated donor (MUD) allogeneic bone marrow transplantation. 
Induction therapy was given according to the induction therapy scheme HOVON42A of the 
Hemato-Oncology Foundation for Adults in the Netherlands.15 At initiation of induction therapy, 
the bone marrow contained 15.7% blasts, with 10-50% dysplasia in all lineages. Routine 
cytogenetic and molecular diagnostics revealed a trisomy 21 (47, XY, +21 [14] /46, XY [4]), with 
no additional abnormalities (AML-ETO, CBFB-MYH11, FLT3ITD, FLT3TKD, mutations in NPM1, NRAS, 
KRAS, c-KIT, JAK2 and CEBPA). After the second induction cycle trisomy 21, was undetectable in 
a marrow cytogenetic analysis. The MUD transplantation was administered after myeloablative 
conditioning with chemotherapy and total body irradiation. Two months after the transplantation 
28% blast were detected in the bone marrow, indicating a recurrence of the AML and the patient 
died 3.5 months after the transplant. Figure 1 gives a schematic overview of the disease history.
Figure 1. Chronological overview of the clinical course of the SCN/AML patient. Distinct events in the 
disease course are indicated above the timeline, i.e., the diagnosis of SCN, the initiation of G-CSF therapy, the 
discovery of the CSF3R-d715 mutation and the diagnosis of AML. 
Patient cell samples
Ficoll-gradient separated bone marrow cells from the SCN phases and CD34+ leukemic blasts 
from the peripheral blood in the leukemic phase were used. Control DNA was isolated from bone 
marrow-derived fibroblasts. All cell samples were obtained and frozen according to established 
procedures for viable cell cryopreservation as previously described.16 The study was performed 
under the permission of the Institutional Review Board of the Erasmus MC, registration number 
MEC-2008-387 for biobanking and MEC-2012-030 for the genetic analysis of leukemic progression 
in SCN patients. 
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Nucleotide sequencing
Whole exome sequencing (WES). 
Sequencing libraries were prepared according to the SureSelect Target Enrichment system for 
Illumina, protocol version 2.2.1, Nov. 2010. In short, 3 μg genomic DNA was sheared to fragments 
of approximately 170 base pairs using the Covaris S-series Single Tube Sample Preparation 
System, Model S2 (Covaris, Woburn, MA, USA). Fragment sizes were checked on the Bioanalyzer 
(Agilent, Santa Clara, CA). Adapter ligated libraries were prepared according to the manufacturer’s 
protocol using the Paired-End Genomic DNA Sample Prep Kit PE-102-1001 (Illumina, San Diego, 
CA); 5 cycles of amplification were used. Five hundred ng of prepped library was taken for 
hybridization with the SureSelect Human All Exon Kit (G3362A, Agilent). A sample concentration 
of 5.5 picomolar was loaded for sequencing on the Hiseq2000 (Illumina) using 101-bp paired-end 
reads. 
 Sequencing reads were processed with the Casava pipeline (version 1.7, Illumina). For 
alignment the hg18/NCBI36 assembly (March 2006) was used. Detection of single nucleotide 
variants, deletions and insertions was performed with otherwise default settings, while 
snpCovCutoff and indelsCovCutoff were switched off. Variations detected in the AML sample 
in 2 independent sequence runs were further analyzed after removal of germline variations 
(present in the fibroblasts) and single nucleotide polymorphisms (SNPs, dbSNP).17 Next, non-
synonymous variants were determined. Integrative Genome Browser was used for sequence read 
visualization.18
Sanger sequencing. 
WES results were validated by Sanger sequencing, performed according to the manufacturer’s 
protocol (Applied Biosystems, Foster City, CA, USA) using primers indicated in Table S1. Before 
amplicon generation, genomic DNA or cDNA was first amplified using a Whole Genome 
Amplification kit (WGA2, Sigma-Aldrich, Zwijndrecht, The Netherlands). DNA was purified with 
a PCR purification kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol and 
diluted to 50 ng/μl. Hundred nanograms of amplified DNA was used for amplicon generation; 
cycling conditions were 30” at 95°C, 30” at the indicated annealing temperature (Table S1) and 
45’’ at 72°C for 35 cycles. In some instances, the unamplified material was used directly for Sanger 
sequencing (Table S1).
Amplicon-based deep sequencing. 
Amplicons were generated and purified according to the Amplicon Library Preparation Method 
Manual (version May 2010, Roche, Basel, Switzerland). Primers and annealing temperatures are 
indicated in Table S2; 35 cycles were used for amplification. DNA enriched beads, carrying the 
amplification products, were generated according to the emPCR Amplification Method Manual 
– Lib-A (version May 2010, Roche); a beads to amplicon ratio of 1:2 was used. Amplicons were 
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analyzed with the GS junior (Roche). Sequence reads were analyzed using the GS Amplicon 
Variant Analyzer (Roche). For the SCN samples, coverage of at least 1600 was achieved to identify 
mutations present in minor clones within the bone marrow. For the AML sample coverage of 80 
was considered sufficient to validate mutations.
Human myeloid colony assay
Bone marrow was thawed at 37°C, washed twice with IMDM (Gibco Invitrogen, San Diego, CA) 
with 10% FCS (PAA laboratories, Pasching, Austria). Per 4 ml of culture medium, 2.9 ml MethoCult 
(H4230, Stem Cell Technologies, Vancouver, Canada), 980 μl IMDM and human GM-CSF (Immunex, 
Seattle, WA), human G-CSF (Neupogen, Amgen, Thousand Oaks, CA) and human IL-3 (R&D 
Systems, Minneapolis, USA) in final concentrations of respectively 2 ng/ml, 200 ng/ml and 25 ng/
ml were used. Cells were plated at a density of 0.8 x 105/ml. After 2 weeks genomic DNA of single 
colonies was isolated, followed by amplification using the Whole Genome Amplification kit and 
Sanger sequencing of CSF3R-d715, LLGL2 and ZC3H18, as described above. Results were validated 
in an independent round of whole genome amplification for (1) colonies harboring a mutation, 
(2) colonies with unclear sequences and (3) a number of randomly chosen non-mutated colonies 
to rule out amplification artifacts. All colonies harboring mutations in CSF3R, LLGL2 or ZC3H18 
were also analyzed for the presence of the remaining 9 mutations found in the AML sample.
Murine colony assays
Four different CSF3R expression constructs (WT, d715, T595I, d715/T595I) were generated and 
retrovirally transduced into bone marrow cells of Csf3r-deficient FVB/N mice.19 Colony assays of 
these transduced progenitors were performed as previously described.20 Further details of these 
procedures are given in the Supplementary Materials and Methods.
RESULTS
Whole exome sequencing reveals acquired mutations in SCN/AML
WES was done on genomic DNA from the CD34+ leukemic blast fraction and the fibroblast 
control sample. Acquired non-synonymous mutations were detected by identification of single 
nucleotide variants and small insertions and deletions, followed by subtraction of variants 
present in the control fibroblasts and known single nucleotide polymorphisms.17 Twelve non-
synonymous acquired mutations were identified and validated by Sanger sequencing (Table 1, 
Figure S1). Except for the mutation in FBXO18, all mutations occurred in evolutionary conserved 
amino acids (Figure S2). With the exception of LAMB1, all mutant transcripts were detectably 
expressed in the leukemic blasts (Figure S3). Mutations in ASXL1 and RUNX1 are known in myeloid 
malignancies.21,22 
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Deletions in EP300, distinct from the 7-bp deletion found in this patient, have been reported in 
lymphomas.23,24 The ATT insertion in SUZ12 duplicates an isoleucine at amino acid position 597, 
located in the conserved VEFS-box. Mutations in this region, which is involved in the interaction 
between SUZ12 and the histone methyltransferase EZH2 in the polycomb repressor complex 
2 (PRC2), have recently also been identified in myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN) with 17q abnormalities.25 As expected, the previously identified CSF3R delta mutation 
(CSF3R-d715) was present in the leukemic blasts, but remarkably a new CSF3R mutation, T595I, 
was now also present. Furthermore, the CSF3R-T595I mutation was located on the same allele as 
the delta mutation, as determined by Sanger sequencing of single amplicons generated from 
cDNA. Using exome sequencing data from 199 AML cases reported by The Cancer Genome Atlas 
(TCGA), a similar single CSF3R-T595I mutation was detected. Additionally, mutations in ASXL1 
(n=5), CCDC155 (n=1), LLGL2 (n=1), MGA (n=1), RUNX1 (n=17), SUZ12 (n=2) and ZC3H18 (n=2) were 
found in the TCGA data set (Table S3).26 
Amplicon-based sequencing reveals an early pre-leukemic clone that 
expands over time
Amplicon-based deep sequencing was applied to analyze the presence of all 12 somatic mutations 
in the bone marrow samples obtained at 15 and 9 years before AML was diagnosed (Figure 1). Not 
only the known CSF3R-d715 mutation, but also mutations in LLGL2 and ZC3H18 were already present 
in these earlier disease phases (Figure 2A, Table S4). We investigated the clonal hierarchy of these 
mutations in single myeloid colonies cultured from the earliest bone marrow sample (15 years 
before AML diagnosis). In the individual colonies (n=88), the mutation status of CSF3R-d715, LLGL2 
and ZC3H18 was determined. Fifteen colonies (17%) harbored both the CSF3R-d715 and the LLGL2 
mutation, whereas none of the colonies exhibited exclusively either the LLGL2 or the CSF3R-d715 
mutation (Figure 2B, Table S5). Two of the CSF3R-d715 and LLGL2 mutated colonies also carried the 
ZC3H18 mutation (Figure 2B, Table S5), indicating that this mutation had emerged later in time. 
None of the other 9 mutations found in the AML cells was apparent in these colonies (Table S5). 
 A previous report has shown that multiple CSF3R delta mutations can be present in distinct 
progenitors in the bone marrow of an individual SCN patient.7 In line with this previous report, 
we found myeloid colonies with CSF3R-d717 (n=2) and CSF3R-d725 (n=1) (Figure 2B, Table S5). 
Each of these mutations and yet an additional delta mutation (CSF3R-d730) were detected in the 
SCN phase at low frequencies by amplicon-based deep sequencing (Figure 2C, Table S6). None 
of these variant CSF3R mutant clones harbored LLGL2 or ZC3H18 mutations, nor were they seen 
as dominant clones in the AML (Figure 2, Table S5-S6). No viably frozen cells were available from 
the bone marrow sample obtained 9 years before AML development and colony analysis could 
not be performed at this stage. However, by amplicon-based deep sequencing we observed a 
parallel increase of the CSF3R-d715, LLGL2 and ZC3H18 mutations from 15 to 9 years before AML 
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development (Figure 2A). Together with the finding that these mutations are present in the same 
myeloid progenitor cells (Figure 2B), this observation is consistent with a selective outgrowth of 
clones carrying these 3 mutations.
Figure 2. Acquisition of mutations in the evolution of SCN towards AML. (A) The 12 somatic non-
synonymous mutations identified in the leukemic blasts were analysed in the SCN phase using amplicon-
based deep sequencing. Per mutation, the percentage of mutated amplicons is shown. (B) Single myeloid 
colonies grown from the bone marrow sample obtained 15 years before leukemia development were 
analysed for the presence of mutations in CSF3R, LLGL2 and ZC3H18. See also Table S5. (C) The presence of 
different CSF3R mutations in the bone marrow obtained 15 and 9 years before leukemia development and in 
the leukemic phase was investigated by amplicon-based deep sequencing. Per mutation, the percentage of 
mutated amplicons is shown. T595I: CSF3R mutation T595I, d715-d730: CSF3R delta mutations at amino acid 
position 715 to 730. 
Sequential gain of a second CSF3R mutation results in G-CSF independence
A new CSF3R mutation, acquired at the CSF3R-d715 mutant allele, was found exclusively in the 
AML blasts and changed a polar threonine residue at amino acid position 595 into a nonpolar 
isoleucine. This residue is located in a highly conserved threonine-rich region in the extracellular 
domain of the G-CSF receptor (Figure S2). Introduction of human CSF3R mutant receptors, 
carrying this new T595I mutation (Figure 3A), into Csf3r-deficient primary mouse bone marrow 
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progenitors resulted in the autonomous outgrowth of myeloid colony-forming cells (Figure 3, 
Table S7). Thus, in the AML phase of disease evolution two different co-existing mutations, i.e., the 
T595I single amino acid substitution and the CSF3R-d715 mutation had accumulated in the gene 
encoding the G-CSF receptor. Because expression of the new CSF3R mutant without the delta 
mutation conferred G-CSF independence as did the mutant receptor carrying both the delta and 
the extracellular mutation, this gain of function can entirely be attributed to the T595I mutation. 
However, the T595I/d715 colonies were bigger than the T595I colonies (Figure S4), which is 
suggestive of a higher proliferation capacity by the addition of the CSF3R-d715 mutant.
Figure 3. Functional analysis of CSF3R mutants in myeloid progenitor cell assays. In vitro colony growth 
of Csf3r-deficient murine hematopoietic progenitor cells expressing different CSF3R mutants. (A) Graphical 
representation of the different CSF3R constructs. Wild type (wt), T595I (containing the extracellular mutation 
at amino acid position 595), d715 (containing the intracellular mutation, Q716X, causing the introduction of 
a stop codon at amino acid position 716) and T595I/d715, containing both mutations as found in the SCN/
AML patient. Ig: Immunoglobulin like domain; CRH: cytokine receptor homology domain; FNIII: fibronectin 
type III repeats; TM: transmembrane domain; cyto: cytoplasmic domain. Nomenclature has been adopted 
from Layton et al.27 (B) Colonies were grown in the presence of puromycin, either without growth factor (no 
GF) or with 100ng/ml human G-CSF. The induced colony growth is dependent on the transduction efficiency 
and the type of CSF3R construct. The transduction efficiency can be deduced from the number of GM-CSF-
induced colonies under puromycin selection as the CSF3R constructs confer puromycin resistance, but do not 
affect GM-CSF-induced colony growth. Hence, by dividing the number of colonies by the number of GM-CSF 
induced colonies the transduction efficiency was corrected for.
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DISCUSSION
The results of the present study identified non-synonymous mutations acquired in an SCN patient 
who progressed to AML.The availability of sequential hematopoietic samples from the childhood 
SCN phase to overt AML, spanning a period of 17 years, provided the unique opportunity to 
identify the early and late genetic defects associated with leukemic progression (Figure 4). The 
CSF3R-d715 mutation and a mutation in LLGL2, encoding the human homologue of the Drosophila 
lethal giant larvae (Lgl) gene, were the first 2 acquired mutations in the early SCN phase. Loss of 
Lgl in Drosophila leads to inadequate distribution of the cell polarity protein Numb, resulting in 
inappropriate cell fate determinations and tumor formation in epithelial tissues and the brain.28-30 
In man, the NUMB protein has been implicated in controlling the balance between symmetric 
versus asymmetric hematopoietic stem cell divisions. Interestingly, deregulation of NUMB 
expression has been associated with blast transformation of chronic myeloid leukemia.31,32 How 
the LLGL2 mutation found in this study affects hematopoietic stem cell divisions is still unknown; 
however, the fact that CSF3R-d715 and LLGL2 mutations were uniformly present in the same 
myeloid cells could suggest that they cooperate. Hierarchically, the next genetic abnormality 
occurring in the early SCN phase in the CSF3R-d715- and LLGL2-mutated clone was a mutation 
in ZC3H18. ZC3H18 is a putative mRNA binding protein with a still unknown function, but in 
trypanosomes it is shown to be essential for differentiation.33 
 Additionally, we found small subpopulations harboring distinct CSF3R delta mutations in the 
bone marrow at the early SCN stage. All these clones disappeared during the disease course, 
except the CSF3R-d715 clone which evolved towards AML. The different CSF3R delta mutations 
cause expression of distinct truncated G-CSF receptors that all have similar consequences for 
signaling; they result in a sustained activation of signal transducer and activator of transcription 
5 (STAT5).8 STAT5 is a transcription factor, implicated in abnormal signaling responses of leukemic 
cells with mutated forms of the FLT3 receptor (FLT3-ITD) in AML and the BCR-ABL fusion protein in 
CML.34,35 Furthermore, why one of these CSF3R delta mutant clones survived in vivo and progressed 
towards a fully transformed AML clone while the other CSF3R delta variants extinguished during 
disease development currently remains unexplained. However, it is conceivable that the additional 
mutations in LLGL2 and ZC3H18, exclusively present in the CSF3R-d715 clone, conferred a 
competitive growth advantage of this particular subclone representative of essential early steps in 
leukemic progression that cooperate with the aberrant signaling from the truncated G-CSF receptor.
 Besides early genetic events, we found 9 mutations that occurred later in the process of 
leukemic transformation. Of particular interest is the novel CSF3R mutation (T595I), which 
appeared exclusively in the AML stage and imposed growth factor independence on an already 
functionally defective G-CSF receptor. A different mutation in the CSF3R transmembrane domain, 
CSF3R-T617N, with a similar downstream effect was previously found as a constitutive mutation in 
a family with hereditary chronic neutrophilia and as an acquired mutation in 2 AML patients. This 
mutation is suggested to cause ligand independent homodimerization and induces growth factor 
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independent proliferation and differentiation.36,37 The major difference between the T617N and the 
T595I mutation in our patient is that the latter one is located on the already affected CSF3R-d715 
allele, which has been shown to cause increased proliferation and impaired differentiation in 
cell line and animal models8,38,39 and which could explain the increase in colony size between 
the T595I mutant and the T595I/d715 mutant. The acquisition of autonomous growth abilities by 
myeloid progenitor cells that already express a hyper-responsive G-CSF receptor mutant strongly 
suggests that perturbed G-CSF signaling was of vital importance for malignant transformation in 
this case of SCN. To our knowledge, this is the first example of a gain of 2 different mutations in the 
same receptor in the process of malignant transformation. An important, but still open question, 
is whether the administration of G-CSF to this patient had contributed to the acquisition of this 
additional mutation. Possibly, the continuous proliferative pressure imposed by G-CSF on clones 
carrying mutations in CSF3R-d715 and LLGL2 and later also in ZC3H18 may have provided the 
context for the selection of a clone harboring this self-activating CSF3R mutation, pushing it to 
become an autonomously proliferating and dominant leukemic clone. 
 Abnormalities appearing in the AML phase included mutations in ASXL1, SUZ12, and EP300, 
genes encoding proteins involved in chromatin modification. Mutations in ASXL1 have been 
reported previously in AML and are associated with an unfavorable prognosis.40 SUZ12 is a 
member of the PRC2 complex that also contains EZH2, the histone methyl transferase responsible 
for the di- and tri-methylation of lysine 27 in the tail of histone 3 (H3K27), imposing a chromatin 
mark that represses gene expression. Mutations affecting EZH2 and less frequently SUZ12 have 
been detected in MDS/MPN patients.25,41,42 In contrast, mutations in EP300 and the highly related 
CREBBP, encoding histone acetyl transferases that act as transcriptional co-activators, have not 
yet been reported in myeloid malignancies but are the most frequent structural abnormalities 
in follicular lymphoma and diffuse large B cell lymphoma.23,24 Mutations in CCDC155, encoding 
coiled-coil domain containing protein 155 with unknown function; FBXO18, encoding a DNA 
helicase involved in DNA repair and genomic integrity; LAMB1, encoding an extracellular matrix 
protein; and MGA, encoding a Max gene associated antagonist of Myc oncoproteins, all represent 
novel mutations with currently unknown functional significance. 
 Recurrence is an important criterion to discriminate driver from passenger mutations in 
the process of malignant transformation. Interestingly, mutations in CCDC155, LLGL2, MGA and 
ZC3H18 were recently also reported by the TCGA consortium in a panel of AML patients (n=199), 
albeit at low frequencies.26 Because frequencies of specific mutations have been shown to vary 
with the natural history of AML, e.g. de novo versus secondary to MDS/MPN or different bone 
marrow failure syndromes14,43, it will be of interest to establish how often the newly identified 
genes are affected in distinct subtypes of secondary AML. Specifically, it will be important to 
determine whether LLGL2, ZC3H18 or functionally related genes are more generally affected in 
bone marrow failure syndromes prone to progress to AML and to establish how these mutations 
contribute to malignant transformation in conjunction with cooperative gene defects.  
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Figure 4. Schematic representation of the clonal evolution of SCN towards AML. The sequential genetic 
events, starting with the presence of a germ line mutation in the gene encoding neutrophil elastase (ELANE) 
are indicated. A sequential gain of CSF3R delta mutations and an LLGL2 mutation is observed in the early SCN 
phase. Only the clone harboring the CSF3R-d715 and the LLGL2 mutation gained an additional mutation in 
ZC3H18, followed by its expansion in the intermediate SCN phase. Gain of 9 additional mutations and trisomy 
21 in the mutated population preceded complete transformation towards AML. CSF3R-d715-d730: CSF3R 
delta mutations at amino acid position 715 to 730.
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ABSTRACT
Chromosomal rearrangements without gene-fusions have been implicated in leukemogenesis by 
causing deregulation of proto-oncogenes via relocation of cryptic regulatory DNA elements. AML 
with inv(3)/t(3;3) is associated with aberrant expression of the stem-cell regulator EVI1. Applying 
functional genomics and genome-engineering, we demonstrate that both 3q-rearrangements 
reposition a distal GATA2 enhancer to ectopically activate EVI1 and simultaneously confer GATA2 
functional haploinsufficiency, previously identified as the cause of sporadic familial AML/MDS 
and MonoMac/Emberger syndromes. Genomic excision of the ectopic enhancer restored EVI1 
silencing and led to growth inhibition and differentiation of AML cells, which could be replicated 
by pharmacologic BET-inhibition. Our data show that structural rearrangements involving single 
chromosomal repositioning of enhancers can cause deregulation of two unrelated distal genes, 
with cancer as the outcome.
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter7/
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INTRODUCTION
Chromosomal inversions and translocations play a central role in the pathogenesis of almost 
all types of cancers, frequently by formation of oncogenic fusion genes via rearrangement of 
coding sequences of the involved partner genes.1-3 Mechanisms of transformation remain largely 
unknown in malignancies arising from chromosomal inversions/translocations that do not cause 
fusion products, although it is thought that destabilization of cryptic regulatory elements affects 
genes in the vicinity of the structural rearrangement, as has been shown in Burkitt’s4 or follicular 
lymphoma.5,6
 In the World Health Organization (WHO) category of myeloid malignancies with inv(3)
(q21q26.2) or t(3;3)(q21;q26.2), deregulation of the proto-oncogene EVI1 (also termed MECOM 
or PRDM3) at 3q26.2 is speculated to occur via juxtaposition of a cryptic enhancer of the 
housekeeping gene RPN1 from 3q21.7 However, this hypothesis has not been experimentally 
validated and the molecular basis of this prognostically unfavorable subtype of malignancies 
remains obscured. EVI1 expression and function is indispensable for proper regulation of 
the hematopoietic stem cell compartment and genomic integrity.8-10 The gene was originally 
described as a hotspot for proviral integration in retrovirally induced murine myeloid leukemias11, 
and also represents an important insertional mutagenesis site in humans following gene therapy 
for X-linked granulomatous disease.12
 We tested the hypothesis that rearrangements causing the transcriptional activation of EVI1 
involve the reallocation of an enhancer element to the ectopic 3q26.2/EVI1 target site, which 
may possibly coincide with a loss of enhancer activity at its endogenous location. We applied an 
integrated functional genomics and genome-engineering approach to identify a distal enhancer 
of the GATA2 gene that, upon chromosomal 3q-rearrangements, ectopically activates EVI1 
expression. Simultaneously, the removal of this enhancer from its natural genomic context causes 
functional GATA2 haploinsufficiency, i.e. reduced GATA2 expression only from the remaining 
normal allele.
RESULTS
An 18 kb non-coding region near RPN1 commonly translocates to EVI1 in 
inv(3)/t(3;3) disease
We performed targeted next generation sequencing (NGS) of the long arm of chromosome 3 
(3q-seq) using genomic DNA isolated from 41 samples with confirmed EVI1 overexpression (EVI1+) 
and harboring an inv(3)(q21q26.2) or a t(3;3)(q21;q26.2) [inv(3)/t(3;3)]. The samples included 38 
primary bone marrow samples from patients, i.e. AML (n=33), CML-BC (n=2), and MDS cases (n=3), 
as well as three cell lines (MUTZ-3, MOLM-1, and UCSD-AML1) (Table S1). Chromosomal breakpoint 
positions and novel junction sequences of each case were determined by a breakpoint detection 
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algorithm in conjunction with a de novo assembly tool and validated by Sanger sequencing. 
Characteristic breakpoint patterns emerged at both 3q21 and 3q26.2 breakpoint cluster regions 
(Figure 1A). At the 3q26.2 site, samples harboring an inv(3) exclusively exhibited breakpoints in 
the last intron or downstream of EVI1. Breakpoints in t(3;3) cases distinctly mapped upstream 
of EVI1, i.e. within the gene locus of the longer splice variant that includes MDS1-EVI1 (Figure 
1A). At the 3q21 site, breakpoints occurred in a 130 kb region between GATA2 (centromeric) and 
RPN1 (telomeric). A minimal 18 kb non-coding region 3’ of RPN1 demarcated by chromosomal 
breakpoints was identified as a commonly translocated segment (hereafter referred to as CTS) 
(Figure 1B), which in all cases underwent transpositioning to the vicinity of EVI1 due to the 
inv(3)/t(3;3) rearrangement. This converging tell-tale pattern of 3q21 breakpoints toward an 
unaffected 18 kb genomic segment led us to predict the presence of potent regulatory elements 
within the CTS, essential for aberrant activation of EVI1 upon rearrangement.
The EVI1 promoter and the 18 kb CTS physically interact
A hallmark of distal enhancer elements is their engagement in chromatin loops physically 
contacting with promoters to induce transcription factor assembly and polymerase II 
recruitment.13-16 To test whether the CTS harbored elements physically interacting with the 
EVI1 promoter, we performed high-resolution chromosome conformation capture sequencing 
(4C-seq) experiments.17 Using viewpoints placed on the EVI1 promoter in viable inv(3)/t(3;3) 
AML samples and cell lines, we identified a genomic segment of approximately 9 kb size within 
the 18 kb CTS contacting with the EVI1 promoter (Figures 1C and 1D). Other contact regions 
located centromeric of this 9 kb contact hotspot in closer distance to the EVI1 promoter after 
the rearrangement, as observed in individual samples with different breakpoint positions, were 
considered less likely enhancer candidates. These regions were non-overlapping across different 
samples and thus represented less specific contacts, which became more evident after integrative 
analysis of all 3q-rearranged AML samples (Figure 1D). Reciprocal 4C-seq experiments with the 
putative 9kb region as viewpoint showed that the interaction with the EVI1 promoter area was 
also evident (Figure S1). As expected, no substantial chromatin interactions with the distant 
EVI1 promoter could be detected in 4C-seq experiments with non-3q-rearranged control (U937), 
suggesting an inv(3)/t(3;3) disease-specific feature (Figures 1C and S1).
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Figure 1. Chromosomal breakpoint architecture in inv(3)/t(3;3) AML and local 3q21 chromatin 
interaction profiles of the EVI1 promoter. (A) Mapping of chromosomal breakpoints (arrowheads) by 
targeted 3q-capture NGS revealing two characteristic breakpoint patterns at 3q21 (left panel) and 3q26.2 (right 
panel). (B) The 3q21 breakpoint cluster and rearranged chromosomal segments of individual AML samples are 
represented by red arrowed lines, plotted by distance to the RPN1 gene locus. A breakpoint-free commonly 
translocated segment (CTS) of 18 kb size is indicated (blue box). (C) The local chromatin interaction profile 
of the EVI1 promoter region with the 3q21 breakpoint cluster was determined by 4C-seq in representative 
inv(3)/t(3;3) cases. The 4C signal is measured by the calculation of a sliding window average (running mean) 
of the normalized read counts (window size is 21 fragment ends). The vertical axis is scaled to the maximum 
4C signal per sample. An overlapping contact hotspot of 9 kb size within the CTS in 3q-rearranged cases is 
highlighted as a blue box. The non-3q-rearranged cell line U937 was used as control. (D) Integrated local 
contact profile analysis of all 3q-rearranged samples. In the top panel (main trend), the contact intensity (black 
line) is calculated by using a running median analysis of normalized read counts with a 5 kb sliding window. 
The 20th and 80th percentile are visualized as a grey trend graph. In the bottom panel, contact intensities 
are computed using linearly increasing sliding windows (scaled 2-50 kb) and are displayed as a color-coded 
heatmap of positive 4C signals (maximum of interaction set to 1). Local color changes are log-scaled to 
indicate changes of statistical enrichment of captured sequences, corresponding to the enhancer-promoter 
interaction.
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A p300-bound genomic element in the 18kb CTS is essential for EVI1 
activation
In order to identify a more defined, targetable key enhancer element within the 9 kb EVI1-
promoter-contact part of the 18 kb CTS, we integrated data from 4C-seq with ChIP-seq data 
obtained from inv(3) cell lines MOLM-1 and MUTZ-3 (Figures 2A and S2). Prominent deposition of 
H3K27ac, H3K4me3, and H3K4me1 was observed within the 18 kb CTS, as well as strong binding 
of p300 to two regions of approximately 1 kb size in MOLM-1 (Figure 2A). 
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Figure 2. Combined ChIP-seq and 4C-seq discloses putative enhancer elements in the EVI1 promoter 
interacting rearrangement site. (A) Binding of p300 (red track) in the 9 kb EVI1-interaction domain of the 18 
kb CTS (divided blue box) is detectable in inv(3)/t(3;3) samples. ChIP-seq profiles of p300 and active chromatin 
marks H3K27ac, H3K4me3, and H3K4me1 of the inv(3) cell line MOLM-1 indicate an inv(3) cell-type specific 
enrichment in the CTS, not found in non-3q rearranged cell lines of various tissue origin (ENCODE: GM12878, 
H1-hESC, HeLa-S3, HepG2, HSMM, HUVEC, K562, NHEK, NHLF). Based on ChIP-seq enhancer profiles and CpG 
island prediction, two candidate enhancer regions were selected both inside (denoted 1st p300 and CpG1; blue 
and green bars) and outside (denoted 2nd p300 and CpG2; blue and green bars) of the 9 kb EVI1-interaction 
domain of the CTS, respectively, for subsequent reporter assays. (B) Selected candidate elements were cloned 
into EVI1-promoter luciferase reporter constructs and transfected into MUTZ-3, MOLM-1, HEK293T, or Jurkat 
cells. After 48 h, cells were harvested and luciferase assays were performed. Relative luciferase induction is 
plotted as fold change compared to enhancer-empty control vector (mean ± s.e.m.).
Ch
ap
te
r 7
Oncogenic enhancer-rearrangement in leukemia
123
In MUTZ-3 cells only one p300-interacting region was identified (Figure S2), which is the p300 peak 
located in the 9kb EVI1-promoter-contact part of the CTS as determined by 4C-seq. Comparison 
with ENCODE ChIP-seq data of various non-myeloid cell lines and transcription factor motif 
analysis pointed to a 1 kb myeloid hematopoiesis-specific enhancer (Figures 2A and S2). This p300 
binding site was chosen as the most likely candidate enhancer element responsible for ectopic 
EVI1 activation after the rearrangement event. We placed the two candidate enhancers (1st and 
2nd p300) into an EVI1-promoter luciferase reporter construct to study their potential enhancer 
activity (Figure 2B). A strong induction of reporter gene activity could be observed specifically 
in inv(3) myeloid cell lines MUTZ-3 and MOLM-1 using the first candidate enhancer element, 
whereas the second candidate enhancer element (2nd p300 peak) located within the 18 kb CTS, 
but outside of the 9kb EVI1-promoter-contact region, showed no enhancer activity. No activity 
was found for two distinct CTCF-interacting CpG islands co-localizing to the CTS. Moreover, EVI1 
promoter reporter assays demonstrated no substantial enhancing effect of the candidate 1 kb 
enhancer in non-myeloid HEK293T or Jurkat cells, pointing to a myeloid-specific transcription 
factor repertoire required for successful enhancer-EVI1-promoter engagement.
Genome-editing of the translocated p300-interaction domain leads to 
EVI1 silencing and growth inhibition of inv(3) AML cells
We next undertook a TALE nuclease genome-editing approach to target the ectopic EVI1 
enhancer locus in the MUTZ-3 cell line and to examine whether EVI1 transcriptional activity in 
inv(3) AML cells is dependent on the presence of the rearranged candidate enhancer (1st p300 
peak). TALE nucleases were assembled as previously published18, and targeting of the minimal 
ectopic enhancer site was performed in a 2x2 design (details in Experimental procedures section), 
directing TALEN heterodimers to enhancer-flanking recognition sequences to induce a segmental 
deletion by double-strand breaks (DSB) (Figure 3A). Mutation-specific primers allowed for allelic 
detection of the deletion event (Figure 3B) and for screening of clones using an informative SNV 
in the candidate enhancer locus of MUTZ-3 (Figures 3B, S3A, and S3B). Overall targeting efficiency 
was 1% with 4/384 single-cell derived clones harboring a monoallelic enhancer deletion on the 
inv(3) allele (Figure S3C). Enhancer-targeting effectively attenuated EVI1 mRNA expression in 
deletion clones as compared with non-targeted MUTZ-3 control clones taken along in the same 
targeting process (Figure 3C). RPN1 and GATA2 mRNA expression remained unchanged in inv(3)-
targeted clones. Notably, all four TALEN-modified MUTZ-3 clones showed severely impaired 
colony-forming and replating capacity compared to non-targeted clones (Figure 3D).
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Deletion of the ectopic EVI1 enhancer releases the maturation block of 
inv(3) AML cells
Genome-editing in MUTZ-3 AML cells using TALENs did not allow for high yields of viable cells 
lacking the enhancer because of the low targeting efficiency of this genetic tool in the inv(3) cell 
line model followed by a long and indirect selection process of growth-impaired deletion clones. 
To better characterize the cellular phenotype and fate after enhancer deletion, we designed an 
alternative targeting approach using the CRISPR/Cas9 genome-editing system with a site-specific 
homology repair (HR) donor for direct labeling and tracking of successfully targeted cells (Figures 
4A and 4B). In brief, enhancer deletions were induced by two short guide-RNAs (gRNA) directing 
hSpCas9 to two enhancer-flanking recognition sequences for DSB formation and HR-mediated 
repair of the induced segmental deletion by means of a co-transfected HR donor construct 
containing a conditional (loxP-) GFP selection cassette directed against the enhancer (details in 
Experimental procedures section). The pCMV-GFP cassette was subsequently removed by using 
exogenous cell-permeant Cre recombinase (TAT-Cre). This approach enabled us to isolate sufficient 
cell numbers for phenotypic characterization. Deletion events and transcriptional changes were 
confirmed by Sanger sequencing and qPCR (Figures 4C and S3D). Compared to untargeted control 
MUTZ-3 cells, targeted cells exhibited a markedly reduced proliferative rate as assessed by viable 
cell count using trypan blue staining (Figure 4D). Cell cycle analysis showed depletion of S phase 
and G2/M phase combined with higher rates of cell death (sub-G0/G1 peak) and a stationary G0/
G1 cycle arrest (Figure 4E). Remarkably, flow cytometric immunophenotyping of engineered cells 
using a panel of informative myeloid differentiation markers (see Supplemental Experimental 
Procedures for detailed list) according to published guidelines19 revealed a substantial skew 
toward a more mature, myelomonocytic stage as per cMPO and CD14 expression levels three 
weeks after genome-editing (Figure 4F). Cytologic evaluation of enhancer-targeted MUTZ-3 cells 
in week 3 after genomic modification confirmed morphologic changes from the predominantly 
immature, myelomonocytic appearance of untargeted cells toward a more differentiated, 
monocyte/macrophage-like shape (Figure 4G). This also translated into a higher apoptotic rate of 
CRISPR-targeted MUTZ-3 cells three weeks after enhancer deletion (Figure 4H).
Figure 3. TALEN-targeted candidate enhancer-deletion clones exhibit severely reduced EVI1 mRNA 
levels and replating capacity. (A) Schematic of the targeting construct and target sites flanking the previously 
identified p300-binding candidate enhancer (red ChIP-seq track) in the 9 kb EVI1-interaction domain of the 
CTS (blue box). Four TALENs were designed for pairwise heterodimeric binding to indicated target sequences 
(blue) and cleavage at the 16-18 bp intervening linker sequence (black). Arrows indicate primer locations for 
PCR analysis. (B) Representative gel image demonstrating efficient induction of segmental deletions only in 
the presence of two TALEN pairs (MUTZ-3 cell line; 2.4% targeting efficiency as per gel quantification 48 h 
after transfection). (C) EVI1, GATA2, and RPN1 mRNA expression analysis by qPCR of genome-edited MUTZ-3 
mutants after TALEN-targeting of the candidate enhancer on inv(3). (D) Comparison of colony formation of 
targeted and unmodified clones. Colony numbers and sizes were determined after two and six weeks after 
replating in methylcellulose.
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 Off-target mutagenesis at alternative in silico predicted sites was excluded by Sanger 
sequencing (Figure S3E). The phenotype observed upon enhancer deletion by genome-editing 
tools was highly comparable to what was found with small hairpin RNA (shRNA)-mediated EVI1 
knockdown in the MUTZ-3 cell line (Figures S4A-S4H), emphasizing that MUTZ-3 cells are addicted 
to EVI1 and blocked in their differentiation. We did not observe outgrowth of biallelic enhancer 
deletion or monoallelic mutants of the non-rearranged chromosome 3 allele, hinting toward 
negative selection of these mutants upon disruption of the enhancer at its natural genomic 
location. 
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The candidate enhancer translocated to EVI1 is an original upstream 
enhancer of GATA2
The most likely candidate for off-target mutagenesis at the original enhancer-associated domain 
on the normal chromosome 3 allele appeared to be RPN1 due to its immediate proximity to 
the candidate enhancer. Concordantly, RPN1 has therefore generally been the assumed origin 
of ectopic EVI1 regulatory elements, since it is located in the proximity of the chromosome 3 
breakpoint cluster.7,20 Thus, disturbance of the housekeeping function of RPN1 on the remaining 
normal allele in our TALENs experiment would most likely be deleterious. However, analysis of our 
4C-seq profiling data instead revealed substantial interactions between the candidate enhancer 
and the promoter of GATA2 rather than with the promoter of RPN1 (Figures 5A, 5B, and S5A). 
GATA2 is a crucial hematopoietic stem cell regulator, located on the contralateral side of the 3q21 
breakpoint cluster. This suggests that the candidate enhancer is an original upstream regulatory 
element for GATA2, rather than RPN1. Hi-C data confirm that the candidate enhancer is together 
with the GATA2 locus in a topological domain, physically segregated from the more proximal 
RPN1 promoter (Figure S5B).21 
 Consequently, we first aimed to examine the effect of loss of the candidate enhancer in a 
human cell line without 3q-rearrangements and the functional impact on either RPN1 or GATA2 
expression. We generated custom CRISPR/Cas9 nucleases against the candidate enhancer locus 
in the GATA2-expressing erythroleukemia cell line K562 (Figure 6A). We effectively deleted the 
candidate enhancer in K562 cells and observed profoundly reduced levels (10.8-fold) of GATA2 
mRNA in targeted K562 pools (Figure 6B), whereas RPN1 expression levels remained unchanged. 
Luciferase GATA2-promoter reporter studies confirmed strong GATA2-specific enhancer activity of 
the candidate locus in a myeloid context (Figure 6C). Thus, the candidate ectopic enhancer, which 
upon translocation is repositioned to the EVI1 locus, is a strong enhancer of GATA2 in its original 
chromosomal context.
Figure 4. Genomic enhancer excision induces proliferative and differentiation changes in inv(3) AML 
cells. (A) Schematic representation of the CRISPR/Cas9 licensing gRNAs with protospacer-adjacent motifs 
(PAM) highlighted in blue, the target locus, and the donor construct for site-directed homology repair using 
a conditional, floxed pCMV-GFP selection cassette. (B) Timeline of genomic targeting of MUTZ-3 AML cells. (C) 
Detection of deletion events by genomic PCR of sequential cell fractions. Representative Sanger sequencing 
tracks of purified PCR amplicons of the GFP-insertion band (2.3 kb) and a remaining lower-running, normal 
allele band of 1.5 kb size are shown (from GFP+ fraction of day 14), revealing a monoallelic deletion indicated 
by a loss of heterozygosity of the SNV present in the targeted enhancer locus (red asterisk). (D) Proliferation 
of untargeted control and targeted cells was measured by counting of viable cells using trypan blue. (E) 
Cell cycle analysis of control and genome-edited MUTZ-3 cells harvested after three weeks of selection. (F) 
Immunophenotyping of control and enhancer-targeted MUTZ-3 cells. The left panel includes two dot plots per 
sample (CD34/CD14 and CD34/cMPO) that show the myelomonocytic maturation. The right panel shows the 
distribution of the various maturation stages, simplified in three stages: immature (CD34+/CD14-) = blast cell; 
intermediate (CD34-/CD14-) = promonocyte; mature (CD34-/CD14+) = monocyte. (G) Representative images 
of May-Grünwald-Giemsa staining of control and enhancer-targeted MUTZ-3 cells (100x magnification). 
(H) Assessment of apoptosis in control (top panels) and enhancer-targeted MUTZ-3 cells (bottom panels). 
Representative flow cytometry plots for Annexin V and 7-AAD staining with percentages for each gate are 
shown.
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Figure 5. The non-rearranged candidate enhancer is part of the GATA2 enhancer complex. (A) 
Representative 4C data (n=7 biological replicates) showing the local contact profile using a window of 21 
fragment ends with the 1st p300 peak site as viewpoint (red dashed line) (B) Integrative 4C analysis using 
a viewpoint from the GATA2 promoter region (n=7 biological replicates). In the top panel (main trend), the 
contact intensity (black line) is calculated by using a running median analysis of normalized read counts with 
a 5 kb sliding window. The 20th and 80th percentile are visualized as a grey trend graph. In the bottom panel, 
contact intensities are computed using linearly increasing sliding windows (scaled 2-50 kb) and displayed as 
a color-coded heatmap of positive 4C signal (maximum of interaction set to 1). Local color changes are log-
scaled to indicate changes of statistical enrichment of captured sequences, corresponding to the enhancer-
promoter interaction (red dashed lines).
Rearrangement of the GATA2 enhancer to EVI1 causes functional 
haploinsufficiency of GATA2
To study the effects of the enhancer translocation on GATA2 expression in inv(3)/t(3;3) AML 
samples, we analyzed allele frequencies of informative SNPs in the GATA2 locus by combining 
3q-seq and RNA-seq data. This integrative analysis revealed a monoallelic expression pattern of 
GATA2 in all 36 inv(3)/t(3;3) cases studied (Figures 6D and S6). Non-3q-rearranged AML patient 
samples and cell lines, as well as variant t(3q26) AML cases with breakpoints outside of the 3q21 
cluster region [e.g., inv(3)(q21q25); t(3;7)(q26;p15)] displayed a normal, biallelic GATA2 expression 
pattern (not shown). To ascertain monoallelic GATA2 expression originating from the normal 
chromosome 3 allele, we performed an allele-specific chromosome conformation capture 
sequencing approach (Experimental procedures for details), in which captured informative SNPs 
of the GATA2 locus can only be amplified by allele-specific primers on the non-rearranged, linear 
chromosome 3 template. Results were validated by long-range, breakpoint-spanning PCR and 
Sanger sequencing. By integration of results from these NGS platforms (3q-seq, RNA-seq, and 
allele-specific 4C; Figure 6D), we found monoallelic GATA2 expression as a consequence of GATA2 
inactivation on the rearranged allele in cases harboring inv(3) or t(3;3). Notably, GATA2 expression 
levels in primary inv(3)/t(3;3) AML cases and cell lines (n=69) were found to be significantly 
reduced as compared to controls (213 AML patients) (Figure 6E). Thus, our data indicate that the 
inversion/translocation event in inv(3)/t(3;3) malignancies reorganizes an originally upstream 
regulatory element of the GATA2 domain, causing reduced and monoallelic expression of GATA2.
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Figure 6. Loss of the GATA2 candidate enhancer leads to functional haploinsufficiency of the affected 
GATA2 allele. (A) Schematic of the CRISPR nuclease design for candidate enhancer targeting. Arrows indicate 
primer locations for PCR analysis. For each construct, the protospacer sequence and the Cas9-specific 
proximal-adjacent motif (PAM; magenta highlight) are indicated. (B) Upon transfection of the candidate 
enhancer-flanking CRISPR constructs, K562 cells were analyzed by deletion-specific PCR (gel image). Unsorted 
cells represented pools of CRISPR-targeted and non-targeted cells. GFP-sorted and isolated deletion clones 
harbored predominantly biallelic deletion mutants. GATA2 and RPN1 mRNA expression was analyzed by qPCR 
(right panel). (C) The p300-binding core enhancer region and an adjacent control region (2nd p300 peak 
region) were cloned into a GATA2-promoter luciferase reporter construct, and luciferase activity was measured 
48 h after transfection of indicated cell lines. GATA2+ MUTZ-3 cells, as well as GATA2 non-myeloid HEK293T and 
Jurkat cells were assayed. (D) Integrated analysis of 3q-DNA-seq, RNA-seq, and allele-specific 4C-seq data of a 
representative inv(3) AML case reveals monoallelic expression of GATA2 mRNA from the intact chromosome 
3q21 allele. (E) GATA2 expression level analysis by qPCR in inv(3)/t(3;3) AML (n=69) and unselected, non-3q-
rearranged AMLs (n=245; Mann-Whitney-U test, p=0.002).
The 18 kb CTS and p300-interaction domain are part of a translocation-
derived super-enhancer
We have shown that targeting of the candidate enhancer site in inv(3) AML cells by genome-
editing techniques is feasible, based on the premises that the enhancer element interacts with 
the EVI1 promoter, binds the transcriptional co-activator p300, and is embedded in a region of 
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open, potentially regulatory chromatin, and thereby also accessible for endonucleases. However, 
ChIP-seq data obtained from the inv(3) cell line MOLM-1 manifested a large segment of H3K27ac 
deposition that extends beyond the entire 18 kb CTS and p300-interaction domain, covering a 
region of approximately 40 kb (Figures 2A and 7A). These exceptionally large enhancer domains 
with high levels of H3K27ac and the chromatin regulator BRD4 have recently been characterized as 
super-enhancers.22,23 Using the bioinformatic analysis tool ROSE22, the 40 kb H3K27ac-deposition 
region was identified as a super-enhancer, ranking second among 291 super-enhancers in the 
MOLM-1 genome (Figures 7A and 7B). RNA-seq analysis revealed the presence of intense read-
through enhancer RNAs (eRNAs) spanning the entire super-enhancer area including the 18 kb 
CTS in MOLM-1 (Figure 7A). Of note, read-through transcription commenced precisely at the 
breakpoint positions, representing the fusion point of 3q21 with 3q26/EVI1 segments. RNA-seq 
carried out in all available inv(3)/t(3;3) leukemia samples disclosed identical patterns of large 
read-through areas of eRNAs (Figure 7A). Consistently, BRD4-occupancy was found at the super-
enhancer site in 3q-rearranged samples, particularly in the p300-interaction domain (Figure S7A). 
Non-3q-rearranged samples entirely lacked traces of transcriptional read-through (Figure 7A) and 
exhibited no H3K27ac deposition, or, if any at all, only in a confined 3-4 kb region immediately 
downstream of the RPN1 gene, as shown by comparison with ENCODE ChIP-seq data of various 
non-3q-rearranged cell lines (Figures 2A and S2). Furthermore, combining 3q-capture DNA-
seq with ChIP-seq data of MOLM-1 showed the presence of informative heterozygous SNPs in 
the putative 3q21 super-enhancer locus on genomic DNA level, whereas the chromatin after 
H3K27ac pull-down revealed a skew in the allelic ratio of these SNPs in the same locus (Figure 7C). 
These observations suggest the presence of an active, rearranged super-enhancer in inv(3)/t(3;3) 
leukemia samples, as was previously observed for MYC-rearrangements in multiple myeloma.22
BET-inhibition leads to EVI1 silencing and growth arrest of inv(3)/t(3;3) 
AML cells
Our genome-editing results underline that EVI1 is the key oncogenic driver in inv(3)/t(3;3) AML and 
vulnerable to interference with its ectopic enhancer. As reported previously, BET-bromodomain 
inhibition of super-enhancers represents a novel therapeutic avenue to target genes particularly 
regulated by super-enhancers.22,23 The observation that the p300-binding ectopic EVI1 enhancer is 
embedded in a large 3q21 super-enhancer complex (Figures 7A and 7B) prompted us to investigate 
whether EVI1 transcription in inv(3)/t(3;3)-rearranged AMLs is sensitive to enhancer interference 
by treatment with BET-bromodomain inhibitors (JQ1). Exposure of MUTZ-3 and MOLM-1 cells, 
as well as primary inv(3)/t(3;3) AML samples to JQ1 profoundly inhibited proliferation with 
concentrations >50 nM (Figures 7D and S7C). EVI1-expressing K562 cells (no 3q-rearrangement), 
however, were not responsive to JQ1, as was previously shown.24 EVI1 mRNA levels in MUTZ-3 and 
MOLM-1 cells significantly decreased after JQ1 treatment contrary to K562 cells, in which BRD4 
density at the enhancer locus is lower by comparison (Figures 7E, S7A, S7D, and S7E). 
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Figure 7. The ectopic enhancer is part of a 3q21 super-enhancer. (A) H3K27ac ChIP-seq (orange track) of 
the MOLM-1 cell line and RNA-seq (black tracks) of representative inv(3)/t(3;3) samples and non-3q-rearranged 
cell lines. Red arrowheads denote chromosomal breakpoint positions per sample. The super-enhancer region 
defined by the H3K27ac enrichment score is indicated as a red bar. (B) Ranking of super-enhancers identified 
in the MOLM-1 genome as per H3K27ac enrichment. (C) Allelic imbalance of the 3q21 super-enhancer region 
is determined by comparison of allelic ratios obtained from 3q-seq and H3K27ac ChIP-seq using informative, 
heterozygous SNPs (n=6) present in the super-enhancer domain. Allelic imbalances for SNPs are tested using 
a χ2 goodness-of-fit test to identify regions exhibiting ChIP-seq allelic ratios significantly different from the 
genomic allelic ratios (H0 = allelic ratios identical between ChIP-seq and 3q-DNA-seq experiments). (D) JQ1 
treatment is effective in 3q-rearranged AML cells (MUTZ-3) vs. non-3q-rearranged cells (K562). JQ1 sensitivity 
was measured by mitochondrial dehydrogenase (MTT assay) after 6, 24, 48, and 72 h of exposure with JQ1 (5, 
50, 500, or 1,000 nM) or vehicle control (DMSO, 0.05%). (E) Analysis of EVI1 and GATA2 mRNA expression levels 
in MUTZ-3 and K562 by qPCR at different time points following JQ1 exposure (1,000 nM). (F) ChIP-seq binding 
profiles for BRD4 (blue) and H3K27ac (orange) at the 3q21 super-enhancer locus (left panel) or at the WDR74 
upstream enhancer after treatment of MOLM-1 cells with JQ1 (1,000 nM) or DMSO (0.05%) for six hours. (G) 
Cell cycle analysis of MUTZ-3 cells after treatment with DMSO (0.05%; upper panel) or JQ1 (1,000 nM; lower 
panel) for 24 h. (H) Transient EVI1 rescue counteracts JQ1 antiproliferative effect. Cells were nucleofected either 
without DNA (mock), or with an empty GFP-expressing vector (EV) or an GFP-EVI1-expressing construct (EVI1), 
GFP-sorted after 24 h, and subsequently exposed to JQ1 (1,000 nM) for following viability measurements at 
indicated time points.
Furthermore, GATA2 mRNA levels did not change upon JQ1 treatment, substantiating the notion 
that the ectopic super-enhancer/core p300 element is indeed a fusion result regulating EVI1 on 
the rearranged allele rather than GATA2 on the remaining normal allele. BRD4 load as well as 
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read-through transcription at the ectopic EVI1 super-enhancer site were substantially decreased 
after JQ1 treatment (Figures 7F and S7B), whereas displacement of BRD4 in typical enhancer 
regions was less profound, as has previously been reported.23 Similar to the observed effects 
upon enhancer excision, we observed a profound S phase reduction along with a G0/G1 cell cycle 
arrest, higher rates of maturation and apoptotic events upon BRD4-inhibition (Figures 7G, S7F, 
S7G, and S7H). Reintroduction of EVI1 by nucleofection of MUTZ-3 cells prior to JQ1 treatment, 
allowing for transient EVI1 expression, partly rescued MUTZ-3 from JQ1 cytotoxicity, arguing for 
relative selectivity of JQ1 for the EVI1 super-enhancer as opposed to globally inhibiting other 
putative oncogenic drivers (Figure 7H).
DISCUSSION
In summary, inv(3)/t(3;3) chromosomal rearrangements cause dysregulation of two specific AML 
predisposition genes by aberrant activity of a single enhancer element in its ectopic chromatin 
environment: (I) Overexpression of EVI1 is caused by inappropriate transcriptional control of 
the ectopic GATA2 regulatory element, while (II) GATA2 transcriptional impairment results from 
the removal of that same enhancer from its genomic origin. These dual events mediated by a 
single enhancer rearrangement, without formation of an oncogenic fusion product, highlight the 
vulnerability of genome organization into long-range regulatory interaction domains in case of a 
chromosomal break. The enhancer we identified appears to originally control transcription of the 
110 kb distant GATA2 gene at 3q21, and not the nearby gene RPN1. Our finding is in accordance 
with reports demonstrating a highly homologous -77 kb enhancer element to constitute a 
component of the murine Gata2 master regulatory complex25, and that this element is indeed 
leukemogenic via EVI1 activation in transgenic mice harboring the human 3q21q26-rearranged 
allele.26 In case of an inv(3)/t(3;3), the rearranged enhancer engaged in chromatin loops with the 
EVI1 promoter, in certain samples over a distance of more than 200 kb. Our data emphasize that 
the function of an enhancer is not only determined by its location, but in particular by its ability 
to physically bind to an appropriate promoter, which can even occur in a different chromosome 
topology. Our findings show that not RPN1, as reported in the nomenclature of the WHO2008 
classification [inv(3)/t(3;3)/RPN1-EVI1], but rather the GATA2 locus is the source of the ectopic 
enhancer activating EVI1 in this type of leukemia.
 Besides aberrant EVI1 activation, rewiring of parts of the GATA2 and EVI1 domains led to a 
reduction of GATA2 expression levels. EVI1 activation in this subtype of AML argues for a primitive 
HSC defect.8,9,27-31 Since GATA2 is a critical hematopoietic stemness factor, primitive hematopoietic 
precursors will be particularly susceptible to disturbances of GATA2 homeostasis. Thus, GATA2 
deficiency may provide the right spatiotemporal context for EVI1 oncogene activation, i.e. in the 
right cell at the right stage of differentiation for subsequent malignant transformation. Functional 
haploinsufficiency arising from inactivating mutations in GATA2 DNA-binding domains or in 
GATA2 regulatory sequences represents a well-established underlying cause of MDS/AML and 
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Emberger/MonoMAC syndromes32-36, of which the latter are characterized by monocytopenia, 
immune deficiency, and predisposition to myeloid leukemia with frequent monosomy 7. AML 
with inv(3)/t(3;3) most commonly associates with monosomy 7 and trilineage dysplasia, and, 
as demonstrated here, it is accompanied by impaired GATA2 expression as well. It will be of 
particular interest to investigate whether in Emberger and MonoMAC patients 3q26 defects 
and consequently aberrant EVI1 expression are also drivers of disease progression toward AML/
MDS. Of note, the enhancer-containing 3q21 locus is rarely, but consistently involved in other 
chromosomal rearrangements with PRDM homologues of the EVI1 gene (e.g. BLIMP1/PRDM1 or 
MEL1/PRDM16) and their aberrant activation.37 Both disease categories [inv(3)/t(3;3) and other 
t(3q21) AMLs] resemble each other by their high white blood cell and exceptionally high platelet 
counts at diagnosis. Further studies using in vivo models are warranted to investigate how the 
combined effects of GATA2 haploinsufficiency and overexpression of EVI1 or its homologues 
cooperate in malignant transformation of primitive hematopoietic progenitors.
 The ectopic EVI1 enhancer was embedded in a genomic region exhibiting large deposition of 
active chromatin marks and presence of read-through transcripts. This class of DNA elements has 
recently been recognized as so-called super-enhancers23, which represent large open chromatin 
regions of >10 kb in size with key regulatory function for cellular identity and oncogene 
regulation in cancer. The observation that the GATA2 enhancer region upon translocation had 
acquired characteristics of a super-enhancer, dominantly ranking in the MOLM-1 genome, 
provided the rationale for treatment with bromodomain/BET-inhibitors.22 The presence of a 3q21 
super-enhancer might also explain why JQ1 is effective in inv(3)/t(3;3) cell lines as opposed to 
various non 3q-rearranged AML cell lines with EVI1 overexpression.24 The effects seen after JQ1 
treatment recapitulated the observations obtained by genome-editing experiments involving 
the translocated p300-interaction domain. Remodeling of the cancer genome by using in vivo 
nuclease as applied in this study helped to experimentally validate EVI1 as an oncogenic driver 
lesion and warranted further pharmacologic experiments interfering with enhancer activity. 
These experiments emphasized that targeting EVI1 transcriptional regulation using drugs 
directed against enhancer complexes could have therapeutic potential for this highly refractory 
subgroup of AML and diseases driven by similar mechanisms.
EXPERIMENTAL PROCEDURES
Subjects
Patient recruitment and sample processing were performed according to protocols from the 
German-Austrian Acute Myeloid Leukemia Study Group (AMLSG trials 06-04, 07-04, HD93A, 
HD98A/B) and the Dutch-Belgian Hematology/Oncology Cooperative Group (HOVON trials 04/A, 
29, 42, 43, 81, 92). All studies were approved through institutional human ethics review board, and 
all patients provided written informed consent in accordance with the Declaration of Helsinki.
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Generation of TALEN constructs
Construction of TALE DNA-binding domains directed to selected genomic loci was performed as 
described previously.18 Genomic target coordinates were selected and filtered for off-target sites 
using the TAL Effector Nucleotide Targeter 2.0 tool (https://tale-nt.cac.cornell.edu/node/add/
talen). Spacer length was defined within a range of 16-20 bp, and repeat array length was set to 20 
bp. The NN repeat variable domain targeting base G was chosen in the assembly. In brief, hexamer 
modules were assembled from a PCR-amplified monomer library using a hierarchical digestion-
ligation reaction and subsequently cloned into a full-length TALEN construct. Plasmids were 
verified by Sanger sequencing and tested for functionality upon transfection in HEK293T cells. To 
induce a genomic deletion, two TALEN pairs were transfected owing to dimerization requirement 
of the FokI nuclease for double-strand break formation. Repair of chromatin cleavage at the left/
upstream and right/downstream boundaries of the target locus relies on non-homologous end 
joining (NHEJ) in the absence of a repair donor and results in the deletion of a TALEN-targeted 
DNA segment.
Generation of CRISPR constructs
In this study, the RNA-guided endonuclease genome-editing system was employed in 
experiments involving the cell line K562 owing to its cell line-specific superior targeting efficiency 
compared with TALENs genome-editing approaches.38 Publicly available plasmids expressing 
the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system were used 
for cloning of targeting constructs following recently published protocols.38,39 In brief, custom 
target-specific oligonucleotides were cloned into a chimeric guide RNA array of an hSpCas9-
expressing targeting vector. Oligonucleotides for site-specific chromatin cleavage of genomic 
target regions were designed following described guidelines and selected for uniqueness using 
a bioinformatic filtering tool (http://www.genome-engineering.org/crispr/). To induce segmental 
deletions of candidate regulatory DNA regions, two CRISPR plasmids were transfected into cells. 
Each construct was directed to flanking target site positions of the intervening DNA segment for 
induction of NHEJ-mediated repair upon DSB formation. Cells were screened for deletion events 
48 hours later by mutation-specific PCR analogous to TALENs experiments.
Clone screening and sequencing
Upon expansion of TALEN- or CRISPR-targeted clones, genomic DNA was isolated with the 
QuickExtract DNA Extraction Solution (Epicentre) and screened for deletion events by mutation-
specific PCR using primers spanning the breakpoint junction. A shift in amplicon size visualized 
by appearance of a lower running band on gel electrophoresis indicated successful targeting, and 
candidate clones were subsequently checked for monoclonality. The native amplicon and novel 
fusion fragment of candidate clones were separately purified, and sequences of informative, 
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heterozygous SNVs in the target region was determined by Sanger sequencing. Monoallelic 
targeting was confirmed by loss of heterozygosity at the SNV-specific nucleotide site. Monoclonal 
biallelic deletion mutants were detected by loss of the native amplicon and presence of a single, 
novel fusion fragment represented by the lower running band.
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ABSTRACT
Myeloid malignancies bearing chromosomal inv(3)/t(3;3) abnormalities are among the most 
therapy-resistant leukemias. Deregulated expression of EVI1 is the molecular hallmark of this 
disease; however, the genome-wide spectrum of cooperating mutations in this disease subset has 
not been systematically elucidated. Here, we show that 98% of inv(3)/t(3;3) myeloid malignancies 
harbor mutations in genes activating RAS/receptor tyrosine kinase (RTK) signaling pathways. In 
addition, hemizygous mutations in GATA2, as well as heterozygous alterations in RUNX1, SF3B1, 
and genes encoding epigenetic modifiers frequently co-occur with the inv(3)/t(3;3) aberration. 
Notably, neither mutational patterns nor gene expression profiles differ across inv(3)/t(3;3) AML, 
CML, and MDS cases, suggesting recognition of inv(3)/t(3;3) myeloid malignancies as a single 
disease entity irrespective of blast count. The high incidence of activating RAS/RTK signaling 
mutations may provide a target for a rational treatment strategy in this high-risk patient group.
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter8/
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INTRODUCTION
Acute myeloid leukemia (AML) with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is a distinct 
disease entity in the current World Health Organization classification.1 High therapy-resistance 
is the common feature of myeloid malignancies, particularly AML with 3q21/3q26 aberrations, 
manifesting in low rates of complete remission and subsequent failure of current treatment 
strategies.2-4 Appearance of the characteristic 3q aberrations also indicates disease progression 
and portends adverse outcome in myelodysplastic syndrome (MDS) and chronic myeloid 
leukemia (CML).5-7 Therapy resistance in this subtype of malignancies is linked to the inappropriate 
activation of the proto-oncogene Ecotropic Viral Integration-1 (EVI1) as a consequence of the 
chromosome 3 rearrangements. EVI1 is a hematopoietic stemness factor and transcription factor 
with chromatin remodeling activity.8-10 EVI1 is also overexpressed in approximately 11% of all 
AML cases in the absence of 3q aberrations and represents an independent adverse prognostic 
factor in these patients.11 We and others have shown that, as a consequence of inv(3)/t(3;3) 
rearrangements, EVI1 becomes activated via structural repositioning of a distal GATA2 enhancer 
from 3q21 to the EVI1 locus at 3q26.12,13 Relocation of the enhancer additionally confers reduced 
and monoallelic GATA2 expression in this AML subtype. Notably, GATA2 deficiency has been 
shown to impair hematopoietic stem cell frequency and fitness14-16, and Evi1 activation in murine 
inv(3)/t(3;3) models is followed by leukemia onset after a long latency of 6 months.13 Hence, we 
hypothesize that additional cooperating genetic events, other than EVI1 and GATA2 deregulation, 
are required for full leukemic transformation, resulting in a myeloid disease with dismal outcome. 
Full understanding of the complete spectrum of molecular defects associated with this highly 
refractory AML subtype may provide additional rationale for treatment and to overcome 
therapeutic nihilism in this incurable disease category. Therefore, within this study, we sought to 
extend the molecular characterization of myeloid disorders with inv(3)/t(3;3) aberrations by next-
generation sequencing (NGS).
METHODS
Patient samples
From the combined study groups of the Dutch-Belgian Cooperative Trial Group for Hematology-
Oncology (HOVON) and the German-Austrian AML Study Group (AMLSG) we selected 32 AML 
(including 2 cell lines MUTZ-3 and UCSD-AML1), 4 CML-BC (including 2 cell lines HNT-34 and MOLM-
1), and 5 MDS cases for NGS analysis. Included patients harbored an inv(3)/t(3;3) aberration on 
chromosome banding analysis (Supplemental Table 1) and was subsequently confirmed by NGS 
analysis. Cultured CD3+ T-cells from diagnostic bone marrow served as whole exome sequencing 
(WES) germline control. Written informed consent was obtained from all individuals. All samples 
were sequenced on the Illumina HiSeq 2500 system and processed as described previously.12
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3q-capture sequencing
From the collected patient material the genomic DNA was sheared with the Covaris S2 device 
(Covaris) with default settings. Subsequently, the sample libraries were prepared using the TruSeq 
DNA Sample Preparation Guide (Illumina). The target chromosomal regions 3q21.1-3q26.2 (~40Mb) 
were captured by employing a custom in-solution oligonucleotide baits (Nimblegen SeqCap EZ 
Choice XL). The final sample libraries were subjected to paired-end sequencing (2x100bp) and 
were aligned against the human genome 19 (hg19) using the Burrows Wheeler Aligner (BWA) 
with default settings.17 Exact breakpoint positions were determined with Breakdancer v1.1.18 
Exact breakpoint sequences were resolved by extracting proximal reads supporting or spanning 
the breakpoint using the identified breakpoint positions and an algorithm able to extract the 
relevant reads from BAM files by employing the Samtools API.19 Relevant reads were identified by 
their discordant distance to the paired mate read due to the inv(3)/t(3;3) aberration (supporting 
reads) or being a member of a cluster of truncated reads with the same clipping position 
(spanning reads). The extracted reads were subsequently used as input for the de novo assembler 
Velvet v1.0.1720 with default settings and the assembled region was validated with UCSC Blat.21 If 
resolved, the breakpoint sequences of 3q21 and 3q26 were used for the estimation of the variant 
allele frequency (VAF) to infer the cellular prevalence of the inv(3)/t(3;3) aberration. All 3q-capture 
sequencing (3q-Seq) reads were aligned against the resolved breakpoint sequences of 3q21 and 
3q26 and their respective native wild type sequences. The VAF was estimated by comparing the 
total number of reads aligning on the breakpoint sequence to the total number of reads aligning 
to the respective native wild-type sequence.
RNA-Seq and whole exome sequencing
From the collected patient material total RNA was extracted with phenol-chloroform and 
subsequently transcribed by using Superscript II RT (Invitrogen). Shearing of the cDNA was 
performed with the Covaris S2 device (Covaris) with the default settings and further constructed 
according to the TruSeq RNA Sample Preparation v2 Guide (Illumina). The sample libraries were 
subjected to paired-end sequencing (2x75bp) and aligned against hg19 using TopHat v2.22 
Genomic DNA from patients and in vitro cultured control CD3+ T-cells were processed similar to 
3q-Seq protocols and captured by exome bead capture (SeqCap EZ Human Exome Library v3.0). 
The sample libraries were paired-end sequenced (2x100bp) and subsequently aligned against 
hg19 using BWA with default settings.17
 Overall, we performed whole transcriptome sequencing (RNA-Seq) on 41 and WES on 10 out 
of these 41 inv(3)/t(3;3) myeloid malignancies. Read and alignment statistics for RNA-Seq and 
WES data are found in the Supplement (Supplemental Figures 1A-C, Supplemental Table 4). On 
average we observed a medium to high coverage for the targeted exome in WES data (~62x), 
sufficient to detect mutations with a VAF of 10% or more. Reads generated for RNA-Seq analyses 
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predominately fell within transcribed regions (~52%), i.e. ribosomal genes, coding sequence, and 
UTRs, according to the RefSeq Transcriptome database, and on average 91% of the reads could 
be aligned to hg19. Gene expression profiles (GEP) for 24 inv(3)/t(3;3) patients were constructed 
for differential expression, clustering, and principle component analyses with the DESeq2 
package.23 Copy number variation (CNV) profiles from the WES data were calculated by CNVsvd 
(M.A.S., R.H, and P.J.M.V., manuscript in preparation; Supplemental Figure 2). In brief, per patient 
the total number of fragments was determined for each exon or determined from consecutive 
500 nucleotide-wide windows for large exons. The estimation of CNVs is hampered by systematic 
variance introduced by sequence technology bias or repetitive and homologous sequences, 
which can be observed in all sequenced cases. By utilizing a control reference data set under 
the assumption that these cases have a normal karyotype (i.e., the in vitro cultured CD3+ T-cells) 
allows for the determination of the local variance composition. These estimated local variance 
components can be used to attenuate the systematic variance in all sequenced cases. Finally, the 
normalized count statistics were used for the estimation of the CNV WES profile.
Variant detection
RNA-Seq data were preprocessed for variant detection by splitting the exon boundary spanning 
reads using the Genome Analysis Toolkit (GATK).24 Subsequently, the variants were determined 
with the Samtools API and MuTect for RNA-Seq and WES data.19,25 The detected variants were 
annotated with AnnoVar26 and further characterized by multiple read statistics determined by 
an in-house developed algorithm. In brief, the algorithm determines for each variant the VAF, 
local read statistics based on the alignment and base qualities, mutation likelihood given the 
local sequence context, recurrence given the catalogue of somatic mutations in cancer (COSMIC), 
recurrence determined from population-based sequencing efforts (1000 genomes project), and, 
when available, the likelihood of the mutation given the same set of read statistics in a control 
sample. The validity of our approach combining WES data with RNA-Seq data to infer variants 
is substantiated by the observation that nonsense-mediate decay (NMD) was negligible for 
mutant allele detection, as demonstrated by similar VAFs of mutant disease alleles observed 
within cases characterized by both WES and RNA-Seq (Supplemental Figure 3). Frameshift and 
premature stop codon-introducing mutations were selected and dichotomized on their location 
in the gene body. Mutations located in the terminal exon or approximately 50 bp from the exon 
boundary of the penultimate exon should, theoretically, be unaffected by NMD while stop codon-
introducing mutations situated in other locations of the gene body should be affected. Finally, 
variants were examined when recurrently detected in more than two patients or previously 
linked to leukemogenesis or cancer pathogenesis.27,28 All listed variants were validated by Sanger 
sequencing, except for FLT3-ITD which was determined by RT-PCR.
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Allelic imbalance of GATA2
In total, 30 inv(3)/t(3;3) cases accommodate informative heterozygous single nucleotide 
variants (SNV) in the GATA2 locus according to the 3q-Seq data. We have previously shown 
that the inv(3)/t(3;3) causes monoallelic expression of GATA2 from the non-rearranged allele.12 
Subsequently, we determined the allelic contribution of the genotypes of the heterozygous SNV 
in the matched RNA-Seq case. The average of the allelic contribution was taken when multiple 
heterozygous SNVs were accommodated in the GATA2 locus. The polar histogram was constructed 
with the R package “phenotypicForest”.29
Clonality analysis
The VAFs of the acquired mutations were estimated from the 10 paired inv(3)/t(3;3) myeloid 
malignancies characterized with WES. The VAF of the inv(3)/t(3;3) aberration was estimated from 
the 3q-Seq data, unless the breakpoints could not be resolved or no 3q-Seq data was available. In 
these cases the cytogenetically determined inv(3)/t(3;3) positive metaphases were used. The VAFs 
were corrected by the local CNV, determined by CNVsvd, and possible loss-of-heterozygosity, 
ascertained by determining the loss of proximal heterozygous SNVs with respect to the control 
WES data. The clonal architecture was illustrated in violin plots. In brief, the density of mutations 
with a similar VAF was determined by a kernel density approach and is represented by the width 
of the graph. These plots were generated by the R package “easyGgplot2”.30
RESULTS
Mutant disease allele categorization
We first assigned mutations to mutational categories in order to discern patterns of mutations 
within inv(3)/t(3;3) myeloid disease (Figure 1A).28 All identified mutations were confirmed to be 
somatic in samples with available paired T-cell control (10 out of 41 cases). In addition to the 
“hardwired” deregulated expression of EVI1 and GATA2, all 41 samples contained at least one 
additional mutation in one of the categories relevant for leukemia pathogenesis (average 2.3 
category mutations per sample [Figure 1A, Supplemental Tables 2 and 3]). Notably, all AML and 
CML-BC, as well as 4 of 5 MDS samples contained mutations in genes activating RAS/RTK signaling, 
amounting to an incidence of 98% of all malignancies with an inv(3)/t(3;3). Furthermore, mutations 
were frequently found in myeloid transcription factor genes (32%), splice factor-encoding genes 
(29%), epigenetic modifier genes (29%), tumor-suppressor genes (10%), DNA-methylation genes 
(10%), and cohesin-complex genes (5%) (Figure 1A).
 Complementing previous reports on the high incidence of NRAS mutations in inv(3)/t(3;3) 
AML,3,6 we found on aggregate 47% of all samples containing mutations directly affecting RAS, i.e. 
NRAS (27%), KRAS (11%), and NF1 (9%) (Figure 1B). These mutations were mutually exclusive and 
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also largely non-overlapping with any other mutation affecting signaling pathways involving RAS, 
i.e. PTPN11 (20%), FLT3 (13%), CBL (7%), KIT (2%), and BCR-ABL1 (12%) (Figure 1B). GATA2 was the 
most commonly mutated transcription factor in inv(3)/t(3;3) myeloid malignancies (15%; 5 AML 
and 1 MDS patient) and occurred in all cases in one of the two GATA2 zinc finger domains. RUNX1 
mutations were present in 12% and did not coincide with GATA2 mutations, however mutations in 
the splice factor encoding gene SF3B1 (27%) were enriched in GATA2 mutated samples. Mutations 
in GATA2, SF3B1, and RUNX1 were established to be somatic in all cases with control material 
available. Interestingly, we detected novel truncating mutations and CNVs resulting in the loss of 
one copy of the transcription factor FOXP1 (10%), which is recurrently involved in chromosomal 
aberrations within lymphoma31, but its association with AML pathogenesis is unknown. The 
predominant monosomal karyotype within inv(3)/t(3;3) myeloid malignancies, mainly conferred 
by monosomy 7 (68%), is contrasted by the low incidence of TP53 mutations (5%) (Figure 1A), 
which had been suggested to be involved in the etiology of complex and of monosomal karyotype 
AML.32,33
 No mutational pattern alluded to the high coincidence of the loss of chromosome 7 in 
inv(3)/t(3;3) myeloid disease (Figure 1A, Supplemental Tables 2 and 3). However, previous reports 
have indicated that haploinsufficiency for CUX1, a gene strongly downregulated in our cohort 
of inv(3)/t(3;3)/-7 patients (Supplemental Table 5), activates phosphoinositide 3-kinase (PI3K) 
signaling by transcriptional downregulation of the PI3K inhibitor PI3KIP1,34 and could therefore 
be an important cooperating lesion in inv(3)/t(3;3)/monosomy 7 myeloid syndromes.35
 To date, no independent prognostic factor within the inv(3)/t(3;3) AML subset has been 
identified due to its low incidence and the extremely short median survival of inv(3)/t(3;3) AML 
patients (10 months).3 Baseline patient characteristics and clinical outcome data were available in 
21 individuals with inv(3)/t(3;3) AML. The high frequency of RAS/RTK pathway mutations allowed 
us to perform an exploratory analysis within this small patient cohort. There were no statistically 
significant differences in patient characteristics, nor overall and event-free survival in cases with 
RAS mutations (NRASmut, KRASmut, NF1mut) compared to cases with other mutations activating 
signaling pathways (Supplemental Figure 4). The median overall survival (OS) of RASmut patients 
was 9.8 months versus 8.9 months of RTKmut patients.
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Mutational categories in inv(3)/t(3;3) myeloid malignancies
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DNA Methylation 1 1 1 1 10
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FLT3 1 1 1 1 1 1 15
CBL 1 1 1 7
BCR-ABL1 1 1 1 1 1 12
KIT 1 2
NRAS 1 1 1 1 1 1 1 1 1 1 1 1 29
KRAS 1 1 1 1 1 12
PTPN11 1 1 1 1 1 1 1 1 1 22
NF1 1 1 1 1 10
GATA2 1 1 1 1 1 1 15
RUNX1 1 1 1 1 1 12
FOXP1 1 1 1 1 10
SF3B1 1 1 1 1 1 1 1 1 1 1 1 27
ZRSR2 1 2
BCOR 1 1 1 1 1 1 15
NCOR 1 2
ASXL1 1 1 1 1 1 12
TP53 1 1 5
WT1 1 1 1 7
DNMT3A 1 1 5
TET2 1 1 5
SMC1A 1 2
RAD21 1 2
Number of driver mutations 5 4 4 3 3 4 5 3 3 3 2 2 3 5 2 2 2 2 4 2 2 2 2 2 3 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 3  2,3
Monosomy 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 68
Additional chromosome aberrations 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 83
AML
CML-BC
MDS
Figure 1. Mutational spectrum observed in inv(3)/t(3;3) myeloid malignancies. (A) Distribution of 
acquired mutations in 41 inv(3)/t(3;3) myeloid malignancies in conjunction with the aggregation of the 
mutations into mutational categories: mutant (green), positive for cytogenetic abnormality (dark gray), 
wild-type (gray). (B) Distribution of mutations within mutational categories present in more than 10% of the 
inv(3)/t(3;3) myeloid malignancies.
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Clonality analysis
To address the question whether the highly overrepresented RAS/RTK pathway mutations and 
other recurrent somatic alterations in inv(3)/t(3;3) AML co-occurred in the same dominant clone, 
we assessed the allelic ratios of the EVI1-rearranged and mutant candidate disease alleles (Figure 
2). WES analysis in conjunction with germline T-cell control was available from 10 AML patients. 
Cytogenetic evaluation of blast percentage and NGS read count estimation of the percentage of 
the 3q21q26.2 fusion (allele frequency) were concordant. In two cases (AML 20908 and 29656) 
without available 3q-Seq data cytogenetics served to estimate the percentage of the inv(3) 
allele. The inv(3)/t(3;3) aberrations were detectable in the majority of cases (7/10 cases) in up to 
100% of the cells (i.e., resulting in an allelic ratio of the heterozygous 3q21q26.2 fusion allele of 
approximately 0.5), reflecting high blast percentage in these cases. The RAS and RTK mutations 
were mainly found in the dominant EVI1-rearranged clone, and a similar pattern is found for all 
other identified alterations (e.g., in transcription factor, splice factor, and epigenetic modifier 
genes), which mostly co-occur at similar frequency as the RAS/RTK mutations. 
Figure 2. Clonal architecture inferred from somatic mutations observed in 10 inv(3)/t(3;3) myeloid 
malignancies. Distribution of estimated variant allele frequencies (VAF) determined from whole exome 
sequencing. The width of the graph represents the density of mutations with similar VAFs. The yellow dot 
denotes the VAF of the 3q-aberration [(inv(3)/t(3;3)], the blue dot denotes the VAF of the RAS/RTK-associated 
mutation, and open circles denote the VAF of all other mutations.
However, in AML 12383 (PTPN11 mutation) and AMLs 29656 and 30309 (both NF1-mutated), 
the 3q-rearrangement was found in the major clone, whereas the RAS pathway mutations were 
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present in only about half of these cells. In 2 cases (AML 20613 and 20908) the inv(3)/t(3;3) 
aberrations were less frequent than other concomitant mutations. In the inv(3) MDS case 28382 
without any detected activating signaling mutation, the allelic ratio of the inv(3) was about 0.25, 
suggesting that both dysplastic-appearing cells as well as myeloblasts (blast percentage as per 
cytologic evaluation <20%) carried both the inv(3) aberration and coincident gene mutations 
(SF3B1, TP53, DNMT3A; see Figure 1A). Together, these data suggest that the inv(3) or t(3;3) 
aberration is the primary genetic hit in this subset of malignancies, with high proportion of clones 
harboring concurrent activating signaling mutations. Owing to the very short survival of these 
patients and general failure to achieve CR, no time-course monitoring could be performed to 
reveal clonal evolution.
Expression of mutant GATA2
The inv(3)/t(3;3) chromosomal rearrangements separate an upstream GATA2 enhancer from 3q21 
and fuse it to the 3q26.2/EVI1 locus, thereby acquiring features of a monoallelic super-enhancer 
on the rearranged 3q allele.12,13,36,37 Integrative analysis of RNA-seq with 3q-capture DNA-seq data 
using informative, heterozygous SNPs revealed almost exclusive monoallelic expression of the 
mutant GATA2 alleles in 30 inv(3)/t(3;3) cases including cell lines available for analysis (Figure 3), 
as shown in the polar plot by the contribution of the rearranged 3q and nonrearranged 3q allele 
read counts for GATA2 on the basis of the SNVs (SNPs plus somatic mutations) for each patient.
* GATA2 mutation on the non-rearranged
 
allele
Figure 3. Polar histogram plot of allelic imbalance of GATA2 expression observed in RNA-Seq. For each 
patient the average VAF is estimated from informative heterozygous SNVs from the 3q-Seq data. Average 
RNA-Seq GATA2 VAF is estimated from the same SNV positions. Asterisks denote the presence of a somatic 
GATA2 mutation in the indicated sample on the non-rearranged allele.
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This observation indicates that the remaining active, non-rearranged GATA2 allele acquired 
the mutation, whereas the non-mutated GATA2 allele was silenced due to the chromosomal 
rearrangement. Thus, in our inv(3)/t(3;3) AML cohort, heterozygous GATA2 mutations were 
“functionally” hemizygous due to GATA2 silencing.
A
B
Type -7/-7q SF3B1 GATA2 NRAS ASXL1
Legend
Absent
Present
Figure 4. Gene expression profile (GEP) analysis. (A) Clustering of GEPs using the Euclidean distance metric 
and hierarchical clustering. The adjacent table details the acquired mutations of the clustered malignancies. 
(B) Principle component analysis performed on the GEPs of 24 inv(3)/t(3;3) myeloid malignancies displays no 
discrimination between AML and MDS.
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Gene expression and mutation patterns in AML and MDS
It is a matter of debate whether MDS with the distinct inv(3)(q21q26.2) or t(3;3)(q21;q26.2) should 
be regarded as AML irrespective of blast percentage in the bone marrow, similar to the current 
WHO guidelines applied in diagnosis of core binding factor AML with inv(16)/t(16;16) or t(8;21) and 
of acute promyelocytic leukemia with t(15;17).1,5,6,38 In an effort to discriminate MDS and AML with 
inv(3)/t(3;3) based on gene expression programs and the spectrum of coincident gene mutations 
we performed cluster and principle component analyses (Figures 4A and 4B). No cluster formation 
emerged, neither based on the MDS/AML dichotomy nor any other unsubstantiated group within 
our dataset. Furthermore, we performed a differential expression analysis to infer genes that 
could differentiate between MDS and AML. In summary, after Benjamini-Hochberg correction for 
multiple testing, we could only detect two differentially expressed genes (C11orf45: p=0.0009, 
CILP: p=0.04) without a documented role in leukemogenesis. Additionally, we observed that MDS 
patients with inv(3)/t(3;3) are equally therapy-resistant as their AML counterparts in a small set 
of cases analyzed (data not shown). In conclusion, we were unable to detect cluster formation, 
indicating the strong homogeneity of inv(3)/t(3;3) myeloid malignancies based on GEPs and the 
pattern of cooperating genetic lesions.
DISCUSSION
Collectively, we present data that suggest a common genetic background of myeloid malignancies 
harboring inv(3) or t(3;3) and show that RAS alterations and activating RTK mutations are more 
frequent in this disease subset than previously reported.3,6,39,40 The spectrum of secondary genetic 
lesions is generally found in the same EVI1-rearranged dominant clone. No unique cluster within 
inv(3)/t(3;3) myeloid malignancies could be identified, neither by gene expression or mutation 
profiling, nor by analysis of patient characteristics or clinical outcome. Thus, our data further 
support the notion that inv(3)/t(3;3) myeloid disorders could be categorized as AML irrespective 
of blast count, similar to WHO AML categories t(8;21), inv(16)/t(16;16), or t(15;17), which is also 
suggested by the molecular pathobiology common to all inv(3)/t(3;3) myeloid malignancies.12,13
 Reclassification of the currently annotated WHO AML subtype inv(3)/t(3;3); RPN1-EVI1 as 
inv(3)/t(3;3); GATA2-EVI1-rearranged AML is supported by the observation that GATA2 allelic 
imbalances and monoallelic expression of heterozygous GATA2 mutations occur due to the 
distinct chromosomal rearrangements. Whether or not this and other myeloid transcription factor 
alterations contribute to disease biology and the highly adverse clinical phenotype of inv(3)/t(3;3) 
patients remains to be shown, although GATA2 and other transcription factor disturbances have 
described to be preleukemic lesions.28,41-45 Of note, myeloid malignancies with inv(3) or t(3;3) 
define yet another subset of AML with high enrichment of GATA2 mutations next to CEBPA-
mutated AML.46,47
 We included CML cases in blast crisis with an inv(3)/t(3;3) under the assumption that CML-BC 
closely resembles AML biology.48 The BCR-ABL1 fusion is an RTK mutant that in itself activates RAS 
Mutational spectrum of myeloid malignancies with inv(3)/t(3;3)
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pathways and is the first event in transformation of myeloid precursors, as opposed to MDS and 
AML cells that first acquired inv(3)/t(3;3).49,50 Despite the difference of biology and etiology of CML, 
the mutational spectrum of inv(3)/t(3;3) CML-BC cells appears to be same, as further suggested by 
transcriptome analysis, which showed that gene expression profile of the single CML-BC case did 
not differ from that of AML and MDS cases. However, the small number of inv(3)/t(3;3) MDS and 
CML cases in our study preclude conclusive assessment of the role of inv(3)/t(3;3) with regards to 
clinical phenotype.
 In summary, inv(3)/t(3;3) myeloid malignancies harbor a common set of molecular alterations, 
i.e. EVI1 and GATA2 deregulation coupled with mutations activating key signaling pathways. The 
dependence on constitutive RAS/RTK signaling activity of inv(3)/t(3;3) transformed AML cells 
might be the molecular correlate of the observed high white blood cell counts in this disease 
subset. Also, in view of the negative impact of GATA2 deficiencies on proliferation and regeneration 
of myeloid progenitors,15,41,51,52 these activated signaling mutations may be indispensable for 
survival and propagation of inv(3)/t(3;3)-transformed myeloid progenitors. The high mutational 
burden of inv(3)/t(3;3) cells as compared to other AML subtypes27 (Supplemental Table 2) could 
also provide clues as to why inv(3)/t(3;3) malignancies invariably associate with an extremely poor 
prognosis. As these rare inv(3)/t(3;3) myeloid malignancies form a highly unmet medical need, 
novel therapeutic approaches could be derived from the observation of constitutive activation of 
the MAPK pathway in almost 100% of these tumors. Exploiting signaling pathways therapeutically 
by using FLT3- or PI3K-inhibitors53 or hypothetically by interfering with RAS-signaling, possibly in 
combination with BET-inhibitors12, may serve as valuable adjuncts to the scarce armamentarium 
of chemotherapeutic drugs effective in this subset of malignancies.
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ABSTRACT
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are heterogeneous 
malignancies characterized by a variety of acquired genetic abnormalities and variable response 
to treatment.1,2 In the last decade a number of novel molecular genetic abnormalities have been 
revealed in MDS and AML by applying novel genome-wide technologies, such as massively parallel 
sequencing.2,3 The different recurrent genetic aberrations shed light on possible mechanisms 
involved in leukemogenesis and refine risk-stratification of both diseases.1 Although recurrence 
of aberrations in MDS and AML is the major guide to reveal general mechanisms regarding 
leukemogenesis, unique abnormalities can also be highly informative. Here we describe a unique 
fusion of the lysine (K)-specific methyltransferase 2A (KMT2A) gene (mixed-lineage leukemia gene 
(MLL)), located on chromosome 11q23, and the gene encoding smooth muscle myosin heavy 
chain 11 (MYH11), located on chromosome 16p13, in a patient with MDS and subsequently AML, 
both harboring the cryptic translocation t(11;16). KMT2A and MYH11 are involved in recurrent 
translocations in AML, but fusions of these two genes have never been demonstrated. 
RNA-Seq reveals KMT2A-MYH11 fusion transcript in AML
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INTRODUCTION
KMT2A is a transcriptional activator, which regulates gene expression, including HOX genes, by 
methylation of histone H3 lysine 4 (H3K4).4 The KMT2A gene on 11q23 is involved in translocations 
in approximately 5% of adult AML cases4 and more than 70 translocation partners of KMT2A have 
been described.5 The majority of KMT2A fusions incorporate the N-terminal portion of KMT2A, 
containing three short AT-hook motifs, two speckled nuclear localization sites and a transcriptional 
repression domain (Figure 1B).4,5 Leukemic KMT2A fusions impair H3K4 methylation and transform 
hematopoietic cells very efficiently. 
 MYH11 is a subunit of a major contractile protein consisting of two heavy chain subunits 
and two pairs of non-identical light chain subunits. An pericentric inversion or translocation 
of chromosome 16 (inv(16)(p13q22) or t(16;16)(p13;q22)), involving the MYH11 gene, define a 
specific subtype of AML characterized by eosinophilia and favorable treatment outcome and 
are characteristic for core-binding factor (CBF) leukemias.1 These chromosome 16 abnormalities 
result in fusion of MYH11 and core-binding factor β (CBFB) on 16q22. The resulting fusion 
transcript CBFB-MYH11 encodes a protein consisting of the first 133-165 residues of the N- 
terminus of CBFB and variable C-terminal portions of MYH11. There are two models proposed 
for CBF-leukemogenesis both based on impairment of the master regulator RUNX1.6 Briefly, the 
CBFB-MYH11 fusion protein affects RUNX1 either by sequestering RUNX1 from its target genes or 
interfering with RUNX1-mediated gene expression by binding of transcriptional repressors to the 
MYH11 moiety in CBFB-MYH11.6
 The most frequent CBFB-MYH11 fusions in adult AML fuses exon 5 of CBFB to exon 12 (type 
A,>85%), exon 8 (type D,<5%) or exon 7 (type E,<5%) of MYH11.7 Several other fusions of CBFB 
and MYH11 have been demonstrated, however, these are relatively rare (<1%). The variability 
among CBFB-MYH11 fusions makes routine detection of this favorable marker in AML by RT-PCR 
challenging. By applying RT-qPCR aimed for expression of the 3’end of MYH11, which is normally 
not or at very low level expressed in hematopoietic cells, all AML inv(16) cases are reliably 
detectable, independent of the type of CBFB-MYH11.8
RESULTS
Here we describe a 67 year old patient who presented with MDS. After informed consent, 
bone marrow aspirates and peripheral blood samples were taken at diagnosis and at relapse. 
Cytological blood smear examination at diagnosis demonstrated a shift to the left in the blood 
smear with 7% myeloblasts, as confirmed by flow cytometry. Hypogranulated neutrophils were 
observed as were Pseudo Pelger-Huet nuclei and occasionally Auer rods. White blood cell count 
(WBC) was 13.5x109/l. The bone marrow smears were hypercellular with 96% myelopoietic cells 
and 2% myeloblasts. Dysmyelopoiesis was seen, however, no increase of abnormal eosinophils. 
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 The patient was diagnosed as MDS-RAEB II according to the WHO 2008 classification. A 
diagnosis MDS was considered based on the elevated WBC and the shift to the left. The karyotype 
of the patient at diagnosis was 53,XY,+6,+8,+9,+13,+14,+19,+21[15]. Standard FISH both on 
interphase nuclei and metaphases using probes for KMT2A/11q23 (break apart), centromere 7 
and 8, and probes for 5p15.2 and 5q31 revealed a translocation of KMT2A/11q23 to chromosome 
16p13. The t(11;16)(q23;p13) was present in 96% of all cells (LSI MLL Dual color break apart 
probeset (Vysis)). The patient was treated according to the HOVON43 protocol (http://www.hovon.
nl) and a complete remission was achieved, but the patient relapsed after 41 months. At relapse 
the patient was treated with AS602868, a pharmacological inhibitor of the IKK2 kinase, in a Phase 
1 trial, but succumbed after progression of the AML. Cytological examination at relapse showed a 
hypercellular bone marrow, 72% myeloblasts, dysmyelopoiesis and dysmegakaryopoiesis (Figure 
1A). Again Auer rods were seen but no eosinophilia or abnormal eosinophils.  The karyotype was 
53,XY,+6,+8,+9,+13,+14,+19,+21[1]/46,XY[19] FISH demonstrated the t(11;16)(q23;p13) to be 
present in 90% of all interphases.
 All our AML cases are screened with RT-qPCR to detected possible CBFB-MYH11 fusions. 
Interestingly, although the patient did not show an inv(16)(p13q22), t(16;16)(p13;q22) by 
cytogenetic analysis or CBFB-MYH11 by RT-PCR, MYH11 was highly expressed at diagnosis and 
at relapse shown by RT-qPCR8, suggesting that MYH11 was part of a unknown fusion transcript 
between 11q23 and 16p13. However, morphologically this case did not show any signs of inv(16)-
associated eosinophilia.
 To unravel the composition of the MYH11-containing mRNA transcript, we performed RNA 
sequencing (RNA-Seq) on patient material at diagnosis as part of our ongoing AML research. 
In brief, total sample RNA was extracted with phenol chloroform and reverse transcribed using 
Superscript II RT (Life Technologies). The cDNA was sheared with the Covaris device and further 
processed according to the TruSeq RNA Sample Preparation v2 Guide (Illumina). Amplified sample 
libraries were paired-end sequenced (2x36bp) on the HiSeq 2000 system and aligned against the 
human genome (hg19) using TopHat2.9
Figure 1. RNA-Seq reveals the KMT2A-MYH11 fusion transcript (A) May-Grünwald-Giemsa staining of bone 
marrow from MDS and AML patient #5291. (B) Schematic representation of KMT2A, MYH11 and the KMT2A-
MYH11 fusion protein. The KMT2A-MYH11 contains three short DNA-binding AT-hook motifs (ATH 1–3), two 
speckled nuclear localization sites (SNL1 and SNL2) and a transcriptional repression domain (TRD) followed by 
full length MYH11 (plant homology domain (PHD), transcriptional activation (TA) domain, methyltransferase 
domain (SET). The main KMT2A breakpoint region (BCR) is indicated.5 (C) RT-PCR for the KMT2A-MYH11 fusion 
transcript in (patient #5291 (duplicate)); cell lines HL60 and HEL (upper: primer set 13-561/562, lower: primer 
set 13-563/564) as negative controls. (D) Sanger sequencing of the KMT2A (exon 8) and MYH11 (exon 2) 
fusion gene. (E) Pearson’s Correlation View with pair-wise correlations between AML patients with KMT2A-
rearranged AML [KMT2A cases], AML patients with inv(16) [CBFB-MYH11 cases] and patient #5291 [KMT2A-
MYH11] (indicated with arrow). The cells in the visualization are colored by Pearson’s correlation coefficient 
values with deeper colors indicating higher positive (red) or negative (blue) correlations. Molecular data are 
depicted in the columns along the Correlation View: (I) KMT2A rearrangement and (II) CBFB-MYH11 fusion (red 
bar: present and green bar: absent); gene expression of MYH11 (III; 201497_x_at), BRE (IV; 205550_s_at) and 
EVI1 (V; 221884_at). The bars are proportional to the level of expression.
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All reads were aligned against genes annotated within the Ensembl database, as provided 
with the TopHat package. The Integrated Genome Viewer10 was used for data visualization and 
assessment of MYH11 fusion transcripts. The alignment of the RNA-Seq data confirmed the 
overexpression of MYH11, starting in exon 2 upstream of the ATG-start codon. Interestingly, 
paired-end sequencing reads of exon 2 of MYH11 aligned to sequences of exon 8 of KMT2A. These 
results suggested that the t(11;16) resulted in a gene fusion of KMT2A (exon 8) and MYH11 (exon 
2) (Figure 1B). The KMT2A-MYH11 fusions were confirmed by cDNA amplification using the primer 
sets 13-561MLL-MYH11 FW1 (KMT2A ex7): 5’-TTCCAGGAAGTCAAGCAAGC-3’ and 13-562MLL-
MYH11 RV1 (MYH11 ex2): 5’-CTCGAAGCCCTGCTTCTC-3’ (amplicon:298bp) or 13-563MLL-MYH11 
FW2 (KMT2A ex7): 5’-CCGTCGAGGAAAAGAGTGAA-3’ and 13-564MLL-MYH11 RV2 (MYH11 ex2): 
5’-CGTGACCTTCTTGCCATTCT-3’ (amplicon:443bp) (0.25mM dNTP, 15pmol primers, 2mM MgCl2, 
Taq polymerase and 1xbuffer [Life Technologies]). Cycling conditions: 1 cycle 5 min at 94˚C, 35 
cycles 1 min at 94˚C, 1 min at 60˚C, 1 min at 72˚C, and 1 cycle 7 min at ’72˚C. PCR amplification 
with both primer sets resulted in products with the expected size (Figure 1C). These PCR products 
were sequenced by using forward and reverse primers on the ABI PRISM3100 genetic analyzer 
(Applied Biosytems Life Technologies). Sanger sequencing confirmed the KMT2A-MYH11 fusion 
transcript encoding an in-frame KMT2A-MYH11 fusion (Figure 1D). The KMT2A-MYH11 fusion 
was demonstrated to be present at relapse (data not shown). Lack of high quality protein lysates 
prevented detection of the KMT2A-MYH11 fusion protein in the patient's MDS and AML phase. 
 Gene expression analyses demonstrated that the KMT2A-MYH11 AML did not show any 
correlation with CBFB-MYH11 AML (Figure 1E).11,12 Interestingly, however, based on gene 
expression the KMT2A-MYH11 AML grouped together with MLL-rearranged AML (Figure 1E). 
More specifically, the KMT2A-MYH11 AML clustered with MLL-rearranged AML with high EVI1 
expression13 instead of high BRE expression.14
 Extensive analyses of the RNA-Seq data demonstrated a mutation in a well-known AML- and 
MDS-related gene, a non-synonymous mutation in the splicing factor gene U2AF1 (exon2:c.
C101T:p.S34F). This mutation in U2AF1 has been confirmed by Sanger sequencing. Whether this 
mutation is somatic or germline remains to be elucidated.
DISCUSSION
In the past several t(11;16) patients have been described, however, these cases appear to be 
rare. In a study of two MDS patient with a t(11;16)(q23;p13) a recurrent fusion of the genes 
encoding KMT2A and CREB-binding protein (CREBBP (CBP)) was demonstrated.15 A subsequent 
study of eight patients revealed that the t(11;16)(q23;p13) occurred exclusively in patients with 
therapy related t-AML or t-MDS, i.e., previous treatment with Topo2 inhibitors for a variety of 
malignancies.16 Although the breakpoint was not determined in all t(11;16)(q23;p13) cases, it 
is unlikely that these patients carried a KMT2A-MYH11 fusion considering the FISH probes used. 
Furthermore, our patient did not receive any treatment for any prior malignancy.
RNA-Seq reveals KMT2A-MYH11 fusion transcript in AML
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 In this MDS/AML patient we have revealed a unique fusion of the N-terminal part of KMT2A 
and the complete MYH11 protein. This fusion involves two proteins known to be present in 
chromosomal translocations in highly distinct AML subtypes. All KMT2A fusions are subdivided 
in 4 groups based on the KMT2A-fusion partner.4 MYH11 contains several repeated helical rod 
domains important for self-dimerization and multimerization in its C-terminus, which also binds 
transcriptional corepressors. The novel KMT2A-MYH11 fusion most probably belongs to group 
2 of MLL-fusion proteins, including SH3GL1/EEN, MMLT4/AF6, GAS7 and AFX1/FOXO4, which 
all contain oligomerization domains important for transformation. The presence of the t(11;16)
(q23;p13) fusion at diagnosis and relapse suggests that KMT2A-MYH11 occurred in the founding 
clone of the MDS/AML and appears essential for this disease.
AUTORSHIP AND DISCLOSURES
MAS: Performed research, analyzed data and wrote paper; FGK: Performed research and analyzed 
data; AZ: Performed research and analyzed data; ASAAH: Performed research and analyzed data; 
SA: Performed research and analyzed data; HBB: Performed research and analyzed data; KvL: 
Performed research, analyzed data and wrote paper; PJMV: Designed and performed research, 
analyzed data and wrote paper. All authors declare no conflicts of interest
Chapter 9
162
Chapter 9
REFERENCES
1. Marcucci G, Haferlach T, Dohner H. Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and 
Therapeutic Implications. J Clin Oncol. 2011;29(5):475-486.
2. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in 
myelodysplastic syndromes. Blood. 2013;122(22):3616-3627; quiz 3699.
3. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid 
leukemia. N Engl J Med. 2013;368(22):2059-2074.
4. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell 
development. Nat Rev Cancer. 2007;7(11):823-833.
5. Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 
2009;23(8):1490-1499.
6. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and 
future prospects. Int J Hematol. 2011;94(2):126-133.
7. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts 
from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of 
the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 
1999;13(12):1901-1928.
8. van der Reijden BA, Massop M, Tonnissen E, et al. Rapid identification of CBFB-MYH11-positive acute 
myeloid leukemia (AML) cases by one single MYH11 real-time RT-PCR. Blood. 2003;101(12):5085-5086.
9. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes 
in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
10. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 
2011;29(1):24-26.
11. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid 
leukemia. N Engl J Med. 2004;350(16):1617-1628.
12. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia 
based on gene expression profiling. Haematologica. 2009;94(1):131-134.
13. Groschel S, Schlenk RF, Engelmann J, et al. Deregulated Expression of EVI1 Defines a Poor Prognostic 
Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid 
Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol. 2012.
14. Noordermeer SM, Sanders MA, Gilissen C, et al. High BRE expression predicts favorable outcome in adult 
acute myeloid leukemia, in particular among MLL-AF9-positive patients. Blood. 2011;118(20):5613-5621.
15. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome 
fuses the MLL gene to the CBP gene. Blood. 1997;89(11):3945-3950.
16. Rowley JD, Reshmi S, Sobulo O, et al. All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP 
have treatment-related hematologic disorders. Blood. 1997;90(2):535-541.
Chapter 8
Integrated genome-wide genotyping and 
gene expression profiling reveals BCL11B as a 
putative oncogene in acute myeloid leukemia 
with 14q32 aberrations
Saman Abbas1, Mathijs A. Sanders1, Annelieke Zeilemaker1, Wendy M.C. Geertsma-Kleinekoort1, 
Jasper E. Koenders1, Francois G. Kavelaars1, Zabiollah G.Abbas1, Souad Mahamoud1, 
Isabel W.T. Chu1, Remco Hoogenboezem1, Justine K. Peeters1, Ellen van Drunen2, 
Janneke van Galen2, H. Berna Beverloo2, Bob Löwenberg1, and Peter J.M. Valk1
1 Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands
2 Erasmus University Medical Center, Department of Clinical Genetics, Rotterdam, The Netherlands
Haematologica. 2014 May;99(5):848-57
CHAPTER
Chapter 10
164
Chapter 10
ABSTRACT
Acute myeloid leukemia (AML) is a neoplasm characterized by recurrent molecular aberrations 
traditionally demonstrated by cytogenetic analyses. We have used high density genome-wide 
genotyping and gene expression profiling to reveal acquired cryptic abnormalities in AML. By 
genome-wide genotyping of 137 primary AML cases, we disclosed a recurrent focal amplification 
on chromosome 14q32, which included the BCL11B, CCNK, C14orf177 and SETD3 genes, in two 
cases. The BCL11B gene showed consistent high mRNA expression in the affected cases, whereas 
the expression of the other genes was unperturbed. Fluorescence in situ hybridization on 40 
AML cases with high BCL11B mRNA expression (2.5-fold above median; 40 out of 530 cases 
(7.5%)) revealed 14q32 abnormalities in 2 additional cases. In the 4 BCL11B-rearranged cases the 
14q32 locus was fused to different partner chromosomes. In fact, in 2 cases, we demonstrated 
that the focal 14q32 amplifications were integrated into transcriptionally active loci resulting 
in increased expression of full-length BCL11B protein. The BCL11B-rearranged AMLs expressed 
both myeloid and T-cell markers and all carried FLT3 internal tandem duplications, a characteristic 
marker for AML. Generally, in AML, BCL11B mRNA expression appeared to be strongly associated 
with expression of other T-cell specific genes. Myeloid 32D(GCSF-R) cells ectopically expressing 
Bcl11b showed decreased proliferation rates and less maturation. In conclusion, by an integrated 
approach involving high-throughput genome-wide genotyping and gene expression profiling 
we identified BCL11B as a candidate oncogene in AML.
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter10/
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INTRODUCTION
AML is a heterogeneous clonal neoplasm characterized by accumulated genetic aberrations, 
which result in enhanced proliferation, a block in differentiation and increased survival of 
the leukemic blast cells and variable response to therapy.1,2 In the past decades a number of 
recurrent cytogenetic abnormalities have been identified in AML, such as the chromosomal 
aberrations t(8;21) and inv(16).1,2 These recurrent molecular lesions result in the expression of 
fusion proteins of which the leukemic potential, in combination with additional genetic events, 
has been demonstrated by in vitro and in vivo models.3 In addition to cytogenetic abnormalities, 
acquired mutations in disease genes, such as FLT3, NPM1, RUNX1 and CEBPA, have recently been 
demonstrated to be involved in AML.1,2 Several acquired molecular aberrations carry prognostic 
value and have been incorporated in routine molecular analyses of AML.1,2
 Contemporary genome-wide approaches, such as gene expression profiling (GEP), genome-
wide genotyping and next generation sequencing (NGS), enable detailed analyses of hematologic 
malignancies for the identification of novel pathogenic genes.2,4,5 For example, gene mutations in 
IDH1, TET2, DNMT3A, ASXL1, and EZH2  have been demonstrated with these novel technologies in 
myeloproliferative neoplasms.6-11 In addition to balanced translocations, loss or gains of genetic 
material are apparent in the leukemic blast of AML patients, e.g., those involving the partial or 
complete loss of chromosome 5 and 7.1 In the past two decades, attempts to identify the tumor 
suppressor genes located on these chromosomes have failed. By genome-wide SNP genotyping 
it has become possible to simultaneously genotype hundred thousands of single nucleotide 
polymorphisms (SNPs) in a single assay. In addition, SNP platforms can also be conveniently used 
to determine chromosomal copy numbers, similarly to array comparative genomic hybridization 
(CGH). Genomic DNA can be examined with an inter-marker distance of several hundreds of 
base pairs, which makes it feasible to detect (micro)deletions and/or amplifications that are 
missed with conventional cytogenetics. The application of high-throughput SNP genotyping has 
been elegantly demonstrated to be powerful for the identification of disease genes, such as for 
ALL4,12,13 or AML.14 Another major advantage of SNP arrays is the fact that allele losses are directly 
recognizable as loss-of-heterozygosity (LOH). In fact, SNP arrays revealed that approximately 20% 
of AMLs exhibit large non-random regions of homozygosity without changes in copy number 
as a result of segmental uniparental disomy (UPD), often indicating mutations in genes within 
these regions. These areas of UPD have been associated with mutations in CEBPA, WT1, FLT3 and 
RUNX1.15,16 In addition, deletions, amplifications and UPDs could alter the gene expression levels 
of proximal genes. Juxtaposition of regulatory sequences may result in increased or decreased 
expression of affected genes. Thus, genome-wide analyses to detect copy number changes and 
LOH in the context of gene expression may also pinpoint towards pathogenic genes. We recently 
developed SNPExpress, an easily accessible software tool to accurately analyze SNP genotype 
calls, copy number and gene expression in an efficient combinatorial way.17
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 In this study, we identified BCL11B as a candidate oncogene in AML through an integrated 
approach of genome-wide genotyping and GEP, followed by NGS. BCL11B is a Kruppel family 
zinc finger family gene located at 14q32, associated with transcriptional co-repressor complexes 
in mammalian cells and a pivotal regulator of differentiation and survival of haematopoietic 
cells, especially T-cells.18 We demonstrate that BCL11B is involved in a number of cryptic 14q32 
translocations in AML, in which BCL11B and T-cell associated genes expression levels are 
increased concomitantly. Overexpression of BCL11B in a murine myeloid cell line model inhibits 
proliferation. 
METHODS
Patients samples
This study has been approved by our local Medical Ethical Committee (MEC-2004-030 and 
MEC2007-364). After informed consent, bone marrow aspirates or peripheral blood samples of a 
representative cohort of AML patients were collected. Eligible patients had a diagnosis of primary 
AML, confirmed by cytological examination of blood and bone marrow. All patients were treated 
according to the HOVON (Dutch-Belgian Hematology-Oncology Co-operative group) protocols 
(http://www.hovon.nl). For details see Supplementary material.
Genome-wide genotyping and gene expression profiling
Genome-wide genotyping data sets of 48 patients with various subtypes of AML were generated 
using Affymetrix 500K NspI/StyI DNA mapping arrays and 89 patients with cytogenetically normal 
AML (CN-AML) using Affymetrix 250K NspI or StyI DNA Mapping arrays. The copy numbers of all 
AML samples were calculated using diploid references, i.e., 15 normal karyotype AML samples. For 
details see Supplementary material.
  Gene expression profiles of the same AMLs were generated using Affymetrix HG-U133 plus 2.0, 
as described elsewhere (GEO Series accession number GSE6891).19 Pearson correlation analyses 
was performed as described previously.20 The genome-wide genotyping and gene expression 
profiling data sets were examined using SNPExpress.17 
Fluorescence In Situ Hybridization (FISH)
Dual color fluorescence in situ hybridization (FISH) was performed with BAC clones RP11-431B1, 
RP11-876E22, RP11-830F3, RP11-782I5, RP11-450C22, RP11-57E12, RP11-1069L3 and RP11-242A7 
covering the BCL11B encompassing region and regions up- and downstream (BACPAC resources, 
Oakland, USA). For details see Supplementary material.
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Targeted sequencing of the 14q32 genomic region
Library preparation and targeted resequencing was performed following the protocols as described 
previously.21 In brief, high molecular weight DNA of AML #2301 and #7073 were sheared using a 
Covaris E210 waterbath sonificator. The BCL11B 14q32 – tel. genomic region (chr14:93930247-
105928955 (hg19)) was captured with a Roche/Nimblegen SeqCap EZ Choice XL Library. The 
captured region was subsequently paired-end sequenced using the Illumina HiSeq2000. The data 
has been analyzed using an in-house pipeline which identifies single nucleotide variants, small 
and large indels and copy number variations. The chromosomal breakpoints, in the 14q32 region 
and the partner chromosome, were identified using Breakdancer.22 The genomic fusions were 
subsequently confirmed by Sanger sequencing.
Western blot analyses
Western blot analyses were carried out using an affinity-purified rabbit polyclonal anti-BCL11b 
antibody (Novus Biologicals, Littleton, USA). Immune complexes were detected by binding anti-
mouse IgG conjugated to horseradish peroxidase (DAKO, Heverlee, Belgium) followed by the 
enhanced chemiluminescence assay (Amersham Bioscience, Piscataway, NJ) and GAPDH was 
stained with primary affinity-purified rabbit polyclonal antibody (α-GAPDH FL-335) (Santa Cruz 
Biotechnology, California, USA). For details see Supplementary material.
DNA constructs and generation of BCL11B expressing 32D/GCSFR cells
Murine Bcl11b cDNA (kindly donated by Dorina Avram, Albany Medical Center, Albany, NY) was 
subcloned into a pLXSN expression vector under control of a 5’ long terminal repeat (LTR) of the 
Moloney murine sarcoma virus (MoMSV) (Clontech, Mountainview, USA). Vector constructs were 
confirmed by nucleotide sequencing and retrovirally transfected into 32D cells that stably express 
human granulocyte colony-stimulating factor receptor (GCSF-R)23 using Fugene transfection 
reagent (Roche, Indianapolis, USA). Cells were stimulated with interleukin-3 (IL3, 25ng/ml) or 
GCSF (25 ng/ml), counted and assessed for proliferation and granulocytic differentiation. For 
details see Supplementary material.
RESULTS
Genome-wide genotyping of cytogenetically abnormal and normal AML 
cases
In total, DNA mapping array profiles of 137 AML cases were generated (Figure 1), containing 48 
AML cases selected based on previous GEP studies, i.e., 21 AML cases from GEP clusters #4 and #15 
(100% CEBPA mutant or CEBPA silenced24), 13 AML cases from GEP cluster #9 (100% inv(16)) and 
14 AML cases from GEP cluster #10 (adverse prognosis).20 In addition, DNA mapping array profiles, 
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i.e., Affymetrix 250K NspI or StyI DNA mapping array, of 89 CN-AML cases were generated. With 
the Affymetrix 500K NspI/StyI DNA Mapping arrays, all known numerical cytogenetic aberrations, 
i.e., whole chromosome and interstitial deletions and amplifications that had been identified with 
cytogenetic banding analysis, were recognized in the 48 cytogenetically abnormal AML samples, 
as long as the abnormalities were present in over 30% of the AML cells.17 Also, in approximately 
25% of all cases large regions of segmental uniparental disomy were detected, often involving 
whole chromosome arms.17 
 In addition to the known cytogenetic aberrations, relatively low numbers of small interstitial 
deletions and amplifications were detected in the 137 AML cases. However, some of these were 
indicative for the presence of cryptic translocations, such as cryptic t(5;11), t(9;22) and t(4;11), 
which are known to encode chimeric fusion proteins essential for leukemogenesis. All fusion 
transcripts involved in these translocations, i.e., NUP98-NSD125, BCR-ABL and MLL-AF4, were 
confirmed by RT-PCR. Thus, although relatively small numbers of aberrations were found, most 
being non-recurrent, they may reliably mark relevant leukemic lesions. 
Figure 1. Research design. GEP: gene expression profiling.
Integrated analysis of genome-wide genotypes and gene expression 
profiles
By an integrated approach using genome-wide genotyping data and previously determined 
GEPs of the primary AML samples (Figure 1)20, we searched for genes aberrantly expressed as 
a result of numerical changes in the AML genome. Using SNPExpress17, we identified 2 AML 
cases with relatively small interstitial amplifications in the 14q32 region (#2301 amplification: 
482 Kb, 3 copies and #7073 amplification: 460 Kb, 3 copies) (Figures 2A and B). The amplified 
region encompassed BCL11B, CCNK, C14orf177 and SETD3. Interestingly, BCL11B mRNA was highly 
expressed in the 2 AML cases with numerical changes, whereas expression of C14orf177, CCNK 
BCL11B, a novel putative oncogene in AML
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and SETD3 were unperturbed compared to other AML cases (Figures 2A and B). In addition, 
BCL11B mRNA is highly expressed in AML #2301 and #7073, whereas expression is low or absent 
in control AML cases (Figure 2A). This could indicate that as a result of a genomic rearrangement, 
BCL11B has become overexpressed in these AML cases. The small interstitial amplifications in AML 
#2301 and #7073 may pinpoint towards cryptic translocations.
Figure 2. Identification of interstitial amplifications on 14q32.2 using SNPExpress. (A) Copy number 
profiles of chromosome 14q32.2 for four AML samples. Copy numbers are shown for each patient by horizontal 
lines (n=0, 1, 2, 3, 4). SNP genotypes are color coded: AA: red; BB: yellow; AB: blue, No call: white. Gains (default 
n>2.5) are depicted as pink background. Gene expression levels are visualized as vertical white bars. Multiple 
probe sets spanning the same locus is depicted by a green bar proportional to the highest expression value 
observed. Green boxes represent genes and accompanying arrow indicates its orientation. In AML #2301 and 
AML #7073 clear amplifications are visible, whereas these aberrations are absent in the two control AMLs. (B) 
Snapshot of SNPExpress showing the amplified region in AML case #2301 and #7073 including genes located 
within this region. C14orf177 and BCL11B are amplified in both AML cases, whereas SETD3 and CCNK only in 
AML #7073. BCL11B expression is increased in AML #2301 and #7073, as indicated by the green bar (multiple 
probe sets), and absent in control AML cases (Figure 2A).
FISH reveals translocations in AML cases #2301 and #7073 involving BCL11B 
To confirm the amplifications in the BCL11B locus in the 2 AML cases, we performed FISH analysis 
with a probe covering the BCL11B gene (RP11-431B1) and a probe flanking this locus (RP11-74H1) 
(Figure 3A). On metaphase spreads of both AML cases an additional BCL11B allele was apparent 
(Figure 3B). This is in line with the expected copy number change for the BCL11B locus (n=3) as 
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shown with SNPExpress (Figures 2A and B). In fact, through verification using chromosomal paints 
we showed that BCL11B was translocated to chromosome 6 in AML case #2301 and  chromosome 
8 in AML #7073 (data not shown). 
Figure 3. FISH analysis of AML cases #2301 and #7073 using probes specific for BCL11B and its flanking 
region. (A) Schematic representation of the FITC-labeled BAC probe (RP11 431B1) covering the BCL11B locus 
and Texas Red-labeled BAC probe (RP11 242A7) covering the adjacent region. (B) Microscope images of FISH 
analysis performed on metaphases chromosomes of AML cases #2301 and #7073 showing additional green 
signal (RP11431B1) indicative for an extra copy of the BCL11B locus.
Amplified 14q32 genomic regions are integrated into transcriptionally 
active loci 
We performed paired-end sequencing of the 14q32 captured region in AML cases #2301 and 
#7073. We observed paired-end reads spanning 14q32 and 6q25.3 (chr6:156717480 and 
chr14:99110325; chr6:156587275 and chr14:99748893) in AML case #2301 and reads spanning 
14q32 and 8q24.21 (chr8:130485869 and chr14:99179210) in AML case #7073, indicating 
translocation events to partner chromosomes 6 and 8, respectively. These breakpoints were 
confirmed by PCR on genomic DNA, followed by Sanger sequencing. The BCL11B encoding-
amplified DNA integrated into two transcriptionally active regions on chromosome 6 and 8, i.e., 
on 6q25.3 into an expressed sequence tag CB984582  and on 8q24.21 into the large non-coding 
(lnc) RNA gene Coiled-Coil Domain Containing 26 (CCDC26). Both polyA genes are transcriptionally 
active in the 2 AML cases, and various other AML cases, and are subjected to mRNA splicing as 
demonstrated by RNA sequencing (data not shown), indicating that these RNAs are expressed 
in myeloid cells. No fusion transcripts between BCL11B and RNAs encoded by the partner 
chromosomes could be detected by RNA-seq, suggesting that regulatory sequences on 6q25.3 
and 8q24.21 may activate the BCL11B gene in the BCL11B-rearranged AML cases. 
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AML case #2301 expresses full-length BCL11B
The translocations involving BCL11B could result in increased expression of either full-length 
BCL11B or a fusion protein involving BCL11B. In fact, BCL11B mRNA expression in AML#2301 and 
AML#7073, were, respectively, 12- and 8-fold over mean BCL11 mRNA expression in 530 AML cases 
(219528_s_at; 22895_s_at; 224310_s_at).19 Next, we examined the expression profiles obtained 
with Affymetrix Human Exon 1.0 ST Array for AML case #2301. This analysis showed that in AML 
#2301 all four exons of BCL11B were expressed at similarly high levels (data not shown). The fact 
that exon 1 of BCL11B, containing the ATG start codon was expressed, suggested that full-length 
BCL11B is expressed rather than a fusion protein involving parts of BCL11B. Western blot analyses 
of whole, cytoplasmic and nuclear cell lysates of AML case #2301 were used to assess both the size 
and localization of the BCL11B protein. Immunodetection with BCL11B antibodies confirmed the 
expression of full length BCL11B protein restricted to the nucleus (Figure 4). Of note, full-length 
BCL11B was also highly expressed in AML case #2238, an AML without any known aberration 
involving BCL11B.
Figure 4. Western blot analysis of BCL11B in AML case #2301. Western blot analysis with a BCL11B-specific 
antibody demonstrates high expression of full length BCL11B in AML case #2301, in the nuclear compartment 
(upper panel). Whole cell lysates from Jurkat, an acute T-cell leukemia cell line, and AML #2238 show high 
BCL11B expression. AML cases #2195 and #2240 with low BCL11B mRNA expression were used as negative 
controls (#2301w:whole cell lysate; #2301c: cytoplasmic lysate; #2301n: nuclear lysate). β-actin was used as 
loading control (lower panel).   
FISH analyses of selected AML cases with high BCL11B mRNA expression 
reveals additional cases with BCL11B translocations 
FISH analysis of AML cases with high BCL11B expression revealed translocations involving BCL11B, 
thereby raising the possibility that other AML cases with aberrantly high BCL11B expression would 
harbour BCL11B-rearrangements as well. GEP of 530 AML cases19 showed variable expression of 
BCL11B mRNA in AML subsets, including case #2301 and #7073 (Figure 5A). We selected 40 AML 
cases with increased BCL11B mRNA expression, i.e., >2.5-fold above mean BCL11B expression 
in primary AML (Figure 5A), and performed FISH analysis on the BCL11B chromosomal region. 
FISH analyses revealed 2 additional AML cases with a BCL11B translocation (AML #6366 and 
#6451 (Figure 5A and B)). With specific chromosomal paints, we showed that in AML case #6451 
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the BCL11B locus was translocated to chromosome 7 (data not shown). Further FISH could not be 
carried out on AML #6366 due to the lack of material. 
Figure 5. Correlation view based on gene expression profiling of 530 AML cases. (A) Pearson correlation 
view of 530 AML cases showing gene expression correlation based on 2847 probe sets. The black bars 
indicate expression of BCL11B 1: BCL11B expression: 219528_s_at and 2: BCL11B expression: 222895_s_at, 
where the size of the bars is proportional to the levels of BCL11B expression; 3: selection of AML with BCL11B 
overexpression (>2.5-fold mean). The BCL11B-rearranged cases #2301, #6451, #6366 and #7073 are indicated 
by an arrow. (B) FISH analysis performed on metaphase spreads of AML cases #6451 showing disassociation of 
the probe RP11242A7 (red) and RP11431B1 (green) indicating translocation of BCL11B. 
Immunophenotyping and molecular analyses of AML cases carrying BCL11B aberrations
Immunophenotyping of the AML cases harbouring BCL11B translocations expressed, besides 
myeloid markers, also lymphoid markers such as CD2, CD3, and CD7 (Table 1). Cytoplasmic(cy) 
CD3 expression was present in case #2301, suggesting its classification as T-ALL, however, cyCD3 
was absent in the remaining cases. In fact, these AML cases appeared to have a biphenotypic 
signature, i.e., expressing (early) myeloid as well as T-cell associated markers. Well-known recurrent 
molecular abnormalities were determined in the BCL11B-rearranged AML cases, demonstrating, 
with no exception, that these cases carried mutations in the FLT3 gene (Table 1), i.e., internal 
tandem duplications (ITD) or mutations in the tyrosine kinase domain (TKD). We did not identify 
mutations in K-RAS, N-RAS, c-KIT, IDH1, IDH2, ASXL1 or CEBPA. Case #6366 also carried a DNMT3A 
mutation (Table 1).
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 We have analyzed the immunophenotype of the BCL11B non-rearranged cases with BCL11B 
overexpression and did not find a specific pattern of T-cell specific markers. Several cases do 
express CD7, however, this aberrant marker is relatively frequent present on myeloid leukemic 
blasts (app. 30%). Moreover, we were unable to demonstrate a significant association between 
BCL11B overexpression and FLT3-ITD or -TKD mutations in BCL11B non-rearranged AML cases.
Table 1. Clinical, molecular and immunophenotypic data of the AML cases with BCL11B translocations.
Patient number AML #2301 AML #7073 AML #6451 AML #6366
FLT3-ITD pos pos pos pos
FLT3 TKD835 neg neg pos neg
DNMT3A mutation neg neg neg pos
FAB M1 M4 M1 M2
WHO 1 WHO 1 WHO 2 WHO 0 WHO
Gender M M F F
Karyotype 46,XY[21]/ 
?46,XY,inc[9]
46,XY[20] 46,XX,del(7)(q21q35)
[5]/46,idem,add(13)
(q3?4)[17]/ 
46,idem,add(9)(q3?4)
[2]/46,XX[15]
53,XX,+4,+8,+10,+13, 
+14,+15,+20[4]/ 
46,XX[35]
Immunophenotype CD45(+), 
HLA-DR-, 
CD34+, 
TdT+, 
MPOpartial+, 
CD1-,CD2+, 
CD3+,CD4-,CD5-
CD15partial+, 
CD33+,CD7+, 
CD36partial+, 
CD56-,CD65s-, 
CD117partial+, 
CD133+, 
CD4partial+
CD45(+), 
HLA-DR+,CD34+,  
TdTpartial+, 
MPOpartial+, 
CD11c-, 
CD13+,CD15-, 
CD15s partial+, 
CD33-, CD65s-, 
CD117+, CD133+, 
CD2+, CD7partial+
CD45(+),HLA-DR+, 
CD34partial+,TdT-, 
MPOpartial+, 
CD11c partial+, 
CD13partial+, 
CD15partial+, 
CD33+,CD36partial+, 
CD117 partial+, 
CD133+, 
CD4 partial+, CD7(+)   
The mutation status for FLT3, NPM1, N-RAS, K-RAS, CEBPA, c-KIT, ASXL1, IDH1, IDH2 and DNMT3A was determined 
as described previously.26-28 No mutations were present in the 4 AML cases in NPM1, N-RAS, K-RAS, CEBPA, KIT, 
ASXL1, IDH1, and IDH2 (Pos: mutant; Neg: wild-type).
BCL11B is aberrantly expressed in AML and associated with T-cell gene expression signature 
To investigate whether other AML cases with elevated BCL11B mRNA expression show full-
length BCL11B expression, we carried out Western blot analyses on a limited number of cases. 
All analyzed samples with high BCL11B mRNA showed full length BCL11B protein expression at 
variable levels (Figure 6). Due to lack of specimens, BCL11B protein expression analyses in non-
rearranged BCL11B cases was limited to those shown in Figures 4 and 6. To examine which genes 
are co-expressed with BCL11B in AML, we performed a Pearson correlation analysis using GEP data 
of 530 AML cases.19 BCL11B co-regulated probe sets were calculated across all AML patients. The 
top 50 BCL11B correlating probe sets are highly associated with T-cells and T-cell development 
(Supplementary table 1). In fact, the majority of BCL11B associated genes are T-cell specific genes, 
such as CD3, TRBV19, IL32, LCK, TCF7 and CD2, among many others (Supplementary table 1). 
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Figure 6. Western blot analyses for BCL11B primary AML. Immuno-detection of the BCL11B protein in 
AML cases with elevated levels of BCL11B mRNA (+) and cases with undetectable levels of BCL11B mRNA (-) 
(upper panel; Jurkat cell lysate as positive control). GAPDH was used as loading control (lower panel).
Figure 7. Effects of BCL11B overexpression in murine 32D(GCSF-R) cells. (A) Western blot analyses for 
BCL11B in 32D(GCSFR) cells. 32D(GCSFR) clones overexpressing BCL11B are indicated by #2, #4, and #12 (IL3 
for 1 and 10 days). Lysates obtained from these clones were immunostained for BCL11B at day 1 and day 
10 (Jurkat cells: positive control; 32D: 32D(GCSF-R) cells). GAPDH was used as loading control (lower panel). 
(B) Growth curve of 32D(GCSFR) cells with (squares, dashed line) and without (round, solid line) BCL11B 
expression and parental 32D(GCSFR) cells (triangle, dotted line) incubated with interleukin 3. 32D cells were 
counted every 24 h for ten days. (C) May-Grünwald-Giemsa-stained cytospins of 32D(GCSF-R) cells with 
(upper panel) and without (lower panel) BCL11B expression incubated with GCSF for 7 days. Granulocytic 
differentiation is monitored by the presence of cells with segmented nuclei.  
Increased Bcl11b expression results in decreased proliferation of the 
myeloid cell line 32D(GCSF-R)
To investigate the effect of Bcl11b expression on proliferation and differentiation, immortalized 
myeloblast-like murine bone marrow cells stably expressing human GCSF-R (32D(GCSF-R)) 
were transfected with full length murine Bcl11b cDNA. Three 32D(GCSF-R) clones expressing 
Bcl11b were selected and incubated for ten days in the presence of interleukin-3 (IL3) or 
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granulocyte stimulating factor (GCSF). Western blot analyses demonstrated that BCL11B was 
expressed at every time point (Figure 7A). BCL11B expressing 32D(GCSF-R) clones showed a 
consistent decreased proliferation rate when cultured in the presence of IL3 in comparison to 
32D(GCSF-R) clones containing a control empty vector (Figure 7B). Additionally, we evaluated 
the granulocytic differentiation abilities of the same 32D(GCSF-R) clones upon stimulation 
with GCSF. Morphological analyses of cytospins did not show consistent maturation defects in 
the BCL11B expressing 32D(GCSF-R) clones. However, less maturation towards granulocytes in 
32D(GCSF-R) cells expressing BCL11B and more undifferentiated blast cells compared to cells with 
empty vector were present in some 32D(GCSF-R) BCL11B expressing clones (Figure 7C). This effect 
was most apparent in 32D(GCSF-R) BCL11B clones #4 and #12, the 32D(GCSF-R) clones with the 
highest expression levels of BCL11B (Figure 6A).
DISCUSSION
Integrative analyses of genome-wide genotyping and copy number data with GEP enables 
the identification of pathogenic genes aberrantly expressed due to genomic imbalances. The 
outlined integrative approach resulted in the identification of BCL11B as a novel oncogene in 
AML. Interstitial amplification of 14q32 was initially revealed in 2 AML cases by genome-wide 
genotyping encompassing the BCL11B gene. Although other genes were affected by these copy 
number changes, these 14q32 aberrations resulted in unique BCL11B mRNA and full-length 
BCL11B protein overexpression. FISH in a selection of 40 AML cases with high BCL11B mRNA 
expression identified 2 additional AML cases bearing BCL11B translocations.
 The BCL11 family has two members BCL11A and BCL11B.18 Bcl11a was identified as a common 
retroviral insertion site (Evi9) in murine myeloid leukemias and is required for normal B-cell 
development.29 Mice carrying biallelic inactivation of Bcl11b developed thymic lymphomas, 
indicating that loss-of-function mutations in Bcl11b contribute to mouse lymphomagenesis 
and possibly to human cancer development.30 BCL11B is a four-exon gene located on 14q32, 
encoding a Kruppel family zinc finger transcription factor and a key regulator of differentiation 
and survival of thymocytes.18 BCL11B was first associated with hematological malignancies due 
to its recurrent involvement with the homeobox transcription factor TLX3 in a relatively high 
percentage of pediatric and adult T-cell acute lymphoblastic leukemia (T-ALL) carrying the 
cryptic t(5;14)(q35;q32).31,32 Less frequent, T-ALL samples with an inv(14)(q11.2q32.31) carry an in-
frame transcript of BCL11B and the T-cell receptor gene segment TRDV1. These ALL cases do not 
express wild type BCL11B transcripts, suggesting that BCL11B disruption may contribute to T-cell 
malignancies in humans.33 Interestingly, recently a DNA copy number and sequencing analyses 
approach revealed mono-allelic BCL11B deletions and missense mutations in 10-15% of T-ALL.34,35 
Structural homology modeling revealed that several of the BCL11B mutations disrupted the 
structure of the zinc finger domains required for DNA binding.
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 A number of myeloid, mixed-lineage, and non-lymphocytic leukemias with 14q32 abnormalities 
have been reported, however, in these instances the affected genes were not identified.36-40 The 
first evidence of BCL11B involvement in 14q32 translocations in AML was reported by Bezrookove 
et al.37 They reported one case of t(6;14)(q25~q26;q32) in an adult with AML and used bacterial 
artificial chromosomes to demonstrate the involvement of BCL11B in this AML case.37 Due to lack 
of patient material, the investigators could neither establish the deregulation of BCL11B nor the 
identification of the partner genomic locus.37 Of note, the breakpoint in this AML case appeared 
to be located upstream of the BCL11B gene. This is similar to the AML cases described here and 
suggests that the breakpoints in AML are clustered upstream, whereas in ALL they are downstream 
of BCL11B. Specific chromosomal paints demonstrated that different partner chromosomes were 
involved in the AML cases with a BCL11B translocation. The fact that in 2 AML cases the BCL11B-
containing amplified region integrated in transcriptionally active lncRNAs may suggest that 
different regulatory regions of the lncRNAs are capable to activate the BCL11B oncogene. The 
breakpoints in AML #2301 and #7073 are 10kb and 600kb away from the transcriptional start site 
of BCL11B. There is no obvious reason why specifically BCL11B and not the other genes would 
become activated. Interestingly, however, the rearranged BCL11B allele in both AML #2301 and 
AML #7073 is juxtaposed to recently described super-enhancers, which have been shown to act 
as key oncogenic drivers.41,42 These putative super-enhancers are present in the cell line MOLM-1 
and seem to be linked to ARID1B on chromosome 6 (#2301) and MYC/GSDMC on chromosome 8 
(#7073) and may be responsible for increased BCL11B expression. The selective overexpression of 
BCL11B may give the cells a specific advantage, whereas the other genes located on 14q32 would 
not. Interestingly, BCL11B protein appeared to be expressed in additional primary AML cases 
that did not carry BCL11B translocations. In these AML cases other mutations may be present or 
BCL11B may be activated by other means.   
 The 14q32 region, including BCL11B, has been subjected to translocations in T-ALL and 
acute mixed lineage leukemia.23,36-40 In fact, the involvement of 14q32 translocations and BCL11B 
in AML has been debated.43 However, the immunophenotyping and molecular analyses of the 
AML samples with BCL11B translocations described here showed that these leukemias have a 
biphenotypic immunophenotype, but also all carry a common AML-associated FLT3-ITD mutation. 
These leukemias do, therefore, share a characteristic genetic feature with AML. 
 BCL11B is expressed in T-lymphocytes and T-cell leukemias and is a pivotal regulator of a 
number of genes related to T-cell proliferation and differentiation such as IL2, NF-kappaB, TCRβ 
and p21.44-48 It was shown recently that the expression of BCL11B in T-cell lines resulted in markedly 
increased apoptosis resistance following treatment with radiomimetic drugs accompanied by 
a cell cycle delay caused by accumulation of cells at G1.49 We examined the consequences of 
Bcl11b overexpression on proliferation and differentiation in a mouse myeloid 32D(GCSF-R) cell 
line model. 32D(GCSF-R) cells, expressing full length murine Bcl11b cDNA, showed a consistent 
decreased proliferation rate compared to cells expressing the empty vector or to the parental 
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untransfected cells. Upon stimulation with GCSF, 32D(GCSF-R) cells overexpressing BCL11B 
showed less maturation towards granulocytes compared to cells expressing empty vector, giving 
supporting evidence that BCL11B is partially blocking or delaying differentiation in 32D(GCSF-R) 
cells. The decreased proliferation rate in BCL11B expressing cells may suggest that a proliferative 
mutation, such as a FLT3-ITD, may indeed be required for full leukemic transformation.
 In conclusion, we show that BCL11B is involved in 14q32 translocations with different putative 
chromosomal partners in well-characterized AML cases using high-throughput genome-wide 
genotyping, cytogenetics and GEP. In these translocations, full length BCL11B is highly expressed 
concomitantly with T-cell specific markers. We speculate that due to the translocations, BCL11B 
expression is influenced by active transcriptional elements on the partner chromosomes 
resulting in high BCL11B expression and consequently T-cell associated genes. The murine cell 
line 32D(GCSF-R) overexpressing BCL11B shows decreased proliferation and partial delayed 
differentiation, which provides evidence that BCL11B may have suppressive and disruptive effects 
on cell proliferation and differentiation of myeloid cells. Altogether, these analyses revealed 
BCL11B as a putative oncogene in AML with and possibly without aberrations involving 14q32.
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ABSTRACT
A major cancer research field involves itself with the accurate detection of genetic lesions for 
the identification of novel cancer-related genes. Different next generation sequencing (NGS) 
platforms generate high-quality data enabling the estimation of copy number variations (CNVs). 
Various CNV estimation algorithms for NGS data have been developed, however, the ability to 
fully mitigate recurrent noise is still lacking. Therefore, a robust assessment of CNVs in high-
variable regions, conferring recurrent statistical noise, is required. We developed a statistical 
framework utilizing information derived from diploid reference set samples and demonstrated 
a highly improved CNV estimation compared to contemporary methodologies. To exemplify 
the algorithm’s strengths we applied our model on datasets derived from two distinct genome 
sequencing archetypes: (1) whole genome sequencing (WGS) data generated by Complete 
Genomics (CG) technology and targeted resequencing data generated on the Illumina HiSeq 
2000, and (2) whole exome sequencing (WXS) data. The former embodies library strategies 
generating sequencing data from continuous regions, while the latter embodies a library strategy 
generating sequencing data from non-continuous and non-equidistant regions. To proof the 
effectiveness of our algorithm we compared our detected CNVs to those obtained with the 
Affymetrix DNA mapping arrays. We established that an increase in model resolution correlates 
with the number of detectable focal genetic lesions, largely corroborated by structural variants 
(SVs). Finally, our statistical framework produces good results for WGS and WXS data derived from 
different sequencing platforms, establishing its general applicability. 
Supplemental material: http://hema13.erasmusmc.nl/mathijs_sanders/chapter11/
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INTRODUCTION
Next generation sequencing (NGS) data enable the high-resolution characterization of cancer 
genomes.1-4 In general, the purpose of sequencing genomic material of cancerous tissues is to 
uncover acquired mutations, short insertion-deletions (indels), and structural variants (SV). 
However, NGS reads can also be used for the estimation of copy number variations (CNV). In fact, 
high-density sequence reads enable the detection of genetic lesions serving as guides towards 
the identification of novel cancer-related genes.5-9 
 Estimating CNVs is particularly difficult within high-variable regions. These regions mainly 
comprise repeat elements (e.g. LINEs, SINEs, and LTRs) which are notorious genomic elements 
conferring improper or ambiguous aligned reads. Additionally, systematic bias inherent to the 
individual sequencing technologies result in specific and incorrect fragment count patterns, 
presenting yet another unanswered challenge. These biases result in a consistent number of 
regions with under, but mostly, over-estimated copy number estimations observable in all 
sequenced samples. Additionally, most CNV estimation algorithms provide a spatial resolution 
too large for robust detection of genetic lesions affecting small genetic elements, e.g. exons. 
For example, the Complete Genomics (CG) pipeline provides a spatial resolution of 100 kb for 
sequenced tumor cases, which is sufficient for detecting large genetics lesions, however, is too 
coarse for revealing genetic lesions smaller than the spatial resolution.
 To mitigate these biases and ameliorate the quality of CNV detection, we developed a statistical 
framework for CNV estimation from NGS data by integrating information derived from reference 
set samples. De facto, the high-variable regions are located on the same physical position in 
different individuals, although with different fragment count magnitudes (Supplementary Figure 
1), enabling the extraction of these intrinsic characteristics from the fragment reference sample 
count profiles. These characteristics are used to filter and normalize the noisy fragment count 
profiles from samples of interest, ultimately, producing filtered CNV profiles which could serve as 
input for further analyses.
 We demonstrate the improved CNV estimation procedure by applying it to three distinct 
datasets derived from two genome sequencing archetypes. The first archetype embodies 
technologies sequencing continuous regions, implying that a particular region of the genome 
is completely sequenced without non-sequenced interfering regions. For this archetype context 
we applied the model on whole genome sequencing (WGS) data generated from 3 acute myeloid 
leukemia (AML) cases and matched controls by CG DNA nanoball sequencing technology. 
Subsequently, we utilize our model on targeted resequencing data from the chronic myeloid 
leukemia (CML) cell line K562, generated by the Illumina HiSeq 2000 platform. For the second 
sequencing archetype context, we applied the model on whole exome sequencing (WXS) data 
derived from 6 unrelated de novo AMLs with matched controls and matched relapse samples. 
To assess the model sensitivity we compared the determined CNVs to those obtained with 
Affymetrix DNA mapping arrays. We established that an increased model resolution leads to a 
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gain in detectable CNVs and validated the veracity of these CNVs by corroborating them with the 
independent in silico methodology of structural variants (SVs). In conclusion, we demonstrated 
that the algorithm enables the prediction of CNVs using diverse NGS platforms.
MATERIAL AND METHODS
Package
We compiled all described methods in the package CNVsvd, freely available from http://hema13.
erasmusmc.nl/CNVsvd/. Our package is a C++ (gcc 4.7.2) and R (R 2.15.2) package that extracts 
coverage information from appropriate source materials – coverage information files for CG 
sequencing data and BAM files for other sequencing platforms – according to user preferences 
and generates CNV profiles ready for importation into SNPExpress10, included in the package, 
or CNV segmentation algorithms11,12 for further processing. The package is tested on different 
operating system platforms (Linux: Ubuntu 10.04, Windows: Windows XP and 7).
Sample processing
Complete genomics
Files containing coverage information for 45 healthy reference set samples were downloaded 
from the CG website (Complete Genomics Diversity set repository13, NCBI 36, Pipeline 1.10.0). Our 
3 CG AML samples and their matched controls were processed using NCBI 36 and Pipeline version 
1.10.0. Consequently, the reference set and AML samples are directly comparable. Affymetrix 
500K DNA mapping arrays for the same 3 AMLs were processed as reported previously.10
Targeted resequencing
Targeted resequencing data of chromosomal regions 3q21 and 3q26 was generated by targeted 
custom capture beads (Nimblegen v2) for 8 AML samples (cell line K562, and 7 normal karyotype 
AMLs [NK-AMLs]) following the manufacturer’s protocols. Captured samples were sequenced on 
the Illumina HiSeq 2000 and aligned against human genome 19 (hg19) using the Burrows-Wheeler 
Aligner 0.5.9.14 Coverage information per window was extracted by using the SAMtools API 
0.1.1315, included in the software package. Structural variants were determined by BreakDancer 
1.1.16
Whole exome sequencing
WXS sequencing data was generated from exome bead captured material (SeqCap EZ Human 
Exome Library v3.017) for 6 de novo AML cases (Supplementary Table 1), 6 matched in vitro 
expanded T-cell controls, 4 matched relapse AML cases out of the 6, and 24 unrelated in vitro 
expanded T-cell controls functioning as an addition to the reference dataset. Captured samples 
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were sequenced on the Illumina HiSeq 2000 and aligned against hg19 using BWA. We developed 
an algorithm that utilizes a provided BED file containing the exon interval structure and extracts 
the fragment counts accordingly. The fragments are extracted by using the SAMtools API.15 
Affymetrix 250K Styl DNA mapping arrays were processed as previously reported.10
In vitro T-cell expansion
T-cells were isolated from the diagnostic material of each AML case and expanded with anti-CD3 
and anti-CD28 monoclonal antibodies in the presence of IL-2. After 2 weeks T-cells were enriched 
with MACS separation columns. All diagnostic material derived T-cell populations were shown to 
be >98% pure and served as normal controls.
Window estimations
Continuous sequenced regions
Fragment count statistics were determined from coverage information within consecutive 
non-overlapping windows positioned along the genome. The window size, i.e. resolution, is 
determined based on the application of desire, e.g., detecting small CNVs with higher resolution. 
Too large windows could result in missing small focal aberrations, while too small windows might 
yield substantial fragment count variability. Coverage information from all nucleotide positions 
within a given window contribute equally to the count statistic. We removed all windows with 
a consistent low or zero coverage in all reference set cases to improve numerical stability. 
Population variation is a strong confounder for estimating CNVs in particular genomic loci due to 
population divergence. Options in the algorithm are included to omit regions devoid of reads in 
a fraction of the reference set to avoid population variation confounding. Due to low numbers of 
male references samples, we excluded chromosome Y and multiplied the coverage information 
of all windows within chromosome X by two for male samples.
Non-continuous sequenced regions
Given the non-continuous nature of WXS we extracted the fragment counts according to the 
exon structure. Fragment counts are extracted from BAM files by utilizing a BED file containing 
the captured region intervals. The algorithm requires, as an input, the desired size of the window 
ω (Figure 1). Captured fragments originating from interval edges normally extend beyond 
the interval, therefore we included a parameter σ extending the interval edges enabling the 
extraction of full fragments. Fragments are only considered when uniquely aligned and count 
estimates are stratified on map quality. Unpaired reads are retained only when aligned uniquely 
with a sufficient mapping quality. Consecutive non-overlapping windows are used when an exon 
is sufficiently large to encompass multiple windows. If a portion of the exon remains uncovered 
by a window, i.e. due to the window size, a new window is introduced if this portion is larger than 
half of the window size; otherwise it is added to the adjacent window.
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Figure 1. Generating CNV profiles from WXS data. Specific regions of the genome are captured, e.g. exome. 
The algorithm determines based on the window size ω, the extension parameter σ and exome structure how 
to optimally place the windows. For each window the fragment counts are determined. Within the depicted 
locus a region, encompassing partially exon 2 and completely exon 3, is deleted resulting in a lower number of 
fragment counts. The deletion also results in a SV depicted by a paired-end read with discordant distance. The 
fragment counts are processed by the algorithm and compared to the reference set. The resulting CNV profile 
is illustrated in SNPExpress10 and the same deletion is visualized for two patients (baby blue).
Normalization
Supervised quantile normalization
All resulting count profiles derived from continuous regions were normalized by supervised 
quantile normalization.18 Reference set samples were used to construct a reference distribution 
and all samples, including AML samples, were normalized against this distribution. 
Adapted FPKM
We developed a normalization technique based on the fragments per kilobase of exon per 
million fragments mapped (FPKM) statistic. Given the non-continuous exome structure and 
differing window sizes the FPKM statistic would better suit the nature of WXS. The adapted FPKM 
is calculated for every window by:
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Where FPKM
i
 is the FPKM statistic, F
i
 is the fragment count, and L
i 
the length for window i. Finally, 
the statistic is normalized by the total number of counted fragments N passing the quality criteria.
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Scaling
Subsequently, the fragment statistics are scaled for further processing. First, the mean fragment 
count for each window was computed from the reference set samples. For all samples, including 
the reference set samples, the fragment counts were divided by the calculated mean per window. 
If the genomic locus of the current window is not afflicted by a genetic lesion, the resultant 
statistic would equate to 1.
Singular value decomposition of the reference samples
We assume that for reference set samples, e.g. healthy individuals, on average the copy number 
equals 2. Commonly healthy individuals harbor many different natural CNVs19,20, nevertheless, we 
assume that these are not recurrent in the majority of the reference set samples. Given these 
assumptions we hypothesized that recurrent variation stems from high-variable regions and 
systematic biases inherent to the sequencing technology. The high-variable regions share the same 
genomic loci for all sequenced cases, irrespective of disease background (Supplemental Figure 1 
and Figure 2A). Interestingly, this variation is described by the first few principal components 
derived from the reference set fragment count profiles, called systematic noise components. We 
found that typically the first two components contain most of the systematic variance (data not 
shown), however, an appropriate number of components can be determined from the singular 
values.21 Utilizing singular value decomposition (SVD) for noise eliminating is an established 
methodology.22 Systematic noise removal by principal components for AML cases harboring 
monosomies, i.e. loss of chromosomes, or a complex karyotype, i.e. a mixture of chromosomal 
losses and gains, presents a difficult context. Numerical changes of chromosomes is prevalent 
among different cancer subtypes and strongly associated with prognosis and treatment outcome, 
e.g. AML.23 Utilizing principal components, without appropriate preprocessing, results in the 
obscuration of chromosomal losses or gains. This conundrum is solved by calculating a mean 
statistic from the normalized count profile for every chromosome of a sample. This mean statistic 
is subtracted from the normalized profile per chromosome resulting in a count profile centered 
around 0. These statistics are preserved to be re-added after noise removal. This procedure is 
viable as it does not interfere with SVD or noise removal. First, we calculate:
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 is the normalized count profile centered around 0 for sample i and 
chromosome j, 
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is the normalized count profile and μ
i,j the mean statistic of the count profile 
for sample i and chromosome j. For every chromosome the normalized data of the reference set 
samples are structured into a data matrix X (n samples x m covariates, n < m). Using SVD we have 
the following:
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Here U (n x n) and V (n x m) are matrices with orthogonal basis vectors. The matrix Σ (n x n) contains 
the singular values. The matrix V contains the systematic noise components, describing variance 
observed in the reference set while the singular values amount to the variance strength. 
 For SVD it is important not to include the centered count profiles of cancer samples into X. 
Including cancer samples runs the risk of removing components describing recurrent genetic 
aberrations seen in the disease of interest, especially if the reference data set is small relative to 
the cancer data set. To determine the systematic noise components from these large matrices 
would be computational intensive. Therefore, we combined eigenvalue and singular value 
decomposition:
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The data matrix given in (equation 1.3), is only of size n x n (i.e. 45 x 45 for the CG data, 7 x 7 for the 
targeted resequencing, and 30 x 30 for the WXS data), and enables the fast computation of the 
matrices D and U. We subsequently determined the  noise component matrix V:
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Principal component regression
SVD determines n high-dimensional noise components per chromosome. We used the g strongest 
noise components in a principal component regression procedure estimating their contribution 
to the count profiles of the AML and matched control samples:
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The systematic noise present in the fragment count profile of sample i and chromosome j is 
modeled by 
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, determined by fitting the systematic noise components to the centered 
fragment count profile (Figure 2A). Ultimately, we remove the estimated noise contribution from 
the normalized data and re-add the mean statistic to preserve the possibility to detect whole 
chromosome aberrations:
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The resultant filtered fragment count profiles contain residual sample specific noise and copy 
number variations. 
Highly improved DNA CNV estimation from NGS data
189
Ch
ap
te
r 1
1
Copy number estimation
Principal component regression is effective for noise removal in high variable regions, however, 
it cannot reduce sample specific noise. Therefore we performed spatial filtering (median 
smoothing) for applications involving continuous regions, trading some spatial resolution for less 
noisy coverage estimation. Finally, the filtered residuals are linearly transformed to represent the 
correct copy number variation estimations (Figure 2B). Due to the non-equidistant spacing of the 
exome, median smoothing has not been applied on WXS data. Instead, for WXS we considered a 
genetic aberration detected if three adjacent windows with similar CNV estimates were observed.
Figure 2. Fitting noise components to the count profile. (Blue) Count profile for chromosome 3 was 
generated with a 0.5 kb resolution from CG data (Red). Noise profile was determined by fitting the noise 
components to the count profile. (A) First noise component fitted to the count profile of an AML case. Of 
note, some blue peaks are almost completely covered by the noise profile. (B) Estimated CNV profile after 
normalization and noise removal of the same AML case.
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DATA DESCRIPTION AND VALIDATION
Complete genomics data set: continuous sequenced regions
(I)  Comparing to CG CNVs
We obtained 3 unrelated AMLs with matched controls sequenced with CG’s DNA nanoball 
sequencing technology. Initially, we compared the CNVs detected by our algorithm with different 
window sizes, 5 and 10 kb, to those detected with CG’s pipeline which uses 100 kb windows for 
tumor samples.
(II) Comparing to DNA mapping arrays
To demonstrate the sensitivity of our algorithm we characterized all 3 AMLs on the Affymetrix 
500K DNA mapping array. Subsequently, we compared CNVs detected with our algorithm, yielded 
with a 5 kb window size, to those detected with the array. 
(III) Increased resolution within the algorithm
To infer if an increase in the resolution of the algorithm yielded a gain in CNV detection sensitivity, 
we compared CNVs detected with a window size of 5 kb those obtained with a window size of 0.5 kb.
(IV) Corroboration with structural variants
The veracity of detected CNVs, detected with a 0.5 kb window size, is assessed by corroboration 
with SVs. This in silico methodology independently detects genetic lesions and provides further 
evidence. SVs are mainly used for the detection of deletions, large inter- and intrachromosomal 
events (e.g. translocation, inversions), and tandem duplications, however, is not used for detecting 
amplifications or complex genetic aberrations. The nature of the SVs prevents the detection of  all 
amplification events, resulting in our primary focus on deletion CNVs, i.e. copy number of 0 or 1, 
for corroboration with SVs.
(V) Somatic CNVs
Finally, assessing the somatic status of CNVs (sCNV) is essential for cancer research. The matched 
control is used to determine the number of somatic CNVs detected with a 0.5 kb window size.
Targeted resequencing data set: continuous sequenced regions
(I)  CNV estimation 
We determined CNVs in the CML cell line K562 from targeted resequencing of the 3q21 and 3q26 
chromosomal loci. In total 7 NK-AMLs were utilized as reference set samples. CNV detection was 
performed by setting the window size to 0.5 kb. SVs were detected and used as corroborating 
evidence for the determined CNVs.
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Whole exome sequencing data set: non-continuous sequenced regions
(I) CNV estimation
CNVs were determined from the WXS dataset with a 0.5 kb window size, an extension parameter 
of 0.1 kb, and utilizing a BED file describing the exon structure. The data set comprises 6 diagnostic 
de novo AML with 4 matched AML relapse samples and for all samples a matched T-cell control, 
implying that 2 de novo AML cases did not have matched relapse samples. The reference set 
included 24 unrelated T-cell control samples derived from other AML patients and the 6 matched 
T-cell control samples.
(II) Comparing to DNA mapping arrays
All 6 de novo AML samples were characterized on Affymetrix 250K StyI DNA mapping arrays. We 
compared the CNVs detected by our algorithm to those obtained with the DNA mapping arrays.
(III) Conundrum and validation
Validating CNVs in WXS data is challenging. Unless the breakpoint occurs directly in an exon 
or its proximity, there are no structural variants validating the determined CNVs. To resolve this 
issue detected CNVs in the AML samples were deemed true if it was also detected in the relapse 
samples, but not in the T-cell controls, i.e., a sCNV, or in both the relapse and control samples, i.e., 
a germline CNV.
RESULTS
We investigated the robustness of the newly developed algorithm within two genome 
sequencing archetypes. Each sequence archetype presents its own set of conundrums addressed 
by the novel statistical framework irrespective of the sequencing platform. Using three data sets 
representing the two archetypes we highlight examples and aspects exemplifying the strength 
and adaptability of the algorithm.
CNV estimations in continuous sequenced regions
Complete Genomics DNA nanoball sequencing technology
We demonstrate the algorithm sensitivity and exactness of the detected CNVs by using different 
comparisons. The results are highlighted by a single index AML patient, AML #1. The results for 
the remaining AML cases, AML #2 and #3, are listed in the tables or in the supplementary material 
whenever noted.
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Comparison to the CG pipeline
We appraised the efficiency of noise estimation and removal by comparing the CNVs determined 
by the CG pipeline to those obtained with our algorithm with 5 and 10 kb window sizes. Genome-
wide CNV profiling by the CG pipeline revealed a number of regions with medium to very high 
copy numbers (Figure 3A) observed consistently in the AML as well as reference samples (data not 
shown), comprising high-variable or pericentromeric regions, impairing robust CNV estimation. 
Our model mitigates this intrinsic bias, thereby decreasing the contribution of systematic noise to 
the AML CNV profiles (Figure 3B an 3C). Interestingly, the model revealed additional focal genetic 
lesions, smaller than the spatial resolution of the CG pipeline (orange box Figure 3, detailed in 
Supplementary Figure 2). Irrespective of the window size, 5 or 10kb, similar CNV profiles were 
estimated with only some additional genetic lesions detected using the smaller window size, 
indicating that an increased resolution correlates with CNV detection efficiency (Figure 3B).
Figure 3. Copy Number estimations for the complete genome of one AML case. (A) CG CNV profile 
estimated with 100 kb windows. (B) Copy number estimations from consecutive 5 kb windows. (C) Copy 
number estimations from consecutive 10 kb windows. (Orange box) Some deletions detected by our 
algorithm, but not by CG’s pipeline. Regions shown in more detail in Supplementary Figure 2.
CNV estimation is essential for delineating genetic events
Enhanced CNV estimation provides a beneficial feature for disease delineation. Not all genetic 
lesions are detected by SVs and enhanced CNV estimation could provide further evidence for 
genetic lesion acquisition. For example, the AML index patient revealed copy number gains 
encompassing the gene BCR on chromosome 9 and ABL1 on chromosome 22 (Supplementary 
Figures 3 and 4), formed by an unbalanced translocation, resulting in the BCR-ABL1 fusion 
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transcript, a tell-tale marker of CML, missed by routine cytogenetics. We confirmed the presence 
of the BCR-ABL1 fusion transcript in AML#1 by RT-PCR (Supplemental Figure 5). The translocation 
was detect by SVs, however, the gain of genetic material on each side of the breakpoint remained 
undetected.
Detecting additional CNVs with respect to DNA mapping arrays
DNA mapping arrays are the traditional methodology for estimating CNVs. Probe sets designed 
to measure single nucleotide polymorphism (SNP) genotypes are also utilized for CNV estimation. 
We compared the CNVs detected by our algorithm to those obtained with the DNA mapping 
array and determined the overlap and differences (Table 1A), revealing that our algorithm detects 
substantially more CNVs (e.g., Figure 4). CNV analysis on the index AML case demonstrated that 
the algorithm detected all genetic lesions observed with DNA mapping arrays and more (Table 
1A and Supplementary Figure 6). Interestingly, not all CNVs detected by DNA mapping arrays for 
the remaining two AML cases were detected by our algorithm. Diligent visual inspection of the 
missed CNVs revealed that these are presumably false positives, given the local pattern of CNV 
profile variance (e.g. intermittent gains and losses at the same genomic locus), or are located at 
regions difficult for reliable CNV estimation (e.g. pericentromeric or high-variable regions). The 
latter case demonstrates that the principle component procedure attenuates the effect of these 
regions on the CNV profile estimation.
Figure 4. CNV on chromosome 3. (A) Deletion of a region (baby blue) on chromosome 3 for AML sample #1 
detected by CNV estimates from our algorithm utilizing CG data. (B) This deletion is not detected when AML 
sample #1 was analyzed using the Affymetrix 500K DNA mapping array.
Increased resolution correlates with enhanced CNV detection
An increased resolution of the CNV estimation algorithm enables the detection of smaller genetic 
lesions, which could play a pivotal role in the pathogenesis of leukemia.24 While large genetic 
lesions frequently occur in cancerous tissues, small and specific genetic lesions enable the 
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determination of novel cancer-related genes, especially in regions harboring CNVs of different 
sizes. Focal aberrations substantially smaller than the window size will not confer a large difference 
in the total fragment count and are therefore likely to be missed.
 Increasing the algorithm’s resolution from 5 kb to 0.5 kb enhanced the CNV detection rate. Most 
additionally detected CNVs were of the size 1.5-6 kb, implying that a 5 kb resolution is insufficient 
for detecting lesions. In the AML index patient, all but a single CNV identified with a 5 kb resolution 
were also identified with a 0.5 kb resolution (98% for AML #1, Table 1B). Similar patterns were 
observed in the other two AML cases (68% and 80% for AML #2 and AML #3 respectively). CNVs 
remaining undetected with the higher resolution, 0.5 kb, but detected with the lower resolution, 
5 kb, are mostly associated with regions encompassing multiple high-variable regions increasing 
the fragment count variance substantially. The increased granularity, due to a higher resolution, 
enables the delineation of local systematic noise signatures into separate components.
Structural variants corroborate the detected CNVs
WGS enables the determination of structural variants which are utilized for determining indels, 
translocations, and inversions.25 Paired-end reads derived from homologous regions, e.g. repeat 
regions and pseudogenes, are the leading cause for detecting false positive SVs, if aligned to 
ambiguous positions. CNV estimations could serve as independent corroborating evidence for 
deletion events, further increasing the detection likelihood for true genetic lesions.
 Increasing the model resolution led to a gain in CNVs detected, however, the question 
remains if they represent true genetic lesions. We determined that most CNVs detected by a 5 
kb resolution are corroborated by SVs increasing the likelihood that these CNVs are true genetic 
lesions. Subsequently, we determined that the majority of detected CNVs with a 0.5 kb resolution 
case are corroborated by SVs (Table 1C). On average, 60% of additionally detected CNVs are 
corroborated by SVs. Careful visual inspection confirmed that most non-corroborated CNVs are 
likely true genetic lesions. Strikingly, these CNVs are supported by multiple consecutive windows 
with consistent similar copy number estimates. In some instances, the same CNV is detectable in 
the matched control sample hinting at a germline CNV not detected by SVs. Likewise, analyses 
from the other 2 AMLs demonstrated a similar pattern, a substantial proportion of CNVs are 
corroborated by SVs (Table 1C). Similar to the index patient the non-corroborated CNVs are strongly 
supported by CNV estimates from multiple consecutive windows (Supplementary Figure 7).
Somatic CNVs
CNV profiles for matched controls where generated, i.e from in vitro expanded T-cells, by applying 
the same statistical framework, enabling the determination of sCNVs. Surprisingly, most of the CNVs 
detected in the three AML cases appeared germline CNVs as they were detected in the matched 
control. In the index AML patient only 10 CNVs were deemed somatic (Table 1D), which comprised 
small (1.5 – 6 kb) and large CNVs. For the other two AML cases the number of sCNVs was even lower.
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Table 1. Detection of CNVs in 3 AML cases characterized by NGS and DNA mapping arrays.
A. SNP array - 5kb. windows B. 5kb. - 0.5 kb. windows C. Detected by SV 
(deletions)
D. 0.5 kb
Array 5 kb. Overlap 5 kb. 0.5 kb. Overlap 0.5 kb. Overlap Somatic
AML #1 9 42 9(100%) 42 121 41(98%) 80 54(68%) 10(8%)
AML #2 5 31 3(60%) 31 112 21(68%) 81 48(59%) 2(2%)
AML #3 3 44 1(33%) 44 110 35(80%) 66 44(67%) 8(7%)
(A) Novel against traditional. The NGS algorithm utilizing CG data with 5kb resolution in comparison to the 
Affymetrix 500K DNA mapping array. (B) Resolution. CNVs detected by increasing the resolution from 5 kb to 
0.5 kb. (C) Intersection of CNVs detected with a resolution of 0.5kb and the detected SVs (D) sCNVs detected 
in the tumor sample.
Targeted resequencing of predefined genomic loci
We investigated whether the algorithm is applicable to sequencing data derived from different 
sequencing platforms, e.g. Illumina HiSeq 2000. The CNV profile for the K562 cell line was 
determined by utilizing a reference set comprising 7 NK-AMLs. In total, 7 CNVs, i.e. 6 tandem 
duplications and 1 focal deletion, were detected and mainly conferred by tandem duplications 
as evidenced by SVs. For example, an amplification involving the gene PPM1L was detected 
(Supplementary Figure 8 and 9) and revealed by SV analysis to be a consequence of a tandem 
duplication.
 Additionally, our algorithm detected, in conjunction with a corroborating SV, a specific 
tandem duplication within the gene MECOM (MDS1-EVI1 complex locus), encoding for MDS1 
and EVI1 (Supplementary Figure 10). The gene EVI1 encodes a proto-oncogene which, upon 
overexpression, confers a dismal prognosis in AML.26,27 This yet unreported genetic lesion may 
explain EVI1 overexpression, previously reported for K562.28 The identified tandem duplication 
was validated by Sanger sequencing (Supplementary Figure 11).
Conclusion
Ultimately, these data demonstrate that our analysis tool is applicable to sequencing data derived 
from different sequencing platforms. Both sequence methodologies, i.e. CG DNA nanoball 
sequencing and Illumina HiSeq 2000, demonstrate systematic noise in the fragment count profiles, 
which is substantially mitigated by our algorithm. We have established its general applicability, 
increased sensitivity, and overall increased specificity on data derived from continuous sequenced 
regions.
CNVs estimations in non-continuous sequenced regions
Whole exome sequencing
Sequencing of non-continuous and non-equidistant regions is difficult for robust CNV estimation 
due to the mainly unrelatedness of adjacent windows. Although WXS data is less affected by high-
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variable regions, located mainly in intergenic and intronic regions, it is still perturbed by other 
inherent properties of the capture design, e.g. the capture of pseudogenes.
Detecting CNV aberrations
We next investigated the robustness of the newly developed algorithm for CNV detection in 
non-continuous sequencing data. First, we demonstrated that our algorithm is able to detect 
whole chromosomal aberrations, therefore accommodating the detection of aneuploidy. A gain 
of chromosome 8 was detected in the leukemic blasts of patient 2215 corroborated by a DNA 
mapping array and standard cytogenetics (Supplementary Figure 12A, Supplementary Table 1). 
Of note, cytogenetics denoted that this gain was present in 60% of the cells, implying that the 
algorithm detects subclones. An acquired gain of chromosome 11 was detected in patient 2226, 
corroborated by a DNA mapping array and cytogenetics (Supplementary Figure 12B). Finally, 
multiple CNVs of differing sizes have been detected for all 6 AML patients (range: 7-21, Figure 5).
Comparison to DNA mapping arrays
All 6 de novo AML cases were characterized by DNA mapping arrays. Careful inspection revealed 
that the algorithm was able to corroborate all CNVs detected by DNA mapping arrays, except for a 
single CNV encompassing the pseudogenes IGLL3P and LRP5L. Visual inspection of DNA mapping 
array data revealed that this region remains difficult for robust CNV estimation (data not shown), 
as it comprises multiple pseudogenes and could be equated to high-variable regions. The effect 
of this region on the fragment count profile was mitigated by the noise removal methodology 
within the algorithm.
 AML patients have an exceptionally low number of CNVs, with a mean of 2.38 CNVs per case 
as determined by DNA mapping arrays.29 Strikingly, compared to the DNA mapping arrays, the 
algorithm detected additional CNVs in all 6 AML cases. Interestingly, most additionally detected 
CNVs are corroborated by the matched control or relapse samples. We observed a significant 
increase in CNVs detected by our algorithm when compared to DNA mapping arrays (p=0.0345, 
Figure 5).
The detection of the clinically relevant MLL-PTD
Initially, a gain was detected in the gene MLL, located on chromosome 11, in patient 2226. This 
patient harbors a gain of chromosome 11, however, a specific region within MLL is additionally 
amplified and not observed in the matched control or relapse samples (Supplementary Figure 13). 
Given current knowledge, this implies that the patient acquired a MLL partial tandem duplication 
(MLL-PTD), which remained undetected by DNA mapping arrays. The aberration MLL-PTD 
comprises a duplication of consecutive exons within the gene MLL and is postulated to result in a 
recessive gain-of-function30 and to associate with shortened remission time.31 The partial tandem 
duplication is hard to detect by standard PCR methodology as there is no consensus on which 
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consecutive exons are duplicated in tandem, necessitating multiplexed PCR, which occasionally 
produces false positives. The algorithm enables the detection of this aberration, which was 
corroborated by a SV, demonstrating that the MLL-PTD was acquired (Supplementary Figure 14).
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Figure 5. Number of CNVs detected with DNA mapping arrays and WXS. (Pink) Number of CNVs detected 
in 6 de novo AML cases by DNA mapping arrays (Blue) Number of CNVs detected in the same 6 de novo AML 
patients using WXS data. P-value was determined with the Wilcoxon rank-sum test.
DISCUSSION
We developed a statistical model enabling improved and reliable CNV estimation from NGS 
methodologies by removing systematic variation introduced by high-variable regions. The optimal 
choice of systematic noise components depends on the pervasiveness and correlation structure 
of the systematic noise. A scree plot, depicting the persistence of the noise components through 
eigenvalues, facilitates the choice of the optimal number of noise components.21 Choosing a too 
low number of components results in the retention of systematic noise, while there is no heuristic 
for choosing too many components. Systematic noise is mainly contained within the first few 
noise components, while the remaining components mainly comprise variance conferred by 
natural CNVs. These remaining noise component will not optimally fit to count profiles if cases 
of interest do not harbor these natural CNVs, thereby conferring the regression coefficient to 
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become approximately zero and omitting the noise component from contributing to the noise 
estimation. Interestingly, for WXS sequencing applications, only one principal component seems 
sufficient, contrasting to WGS data for which at least two components are necessary. We advance 
the hypothesis that this is due to the nature of the exome, containing little to no repeat sequences. 
Systematic noise in WXS data mainly arises from systematic technical noise and the accidental 
capture of pseudogenes. Using normalization in combination with noise reduction we were able 
to generate high-resolution CNV estimations from NGS coverage information. Essential for our 
methodology is the presence of a reference data set of diploid controls, used for normalization 
and determination of the systematic noise components.
 In comparison, the WGS based CNV estimation algorithm CNVnator5 uses fragment count 
information from tumor and normal pairs, however, is unable to reduce systematic variance as it 
does not utilize variance information derived from a reference set. Varscan 27, a WXS based CNV 
estimation algorithm, uses fragment count information from tumor and normal pairs to estimate 
CNVs, however, it does not provide methods for dealing with high-variable regions. CoNVEX32, 
specifically designed for WXS data, uses discrete wavelet transformation (DWT) for noise reduction 
and estimates the CNVs using a Hidden Markov Model (HMM). It uses average read depth ratios 
from tumor and matched normal as input. Although the DWT will reduce noise in some instances, 
it will not be able to: (I) calculate the absolute CNV, only denoting if regions are gained or lost, (II) 
capture the normal population fragment count variance. The latter results in the retention of high-
variable regions, especially when not present in the matched normal control. CoNIFER33, specific 
for WXS based CNV estimation, closest resembles our algorithm. Likewise, it employs SVD to 
normalize count profiles of samples of interest. Fundamental differences lay in the normalization, 
derivation of the SVD and the use of its singular value components. CoNIFER derives the SVD from 
all sequenced samples simultaneously, i.e., from a mix of cases and controls. This methodology is 
valid only under the assumption that there are no recurrent genetic aberrations in the sequenced 
samples of interest, which could contribute to a strong systematic noise component. Sequencing 
experiments involving cancerous tissues with similar genetics lesions provides an example which 
invalidates this assumption. CoNIFER generally classifies these aberrations as noise, subsequently 
removes them, and is therefore unable to detect whole chromosome aberrations in aneuploidic 
samples. Known examples of whole chromosomal aberrations involve chromosome 5 and 7 in 
AML, which have been associated with poor prognosis.34,35 Missing those aberrations would omit 
vital information for correct classification or prognostication of these AML cases. Similar to our 
algorithm, CoNIFER normalizes the fragment count statistics to make them comparable. However, 
unlike our algorithm, CoNIFER’s Z-RPKM loses the ability to detect absolute copy number without 
a large set of additional samples. Knowing the absolute copy number could be essential for 
prognostication and delineating the pathogenesis of the disease of interest.36,37
 The algorithm enables CNV estimation on data generated from different library strategies. 
We demonstrated, based on a CG data set, that the algorithm detects more validated CNVs than 
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provided by CG’s native algorithm and at a higher resolution. Additionally, the comparison of 
high-density DNA mapping arrays to our algorithm demonstrated the superiority of the latter to 
detect novel CNVs. We have increased the detection resolution as far as 0.5 kb and compared it to 
a statistically more robust, but less detailed resolution of 5 kb. The algorithm detected additional 
CNVs, mostly corroborated by SVs, with sizes as small as 1.5 kb. Subsequently, we detected 
many tandem duplications in the targeted resequencing data of the cell line K562 which were 
corroborated by SVs. We demonstrated a tandem duplication within the MECOM locus, which 
could result in the overexpression of the dismal marker EVI1.
 In addition we demonstrated that our algorithm is applicable to sequencing data from non-
continuous regions. We demonstrated that the algorithm, using WXS data, is able to detect all 
CNVs detected with DNA mapping arrays except one. Interestingly, the algorithm detected more 
CNVs compared to DNA mapping arrays, which is striking as consensus dictates that AML has 
a very low frequency of genetic aberrations. Additionally, we were able to detect aberrations 
leading to partial tandem duplications in the gene MLL, which were not detected by the DNA 
mapping arrays. 
 In conclusion, we demonstrated that our novel statistical framework reliably detects more 
focal CNVs in different types of NGS data which is of great importance for detecting genetic 
abnormalities underlying the disease of interest.
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1. SUMMARY
The advent of array-based and next generation sequencing (NGS) technologies has increased 
our knowledge about the underlying genetic abnormalities in human acute myeloid leukemia 
(AML). Subsequently this led to further molecular categorization reflected by the recognition 
of AML entities defined by genetic mutations (WHO 2008). It is increasingly recognized that 
the epigenetic landscape, beside the genetic landscape, plays a pivotal role in leukemic 
transformation as evidenced by recurrent epigenetic alterations. The work presented in this thesis 
provides a detailed account on the use of genome-wide approaches in conjunction with novel 
bioinformatic methodologies to further progress the understanding of human leukemogenesis. 
Rapid succession in technological advances has generated a multitude of analytical tools for the 
genome-wide characterization of AML, with a central role for gene expression profiling (GEP), 
DNA mapping arrays and NGS in the work presented in this thesis.
 In chapter 2, we devised a statistical framework utilizing the multinomial logistic regression 
model with a modified group lasso penalization scheme enabling sparse gene expression 
signature determination and the prediction of multiple classes simultaneously. A gene expression 
signature comprising a limited number of genes is produced for all predetermined classes and 
a gene within this signature is weighted according to the impact of its expression on the class 
prediction. We established, in agreement with previous observations, that the AML entities with 
favorable cytogenetics, i.e., t(15;17), t(8;21) and inv(16), can be predicted with maximum accuracy 
and that the gene expression signatures reflect their molecular characteristics. Additionally, we 
demonstrated that the framework provides a more accurate classification of AML cases harboring 
a combination of mutations in the genes NPM1 and FLT3 (FLT3-ITD). In chapter 3, we investigated 
the clinical outcome and gene expression signatures of CEBPAdm and CEBPAsm AML cases, i.e., 
biallelic mutations or monoallelic mutations in CEBPA, and their respective mutational spectra. 
We observed that CEBPAdm patients are characterized by low numbers of concurrent mutations, 
while CEBPAsm patients frequently harbor concurrent mutations in the genes NPM1 and FLT3. 
We demonstrated that the CEBPAsm marker bears no prognostic significance and, contrastingly, 
we reported that CEBPAdm is a strong prognostic marker associated with favorable outcome. We 
employed logistic regression model with a lasso penalization scheme, reminiscent to the model 
described in chapter 2 for two-class prediction, and demonstrated that CEBPAdm AML cases can be 
accurately classified in a validation AML cohort while the CEBPAsm cases do not exhibit a consistent 
gene expression signature.
 In chapters 4 and 5, we investigated the genetic aberrations underlying AML and acute 
lymphoblastic leukemia (ALL) by utilizing DNA mapping arrays. In chapter 4, we reported on a 
software package enabling the visualization of data from DNA mapping arrays with the capacity 
to integrate GEP data. Copy number variation (CNV) profiles of multiple patients can be displayed 
simultaneously enabling the identification of recurrent genetic aberrations. In addition, we 
constructed a hidden markov model for the inference of loss-of-heterozygosity (LOH) regions 
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for AML cases without data derived from remission or normal tissue control material. In chapter 
5, we investigated the recurrence of genetic aberrations in adult ALL and AML cases by DNA 
mapping arrays and NGS. We demonstrated that ALL is characterized by a multitude of recurrent 
small deletions and amplifications, while AML has scarce recurrent genetic aberrations. We 
observed genetic aberrations common in ALL or specific for B-ALL or T-ALL. Strikingly, all T-ALL 
cases acquired a deletion of the genes CDKN2A/B or genes involved in the same pathway. We 
discovered that the proximal genes NF1 and SUZ12 are commonly deleted in a subset of T-ALL 
and AML patients, strikingly, both genes were significant down regulated. Deep sequencing of 
the remaining NF1 wild-type allele demonstrated concurrent mutations. In line with previous 
reports we postulated that the loss of NF1, activating the RAS pathway, cooperates with the loss 
of the polycomb repressive complex 2 (PRC2). Finally, we observed specific B-ALL cases with 
deletions predominantly involving promoters or the first few exons of genes. Whole exome 
sequencing (WES) and targeted resequencing of deleted regions in 5 B-ALL cases revealed cryptic 
recombination signal sequences (RSSs) flanking the breakpoints, on one or both sides, for 91% of 
the somatic deletions and the insertion of random nucleotides at the breakpoints. De novo motif 
detection demonstrated that the deletions are flanked by 12-bp and 23-bp spacer RSS motifs 
implying that the rearrangements are the result of illegitimate V(D)J recombination. Analyses 
of epigenetic data derived from a B-lymphoblastic cell line revealed that the breakpoints are 
enriched for H3K4me3, H3K27ac and RNA polymerase II binding reminiscent to antigen receptor 
rearrangement foci. Cross-species analysis revealed that the human breakpoints are enriched for 
Rag2 binding in murine thymocytes. Finally, we demonstrated that RAG-rearrangements invoke 
open-and-shut joints of RSS motifs likely through error-prone non-homologous end joining 
(NHEJ).
 Chapters 6 through 10 focus on the understanding of the AML genetic and epigenetic 
landscape determined by NGS approaches while chapter 11 focuses on a novel algorithm for 
detecting CNVs from NGS data. In chapter 6, we utilized WES for determining the longitudinal 
mutational spectrum of a severe congenital neutropenia (SCN) patient who develops AML after 
17 years of G-CSF treatment. We detected in total 12 somatic alterations, including mutations in 
the genes RUNX1, ASXL1 and SUZ12, in the leukemic phase and revealed that 3 mutations were 
already present in the early SCN phase, including the truncating mutation CSF3R-d715. In the 
leukemic phase an additional CSFR3 mutation, i.e. CSF3R-T595I, is acquired, on the same allele 
as the truncating mutation, conferring G-CSF independence. In chapter 7, we investigated 
the underlying mechanism driving the overexpression of the proto-oncogene EVI1 upon the 
acquisition of inv(3)(q21q26.2) or t(3;3)(q21;q26) (inv3/t(3;3)) in myeloid malignancies. Targeted 
resequencing of the breakpoint loci revealed an asymptotic pattern of breakpoint positions in 
the 3q21 locus, implying that a breakpoint-free common translocated segment (CTS) always 
repositions towards the 3q26 locus. We demonstrated by integrating RNA-Seq, Chip-Seq and 
4C-Seq data that a distal GATA2 enhancer is located within this CTS and upon repositioning 
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interacts with the EVI1 promoter driving its overexpression. Concurrently, GATA2 expression is 
reduced and only expressed from the non-rearranged allele. Ablation of the ectopic enhancer 
in the cell line MUTZ-3, by genome editing technology, demonstrated the abrogation of EVI1 
expression and subsequent growth inhibition and differentiation of the cell line. Finally, upon 
translocation of the 3q21 locus a super-enhancer is formed demonstrated by the high levels of 
H3K27ac spanning the complete CTS region. Treatment of the inv(3)/t(3;3) cell lines MOLM1 and 
MUTZ-3 with a BET-bromodomain inhibitor (JQ1) demonstrated abrogation of EVI1 expression, 
growth inhibition, differentiation and increased apoptosis reminiscent to the genome editing 
experiment, while this was not observed in the EVI1 overexpressing cell line K562. In chapter 
8, we determined the mutational spectrum of inv(3)/t(3;3) myeloid malignancies by WES and 
RNA-Seq. We observed that 98% of the inv(3)/t(3;3) cases acquire activating mutations in the 
RAS/RTK signaling pathways. In addition, mutations in the remaining wild type allele of GATA2 
as well as heterozygous alterations in SF3B1, RUNX1 and genes encoding epigenetic modifiers 
frequently co-occured with the inv(3)/t(3;3) aberration. Notably, we observed neither differences 
in mutational patterns nor GEP across inv(3)/t(3;3) myelodysplastic syndrome (MDS), chronic 
myeloid leukemia in blast crisis (CML-BP) and AML cases, suggesting that inv(3)/t(3;3) myeloid 
malignancies could be recognized as a single disease entity. In chapter 9, we employed RNA-Seq 
on leukemic blasts from a patient which progressed from MDS to AML. We discovered that the 
unreported KMT2A -MYH11 fusion transcript was already present in the MDS phase. In chapter 10, 
we investigated AML cases with an amplification involving the gene BCL11B and its consequent 
overexpression. Targeted resequencing of the BCL11B locus in these AML cases revealed that the 
additional copy is the consequence of a jumping translocation by which the donor BCL11B locus 
integrates into super-enhancer regions located on different chromosomes. In chapter 11, we 
provided a novel statistical framework for estimating CNV profiles from NGS data. We constructed 
an algorithm that infers systematic noise from a reference dataset comprising diploid cases, i.e., 
healthy individuals or remission material, and demonstrated that these inferred systematic noise 
components can be utilized to generate accurate CNV profiles from whole genome sequencing 
(WGS) and WES data. In comparison to classical DNA mapping arrays, we demonstrated that the 
framework detects more CNVs corroborated by structural variants.
2. GENERAL DISCUSSION
This final part puts the results and remaining hypotheses, provided in this thesis, in the perspective 
of contemporary knowledge and their possible implications are discussed in detail. The work 
presented in this thesis was divided in three parts each addressing different research questions 
by employing a specific genome-wide approach. Concluding, the prospectives and perspectives 
of future leukemic research are provided with a focus on mutational and functional relevance, 
clonal evolution, genome editing and translational medicine.
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2.1 Gene expression profiling in acute myeloid leukemia
Initially, transcriptome-driven analyses revealed the heterogeneity of AML and the existence 
of molecularly defined AML subtypes.1-3 It remained a pending question whether GEP-based 
classification could replace traditional diagnostic methodologies, e.g., cytogenetics and 
standard PCR-based techniques, or would only serve as a discovery tool for research purposes. 
Therefore, additional experiments were conducted demonstrating that GEP profiling is valuable 
for classifying AML entities with favorable cytogenetics2, i.e., characterized by t(15;17), t(8;21), 
inv(16) cytogenetic abnormalities, and AML cases with mutations in the genes CEBPA4 and 
NPM15, however, predictive signatures could not be found for AML cases with mutations in RAS 
or receptor tyrosine kinase (RTK) affiliated genes, e.g., FLT3, NRAS and KRAS. Reasons for the miss-
classification of AML cases were focused on the greater than expected heterogeneity within AML 
subgroups, the number of AML cases, the minimal effect of activating RAS/RTK mutations on 
gene expression levels and the classification algorithm utilized. The absence of predictive value 
for a molecular AML marker could be due to the following: (I) the effect of the genetic alteration 
on gene expression levels is minimal, (II) the gene expression signature conferred by a genetic 
alteration is overpowered by that of a concurrent mutation. The first situation is intractable and 
could necessitate the use of different genome-wide approaches for class prediction purposes, 
e.g., detection of epigenetic alterations. The second situation necessitates statistical frameworks 
enabling the modeling of concurrent genetic alterations thereby generating independent gene 
expression signatures. In chapter 2 we devised a multinomial logistic regression model with a 
modified group lasso penalization scheme6,7 enabling multiple class prediction and providing 
weighted sparse prediction signatures. Prediction signatures were established from a training 
AML cohort and validated on a large independent AML cohort for the following situations: (I) 
AML cases with mutually exclusive favorable cytogenetic abnormalities reflecting transcriptional 
homogeneous AML subgroups, (II) AML cases harboring mutations in the gene NPM1 (NPM1+) 
and/or internal tandem duplications in the gene FLT3 (FLT3-ITD) reflecting transcriptional 
heterogeneous AML subgroups. The first experiment demonstrated that these AML entities 
are predicted with maximum accuracy, while the second experiment demonstrated increased 
prediction accuracy in comparison to a previous study2, attributed to the adopted multiple class 
prediction procedure. In the previous study, the molecular heterogeneity was not captured due to 
the two-class prediction procedure employed as the NPM1+/FLT3-ITD specific expression pattern 
confounded the predictive signatures of the NPM1+ or FLT3-ITD markers alone. In molecular 
heterogeneous situations GEP-based classification has debatable additive value with respect to 
standard PCR detection techniques, however, for research purposes could be utilized for novel 
class prediction or the provision of gene expression signatures reflecting pivotal biological 
processes underlying the disease of interest.
 Different studies utilized gene expression signatures for prognostication.8,9 Gene expression 
signatures derived from functionally validated leukemic stem cells (LSCs) associate with inferior 
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clinical outcome in AML.10-12 This association reflects the persistence of stemness or stem cell 
programs in the leukemic blasts in poor outcome AML subtypes. Prognostication, likewise to 
GEP-based classification, is limited by molecular heterogeneity precluding the identification 
of prognostically valuable gene expression markers. Correlation of gene expression patterns 
presents another conundrum affecting discrimination and prognostication of AML subtypes. An 
important consideration is whether novel predictive gene expression markers add prognostic 
value to already established prognostic parameters or are completely redundant. Previously, 
we demonstrated that MLL -rearranged AML cases are stratified into a prognostically favorable 
and intermediate group based on gene expression levels of the gene BRE, demarcating a MLL-
rearranged subgroup with a strong gene expression signature.13 Previous reports demonstrated 
that EVI1 gene expression levels enable the stratification of MLL-rearranged AML cases in a 
prognostically poor and intermediate group14 and is anti-correlated to BRE15, rendering the 
question which gene expression marker is prognostically more accurate. Efforts should be directed 
towards the development of statistical frameworks accounting for molecular heterogeneity 
and gene expression correlation structures for classification and prognostication purposes. 
In conclusion, GEP enables the accurate classification and prognostication of a limited set of 
AML entities, however, molecular heterogeneity precludes further classification unless further 
subcategorizations can be introduced.
2.2 Copy number variations
DNA copy number variations (CNVs) are genetic hallmarks of cancer.16,17 The advent of DNA 
mapping arrays enabled the high-resolution identification of CNVs, however, the particular 
challenge is to identify CNVs perturbing specific cancer-related genes. Most CNVs are large 
enough to affect multiple genes thereby invoking the “passenger-driver” obstacle, implying that 
particular genes drive oncogenesis while others are affected by mere coincidence.
2.2.1 Copy number variations in acute leukemia: recurrence and origin
Genetic lesion recurrence is valuable for further subcategorization of molecular subtypes. In 
chapter 5, we determined genetic alterations in 173 adult acute leukemia cases by DNA mapping 
arrays. Strikingly, all T-ALL cases acquired CNVs perturbing the CDKN2A/B pathway. The deletion 
of CDKN2A disrupts cell cycle control and frequently co-occurs with NOTCH1 mutations which 
affects the self-renewal capacity of cells.18,19 The relevance of co-occurrence and the underlying 
mechanism of the frequent deletion of CDKN2A remains unanswered and a topic for future 
research.
 We observed a deletion affecting the proximal genes NF1 and SUZ12 in 5 AML and 3 T-ALL 
cases. NF1 loss activates the RAS pathway due to its inhibitory function20, while SUZ12 is a 
pivotal member of the PRC2 complex.21 Subsequent GEP analysis revealed that both genes were 
significantly down regulated, giving interesting perspectives as recent reports demonstrated 
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that loss of NF1 cooperates with loss of PRC2 in malignant peripheral nerve sheath tumors 
and melanoma.22,23 Deep targeted resequencing of the remaining NF1 wild type allele revealed 
premature stop codon introducing mutations imparting its complete loss. Following the same 
line of reasoning as the previous reports, we expect that RAS activation cooperates with PRC2 
loss in a subset of patients with AML or T-ALL. It is valuable to investigate if the reduced SUZ12 
expression causes a disintegration of the PRC2 complex, subsequently reducing H3K27me3 levels 
and changes in gene expression levels.
 Previous studies demonstrated that pediatric and adult ALL acquire recurrent CNVs affecting 
genes involved in lymphoid development.24-26 A recent study demonstrated that the recurrent 
genetic lesions are partially invoked by RAG-mediated rearrangements.27 Targeted resequencing 
of the deletions in 5 BCR-ABL1/BCR-ABL1-like cases revealed that the breakpoints were 
predominantly flanked (91%) by cryptic RSS motifs, implying RAG-mediated rearrangements 
in almost all deletion events. A pending question remains why the illegitimate RAG-mediated 
rearrangements occur outside the antigen receptors in ALL. Fulfillment of these rearrangements 
must meet a few prerequisites: (I) expression of the proteins RAG1 and RAG2, (II) presence of 
12/23-bp spacer RSS motifs, (III) accessible DNA marked by H3K4me3 and H3 acetylation, (IV) 
CTCF binding and long range interactions, (V) a functional NHEJ pathway.28-30 Most of the B-ALL 
cases continually express RAG1 and RAG2, or temporarily expressed these proteins as evidenced 
by extensive V(D)J
rearrangements. We provided evidence that the breakpoints are predominantly flanked by 
cryptic RSS motifs and enriched for active chromatin markers. In all likelihood the long range 
interactions occurred due to the proximity of the breakpoints during repair. The increased activity 
of illegitimate RAG-mediated rearrangements could be twofold: (I) increased activity of the RAG 
complex, (II) deficiency in the DNA repair capacity. The HMG-box family proteins HMGB1 and 
HMGB2 are required for RAG complex assembly and modulate its activity by bending the DNA 
in a catalytically favorable manner for cleavage.31,32 The increased activity hypothesis provides 
an interesting perspective as the RAG2 protein harbors a PHD domain enabling the binding 
to H3K4me3.29,33 Rag2 Chip-Seq data derived from murine thymocytes revealed the genome-
wide binding to H3K4me3 enriched loci33 deposited mainly in promoter and enhancer regions 
predisposing these regions to RAG-mediated rearrangements. We did not find any changes in 
HMGB1 or HMGB2 expression levels and efforts should be directed to infer if there are changes on 
the protein level or through posttranslational modifications. The deficient DNA repair pathway 
hypothesis provides another interesting perspective as the sequenced cases comprised BCR-ABL1 
and BCR-ABL1-like cases. Previous studies demonstrated that c-ABL and BCR-ABL1 interact with 
and down regulate the pivotal NHEJ DNA repair protein DNA-PKcs.34,35 This warrants the study of 
DNA-PKcs protein expression level or its phosphorylation by BCR-ABL1 or other kinase-activating 
lesions. Whether the RAG activation or the deficient repair pathways confers illegitimate RAG-
mediated rearrangements remains yet elusive.
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2.2.2 Driver or passenger: one car multiple seats
CNVs predominantly affect multiple genes simultaneously and determining the specific gene 
driving oncogenesis remains difficult. Different studies resort to defining a minimally affected 
region (MAR), however, this procedure would preclude the identification of cancer-related 
genes cooperatively affected or those flanking the recurrent CNV. For example, in chapter 5, we 
identified the recurrent deletion simultaneously affecting the promoter of the gene MKKS and 
the gene SLX4IP (Figure 1A). We observed that SLX4IP expression levels remain unperturbed while 
MKKS expression levels became significantly reduced (Figure 1B). The MAR procedure would have 
identified SLX4IP as a potential oncogenic driver, while GEP would have highlighted MKKS as a 
potential oncogenic driver. Promoter deletion is common in B-ALL pathogenesis and warrants 
a different cancer-related gene detection approach. We adopted a kernel density procedure 
with a flat top normal distribution kernel36 for the identification of recurrently affected genes. 
This procedure enriches for genes affected by genetic lesions if it is: (I) frequently affected, 
(II) specifically affected or (III) frequently flanking breakpoint loci. The disadvantage of this 
methodology is that it still relies on frequencies for enriching genes.
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Figure 1. Deletion perturbs gene expression levels MKKS. (A) Common deletion of the MKKS promoter in 
ALL, (B) MKKS is significantly down regulated in ALL cases with the deletion of the MKKS promoter (MKKS-, p 
< 0.001).
2.3 Next generation sequencing
2.3.1 Next generation sequencing in AML
Whole exome and genome sequencing
The recent introduction of next generation sequencing (NGS) commenced the determination 
of the genetic and epigenetic landscape of different human diseases.37-39 The broad spectrum 
of NGS approaches enables the molecular characterization of cancer material. Chief amongst 
those approaches are whole genome sequencing (WGS) and whole exome sequencing (WES) 
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enabling the determination of the mutational spectrum of cancer material, e.g. de novo AML.40 
The mutational spectrum provides details related to the process of leukemogenesis, concurrence 
or mutual exclusivity of mutations, and signatures of mutational processes.41 In chapter 6, we 
determined the longitudinal mutational spectrum of a SCN patient progressing towards AML. 
Specific focus is put on the process of leukemic transformation and clonal evolution, however, a 
large gap of 9 years between the SCN and leukemic phase precludes the accurate identification of 
mutations driving leukemic transformation as some might be acquired during the pre-leukemic 
phase or lost due to clonal tides.42 In chapter 8, we conducted WES on inv(3)/t(3;3) myeloid 
malignancies and demonstrated mutations affecting the RAS/RTK signaling pathways, GATA2, 
SF3B1, RUNX1 and epigenetic modifiers. Both chapters use WES for determining the mutational 
spectrum and the process of clonal evolution. Novel tools are continuously developed for the 
analysis of WGS and WES data. Variant detection analysis tools, such as SAMtools43 or MuTect44, 
sometimes sub-optimally analyze the data. The different variant detection lists generally overlap, 
however, there are some differences. In the end, the final variant list is created by a pipeline which 
efficiently combines all variant lists produced by different variant detection tools. Future efforts 
should focus on developing a variant detection tool capable of accounting for all requisites 
established in the various variant detection tools.
 Alignment algorithms accidentally introduce false positive mutations, especially in regions 
containing repeat elements or multiple complex SNPs. Recent efforts produced variant detection 
algorithms based on de novo assembly procedures45 which could, with a proper germline control, 
resolve this issue. Standard alignment algorithms commonly introduce insertions and deletions 
in reads to achieve genome alignment, frequently resulting in ambiguous alignments. De novo 
assembly procedures disregard the target genome and produce linear assembled sequences, 
making them directly comparable between case and control.
 CNV profiles can be determined from WGS or WES data46,47, yet many algorithms are impaired 
by the systematic noise inherent to the sequencing technology. In chapter 11, we constructed a 
novel statistical framework for determining CNVs from WGS and WES data by taking into account 
systematic noise extracted from a diploid reference set. This methodology attenuated systematic 
noise and accurately detects more CNVs than DNA mapping arrays. Additionally, the framework 
is applicable to NGS data derived from different organisms (data not shown). This study implies 
that traditional DNA mapping arrays could be replaced by NGS derived CNV estimates due to its 
increased accuracy and detection resolution.
Whole transcriptome sequencing
Transcription deregulation plays an important role in leukemic transformation. RNA-Seq enables 
gene expression level estimation, transcript isoform detection, transcript fusion detection, 
and variant detection. The pending question remains if RNA-Seq can completely replace 
microarray technology, traditional cytogenetics and PCR-based techniques, for determining 
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molecular AML entities and prognostication.48 RNA-Seq, in addition to the gene expression level 
estimation, enables the determination of recurrent cytogenetic abnormalities by fusion transcript 
detection49, including information of the fusion transcript exon structure making it comparable 
to standard PCR detection. Interestingly, fusion detection in RNA-Seq supersedes standard PCR 
detection in some aspects as it enables: (I) the detection of multiple fusion transcripts in one 
experiment, (II) the detection of novel, complex or non-canonical fusion transcripts. RNA-Seq, 
in contrast to microarray technology, is not limited to a predefined set of measurable loci and 
enables the detection of more transcripts including long non-coding transcripts. Gradually, 
traditional microarray technology and standard PCR detection protocols will be replaced by RNA-
Seq approaches due to its generality and the additional molecular information provided.
Epigenetics
Epigenetic alterations represent an additional layer of control conferring regulation of cellular 
processes. These alterations, e.g., DNA methylation or histone methylation, are dynamically 
removed or deposited.50 Epigenetic characterization of leukemic blasts by array-based 
approaches, e.g., tilling and Chip-on-Chip arrays, demonstrated that AML is also heterogeneous at 
the epigenetic level.51 Additionally, mutational profiling demonstrated that AML is characterized 
by frequent mutations in epigenetic modifiers.52,53 Recent studies examining the epigenetic 
landscape of cancer demonstrated the existence of super-enhancers driving the expression of 
proto-oncogenes, e.g. MYC.54
 NGS approaches enable the determination of many different aspects of the epigenetic 
landscape in detail: (I) DNA methylation: bisulphite sequencing, MeDIP-Seq, (II) Protein binding 
and histone alterations: Chip-Seq, (III) chromatin conformation: 4c-Seq, HiC, ChiA-PET, (IV) open 
chromatin: DNAse-Seq. The many different NGS approaches developed and the increased 
resolution it provides implies the gradual replacement of array-based technologies.
 Epigenetic regulation is a dynamic process mandating a demarcated experiment for optimal 
detection, e.g, type of epigenetic alteration, cell type or timing, as determining these alterations 
ad libitum could present confounding results. The unprecedented epigenetic characterization of 
AML enables the determination of dynamic leukemogenic mechanisms, however, it will also likely 
introduce additional sources of heterogeneity complicating AML subcategorization.
2.3.2 Integrative approaches
Determining the mutational, transcriptional or epigenetic landscape enables further delineation 
of the leukemogenic process. Further improvements in understanding leukemogenic processes 
should be expected from integrating these data types. Epigenetic alterations modulate the 
transcriptional activity of target genes, while mutations modulate genome-wide epigenetic 
patterns, implying interactions on different levels. In chapter 7, we demonstrated that the proto-
oncogene EVI1 is overexpressed due to the repositioning of a distal GATA2 enhancer through 
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the integration of targeted resequencing, RNA-Seq, Chip-Seq and 4c-Seq data. In chapter 10, 
we demonstrated that the gene BCL11B becomes overexpressed due to an amplification of the 
encompassing region as detected by DNA mapping arrays and GEP. Subsequent breakpoint 
detection by targeted resequencing revealed that a jumping translocation involving BCL11B 
integrates into loci characterized by super-enhancer elements driving the overexpression of the 
translocated BCL11B. These chapters provide examples of integrative approaches utilized for 
understanding the underlying mechanistic process associated with leukemogenesis. 
 Continuous efforts should be put into the development of novel statistical frameworks for 
the analysis and integration of NGS data. The introduction of public NGS databases and projects, 
e.g., the cancer genome atlas (TCGA), requires researchers to distribute their published data and 
enables procurement of already generated or published data. The number of public data sets 
is rapidly increasing and renders generating novel data superfluous, except for very specific 
research questions. Developments in the fields of bioinformatics and statistics introduced novel 
frameworks for integrating NGS datasets. Some of these data integration tools are very specific, 
e.g., the detection of mono-allelic expression55,56, while others are more general57 and are used for 
integrating different types of NGS data. Although general data integration tools are beneficial, 
most specific research questions are addressed by specialized integration methodologies. 
Additionally, novel NGS approaches are continuously developed which require specific data 
processing techniques. The development of data integration tools is an emerging field and, given 
the limited number of tools, requires international efforts for bringing it to maturity.
2.4 Prospects and perspectives on future leukemia research
2.4.1 Basic understanding of mutation functionality and disease development
Functional consequences of mutations
In recent years we have witnessed an increase of NGS studies identifying novel genetic lesions 
associated with cancer development. AML is one of the most well characterized cancer types 
and, in all likelihood, the number of newly detected genetic lesions will decrease rapidly.40,53,58,59 
Currently, the larger question at hand relates to the implications of the already discovered genetic 
alterations. NGS has furnished leukemic research with a wealth of additional genetic markers, 
however, the basic understanding of the implication of most recurrent mutations is still lacking. 
In addition, a considerable number of genetic lesions display patterns of co-occurrence or mutual 
exclusivity implying relatedness, however, a larger number of mutations are patient-specific 
precluding the understanding of their functional implications. Hence, the heterogeneity of AML 
is more than expected based on genome-wide approaches previously employed.
Enigmatic functional consequences: an example
For example, recent efforts demonstrated that DNMT3A is mutated in approximately 20% of the 
AML cases58,60 and mutations are predominantly located in the methyltransferase domain.61 The 
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gene DNMT3A encodes a de novo methyltransferase important for establishing de novo genomic 
DNA methylation patterns.62 Given its function as a de novo methyltransferase, deductive 
thinking provided the hypothesis that mutations impair the establishment of genome-wide 
DNA methylation patterns thereby driving leukemic transformation. Initial experiments 
demonstrated minimal changes in genome-wide methylation levels58,60 and subsequent studies 
observed only limited and focal DNA methylation changes63-65, contrastingly, at some loci 
increased methylation levels. The correlation between methylation level differences and gene 
expression levels is considered weaker than expected in DNMT3A mutated AML cases, especially 
when corrected for the frequently concurrent NPM1 mutation.58,60,63 The question remains why 
mutations in the methyltransferase domain have such limited effect. Recent deep sequencing 
studies demonstrated that DNMT3A mutations are sometimes pre-leukemic66,67 and detectable 
in healthy individuals.66 These pre-leukemic clones can take years before they progress towards 
leukemia.68 The pending question remains if DNMT3A mutations truly invoke leukemic conditions 
by altering DNA methylation levels as: (I) a substantial number of mutations are observed outside 
the methyltransferase domain, (II) methylation changes are limited and focal, (III) mutations 
are found in pre-leukemic clones, taking years to develop, and healthy individuals. Leukemic 
progression in these cases could be due: (I) a necessary concurrent mutation in another gene is 
acquired resulting in synergistic effects driving leukemic development, (II) mutations in DNMT3A 
predisposes for leukemia by another currently unknown mechanism. 
 Previous studies linked DNMT3A aberrations in mouse embryonic stem cells (mESC), including 
ablation, to DNA hypomethylation64,65,69, subsequently associating it to AML. Recent studies in 
the overgrowth syndrome, a group of disorders characterized by an abnormal increase of the 
body or a body part, demonstrated congenital DNMT3A mutations previously identified in 
AML.70 Although an increased incidence of cancer has been observed in overgrowth syndrome 
subgroups, these patients do not specifically develop AML. These two studies provide contrasting 
accounts concerning DNMT3A mutations demonstrating that their functional consequences still 
remain enigmatic.
Basic understanding of mutations in leukemogenesis
Overall, the assessment of mutational functionality is a difficult task with many pitfalls. The 
mutations in DNMT3A remain functionally enigmatic, however, this holds for many genes 
involved in leukemic transformation, e.g., NPM1. The basic understanding of gene mutations is 
fundamental for progressing the mechanistic knowledge of leukemogenesis and becomes even 
more complex when considering concurrently mutated genes. Initially, novel gene mutations are 
postulated to affect the primary function of the protein it encodes, although logical, this might not 
always provide the best hypothesis. For instance, IDH1 and IDH2 mutations result in a neomorphic 
function71 and NPM1 mutations introduce a nuclear export signal72, both partially or completely 
unrelated to their primary protein function. The advent of NGS resulted in the detection of many 
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novel genetic lesions, however, what these lesions functionally engender remains a topic of 
future leukemic research.
2.4.2 Leukemic heterogeneity: making sense of mutational patterns
Mutation patterns, i.e. concurrence or mutual exclusivity of genetic lesions, provide an avenue 
for understanding how recurrent genetic lesions contribute to leukemic development. Genes 
more frequently mutated can be assumed to have a greater impact on disease development. 
Furthermore, mutation patterns are better discernable from genes frequently mutated. 
Mutational patterns exhibiting mutual exclusivity hint towards genes with similar functions. For 
example, aggregating gene mutations into pathways demonstrates how frequently a particular 
process is affected. In chapter 8, we observed that the RAS/RTK signaling pathway is affected in 
98% of inv(3)/t(3;3) myeloid malignancies.
 For example, mutational pattern analysis revealed that mutations in the genes TET273, IDH1 
and IDH2 are mutually exclusive implying functional relatedness. Recent efforts demonstrated 
that all mutations within these genes impair the conversion of 5-methylcytosine to 
5-hydroxymethylcytosine resulting in genome-wide hypermethylation.74,75 Patterns of mutual 
exclusivity were also observed for mutations in the splicing machinery76 and cohesion complex 
genes.53 
 Information concerning synergistic effects can be inferred by ascertaining patterns of 
concurrence. Mutations in DNMT3A, NPM1 and internal tandem duplications in FLT3 are frequently 
co-occurring, however, the underlying synergistic mechanism remains yet to be elucidated. 
 The strength of discerning mutational patterns is highly dependent on: (I) how frequently 
the genes are mutated, (II) frequency of concurrence, (III) frequency of exclusivity, or (IV) the total 
number of patients screened. Genetic alterations observed in a single or a few AML cases remain 
difficult to interpret and could only be investigated by experimental approaches or put in the 
context of contemporary knowledge. The integration of different data types, e.g., RNA-Seq or 
Chip-Seq, could further help elucidate the underlying mechanisms as demonstrated in chapter 7.
2.4.3 Clonal evolution
NGS approaches detect variants at different allele frequencies, therefore enabling the 
determination of the clonal composition.77 Recent time-series or diagnosis-remission-relapse trios 
studies demonstrated the existence of oligoclonality and variegated clonal evolution in AML.78,79 
Small subclones, whether or not derived from the dominant clone, can have survival advantages. 
Therapeutic abrogation of the dominant clone enables the treatment insensitive subclone 
to expand and confer leukemic relapse. In therapy-related AML these subclones could have 
already been present, without developing leukemia, before therapy induction.80 In addition, the 
subclone can acquire additional mutations making it potentially more malignant. Clinically, these 
subclones remained undervalued due to the detection limitations of cytogenetics and standard 
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PCR techniques. Studies investigating the clonal composition of AML demonstrated strong clonal 
evolution propensities, precluding the persistence of remission, in specific AML subgroups.78 For 
example, mutations in DNMT3A, TET2, IDH1 and IDH2 have been demonstrated to exist in pre-
leukemic clones.66,81 Pre-leukemic clones harboring DNMT3A mutations remain unperturbed by 
current treatment protocols as they remain detectable in remission material and confer a strong 
relapse risk, strikingly, sometimes after several years.66 Discerning the clonal architecture and 
understanding the dynamics of clonal evolution provides therapeutic actionable options and 
insight into relapse initiating processes. Treatment modalities can be modulated or combined 
with the knowledge of the complete clonal architecture preventing outgrowth of subclones 
insensitive for standard treatment protocols.
 Recent efforts focused on understanding the clonal architecture and its preceding evolution 
by determining which mutations are acquired in the same clone. The production of subclones 
occur by the following principals (Figure 2A): (I) branching: a mutagenesis sensitive pre-leukemic 
or leukemic clone produces multiple offspring subclones by continual acquisition of mutations, 
(II) linear: a pre-leukemic or leukemic clone acquires an additional mutation and produces a 
subclone with potentially more malignant or treatment-insensitive properties. The principles 
of branching and linear clonal evolution result in a clonal composition decomposable by their 
unique features of inheritance. However, the complete determination of the clonal dynamics 
is frustrated by clonal evolution caveats (Figure 2B): (I) recurrence: multiple subclones acquire 
independently the same subset of mutations invalidating the pattern of unique inheritance, (II) 
clonal tides42: subclones are produced by receding parental clones precluding the correct parental 
clone attribution. The problem of recurrence relates to clonal identifiability and correlates to the 
total number of clones present and genetic markers detected. The addition of detected genetic 
markers increases the identifiability of clonal dynamics as it improves the separation of clonal 
constituents. The caveat of clonal tides remains intractable, unless: (I) the missing clone can 
still be detected with very deep sequencing, (II) strong assumptions are made about mutation 
acquisition order, (III) determination of clonal composition at multiple time points enabling 
enhanced disentanglement of the clonal architecture.
 Current efforts are directed at determining the mutual composition of each clone and the 
complete clonal architecture. Detecting which mutations are acquired in the same clone remains 
difficult. Initially, the variant allele frequency was used for inferring the clonal architecture and 
necessitated strong mutational pattern assumptions. For instance, mutations observed in 50% of 
the reads could be heterozygous in all leukemic blasts or homozygous in only half of the leukemic 
blasts, e.g., SF3B1 mutations are heterozygous therefore observed in all leukemic blasts. These 
assumptions are produced for a limited number of well-characterized mutations, however, are 
rendered invalid when these mutations are acquired in (multiple) subclones. Recent statistical 
developments provided statistical inference algorithms for determining the clonal architecture 
based on very deep sequencing.82,83 Although substantially more efficient than pre-existing 
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methodologies, it still necessitates a priori knowledge concerning: (I) copy number of the affected 
region, (II) LOH status of the affected region, (III) probability that the mutation is heterozygous or 
homozygous in the subclone. In addition, it necessitates very deep sequencing (> 1000x coverage 
depth) and time-series, e.g., diagnosis, relapse and second relapse samples, to determine the 
clonal architecture. These algorithms are rendered invalid when the principle of recurrence is 
established (vide supra) to occur.
Branching Linear
Recurrence Clonal tides
? ?
A
B
Figure 2. Mechanisms of clonal evolution. (A) Principles on clonal evolution. (Branching) A parental clone 
acquires mutations producing one or more subclones. Subsequently these subclones can acquire mutations 
and produce one or more subclones. Unique inheritance of mutations enables the delineation of the clonal 
architecture, (Linear) A parental clone acquires mutations and its offspring subsequently acquires additional 
mutations. Unique inheritance of mutations enables the determination of the clonal architecture. (B) Pitfalls 
in determining clonal evolution (Recurrence) Subclones are produced in a branching or linear manner, 
however, a mutagenic environment enables the recurrence of particular mutations in two or more subclones. 
Very similar clones, only differing in one mutation, can produce subclones from which the inheritance is 
undiscernible precluding the delineation of the clonal architecture, (Clonal tides) Like recurrence a particular 
mutations has been recurrently acquired except the parental clone has receded. Statistical models would 
attribute this subclone to the false parental clone. (Solid arrow) Correct attribution of inheritance, (Dashed 
arrow) incorrect attribution of inheritance.
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Figure 3. Decomposition of the clonal architecture. (A) (I) Genetic alterations are determined from the 
leukemic blasts by WES. (II) Subsequent targeted single cell resequencing of the mutations reveal the clonal 
architecture. Mutations missed by WES, due to reduced coverage or a very minor clone, will not be targeted 
and prohibit the complete decomposition of the clonal architecture. (B) WES single cell mutational analysis 
provides information about concurrence and mutual exclusivity of mutations, while coverage statistics and 
genotype information provide estimations for copy number variations and regions of loss-of-heterozygosity. 
Combined, these data enable the complete decomposition of the clonal architecture. Estimation of the 
clonal contribution to the bulk of the leukemic blasts should subsequently be estimated by targeted deep 
sequencing of the observed mutations.
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 Targeted single cell sequencing enables a more precise definition of the complete clonal 
architecture84 and the introduction of single cell WES enables greater insight in clonal dynamics 
and architecture.85 Two schemes are proposed for delineating the clonal architecture by 
combining WES/WGS with single cell sequencing. The first scheme proposes the use of WES for 
determining mutations in the bulk of leukemic blasts (Figure 3A(I)). These mutations are used for 
targeted single cell sequencing (Figure 3A(II)) enabling the determination of mutational patterns 
and subsequently the delineation of the clonal architecture. WES mutation detection has some 
disadvantages as mutations could be missed due to: (I) minimal or no coverage of the target 
region, (II) undiscovered low abundant clones, (III) the introduction of proximal false positive 
mutations by alignment algorithms.
 The second scheme involves WES of multiple single cells for determining the clonal 
composition (Figure 3B). The total contribution of clones is difficult to estimate from single cell WES 
and subsequent targeted deep sequencing of the mutations in bulk material enables estimating 
the contribution of the clones. The second scheme produces more practical information, however, 
the total cost would render it impractical for analyzing a large AML cohort. The first scheme 
enables the detection of almost all mutations and subsequent targeted single cell sequencing 
enables the characterization of thousands of cells simultaneously. Finally, recently single cell 
approaches for RNA-Seq86,87 and genome-wide bisulfite sequencing88 have been adopted and 
enable the inference of transcriptional heterogeneity and clonal epigenetic variety. Single cell 
RNA-Seq enables clonal decomposition by identifying the genetic lesions in the RNA-Seq reads, 
reminiscent to chapter 8.
2.4.4 Genome editing
Genome editing is a novel field enabling the modulation of the DNA sequence or gene expression 
in vivo. Multiple proteins are able to bind specific DNA sequences and introduce DNA double 
strand breaks (DSB): (I) zinc finger nucleases89, (II) transcription activator-like effector nucleases 
(TALENs)90, and (III) the CRISPR/Cas9 system.91 The induction of proximal DSBs enables the 
deletion of complete regions in cell lines or mouse models. Additionally, target regions can be 
edited by providing an exogenous DNA template during the homology directed repair (HDR) 
of DSBs, enabling the introduction or editing of disease causing mutations.92 In chapter 7, we 
employed TALENs and the CRISPR/Cas9 system in the cell line MUTZ-3 to ablate the repositioned 
enhancer. These genome editing approaches enable the introduction of artificial chromosomal 
rearrangements93 thereby modeling known translocations in an isogenic system. A recent study 
described a protocol for gene editing the components of the human hematopoietic stem and 
progenitor cell (HSPC) compartment retaining engraftment and repopulation capacity.94 Minor 
changes to genome editing approaches enable the specific silencing of genes (CRISPRi) or 
activation of genes (CRISPRa) with minimal off target effects.95
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 Efforts should be directed towards developing genome editing approaches for understanding 
basic mutation functionality. In addition, it enables the modeling of concurrent genetic lesions in 
isogenic systems. The paradigm of clonal evolution can be modeled by observing the behavior of 
successfully edited and engrafted cells at steps of evolution. The isogenicity of the edited model 
system prevents the variability observed in: (I) murine disease models due to different in genetic 
backgrounds, (II) cancer cell lines being notoriously genetically unstable, (III) patient material due 
to additional concurrent mutations, (IV) patients overall due to different genetic backgrounds. 
Genome editing enables the modeling of infrequently observed mutations or subclones 
found with low leukemic burden contribution. Genome editing in combination with xenograft 
models enable further behavioral understanding of leukemic development and the effect of 
recurrent mutations. Determining which mutations are causally related to leukemogenesis 
and their functional etiology remains a major challenge, therefore modeling of mutational 
patterns observed in leukemia through genome editing enables the etiological delineation of 
leukemogenesis.96
2.4.5 Translational medicine
The increasing insight of the functional implications of genetic lesions should at one point 
translate to treatment improvements. The current treatment armamentarium of particular AML 
entities remains scarce, e.g., inv(3)/t(3;3) myeloid malignancies. We demonstrated that these AML 
cases are sensitive for BET-bromodomain inhibitors97 and demonstrated that almost all cases 
acquire activating RAS/RTK signaling pathway mutations. Although many of the RAS pathway 
constituents are notoriously difficult to target98,99 it provides valuable information for treatment 
design if they ever become targetable, e.g., FLT3-ITD.100 Recent efforts led to the development of 
treatment modalities against epigenetic modifiers. Azacytidine prevents hypermethylation and is 
used for high-risk MDS treatment.101,102 Recently, specific mutant IDH2 inhibitors have been shown 
to induce differentiation in primary human AML cells103, whereas mutant IDH1 inhibitors induced 
expression of gliogenic genes in glioma.104 Mislocated enzyme activity of DOTL1 is postulated as 
the oncogenic driver in mixed lineage leukemia and inhibition of DOTL1 results in the apoptosis 
of cells carrying the MLL-rearrangement.105 Initial results of these studies are promising, however, 
if targeted therapeutic agents will ever fully replace current therapeutic protocols remains yet to 
be determined.
 Genes or pathways investigated for treatment development should be selected on: (I) the 
frequency of mutations, (II) the dependency of the cell on the presence of the mutations (Achilles 
heel), (III) the degree of being targetable. High-throughput drug screening with a valuable output 
statistic, e.g., effect on proliferation, survival or resumed differentiation, enables the discovery 
of novel therapeutic compounds affecting AML cells with particular mutational compositions. 
Reverse engineering the etiology of the therapeutic agent produces valuable insight into the 
leukemogenic mechanism of the genetic lesions. Combinatorial treatment modalities, reflecting 
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the mutational composition of the leukemic blasts, could be provided in a personalized medicine 
approach. 
 In conclusion, genome-wide approaches provided the general view that leukemia is a highly 
heterogeneous disease conferred by combinations of genetic lesions. NGS enabled the detection 
of these genetic lesions and demonstrated the existence of clonal dynamics. The major challenges 
ahead will not relate to the detection of additional genetic lesions but in understanding the 
functional implications of the acquired genetic abnormalities. Future research will increasingly 
focus on understanding the leukemogenic mechanism underlying the disease and the dynamics 
of clonal evolution and at one point should translate this understanding into tailored therapies 
for AML patients.
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Hematopoëse is een continue proces waarbij dagelijks verschillende bloedcellen in zeer grote 
aantallen aangemaakt worden. Er zijn een aantal verschillende typen bloedcellen en elk type 
heeft een specifieke functie in het lichaam. Witte bloedcellen, onderverdeeld in granulocyten, 
monocyten, macrofagen en lymfocyten, spelen een belangrijke rol in de verdediging van het 
lichaam tegen pathogene indringers, terwijl rode bloedcellen een belangrijke rol spelen bij het 
vervoeren van zuurstof door het lichaam en bloedplaatjes bij bloedstolling. Al deze bloedcellen 
ontstaan uit één type niet-gespecialiseerde cellen, genaamd “hematopoietische stamcellen”, 
in het beenmerg. Deze hematopoietische stamcellen hebben de capaciteit om voldoende 
functionele bloedcellen te produceren naar gelang de fysiologische behoeften van het lichaam. 
Hematopoietische stamcellen produceren dochtercellen welk verder uitrijpen door een proces 
genaamd “celdifferentiatie”. Na uitrijping worden deze bloedcellen vrijgelaten in het perifere 
bloed vanwaar zij hun functionele eigenschappen kunnen uitvoeren.
 Leukemie, ook wel bloedkanker genoemd, is een ziekte van het beenmerg. De uitrijping 
van één type bloedcel is verstoord en de ongelimiteerde vermenigvuldigingen van deze cel 
leidt tot de complete overwoekering van het beenmerg en leukemische cellen in het bloed. 
De opeenhoping van deze niet-functionele leukemische cellen in het beenmerg verstoort de 
normale productie van bloedcellen wat leidt tot de bijna complete afwezigheid van functionele 
bloedcellen in het bloed. In dit proefschrift is er onderzoek gedaan naar acute myeloïde leukemie 
(AML) en in mindere mate acute lymfatische leukemie (ALL). Acute leukemie wordt onder andere 
gekarakteriseerd door genetische afwijkingen in het DNA. Door klinisch wetenschappelijk 
onderzoek is aangetoond dat bepaalde genetische afwijkingen associëren met een goede 
prognose, terwijl andere minder goede vooruitzichten bieden. De afgelopen jaren zijn er grote 
vorderingen geboekt in de kennis aangaande verworven mutaties en hun (klinische) associatie 
met acute leukemie. Uit deze onderzoeken is gebleken dat AML, maar ook ALL, een verzameling 
van aandoeningen is, waarbij verschillende genetische afwijkingen ten grondslag liggen. Deze 
acute leukemie subtypen worden geïdentificeerd aan de hand van verworven genetische 
afwijkingen in combinatie met klinische en cytomorfologische eigenschappen. De correcte 
bepaling van acute leukemie subtypen is van uitermate belang voor de juiste behandeling en 
prognosestelling en behoeft verder bestudering.
 Recente technologische ontwikkelingen hebben ervoor gezorgd dat het genetische 
materiaal van AML patiënten in detail gekarakteriseerd kunnen worden en hebben geleid tot 
een verbeterde bepaling van de verschillende AML subtypen. De vooruitgang in technologische 
methodieken stelt de onderzoeker in staat om veel verschillende genetische eigenschappen van 
de leukemische cellen te bepalen, denkend aan miljoenen metingen, met bijkomend nadeel dat 
de data onoverzichtelijk wordt voor standaard empirische waarnemingen. De oplossing tot dit 
probleem behoeft het gebruik van computationele biologie of statistische modelering om de 
meeste waardevolle data uit te lichten. Het werk beschreven in dit proefschrift richt zich op de 
identificatie van genetische en epigenetische afwijkingen in AML aan de hand van genoombrede 
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technologieën. De nadruk ligt vooral op het gebruik van drie verschillende genoom-brede 
technologieën: (1) genexpressie microarrays voor gen expressie bepalingen, (2) DNA mapping 
arrays voor het detecteren van genetische afwijkingen; vooral kopieaantal verschillen, (3) next 
generation sequencing (NGS) voor het vaststellen van genetische en epigenetische afwijkingen. 
In dit proefschrift werden deze genoom-brede technologieën, soms in combinatie, gebruikt voor 
de identificatie van nieuwe AML subtypen of om meer inzicht te krijgen in het mechanistische 
proces ten grondslag aan de ontwikkeling van leukemie.
 In hoofdstuk 2 hebben wij een statistische methode ontwikkeld die gebruikt maakt van 
het multinomiale logistische regressie model in combinatie van een aangepaste groep lasso 
regularisatie procedure. Deze methode produceert ijle genexpressie predictie patronen waarmee 
de participatiekans per patiënt voor verschillende klassen tegelijkertijd bepaald kan worden. 
Genexpressie predictie patronen, bestaand uit een gelimiteerd aantal genen, worden voor alle 
vooraf bepaalde klassen bepaald. In elk genexpressie predictie patroon wordt een gen gewogen 
aan de hand van zijn invloed op de klasse-predictie. Wij hebben vastgesteld, vergelijkbaar aan 
voorgaande studies, dat AML subtypen met klinisch gunstige cytogenetische afwijkingen, zoals 
t(15;17), t(8;21) en inv(16), accuraat ingedeeld kunnen worden. Verder hebben wij aangetoond 
dat onze statistische methode een verbeterde indeling geeft voor AML patiënten met een 
combinatie van mutaties in de genen NPM1 en FLT3. In hoofdstuk 3 hebben wij onderzocht wat 
de klinische relevantie is van CEBPA enkel- of dubbelmutanten, genaamd CEBPAsm en CEBPAdm. 
Daarbij is onderzocht of deze mutaties geassocieerd zijn met een specifieke genexpressie patroon 
of gekarakteriseerd worden door een specifiek mutatie spectrum. CEBPAdm AML patiënten 
hebben weinig extra recurrente mutaties, terwijl CEBPAsm AML patiënten veelal mutaties hebben 
in de genen NPM1 en FLT3. Vervolgens stelden wij vast dat de genetische marker CEBPAsm 
geen prognostische waarde heeft, terwijl de genetische marker CEBPAdm een sterke associatie 
heeft met een gunstig klinisch vooruitzicht. Gebruikmakend van een multinomiale logistische 
regressie model met een lasso regularisatie procedure, vergelijkbaar aan het model beschreven 
in hoofdstuk 2, hebben wij aangetoond dat CEBPAdm AML patiënten accuraat voorspeld kunnen 
worden in een AML validatiecohort, terwijl dit niet mogelijk is voor CEBPAsm patiënten.
 In hoofdstukken 4 en 5 hebben wij onderzocht welke genetische afwijkingen aanwezig zijn 
in AML en ALL patiënten door het gebruik van DNA mapping arrays. In hoofdstuk 4 beschrijven 
wij de ontwikkeling van een softwarepakket voor het visualiseren van data afkomstig van 
DNA mapping arrays in combinatie met genexpressie data. DNA kopieaantal veranderingen, 
op dezelfde plaats in het genoom, kunnen worden gebruikt als gids voor het identificeren van 
genen met een belangrijke rol bij de ontwikkeling van leukemie. Voor het bepalen van het 
verlies van heterogeniteit voor AML patiënten zonder beschikbaar genetisch materiaal van 
remissie of normaal weefsel hebben wij een nieuw statistisch model ontwikkeld. In hoofdstuk 
5 onderzochten wij terugkerende genetische afwijkingen in AML en ALL patiënten doormiddel 
van DNA mapping arrays en NGS technologieën. Genetisch materiaal van ALL patiënten vertonen 
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relatief veel kleine verliezen (deleties) of amplificaties in het DNA, terwijl genetisch materiaal van 
AML patiënten weinig (terugkerende) genetische afwijkingen vertonen. Sommige genetische 
afwijkingen zijn ALL-breed, terwijl andere genetische afwijkingen heel specifiek zijn voor B-ALL 
of T-ALL. Opvallend hierbij was dat alle T-ALL patiënten deleties van de genen CDKN2A/B of genen 
geassocieerd met CDKN2A/B hadden verworven. Daarnaast ontdekten wij dat de proximale genen 
NF1 en SUZ12 samen afwijkend zijn in T-ALL en AML subgroepen. De aangetoonde afwijking 
veroorzaakt een significante verlaging van de genexpressie levels van beide genen. Opvallend is 
dat er vaak mutaties gevonden worden op het overgebleven normale NF1 allel. In samenspraak 
met voorgaande studies postuleren wij dat het verlies van NF1, een remmer van het oncogen 
RAS, samenwerkt met het verlies van het polycomb repressive complex 2. Een interessante 
bevinding is dat specifieke B-ALL patiënten een tendens vertonen voor het overmatig genetisch 
verlies van gen promotors of een gedeelte van een gen. DNA sequentiebepalingen van regio’s 
die de deleties flankeren in het genetisch materiaal van 5 B-ALL patiënten, door middel van NGS, 
demonstreerde de aanwezigheid van zogeheten cryptische recombinatie signaalsequenties 
(RSSs). Deze sequentiemotieven waren aanwezig aan één of beide zijdes voor 91% van de 
verworven deleties en bovendien werden er vaak willekeurige nucleotiden aan de breekpunten 
toegevoegd. Sequentiemotief zonder enige vorm van voorkennis toonde aan dat meeste 
deletiebreekpunten worden gekarakteriseerd door 12-basepaar-afstand RSS en 23-basepaar-
afstand RSS sequentie motieven. Dit impliceert dat de deleties het gevolg zijn van onrechtmatige 
genetische herschikkingen door het recombinatie-activerende genen (RAG) eiwitcomplex. 
Epigenetische data analyses op data afkomstig van een B-lymfocytaire cellijn toonde aan dat de 
deletiebreekpunten verrijkt zijn voor de epigenetische veranderingen H3K4me3 en H3K27ac, 
en de binding van RNA polymerase II. Deze epigenetische veranderingen zijn vergelijkbaar 
aanwezig in gebieden welk immuunreceptor-herschikkingen ondergaan door het RAG 
eiwitcomplex. De vertaling van de humane breekpuntlocaties naar homologe gebieden in het 
muisgenoom toonde aan dat deze locaties verrijkt zijn voor Rag2 binding gedetecteerd in muis 
thymocyten. Naast de inductie van deleties kan het RAG eiwitcomplex zogeheten open-en-dicht 
aberraties veroorzaken door gebruik te maken van foutgevoelige DNA-herstelmechanismen. Dit 
mechanisme is momenteel het onderwerp van actieve bestudering
 De hoofdstukken 6 tot 10 richten zich op het onderzoek aan genetische en epigenetische 
veranderingen, terwijl hoofdstuk 11 zich richt op de ontwikkeling van een nieuwe statistische 
methodologie voor het schatten van kopieaantal veranderingen aan de hand van NGS data. In 
hoofdstuk 6, worden de genetische afwijkingen in de sequentiële bloed- of beenmergmonsters 
van een ernstig aangeboren neutropenie (SCN) patiënt bepaald die uiteindelijk na 17 jaar G-CSF 
behandeling leukemie ontwikkelt. In totaal werden er 12 verworven mutaties gevonden in de 
leukemische fase, waarvan 3 van deze mutaties al aanwezig waren in een laag aantal cellen 
jaren voordat de leukemie ontwikkelt. Eén van deze mutaties was verworven in het gen dat 
de G-CSF receptor codeert, daarnaast werd er in de leukemische fase nog een G-CSF receptor 
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mutatie ontdekt. Deze laatst verworven G-CSF receptor mutatie maakt dat de leukemische 
cellen onafhankelijk worden van het G-CSF cytokine. In hoofdstuk 7 onderzochten wij hoe 
afwijkingen op de lange arm van chromosoom 3, zoals inv(3)(q21q26.2) of t(3;3)(q21;q26) 
(afgekort inv(3)/t(3;3)), een overexpressie van het proto-oncogen EVI1 veroorzaken. Inv(3)/t(3;3) 
DNA breekpuntbepalingen toonde aan dat een specifiek gebied altijd wordt gerepositioneerd 
naar het chromosomale 3q26 gebied. De integratie van RNA-Seq, Chip-Seq en 4C-Seq data 
demonstreerde dat er een GATA2 enhancer aanwezig is in het gerepositioneerd gebied. Deze 
gerepositioneerde enhancer ondergaat een interactie met de EVI1 promotor met overexpressie 
als gevolg. Het GATA2 gen verliest een essentiële enhancer op het afwijkende chromosoom, 
waardoor GATA2 alleen nog maar tot expressie komt vanaf het resterende normale chromosoom. 
Inactivatie van de gerepositioneerde enhancer in de cellijn MUTZ-3 veroorzaakt compleet verlies 
van EVI1 expressie. Tijdens het repositioneren van het chromosomale 3q21 gebied vormt er een 
super-enhancer gekarakteriseerd door de verrijking van de epigenetische verandering H3K27ac. 
Behandeling van de cellijn MOLM1 en MUTZ-3 met een BET-bromodomein remmer (JQ1) 
veroorzaakt EVI1 genexpressie verlies, vergelijkbaar met eerdere experimenten. In hoofdstuk 8 
hebben wij verworven mutaties in kaart gebracht voor myeloïde maligniteiten met inv(3)/t(3;3) 
cytogenetische afwijkingen. In 98% van de inv(3)/t(3;3) patiënten worden mutaties in genen van 
het RAS/RTK signaaltransductie-netwerk verworven. Heterozygote mutaties werden gevonden 
in het resterende normale GATA2 allel en de genen SF3B1 en RUNX1. Verschillende verworven 
mutaties werden gevonden in genen coderend voor epigenetische modificeerders. Een 
interessante bevinding is dat mutatie noch gen expressie patronen kunnen differentiëren tussen 
verschillende inv(3)/t(3;3) myeloïde maligniteiten, suggererend dat deze maligniteiten mogelijk 
als één ziekte beschouwd kunnen worden. In hoofdstuk 9 detecteren wij een nog onbekend 
KMT2A-MYH11 fusietranscript in een patiënt die na een myelodysplastische fase uiteindelijk AML 
ontwikkelt. Interessant is het feit dat dit fusietranscript al aanwezig was in de myelodysplastische 
fase. In hoofdstuk 10 beschrijven wij AML patiënten met een verworven extra kopie van het 
gen BCL11B. De extra kopie is het gevolg van een springende translocatie waarbij het BCL11B 
locus integreert in super-enhancers gelegen op andere chromosomen, met BCL11B overexpressie 
tot gevolg. In chapter 11 beschrijven wij de ontwikkeling een nieuw statistische methode voor 
het schatten van DNA kopieaantal veranderingen aan de hand van NGS data. Deze methode 
bepaalt de aanwezigheid van systematisch statistische ruis in een referentie dataset van gezonde 
diploïde (twee kopieën per chromosoom) individuen. De bepaalde systematisch statistische ruis 
wordt vervolgens gebruikt voor het accuraat schatten van DNA kopieaantal veranderingen in 
chromosomen vanuit NGS verkregen data. In vergelijking met de traditioneel gebruikte DNA 
mapping arrays kunnen wij met onze statistische methode meer en preciezer gevalideerde 
DNA kopieaantal veranderingen detecteren. In het afsluitende hoofdstuk 12 worden de meest 
belangrijke bevindingen en hypothesen uit dit proefschrift in een breder context behandeld.
Chapter 8
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“Of all the things which wisdom provides to make us entirely happy,
much the greatest is the possession of friendship.”
Epicurus
Beste lezers, jaren van onderzoek zijn aan dit proefschrift voorafgegaan. Met veel plezier en trots 
kan ik zeggen dat mijn boekje voltooid is. Het voltooien van mijn proefschrift zou zonder de hulp 
van vele mensen nooit gelukt zijn. Daarvoor maak ik gebruik van dit laatste, edoch meest gelezen 
gedeelte van het proefschrift, om een aantal mensen persoonlijk te bedanken.
 Mijn eerste woorden richt ik tot mijn promotor, Bob Löwenberg. Als beginnend bachelor 
student mocht ik op jouw afdeling te werk gaan aan verschillende opeenvolgende projecten 
en uiteindelijk als PhD-student onder jouw hoede. Je stond altijd open voor mijn ideeën en wij 
hebben vele projecten besproken in jouw kamer achterin de kopkamer. Jouw kritische, maar 
opbouwende, kanttekeningen gemaakt tijdens mijn presentaties zijn altijd ten faveure geweest 
voor de kwaliteit van mijn werk. Beste Bob, bedankt voor jouw betrokkenheid, visie en steun. Het 
was mij een waar genoegen om jou als promotor gehad te hebben.
 Tijdens mijn PhD-traject is een additionele promotor toegevoegd, Ruud Delwel. Beste Ruud, 
ik wil jou bij deze bedanken voor jouw persoonlijke en intensieve begeleiding, zeker gedurende 
de laatste maanden tijdens de afronding van dit proefschrift. Op bijna elk moment van de dag 
was jij beschikbaar, waardoor ik altijd kon binnenstormen als ik iets nieuws had te vertellen. 
Met een grap wist jij mijn soms wat iets te naïeve en serieuze houding te doorbreken. Zeker als 
mijn mentor gedurende de volgende stap van mijn onderzoekscarrière zullen wij nog aan vele 
projecten samenwerken.
 Specifieke aandacht wil ik schenken aan mijn co-promotor, Peter Valk. Beste Peter, ik had 
mij geen betere begeleider kunnen toewensen. Als bachelor student ben ik in jouw groep 
begonnen en 10 jaar later eindig ik mijn PhD-traject onder jouw hoede. Het bellen tijdens jouw 
vakanties heb ik toch enigszins gemodereerd. We hebben, wegens congressen, veel reizen naar 
het buitenland gemaakt en tijdens deze reizen hebben wij een voorkeur ontwikkeld om elke 
hoge toren te beklimmen met een niet geringe kans dat ik weer eens van de trap val tijdens de 
afdaling. Ik heb zeer genoten van het Peter-Ruud één-tweetje, waarbij de grappen steeds flauwer 
worden gecorreleerd aan de hoeveelheid geconsumeerd bier. Vanuit mijn PhD-traject hebben 
wij nog projecten ten overvloede om de komende jaren met plezier te vullen. Bedankt voor jouw 
intensieve steun, betrokkenheid, input, drive en de mogelijkheid om op elk moment van de dag 
bij jou langs te komen.
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Beste prof. dr. Jelle Goeman, prof. dr. Sjaak Philipsen en prof. dr. Gert Ossenkoppele bedankt 
voor jullie deelname in de beoordelingscommissie van mijn proefschrift. Beste Jelle, bedankt voor 
jouw begeleiding, inzet en motivatie. Je bent een toonbeeld voor statistici met een verfrissende 
nieuwsgierigheid in de biologische kant van het verhaal. Jouw begeleiding heeft mij geholpen 
bij mijn statistische kennisontwikkeling. Onze reizen naar Frankrijk voor verschillende statistische 
congressen zal ik nooit vergeten. Op zoek naar een restaurant waar geen, maar dan ook zeker 
geen, toeristen komen in de zijstraten van Parijs. De Lamprei-schotel in Bordeaux zag er toch 
wat minder appetijtelijk uit. Ik wens je heel veel succes als nieuwbakken professor statistiek in 
Nijmegen en ik hoop nog op vele projecten samen te werken. Beste Sjaak en Gert, bedankt voor 
jullie deelname en inzet in de kleine commissie.
Beste prof. dr. Ivo Touw, prof. dr. Wouter den Laat en dr. Bert van der Reijden, bedankt voor 
jullie deelname aan de verdediging van mijn proefschrift. Beste Ivo, ook wij werken alweer 10 jaar 
samen. Ik weet nog goed dat ik bij jou op de kamer zat voor een interview over hoe wij MADEx 
konden verbeteren. Jouw aanwezigheid en kritische, doch opbouwende, opmerkingen zijn altijd 
zeer gewaardeerd en waardevol geweest. Bedankt voor jouw inzet, advies en motivatie. Beste 
Wouter, bedankt voor de deelname. Zonder jouw 4C-Seq technologie was onze Cell paper nooit 
tot stand gekomen. Bedankt dat wij de 4C-Seq technologie van jouw groep mochten leren. Beste 
Bert, het was mij een waar genoegen om op een aantal projecten samen te werken. Ik heb altijd 
zeer genoten van jouw advies en inbreng. 
De (ex-)leden van de Valk/Rijneveld research groep; François, Annelieke, Adil, Jasper, Anikó 
en Carla. François, man van het zuiden. Ik heb met heel veel plezier met jou samengewerkt. 
Jouw rigoureuze en accurate handelswijze is bewonderenswaardig. Mocht Dries Roelvink in de 
buurt zijn dan gaan we er samen heen. Annelieke, bedankt voor de vele experimenten die jij 
voor mij in het verleden hebt uitgevoerd en alvast bedankt voor de vele die nog gaan volgen. 
Ik vind het noemenswaardig dat je niet terugdeinst voor het uitvoeren van volledig onbekende 
experimenten (ook binnen de afdeling). A brief switch to English to address our friend from 
Oman, Adil. Adil, the latest addition to the Valk group, your journey has just started and I wish you 
the best. I already observed great potential in your work and scientific career ahead. Soon-to-be 
father, I wish you all the best. You’ll notice it will be tough in the beginning but also the best time 
of your life. Jasper, metal-gast en Euphorbia Leuconeura-man. Een tijdje geleden de Valk groep 
ingewisseld voor de Sonneveld groep, maar niet vergeten. Wij hebben een gedeelde passie voor 
metal muziek en tuinieren, toch wel een beetje vreemde combinatie als je het mij vraagt. Zodra 
Insomnium weer in het land is zullen wij elkaar daar, in de concertzaal, weer ontmoeten. Anikó, 
recent begonnen in de Rijneveld groep en nog iemand die mijn passie voor tuinieren deelt. Mijn 
deur staat altijd open voor NGS-vragen! Carla, bedankt voor alle hulp die je mij geboden hebt! 
Heel veel plezier met de kleine!
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De dames van de Valk diagnostiek groep; Isabel, Wendy, Pauline, Sonja, Marloes, Chantal 
en Antoinette. Ik wil jullie bedanken voor jullie ondersteuning tijdens het voltooien van mijn 
onderzoek en proefschrift. Isabel, rooibos thee is niet te drinken! Wendy, de diagnostiek backup 
staat veilig! Pauline, veel succes met toekomstige wielrenklassiekers! Sonja, ik zal de klinische 
tool binnenkort repareren! Marloes, heel veel succes in Utrecht binnenkort! Chantal, rij niet te 
hard op de motor! Antoinette, succes in Groningen en ik wens je heel veel plezier op de boerderij!
Mijn (ex-)mede-bioinformatici: Remco, Rowan, Erdogan en niet te vergeten Roel Verhaak. 
Beste Remco, wij kennen elkaar al sinds de TU Delft waar wij een overgroot gedeelte van het 
curriculum samen hebben gevolgd. Ik vind het nog steeds geweldig dat je bij ons bent komen 
werken, ondanks je soms wat rare grappen en grollen (*kuch* plakband over de sensor van mijn 
muis *kuch*). Ik hoop nog vele jaren samen te werken. Rowan, de jongste van het stel. Het was 
super dat je het laatste jaar ons kwam vergezellen op de kamer. Ik wens je nog heel veel succes 
toe met het afronden van jouw proefschrift en misschien krijgen wij dan eens de veel beloofde 
appeltaart. Erdogan, de Circos plot-sensei. Ik heb genoten van onze samenwerking en discussies 
over totaal irrelevante onderwerpen. Heel veel succes met de voortzetting van jouw werk bij de 
TU Delft. Roel, mijn voorganger en voorgaande mentor. Dit  proefschrift is een voortzetting van 
jouw en Peter’s werk. De jaren voor mijn PhD-traject zijn een goede voorzet geweest tot waar ik 
nu ben. Recent nog gesproken en ik weet dat je nog steeds van metal houdt. Zelfs nu je ouder en 
wijzer bent en kinderen hebt.
Leden van de Delwel groep; Stefan G., Roberto, Marije, Claudia en Eric. Stefan G., the man 
with the golden hands. Without your excellent scientific and lab skills the EVI1 project wouldn’t 
have gotten as far as it does today. I’m still impressed at what you achieved during just a few 
years in Rotterdam. I sincerely apologies for the frequent midnight calls during the Cell paper 
submission and revision. I still have a bottle of Château Haut-Bages Libéral at home that we 
need to finish. I bid you good luck in Heidelberg and I’m confident you’ll achieve great scientific 
wonders. Roberto, you eat, sleep and breathe CEBPA. I’m confident that “peak 6”, also dubbed 
the black hole-enhancer, will provide you with sufficient scientific material for years to come. I 
thank you for all the discussions we had on a wide variety of scientific and non-scientific topics! 
Claudia en Marije, heel erg bedankt voor de ondersteuning die jullie geleverd hebben aan onze 
projecten. Zonder jullie was het nooit gelukt. Eric, de EVI1-man. De “go-to man” voor al uw vragen 
over EVI1, lab experimenten of next generation sequencing. Heel erg bedankt voor alle inzet en 
adviezen tijdens mijn projecten. Jouw inbreng tijdens mijn werkpresentaties wordt altijd zeer 
gewaardeerd.
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De P.I.’s; Anita, Mojca, Marc, Stefan E., Jan C., Eric B., Frank, Moniek, Dick, Tom en Pieter. Ik 
wil jullie bij deze bedanken voor jullie contributie aan dit proefschrift en niet te vergeten de vele 
opmerkingen en adviezen verkregen tijdens de werkbesprekingen. Ik wens jullie en de projecten 
onder jullie hoede het beste toe.
Dear Elwin, Su Ming, Bas, Sanne, Renée, Jurgen, Eric V., Ferry, Julien, Piotr, Adrian, Saman, 
Mark van Duin, Paulette, Hans de Looper, Annemiek, Tomasia, Menno, Anita S., Peter van 
Geel, Niken, Michael, Natalie, Martijn and Egied, thank you for all your help! Dear Noemi, Kasia, 
Si, Zhen, Keane, Avinash, Davine, Julia, Patricia O., Patricia D., Monica, Michelle, Farshid and 
Roel P., I wish you the best of luck with writing your theses!
De dames van het secretariaat; Leenke, Annelies en Ans. Leenke, bedankt voor alle hulp tijdens 
mijn PhD-traject. Ik ben me ervan bewust dat ik soms erg verstrooid kan zijn. Annelies, bedankt 
voor alle hulp gedurende het einde van mijn PhD-traject. Zonder jou was deze dag nooit tot stand 
gekomen. Ans, recent met pensioen gegaan, wil ik alsnog bedanken. Ik hoop dat je ondertussen 
al een leuke hobby hebt kunnen vinden om je vrije tijd aan te besteden.
Beste Jan van Kapel, man van de computers, software en het jagen. Ik wil je bedanken voor de 
technische ondersteuning die je de afgelopen jaren hebt geboden.
Beste (ex-)collegae van de afdeling medische statistiek en bio-informatica in Leiden, ik 
wil jullie allemaal bedanken voor jullie input, voor de leuke discussies op wetenschappelijk en 
filosofisch gebied en de tijd dat ik bij jullie heb mogen spenderen. Beste Rosa, bedankt voor alle 
hulp en de leuke discussies die wij gevoerd hebben. Veel succes met het afronden van het PhD-
traject.
Most scientific progress results from fruitful collaborations and I wouldn’t do justice without 
thanking all scientific collaborators. Lars Bullinger, Konstanze Döhner and Hartmut Döhner 
(Ulm university), I’m indebted to you for all the valuable input given during the last years and 
AML samples sent in the different projects described in this thesis. I had a great time visiting 
your department this year and hope that we could collaborate on different projects in the future. 
Berna Beverloo (afdeling Klinische Genetica), bedankt voor alle cytogenetische bepalingen en 
het verzorgen van correcte cytogenetische annotatie. Kirsten van Lom (afdeling Hematologie), 
bedankt voor alle cytomorfologische bepalingen, thee en advies. Vincent van der Velden en 
Ton Langerak (afdeling Immunologie), bedankt voor alle bepalingen. Harmen van der Werken 
(afdeling Urologie), dank voor jouw hulp met het verwerken van 4C-Seq data. Elzo de Wit en 
Britta Bouwman (Hubrecht Institute), dank voor jullie hulp voor het opzetten van de 4C-Seq 
technologie binnen onze afdeling. Joop Jansen (afdeling Hematologie, Raboud University Medical 
Centre), dank voor jouw advies en inzet. Marta Pratcorona (Hospital Clínic de Barcelona) helped 
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in setting up the research described in Chapter 5. I wish you all the best back in Barcelona! Dank 
voor alle deelnemende HOVON-centra – zonder hen was dit proefschrift niet tot stand gekomen. 
Wim van Putten en Yvette van Noorden, bedankt voor de up-to-date patiënteninformatie en 
wetenschappelijke input. Jonas Jutzi and Heike Pahl (Freiburg University), I really enjoyed your 
scientific input and time spent together in Rotterdam and Ulm. Hopefully, I could visit Freiburg 
once and enjoy your hospitality.
Beste (oud-)collegae van de afdeling hematologie, ik wil jullie bedanken voor jullie tomeloze 
inzet en wetenschappelijke input, voor alle gezellige tijden samen gespendeerd, leuke discussies 
en alle hulp die ik van jullie heb mogen ontvangen.
Mijn paranimfen Jeffrey van Heck en Mark van den Berg. Het dynamische trio is weer eens 
samengekomen. Al vrienden sinds de kleuterschool en nog steeds goed bevriend na zoveel jaren. 
Ik ben dankbaar voor jullie hulp om deze dag een succes maken. Jeffrey, alweer wat jaartjes 
verhuisd naar Hilversum, maar nog steeds in goed contact. Je bent een goede vriend en een 
echte levensgenieter. Vroeger leken wij heel erg op elkaar, waardoor mensen ons nooit uit elkaar 
konden houden. Recent getrouwd, wat toch als een verrassing kwam, omdat je het nooit wilde 
doen. Ik waardeer je gesprekken, inzet en levensinstelling enorm. Ik hoop nog vele avonturen 
samen te beleven. Mark, tevens hechte vriend en tennis-mattie. We kennen elkaar al sinds 
de kleuterschool waar we vaak bij elkaar thuis verbleven. Bovendien hebben wij jaren samen 
tennis gespeeld, iets wat je nog steeds fanatiek doet. Ik vind het geweldig dat je mij deze dag 
bij wilt staan en moge wij nog vele jaren bevriend blijven! Lieve vrienden, dank jullie voor alle 
bijeenkomsten, feestjes, vrijgezellenfeestjes, de vele avonden samen en de goede gesprekken.
Lieve familie, ik wil jullie bedanken voor al jullie steun gedurende de afgelopen jaren. Ton, Hannie, 
Tom, Lisa, opa en oma Smit, bedankt voor jullie ondersteuning gedurende het verhuizen, de 
geboorte en de drukke dagen. Ik weet dat Jonathan altijd graag bij jullie op bezoek komt.
Lieve grote zus Jorunn, als kleine broer moet ik toch altijd naar je opkijken. Je hebt je eigen weg 
gevolgd, bent meester in de rechten geworden en daarmee altijd gelukkig geweest. Afgelopen 
jaren de moeder geworden van Sana, Isra en Maysa, drie prachtige dochters. Nabil, je bent een 
geweldige zwager. Misschien moet je mij binnenkort toch maar weer eens leren autorijden.
Lieve pa en ma, ik heb enorme bewondering voor jullie. Altijd druk bezig geweest met jullie bedrijf 
en de enige twee mensen die ik ken die zoveel gewerkt hebben. Van jongs af aan hebben jullie 
mij en Jorunn altijd een vrije keuze gegeven en wij hebben ons nooit hoeven te bekommeren of 
de mogelijkheid tot deze keuze wel bestond. Geluk moesten wij zelf maken en ons hart volgen 
en dat hebben wij ook gedaan. Ik dank jullie voor de steun in alle jaren, zonder jullie was dit 
proefschrift nooit tot stand gekomen.
Dankwoord
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Mijn laatste woorden wil ik uiteraard wenden aan mijn lieve Kristel en Jonathan. Lieve Kristel, 
wij zijn alweer tien jaar ontzettend gelukkig samen en zijn daarom recent getrouwd. Jij maakt mij 
compleet en bent een rots in de branding van mijn toch iets chaotische leven. Daarnaast ben je 
een lieve en zorgzame moeder die alles voor onze lieve zoon over heeft. Bedankt dat je er altijd 
voor mij bent! Lieve Jonathan, helaas kan je nog niet lezen, maar ooit ergens in de toekomst zal 
je dit “dan oude” proefschrift oppakken en het misschien wel begrijpen. Naast de ontmoeting van 
jouw moeder ben jij het mooiste wat mij is overkomen! Wie weet, in de toekomst, kunnen wij dit 
proefschrift met elkaar bediscussiëren.
Mathijs
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De auteur van dit proefschrift werd op 24 augustus 1984 geboren in Rotterdam. Na het afronden 
van het Hoger Algemeen Voortgezet Onderwijs aan het Gemini College in Ridderkerk startte hij 
de studie Hogere Informatica aan de Hogeschool Rotterdam in september 2002. Hij voltooide vier 
jaar later de opleiding met een afstudeeronderzoek getiteld, “Cluster analyse van genoom-brede 
gene expressie profielen en het visualiseren van genoom-brede SNP patronen”, onder supervisie 
van dr. Roel G.W. Verhaak en dr. Peter J.M. Valk op de afdeling hematologie van het Erasmus 
Universitair Medisch Centrum (Erasmus MC). Vervolgens begon hij in september 2006 aan de 
opleiding Bio-informatica aan de Technische Universiteit te Delft (TU Delft). Als masterexamen 
(doctoraalexamen) voerde hij aan het Leids Universitair Medisch Centrum (LUMC), onder 
supervisie van dr. Jelle J. Goeman en prof. dr. Marcel J.T. Reinders, 9 maanden onderzoek naar 
specifieke gen expressie predictie patronen verkregen door de integratie van een gemodificeerde 
groep lasso procedure in multinomiale logistische regressie modellen. Na het cum laude behalen 
van het masterexamen begon hij in december 2009 als promovendus in de onderzoeksgroep 
van dr. Peter J.M. Valk op de afdeling hematologie van het Erasmus MC (promotoren prof. dr. Bob 
Löwenberg en prof. dr. Ruud Delwel). Aldaar vond het onderzoek beschreven in dit proefschrift 
plaats. In december 2014 begon hij als postdoctoraal onderzoeker op de afdeling hematologie 
van het Erasmus MC (prof. dr. Ruud Delwel).
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A
4C-Seq Circularized chromosome conformation capture deep-sequencing
ABL1 c-Abl oncogene 1
ALL Acute lymphoblastic leukemia
Allo-HSCT Allogeneic hematopoietic stem cell transplantation
AML Acute myeloid leukemia
AML1 Acute myeloid leukemia 1
ASXL1 Additional sex combs like 1 (Drosophila)
Auto-HSCT Autologous hematopoietic stem cell transplantation
BAC Bacterial artificial chromosome
BCL11B B-cell CLL/lymphoma 11B
BCR Breakpoint cluster region
BET Bromodomain and extraterminal domain family
BM Bone marrow
BRD4 Bromodomain-containing protein 4
BTLA B and T lymphocyte associated
Cas9 CRISPR associated protein 9
CBF Core binding factor
CBFB Core binding factor beta subunit
CD Cluster of differentiation
CDKN2A/B Cyclin-dependent kinase inhibitor 2A/2B
CEBPA CCAAT/enhancer binding protein alpha
CGH Comparative genomic hybdridization
Chip-Seq Chromatin immunoprecipitation followed by deep-sequencing
CI Confidence interval
CLP Common lymphoid progenitor
CML Chronic myeloid leukemia
CML-BC Chronic myeloid leukemia in blast crisis
CMP Common myeloid progenitor
CN Cytogenetical normal
CNV Copy number variation
CNVsvd Copy number variation by singular value decomposition package
CR Complete remission
CRISPR Clustered regularly interspaced short palindromic repeat
CRISPRa CRISPR activation
CRISPRi CRISPR interference
Abbreviations
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cRSS Cryptic recombination signal sequence
CSF3 Colony-stimulating factor 3
CSF3R Colony-stimulating factor 3 receptor
CSF3R-d715 to d730 Mutated CSF3R, truncated receptors at amino acid position 715 to 730
CSF3R-T595I Mutated CSF3R, substitution of threonine to isoleucine at amino acid 
position 595
CSF3R-T595V Mutated CSF3R, substitution of threonine to valine at amino acid position 
595
CTS Common translocated segment
dHPLC Denaturing high performance liquid chromatography
DNA Deoxyribonucleic acid
DNA-pkcs DNA-dependent protein kinase catalytic subunit
DNMT DNA methyltransferase
DSB Double strand break
EFS Event-free survival
ELANE Neutrophil elastase
emPCR emulsion PCR
ErP Erythrocyte precursor
ETO Eight twenty one
ETP Early thymocyte progenitor
EVI1 Ecotropic virus integration site 1
EZH2 Enhancer of zeste homolog 2 
FAB French-American-British 
FISH Fluorescence in situ hybridization
FLT3 fms-related tyrosine kinase 3
GATA2 GATA binding protein 2
G-CSF Granulocyte colony stimulating factor
GEO Gene expression omnibus
GEP Gene expression profiling
GFP Green fluorescent protein
GM-CSF Granulocyte-macrophage colony stimulating factor
GMP Granulocyte monocyte progenitor
GMP Granulocyte myeloid precursor
gRNA Guide RNA
HDR Homology directed repair
HMGB1 High-mobility group protein B1
Abbreviations
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HMGB2 High-mobility group protein B2
HMM Hidden Markov model
HOVON Dutch-Belgian Hemato-Oncology Cooperative Group
HR Hazard ratio
HSC Hematopoietic stem cell
HSCP Hematopoietic stem cell and progenitor
IDH1 Isocitrate dehydrogenase 1
IDH2 Isocitrate dehydrogenase 2
IKZF1 IKAROS family zinc finger 1 
IL-2/-3/-6 Interleukin 2/3/6
Indel Insertion or deletion
IP Immunoprecipitation
ITD Internal tandem duplication
JAK2 Janus kinase 2 
KMT2A lysine (K)-specific methyltransferase 2A
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
L-BFGS-B Bounded low-memory BFGS
LINE Long interspersed nuclear element
LLGL2 Lethal giant larvae homolog 2 (Drosophila)
lncRNA Long non-coding RNA
LOH Loss-of-heterozygosity
LSC Leukemic stem cells
LTR Long terminal repeat
MAS MicroArray Suite
MDS Myelodysplastic syndrome
MECOM MDS1 and EVI1 complex locus 
MEP Megakaryocyte erythrocyte precursor
mESC Mouse embryonic stem cells
MkP Megakaryocyte precursor 
MLL Mixed lineage leukemia
MPN Myeloproliferative neoplasm 
MPP Multipotent progenitor
mRNA Messenger RNA
MYH11 Myosine, heavy chain 11 
NF1 Neurofibromin 1 
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NGS Next generation sequencing
NHEJ Non-homologous end joining
NOTCH1 Notch homolog 1 
NPM1 Nucleophosmin 
NRAS Neuroblastoma RAS viral oncogene homolog 
OS Overall survival
PAX5 Paired box 5 
PB Peripheral blood
PCR Polymerase chain reaction
PML Promyelocytic leukemia 
PRC2 Polycomb repressive complex 2
PTD Partial tandem duplication
RAEB(t) Refractory anemia with excess of blasts(in transformation)
RAG1 Recombination activating gene 1
RAG2 Recombination activating gene 2
RARA Retinoic acid receptor, alpha 
RAS Rat sarcoma
RFS Relapse free survival
RNA Ribonucleic acid
RNA-Seq RNA profiling by deep-sequencing
RQ-PCR Quantitative real-time reverse transcription PCR
RSS Recombination signal sequence
RTK Receptor tyrosine kinase
RT-PCR Reverse transcription PCR
RUNX1 Runt-related transcription factor 1 
SCN Severe congenital neutropenia
SF3B1 Splicing factor 3B subunit 1 
SINE Short interspersed nuclear element
SNP Single nucleotide polymorphism
SNV Single nucleotide variation
STAT3/5 Signal transducer and activator of transcription
SUZ12 Supressor of zeste polycomb repressive complex 2 subunit 
SV Structural variant
TAD Transactivation domain
TALEN Transcription activator-like effector nuclease
Abbreviations
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TCGA The cancer genome atlas 
TET2 Tet methylcytosine dioxygenase 2
TKD Tyrosine kinase domain
UPD Uniparental disomy
VAF Variant allele frequency
WBC White blood cell count
WES Whole exome sequencing
WGS Whole genome sequencing
WHO World health organization
WT1 Wilms tumor 1
ZC3H18 Zinc finger CCCH-type containing 18 
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Name PhD student: Mathijs A. Sanders PhD period: December 2009 - December 2014
Erasmus MC Department: Hematology Promotors: Prof. dr. B. Löwenberg, 
Prof. dr. R. Delwel
Research school: Molecular Medicine Supervisor: Dr. P.J.M. Valk
1. PhD training Year ECTS
General courses   
Basic course R 2009 1.4
In-depth courses   
Course on Molecular Diagnostics 2010 1
Next Generation Sequencing Training: CLC Bio 2011 0.5
Complete genomics 2011 0.3
Course on Molecular Aspects of Hematological Disorders 2014 0.5
Seminars and workshops   
Scientific workshop Acute Myeloid Leukemia “Molecular” 2011 1
Workshop on competing risk models 2011 0.5
Statistical Methods for Post Genomic Data Workshop (Paris) 2011 1
Erasmus Hematology Lectures 2009-2014 4
Oral presentations   
Workdiscussion (department of Hematology, Erasmus MC, 15x) 2009-2014 7.5
Workdiscussion (department of Medical Statistics and 
Bioinformatics, LUMC, 4x)
2009-2013 2
 
AIO/post-doc meeting (department of Hematology, Erasmus MC, 4x) 2009-2014 2
Journal club (department of Hematology, Erasmus MC, 4x) 2009-2014 2
3rd Channel Network Conference (Bordeaux Segalen university) 2011 1
Dutch hematology congress (3x) 2011-2013 3
High-dimensional data modeling (department of Medical
Statistics and Bioinformatics, LUMC, 1x)
2012 0.5
 
Annual MODHEM/SKLM Spring Meeting 2012 1
Daniel den Hoed day (2x) 2012-2013 2
Course on Molecular Aspects of Hematological Disorders 2014 1
Annual conference American Society of Hematology (ASH) 2014 1
National and international conferences   
Benelux Bioinformatics Conference (BBC) 2009 1
Molecular Medicine day (2x) 2010-2011 0.6
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3rd Channel Network Conference (Bordeaux Segalen university) 2011 1
Dutch hematology congress (4x) 2011-2014 1.8
Annual conference Center for Translational Molecular Medicine
(CTMM) (3x)
2010-2012 1
 
Annual conference European Hematology Association (EHA) (2x) 2012, 2014 2
Annual conference American Society of Hematology (ASH) (2x) 2012, 2014 2
Scientific meetings   
Workdiscussion (department of Hematology, Erasmus MC) 2009-2014 5
AIO/post-doc meeting (department of Hematology, Erasmus MC) 2009-2014 2
Journal club (department of Hematology, Erasmus MC) 2009-2014 3.75
Workdiscussion (LUMC) 2009-2012 3
Other   
Writing grant Complete Genomics (granted) 2012 0.5
2. Teaching activities Year ECTS
Supervising students   
Bachelor student (“Bioinformatics” and “Molecular biology”) (2x) 2011-2012 3
Two bachelor exchange students Moscow State University (LUMC) 2011 1
Supervising practical training and excursions   
Organization and supervision invited speaker lunch (2x) 2013-2014 0.2
Introduction SPSS and mixed models, Medical and Biomedical
Science students (LUMC)
2010-2012 1.5
 
Biomedical Research Techniques (Molmed, oral presentations) 2013-2014 2
Total    64.55
Stellingen behorende bij het proefschrift
Computational Biology-Driven Genomic and Epigenomic Delineation
of Acute Myeloid Leukemia
1. De aanduiding van het RPN1-EVI1 leukemietype moet binnen het World Health 
Organisation classificatiesysteem worden gewijzigd naar GATA2-EVI1 (dit proefschrift).
2. Naast het Burkitt’s lymfoom en het multipel myeloom, moet ook acute myeloïde leukemie 
worden beschouwd als een hematologische maligniteit die gedreven kan worden door de 
aberrante activatie van proto-oncogenen door het herpositioneren van super-enhancers 
(dit proefschrift).
3. Genetische afwijkingen bij acute lymfatische leukemie met kinase-activerende afwijkingen 
zijn het gevolg van onrechtmatige genetische herschikkingen door het RAG eiwitcomplex 
(dit proefschrift).
4. Verworven mutaties in RAS/RTK genen dragen essentieel bij aan de leukemische 
transformatie van AML met inv(3)/t(3;3) afwijkingen (dit proefschrift).
5. Het combineren van verschillende genoom-brede technieken kan nieuwe mechanistische 
inzichten verschaffen in de ontwikkeling van leukemie (dit proefschrift).
6. Mutaties in DNA methylatie-gerelateerde genen in pre-leukemische stamcellen spelen 
een belangrijke rol in het vroege ontstaan van acute myeloïde leukemie. (Shlush et al, 
Nature 2014;506:328-33; Jaiswal et al, NEJM 2014;371:2488-98; Genovese et al, NEJM 
2014;371:2477-87)
7. De functionele synergie tussen verschillende co-existente genmutaties is als een 
complex raderwerk; pas wanneer de functie van elk onderdeel bekend is, kan door kleine 
aanpassingen in de functie van elk van de onderdelen het mechaniek van het geheel 
begrepen worden.
8. Communicatieve vaardigheden zijn essentieel bij de uitvoering van multidisciplinair 
onderzoek.
9. Falsificationisme is de grootste vijand van menig wetenschapper.
10. Geen één leukemie is hetzelfde.
11.  “When you are studying any matter, or considering any philosophy, ask yourself only what 
are the facts and what is the truth that the facts bear out. Never let yourself be diverted 
either by what you wish to believe, or by what you think would have beneficent social 
effects if it were believed, but look only, and solely, at what are the facts.” (Bertrand Russell)
Mathijs Sanders
Rotterdam, 17 februari 2015
